

R E M A R K S

Claims 46 to 92 and 119 were objected to for containing "non-elected subject matter."

Claims 93 to 118 were withdrawn from consideration.

It was stated in the Office Action that claims 93 to 118 would be rejoined following allowability of claims 46 to 92 and 119, provided there are no problems under 35 USC 112.

Regarding the penultimate paragraph on page 2 of the Office Action, it is noted that on page 36, line 13 and page 37, line 8 of applicants' AMENDMENT UNDER 37 CFR 1.111 filed on May 17, 2005, it was intended that "MPEP 803.02" be cited.

In reply to applicants' species election for search purposes made in response to the November 19, 2004 Office Action, the Examiner examined a "subgeneric scope of the claims" as set forth on page 3 of the November 19, 2004 Office Action and withdrew from consideration the remaining subject matter included in claims 46 to 92. The "non-elected subject matter" referred to hereinabove is the claimed subject matter which is outside the scope of said "subgeneric scope of the claims." Actually, for the reasons discussed below, applicants never had the opportunity to make an election with regard to said "subgeneric scope of the claims."

Based on an election of species for search purposes only (in reply to the November 19, 2004 Office Action), the previous February 22, 2005 Office Action "jumped" to a restriction between a "Group (i)", namely R^1 and X^1 as defined in the claims; X^2 is oxygen; R^a as defined in the claims, but would not combine together with R^2 ; R^2 is H; R^3 is alkyl; A is $-C_2H_4-$; E is oxygen; and Arom is optionally substituted phenyl, and a "Group (ii)", namely the remainder of the claimed subject matter.

Prior to the November 19, 2004 Office Action, such purported restriction between said "Group (i)" and said "Group (ii)" had not previously been set forth as a Restriction Requirement under 35 USC 121, and applicants were not afforded an opportunity to elect and respond to said purported Restriction Requirement. The election between said "Group (i)" and said "Group (ii)" was in effect made for the applicants by the USPTO.

It is respectfully submitted that the previous February 22, 2005 Office Action did not establish a *prima facie* case for restricting the claims, because no reasons were furnished to justify restriction on the basis of any of (a) a separate classification, (b) a separate status of the art, or (c) a different field of search.

The Examiner is respectfully requested to follow the guidelines of MPEP 803.02 with respect to the elected species (for which no prior art is indicated as having been found) and to expand the examination to additional related species (for which it also appears that no prior art has been found) and continue the examination of the entire claimed subject matter.

Withdrawal of the Restriction Requirement which was set forth in the previous February 22, 2005 Office Action is respectfully requested for the following additional reasons.

The position is taken on page 3 of the June 17, 2005 Office action that the "substantial structural feature" in applicants' compounds is only a single ring with an amide substituent, and consequently running a search could "run the computer out of memory."

It is considered that the reason the Examiner does not see a complex substantial structural feature upon which to base his search is that the compounds in this case are structurally very simple. Furthermore, the range of substituents is very small. By incorporating the potential substituents into the search, it is respectfully submitted that the search is quite feasible and would not "run the computer out of memory," and consequently the first paragraph of MPEP 803.2 is appropriate.

Applicants have been able to run searches on these compounds and the results of such searches are submitted concomitantly herewith. The enclosed paper entitled "Search 1" relates to a search in which X^1 and X^2 were limited to oxygen.

Search 1 identified 94 documents, however, most compounds were in fact outside the scope of the claims, having, e.g., two ester groups on the phenyl ring, which is not permitted in claim 1. Additionally, many of these documents relate only to isolation of such di-substituted compounds from natural sources and with no apparent details of biological effects.

The enclosed two papers for Search 2 are split into the results from the CAS registry (no documents) and those from MARPAT (25).

The enclosed papers entitled "Search 2" relate to the following cases:

- (3) X^1 and X^2 are not both = O
- (4) $X^1 = O$ when $X^2 = S$
- (5) $X^1 = S$ when $X^2 = O$
- (6) Both X^1 and $X^2 = S$.

Search 2 identified 25 documents. Six of these post date the current application. No compounds falling within the scope of the claims were identified.

Also submitted concomitantly herewith are copies of the following papers concerning the corresponding European and International applications: the Supplementary European Search Report, the European Claims and the Translation of the International Preliminary Examination Report ("IPER").


In view of the above, withdrawal of the objection of claims 46 to 92 and examination of the entire scope of the claimed subject matter is respectfully requested.

Reconsideration is requested. Allowance is solicited.

An INFORMATION DISCLOSURE STATEMENT is being filed concomitantly herewith.

If the Examiner has any comments, questions, objections or recommendations, the Examiner is invited to telephone the undersigned at the telephone number given below for prompt action.

Respectfully submitted,



Richard S. Barth
Reg. No. 28,180

Frishauf, Holtz, Goodman & Chick, P.C.
220 Fifth Avenue - 16th Floor
New York, New York 10001-7708
Tel. No. (212) 319-4900
Fax No. (212) 319-5101
E-mail Address: BARTH@FHGC-LAW.COM
RSB/ddf

- Encs.: (1) INFORMATION DISCLOSURE STATEMENT
(2) Copies of the following documents in the corresponding European and International application: Supplementary European Search Report, Translation of the International Preliminary Examination Report and the European claims
(3) Search 1 (255 pages)
(4) Search 2 CAS Registry (14 pages)
(5) Search 2 MARPAT (111 pages)



European Patent
Office

**SUPPLEMENTARY
EUROPEAN SEARCH REPORT**

Application Number
EP 02 71 6323

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
	No further relevant documents disclosed -----		C07C219/30 C07C271/44 A61K31/137
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C07C
	The supplementary search report has been based on the last set of claims valid and available at the start of the search.		
Place of search MUNICH		Date of completion of the search 1 April 2004	Examiner Sen, A
CATEGORY OF CITED DOCUMENTS			
<p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

Translation

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference FP200201	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/JP02/00400	International filing date (day/month/year) 22 January 2002 (22.01.02)	Priority date (day/month/year) 26 January 2001 (26.01.01)
International Patent Classification (IPC) or national classification and IPC C07C 219/22, 271/44, 321/28, 333/04, C07D 317/58, 317/64, 213/64, 213/63, 333/32, 333/40, 215/20, 209/44, 217/14, 217/16, 223/16, A61K 31/27, 36, 4402, 4406, 4409, 44, 381, 47, 472, 4035, 55, A61P 43/00, 25/28, 24, 14, 22		
Applicant SANKYO COMPANY, LIMITED		

<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of <u>3</u> sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of _____ sheets.</p>	
<p>3. This report contains indications relating to the following items:</p> <p>I <input checked="" type="checkbox"/> Basis of the report</p> <p>II <input type="checkbox"/> Priority</p> <p>III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</p> <p>IV <input type="checkbox"/> Lack of unity of invention</p> <p>V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</p> <p>VI <input type="checkbox"/> Certain documents cited</p> <p>VII <input type="checkbox"/> Certain defects in the international application</p> <p>VIII <input type="checkbox"/> Certain observations on the international application</p>	

EPO - DG 1

0 3.10. 2003

109

Date of submission of the demand 22 January 2002 (22.01.02)	Date of completion of this report 21 August 2002 (21.08.2002)
Name and mailing address of the IPEA/JP	Authorized officer
Facsimile No.	Telephone No.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/JP02/00400

I. Basis of the report

1. With regard to the elements of the international application:*

- ☒ the international application as originally filed
- ☐ the description:
 pages _____, as originally filed
 pages _____, filed with the demand
 pages _____, filed with the letter of _____
- ☐ the claims:
 pages _____, as originally filed
 pages _____, as amended (together with any statement under Article 19
 pages _____, filed with the demand
 pages _____, filed with the letter of _____
- ☐ the drawings:
 pages _____, as originally filed
 pages _____, filed with the demand
 pages _____, filed with the letter of _____
- ☐ the sequence listing part of the description:
 pages _____, as originally filed
 pages _____, filed with the demand
 pages _____, filed with the letter of _____

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages _____
- ☐ the claims, Nos. _____
- ☐ the drawings, sheets/fig _____

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rule 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/JP02/00400

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. Statement**

Novelty (N)	Claims	2-7, 16, 21-26, 29-31, 34-36	YES
	Claims	1, 8-15, 17-20, 27, 28, 32, 33	NO
Inventive step (IS)	Claims	2-7, 16, 21-26, 29-31, 34-36	YES
	Claims	1, 8-15, 17-20, 27, 28, 32, 33	NO
Industrial applicability (IA)	Claims	1-36	YES
	Claims		NO

2. Citations and explanations

Document 1: WO, 96-22276, A1 (Nippon Shinyaku Co., Ltd.), 25 July, 1996 (25.07.96), the claims, & AU, 9644589, A

Document 2: JP, 50-35175, A (Tanabe Seiyaku Co., Ltd.), 3 April, 1975 (03.04.75), the claims (Family: none)

The subject matters of claims 1, 8-13, 17-20, 27, 28, 32 and 33 do not appear to be novel or to involve an inventive step in view of document 1 cited in the ISR.

The compounds of the general formula (I) described in claim 1 and drugs containing any of the said compounds are disclosed in document 1.

The subject matters of claims 1, 14, 15, 19, 20, 27, 28 and 32 do not appear to be novel or to involve an inventive step in view of document 2 cited in the ISR.

The compounds of the general formula (I) described in claim 1 are disclosed in document 2.

The subject matters of claims 2-7, 16, 21-26, 29-31 and 34-36 appear to be novel and to involve an inventive step in view of documents 1 and 2 cited in the ISR.

Documents 1 and 2 do not describe that (a) the compounds of the general formula (I) having specific substituent groups and (b) the compounds of the general formula (I) have activity of inhibiting (a) acetylcholinesterase and (b) selective serotonin re-incorporation. This constitution is not considered to be obvious to a person skilled in the art either.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/JP02/00400

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of :

IPC

C07D215/20, 209/44, 217/14,

C07D217/16, 223/16, A61K31/27,

A61K31/36, 31/44, 31/381,

A61K31/47, 31/472, 31/4035,

A61K31/55, A61P43/00, 25/28,


A61P25/24, 25/14, 25/22

Claims:

25. 07. 2003

1. A compound of formula (I):

(91)



[wherein R¹ represents a C₁-C₆ alkyl group, an amino group, a (C₁-C₆ alkyl)amino group, a di(C₁-C₆ alkyl)amino group or a nitrogen-containing saturated heterocyclic group;

R² and R³ are the same or different and represent a hydrogen atom or a C₁-C₆ alkyl group;

Arom represents an aryl group, an aryl group substituted at from 1 to 5 positions by substituent(s) which are the same or different selected from the substituent group α , a heteroaryl group, or a heteroaryl group substituted at from 1 to 3 positions by substituent(s) which are the same or different selected from the substituent group α ;

A represents a C₁-C₆ alkylene group;

R^a represents a hydrogen atom, a C₁-C₆ alkyl group or a C₁-C₆ alkenyl group or, together with R², represents a C₁-C₃ alkylene group (in the case of C₂-C₃, it may contain a double bond);

E represents a single bond, an oxygen atom, a sulfur atom or a group of the formula: -NR⁴- (wherein R⁴ represents a hydrogen atom or a C₁-C₇ alkanoyl group);

X¹ and X² are the same or different and represent an oxygen atom or a sulfur atom]
or a pharmacologically acceptable salt or ester thereof.

<Substituent group α >

halogen atom, C₁-C₆ alkyl group, halogeno C₁-C₆ alkyl group, C₁-C₆ alkoxy group, C₁-C₆ alkylthio group, C₁-C₃ alkylenedioxy

group, C₁-C₇ alkanoyl group, C₂-C₇ alkyloxycarbonyl group, amino group, C₁-C₇ alkanoylamino group, hydroxyl group, mercapto group, cyano group, nitro group and carboxyl group.

2. A compound or pharmacologically acceptable salt or ester thereof according to Claim 1, wherein the group of formula: R¹-C(=X¹)- is a carbamoyl group, a (C₁-C₄ alkyl)carbamoyl group, a di(C₁-C₄ alkyl)carbamoyl group, a thiocarbamoyl group, a (C₁-C₄ alkyl)thiocarbamoyl group or a di(C₁-C₄ alkyl)thiocarbamoyl group.

3. A compound or pharmacologically acceptable salt or ester thereof according to Claim 1, wherein the group of formula: R¹-C(=X¹)- is a (C₁-C₄ alkyl)carbamoyl group, a di(C₁-C₄ alkyl)carbamoyl group, a (C₁-C₄ alkyl)thiocarbamoyl group or a di(C₁-C₄ alkyl)thiocarbamoyl group.

4. A compound or pharmacologically acceptable salt or ester thereof according to Claim 1, wherein the group of formula: R¹-C(=X¹)- is a (C₁-C₄ alkyl)carbamoyl group or a di(C₁-C₄ alkyl)carbamoyl group.

5. A compound or pharmacologically acceptable salt or ester thereof according to Claim 1, wherein the group of formula: R¹-C(=X¹)- is a di(C₁-C₄ alkyl)carbamoyl group.

6. A compound or pharmacologically acceptable salt or ester thereof according to Claim 1, wherein the group of formula: R¹-C(=X¹)- is a dimethylcarbamoyl group or an ethylmethylcarbamoyl group.

7. A compound or pharmacologically acceptable salt or ester thereof according to Claim 1, wherein the group of formula: R¹-C(=X¹)- is a dimethylcarbamoyl group,

8. A compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 1 to 7, wherein R¹ is a

C₁-C₆ alkyl group.

9. A compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 1 to 7, wherein R³ is a methyl group or an ethyl group.

10. A compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 1 to 7, wherein R³ is a methyl group.

11. A compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 1 to 10, wherein R² is a hydrogen atom or a C₁-C₆ alkyl group.

12. A compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 1 to 10, wherein R² is a hydrogen atom, a methyl group or an ethyl group.

13. A compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 1 to 10, wherein R² is a hydrogen atom or a methyl group.

14. A compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 1 to 10, wherein R^a, together with R², is a C₁-C₃ alkylene group which may contain a double bond.

15. A compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 1 to 10, wherein R^a, together with R², is a C₂-C₃ alkylene group which may contain a double bond.

16. A compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 1 to 10, wherein R^a, together with R², is a C₃ alkylene group which contains a double bond.

17. A compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 1 to 13, wherein R^a is a hydrogen atom or a methyl group.

18. A compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 1 to 13, wherein R^a is a hydrogen atom.

19. A compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 1 to 18, wherein Arom is a phenyl group, a phenyl group substituted at from 1 to 3 positions by substituent(s) which may be the same or different selected from the substituent group α , a pyridyl group, or a pyridyl group substituted at one position by a substituent selected from the substituent group α ;

<Substituent group α >

halogen atom, C₁-C₆ alkyl group, halogeno C₁-C₆ alkyl group, C₁-C₆ alkoxy group, C₁-C₆ alkylthio group, C₁-C₃ alkylenedioxy group, C₁-C₇ alkanoyl group, C₂-C₇ alkyloxycarbonyl group, amino group, C₁-C₇ alkanoylamino group, hydroxyl group, mercapto group, cyano group, nitro group and carboxyl group.

20. A compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 1 to 18, wherein Arom is a phenyl group or a phenyl group substituted at from 1 to 3 positions by substituent(s) which may be the same or different selected from the substituent group α ;

<Substituent group α >

halogen atom, C₁-C₆ alkyl group, halogeno C₁-C₆ alkyl group, C₁-C₆ alkoxy group, C₁-C₆ alkylthio group, C₁-C₃ alkylenedioxy group, C₁-C₇ alkanoyl group, C₂-C₇ alkyloxycarbonyl group, amino group, C₁-C₇ alkanoylamino group, hydroxyl group, mercapto group, cyano group, nitro group and carboxyl group.

21. A compound or pharmacologically acceptable salt thereof according to any one of Claims 1 to 18, wherein Arom is a phenyl group substituted at one or two positions by

substituent(s) which may be the same or different selected from the substituent group α_1 , or a phenyl group substituted at three positions by halogen atoms;

<Substituent group α_1 >

halogen atom, C_1 - C_4 alkyl group, C_1 - C_4 alkyl group substituted by from 1 to 3 fluorine atoms, C_1 - C_4 alkoxy group, C_1 - C_4 alkylthio group, methylenedioxy group, ethylenedioxy group, C_1 - C_4 alkanoyl group, cyano group and nitro group.

22. A compound or pharmacologically acceptable salt thereof according to any one of Claims 1 to 18, wherein Arom is a phenyl group substituted at one or two positions by substituent(s) which may be the same or different selected from the substituent group α_2 , or a phenyl group substituted at three positions by fluorine atoms or chlorine atoms;

<Substituent group α_2 >

fluorine atom, chlorine atom, methyl group, trifluoromethyl group, methoxy group, methylthio group, acetyl group, cyano group and nitro group.

23. A compound or pharmacologically acceptable salt thereof according to any one of Claims 1 to 18, wherein Arom is a phenyl group substituted at one or two positions by substituent(s) which may be the same or different selected from the substituent group α_3 , or a phenyl group substituted at three positions by fluorine atoms;

<Substituent group α_3 >

fluorine atom, chlorine atom, methylthio group, acetyl group, cyano group and nitro group.

24. A compound or pharmacologically acceptable salt thereof according to any one of Claims 1 to 18, wherein Arom is a phenyl group substituted at one or two positions by substituent(s) which may be the same or different selected from the substituent group α_4 , or a phenyl group substituted at three positions by fluorine atoms;

<Substituent group α_4 >

fluorine atom, chlorine atom, methylthio group and nitro group.

25. A compound or pharmacologically acceptable salt thereof according to any one of Claims 1 to 18, wherein Arom is a phenyl group substituted at one position by a fluorine atom, a chlorine atom or a nitro group, or a phenyl group substituted at two positions by fluorine atoms.

26. A compound or pharmacologically acceptable salt thereof according to any one of Claims 1 to 18, wherein Arom is a 4-fluorophenyl group, a 4-chlorophenyl group, a 4-nitrophenyl group or a 3,4-difluorophenyl group.

27. A compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 1 to 26, wherein A is a C_1 - C_4 alkylene group.

28. A compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 1 to 26, wherein A is a methylene group or an ethylene group.

29. A compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 1 to 26, wherein A is an ethylene group.

30. A compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 1 to 29, wherein E is an oxygen atom or a single bond.

31. A compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 1 to 29, wherein E is an oxygen atom.

32. A compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 1 to 31, wherein X^2 is an oxygen atom.

33. A pharmaceutical composition containing a compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 1 to 32.

34. An inhibitor of acetylcholineesterase and selective serotonin reuptake containing a compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 1 to 32.

35. A therapeutic or prophylactic drug for Alzheimer's disease, depression, Huntington's chorea, Pick's disease, tardive dyskinesia, compulsive disorders or panic disorders containing a compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 1 to 32.

36. A therapeutic or prophylactic drug for Alzheimer's disease containing a compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 1 to 32.

SEARCH

Connecting via Winsock to STN

Welcome to STN International! Enter x:

Welcome to STN International! Enter x:

LOGINID:

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *

SESSION RESUMED IN FILE 'STNGUIDE' AT 16:06:47 ON 01 MAR 2004

FILE 'STNGUIDE' ENTERED AT 16:06:47 ON 01 MAR 2004

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE 'CAPLUS' ENTERED AT 16:06:58 ON 01 MAR 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Mar 2004 VOL 140 ISS 10

FILE LAST UPDATED: 29 Feb 2004 (20040229/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> act rogers/a

L10 STR
L11 STR
L12 STR
L13 SCR 1842
L14 (567)SEA FILE=REGISTRY SSS FUL (L10 OR L11 OR L12) NOT L13
L15 (556)SEA FILE=REGISTRY ABB=ON L14/COMP
L16 94 SEA FILE=CAPLUS ABB=ON L15

=> d his

(FILE 'HOME' ENTERED AT 15:32:32 ON 01 MAR 2004)

FILE 'REGISTRY' ENTERED AT 15:32:43 ON 01 MAR 2004

L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 STRUCTURE UPLOADED
L4 SCREEN 1842
L5 1 S (L1 OR L2 OR L3) NOT L4 SSS SAM
L6 567 S (L1 OR L2 OR L3) NOT L4 SSS FULL
L7 556 S L6/COMP

FILE 'CAPLUS' ENTERED AT 15:40:29 ON 01 MAR 2004

L8 94 S L7
SAVE TEMP L8 ROGERS/A

FILE 'STNGUIDE' ENTERED AT 15:48:25 ON 01 MAR 2004
L9 1 S CAPLUS/DBN

FILE 'CAPLUS' ENTERED AT 16:06:58 ON 01 MAR 2004
ACT ROGERS/A

```

-----
L10      STR
L11      STR
L12      STR
L13      SCR 1842
L14 (    567)SEA FILE=REGISTRY SSS FUL (L10 OR L11 OR L12) NOT L13
L15 (    556)SEA FILE=REGISTRY ABB=ON  L14/COMP
L16      94 SEA FILE=CAPLUS ABB=ON  L15
-----

```

=> d scan

```

L16  94 ANSWERS  CAPLUS  COPYRIGHT 2004 ACS on STN
CC  27 (Heterocyclic Compounds (One Hetero Atom))
TI  Tetrahydroisoquinolines. I. Formation and acid-catalyzed
rearrangement
      of 10-acetoxy-6-methoxy-2-methyl-7-oxo- $\delta$ 5,6,8,9-
      hexahydroisoquinolines
ST  rearrangement acetoxy oxo isoquinoline
IT  Pomeranz-Fritsch reaction
      (of N-formyl-N-veratrylglycine)
IT  Rearrangement
      (of acetoxymethoxymethyloxohexahydroisoquinoline derivs., mechanism
of
      acid-catalyzed)
IT  21437-91-2
      RL: RCT (Reactant); RACT (Reactant or reagent)
      (Pomeranz-Fritsch reaction of)
IT  15778-79-7
      RL: RCT (Reactant); RACT (Reactant or reagent)
      (debenzylation of, corypalline from)
IT  450-14-6  19373-80-9  35005-99-3  35006-00-9  35006-01-0
      RL: RCT (Reactant); RACT (Reactant or reagent)
      (oxidation and rearrangement of, by lead tetraacetate)
IT  546-67-8
      RL: RCT (Reactant); RACT (Reactant or reagent)
      (oxidation by, of acetoxymethoxymethyloxohexahydroisoquinoline
derivs.)
IT  4876-18-0P  19373-81-0P  19373-82-1P  19373-83-2P  35005-67-5P
      35006-03-2P  35006-04-3P  35006-05-4P  35006-06-5P
      35006-11-2P  35006-12-3P  35006-13-4P  35035-02-0P  114139-18-3P
      RL: SPN (Synthetic preparation); PREP (Preparation)
      (preparation of)

```

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

Chemical Abstracts Results

=> d BIB HITSTR L16 1

THE ESTIMATED COST FOR THIS REQUEST IS 2.15 BRITISH POUNDS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L16 ANSWER 1 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:728107 CAPLUS Full-text

DN 140:128263

TI A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential

agents for Alzheimer's disease

AU Toda, Narihiro; Tago, Keiko; Marumoto, Shinji; Takami, Kazuko; Ori, Mayuko; Yamada, Naho; Koyama, Kazuo; Naruto, Shunji; Abe, Kazumi; Yamazaki, Reina; Hara, Takao; Aoyagi, Atsushi; Abe, Yasuyuki; Kaneko, Tsugio; Kogen, Hiroshi

CS Exploratory Chemistry Research Laboratories, Sankyo Co., Ltd., Shinagawa-ku, Tokyo, 140-8710, Japan

SO Bioorganic & Medicinal Chemistry (2003), 11(20), 4389-4415
CODEN: BMECEP; ISSN: 0968-0896

PB Elsevier Science Ltd.

DT Journal

LA English

IT 444645-82-3P 444645-86-7P 444645-87-8P

444645-89-0P 444645-94-7P 444645-96-9P

444667-98-5P 649722-12-3P 649722-14-5P

649722-16-7P 649722-18-9P 649722-21-4P

649722-23-6P 649722-25-8P 649722-27-0P

649722-29-2P 649722-31-6P 649722-33-8P

649722-40-7P 649722-61-2P 649722-63-4P

649722-67-8P 649722-69-0P 649722-71-4P

649722-74-7P 649722-76-9P 649722-78-1P

649722-80-5P 649722-82-7P 649722-84-9P

649722-90-7P 649722-94-1P 649722-97-4P

649723-00-2P 649723-04-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of dimethylcarbamic acid 2-methyl-1-[2-(4-nitrophenoxy)ethyl]-


2,3-dihydro-1H-benzo[c]azepin-7-yl ester and related compds. as dual

inhibitors of acetylcholinesterase and serotonin transporter)

RN 444645-82-3 CAPLUS

CN Carbamic acid, dimethyl-, 1,2,3,4-tetrahydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-6-isoquinolinyl ester, monohydrochloride (9CI)

(CA INDEX NAME)




● HCl

RN 444645-86-7 CAPLUS

CN Carbamic acid, dimethyl-, 1-[2-(4-chlorophenoxy)ethyl]-1,2,3,4-tetrahydro-

2-methyl-7-isoquinolinyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 444645-87-8 CAPLUS

CN Carbamic acid, dimethyl-, 2,3-dihydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-

1H-2-benzazepin-7-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




RN 444645-89-0 CAPLUS
 CN Carbamic acid, dimethyl-, 1-[2-(4-chloro-3-methylphenoxy)ethyl]-2,3-dihydro-2-methyl-1H-2-benzazepin-7-yl ester, monohydrochloride (9CI)
 (CA INDEX NAME)



RN 444645-94-7 CAPLUS
 CN Carbamic acid, dimethyl-, (1S)-2,3-dihydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester, monohydrochloride (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 444645-96-9 CAPLUS

CN Carbamic acid, dimethyl-, 1-[2-(4-chloro-3-methylphenoxy)ethyl]-2,3-dihydro-2-methyl-1H-2-benzazepin-6-yl ester, monohydrochloride (9CI)

(CA

INDEX NAME)




RN 444667-98-5 CAPLUS

CN Carbamic acid, dimethyl-, (1R)-2,3-dihydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester, monohydrochloride

(9CI)

(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 649722-12-3 CAPLUS

CN Carbamic acid, dimethyl-, 1,2,3,4-tetrahydro-1-[2-(4-nitrophenoxy)ethyl]-6-


isoquinolinyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 649722-14-5 CAPLUS


CN Carbamic acid, dimethyl-, 1-[2-(4-chlorophenoxy)ethyl]-1,2,3,4-tetrahydro-6-isoquinolinyloxy ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 649722-16-7 CAPLUS

CN Carbamic acid, dimethyl-, 1,2,3,4-tetrahydro-1-[2-(4-nitrophenoxy)ethyl]-7-isoquinolinyloxy ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 649722-18-9 CAPLUS

CN Carbamic acid, dimethyl-, 1-[2-(4-chlorophenoxy)ethyl]-1,2,3,4-tetrahydro-

7-isoquinolinyloxy ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 649722-21-4 CAPLUS


CN Carbamic acid, dimethyl-, 1-[2-(4-chlorophenoxy)ethyl]-1,2,3,4-tetrahydro-

2-methyl-6-isoquinolinyloxy ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 649722-23-6 CAPLUS
 CN Carbamic acid, dimethyl-, 1,2,3,4-tetrahydro-2-methyl-1-[2-(3-methyl-4-nitrophenoxy)ethyl]-6-isoquinolinyl ester, monohydrochloride (9CI)
 (CA INDEX NAME)



● HCl

RN 649722-25-8 CAPLUS
 CN Carbamic acid, dimethyl-, 1,2,3,4-tetrahydro-2-methyl-1-[2-(3-nitrophenoxy)ethyl]-6-isoquinolinyl ester, monohydrochloride (9CI)
 (CA INDEX NAME)




● HCl

RN 649722-27-0 CAPLUS

CN Carbamic acid, dimethyl-, 1-[2-(4-fluorophenoxy)ethyl]-1,2,3,4-tetrahydro-

2-methyl-6-isoquinolinyloxydimethylcarbamate monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 649722-29-2 CAPLUS

CN Carbamic acid, dimethyl-, 1-[2-(4-bromophenoxy)ethyl]-1,2,3,4-tetrahydro-2-


methyl-6-isoquinolinyloxydimethylcarbamate monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 649722-31-6 CAPLUS


CN Carbamic acid, dimethyl-, 1,2,3,4-tetrahydro-1-[2-(4-methoxyphenoxy)ethyl]-2-methyl-6-isoquinolinyldimethylcarbamate, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 649722-33-8 CAPLUS


CN Carbamic acid, dimethyl-, 1,2,3,4-tetrahydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-7-isoquinolinyldimethylcarbamate, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 649722-40-7 CAPLUS


CN Carbamic acid, dimethyl-, 1,2,3,4-tetrahydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-5-isoquinolinyl ester, monohydrochloride (9CI)

(CA
INDEX NAME)

● HCl


RN 649722-61-2 CAPLUS

CN Carbamic acid, dimethyl-, 2,3-dihydro-1-[2-(4-nitrophenoxy)ethyl]-1H-
2-benzazepin-7-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




RN 649722-63-4 CAPLUS

CN Carbamic acid, dimethyl-, 1-[2-(4-chloro-3-methylphenoxy)ethyl]-2,3-dihydro-1H-2-benzazepin-7-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




RN 649722-67-8 CAPLUS

CN Carbamic acid, dimethyl-, 1-[2-(4-chlorophenoxy)ethyl]-2,3-dihydro-2-methyl-1H-2-benzazepin-7-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




RN 649722-69-0 CAPLUS

CN Carbamic acid, dimethyl-, 1-[2-(4-fluorophenoxy)ethyl]-2,3-dihydro-2-methyl-1H-2-benzazepin-7-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




RN 649722-71-4 CAPLUS

CN Carbamic acid, dimethyl-, 2,3-dihydro-2-methyl-1-[2-[4-(trifluoromethyl)phenoxy]ethyl]-1H-2-benzazepin-7-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



RN 649722-74-7 CAPLUS


CN Carbamic acid, dimethyl-, 2,3-dihydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-8-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 649722-76-9 CAPLUS


CN Carbamic acid, dimethyl-, 1-[2-(4-chlorophenoxy)ethyl]-2,3-dihydro-2-methyl-1H-2-benzazepin-8-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 649722-78-1 CAPLUS


CN Carbamic acid, dimethyl-, 2,3,4,5-tetrahydro-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 649722-80-5 CAPLUS


CN Carbamic acid, dimethyl-, 1-[2-(4-chlorophenoxy)ethyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-7-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 649722-82-7 CAPLUS

CN Carbamic acid, dimethyl-, 2,3,4,5-tetrahydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




RN 649722-84-9 CAPLUS

CN Carbamic acid, dimethyl-, 1-[2-(4-chlorophenoxy)ethyl]-2,3,4,5-tetrahydro-

2-methyl-1H-2-benzazepin-7-yl ester, monohydrochloride (9CI) (CA

INDEX
NAME)




RN 649722-90-7 CAPLUS

CN Carbamic acid, dimethyl-, 2,3,4,5-tetrahydro-2-methyl-5-methylene-1-[2-(4-

nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester, monohydrochloride (9CI)


(CA INDEX NAME)



RN 649722-94-1 CAPLUS

CN Carbamic acid, dimethyl-, 2,3-dihydro-2,5-dimethyl-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester, monohydrochloride
(9CI)


(CA INDEX NAME)



RN 649722-97-4 CAPLUS


CN Carbamic acid, dimethyl-, 5-ethenyl-2,3-dihydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester, monohydrochloride
(9CI)

(CA INDEX NAME)



RN 649723-00-2 CAPLUS


CN Carbamic acid, dimethyl-, 2,3-dihydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-5-(2-thienyl)-1H-2-benzazepin-7-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



RN 649723-04-6 CAPLUS

CN Carbamic acid, dimethyl-, 5-(4-chlorophenyl)-2,3-dihydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

NO₂

● HCl

IT 474295-96-0P 474295-97-1P 474295-98-2P
 474295-99-3P 474296-00-9P 474296-01-0P
 474296-05-4P 474296-07-6P 649722-11-2P
 649722-13-4P 649722-15-6P 649722-17-8P
 649722-86-1P 649722-87-2P 649722-88-3P
 649722-89-4P 649722-91-8P 649722-92-9P
 649722-95-2P 649722-98-5P 649723-01-3P
 649723-02-4P 649723-07-9P 649723-08-0P
 649723-09-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
 RACT


(Reactant or reagent)
 (preparation of dimethylcarbamic acid 2-methyl-1-[2-(4-nitrophenoxy)ethyl]-
 2,3-dihydro-1H-benzo[c]azepin-7-yl ester and related compds. as
 dual
 inhibitors of acetylcholinesterase and serotonin transporter)

RN 474295-96-0 CAPLUS

CN Carbamic acid, dimethyl-, 4-[(1R)-1-[[[(1,1-dimethylethoxy)carbonyl]amino]-
 3-(4-nitrophenoxy)propyl]-3-(methoxymethoxy)phenyl ester (9CI) (CA

INDEX
 NAME)


Absolute stereochemistry.



RN 474295-97-1 CAPLUS

CN Carbamic acid, dimethyl-, 4-[(1R)-1-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-nitrophenoxy)propyl]-3-hydroxyphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 474295-98-2 CAPLUS

CN Carbamic acid, dimethyl-, 4-[(1R)-1-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-nitrophenoxy)propyl]-3-ethenylphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 474295-99-3 CAPLUS

CN Carbamic acid, dimethyl-, 4-[(1R)-1-[[[(1,1-dimethylethoxy)carbonyl]-2-propenylamino]-3-(4-nitrophenoxy)propyl]-3-ethenylphenyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 474296-00-9 CAPLUS


CN 2H-2-Benzazepine-2-carboxylic acid, 7-[[[(dimethylamino)carbonyl]oxy]-1,3-

dihydro-1-[2-(4-nitrophenoxy)ethyl]-, 1,1-dimethylethyl ester, (1R)-

(9CI)

(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 474296-01-0 CAPLUS

CN Carbamic acid, dimethyl-, (1R)-2,3-dihydro-1-[2-(4-nitrophenoxy)ethyl]-1H-

2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 474296-05-4 CAPLUS

CN Methanesulfonic acid, trifluoro-, 5-[[[(dimethylamino)carbonyl]oxy]-2-[(1R)-

1-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-nitrophenoxy)propyl]phenyl

ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474296-07-6 CAPLUS


CN Carbamic acid, dimethyl-, 4-[(1R)-1-amino-3-(4-nitrophenoxy)propyl]-3-hydroxyphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 649722-11-2 CAPLUS

CN Carbamic acid, dimethyl-, 1,2,3,4-tetrahydro-1-[2-(4-nitrophenoxy)ethyl]-6-isoquinolinyl ester (9CI) (CA INDEX NAME)




RN 649722-13-4 CAPLUS

CN Carbamic acid, dimethyl-, 1-[2-(4-chlorophenoxy)ethyl]-1,2,3,4-tetrahydro-6-isoquinolinyl ester (9CI) (CA INDEX NAME)




RN 649722-15-6 CAPLUS

CN Carbamic acid, dimethyl-, 1,2,3,4-tetrahydro-1-[2-(4-nitrophenoxy)ethyl]-7-isoquinolinyl ester (9CI) (CA INDEX NAME)



RN 649722-17-8 CAPLUS


CN Carbamic acid, dimethyl-, 1-[2-(4-chlorophenoxy)ethyl]-1,2,3,4-tetrahydro-7-isoquinolinyl ester (9CI) (CA INDEX NAME)



RN 649722-86-1 CAPLUS


CN Carbamic acid, dimethyl-, 2,3,4,5-tetrahydro-1-[2-(4-nitrophenoxy)ethyl]-5-nitrophenyl ester (9CI) (CA INDEX NAME)

oxo-1H-2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)




RN 649722-87-2 CAPLUS

CN 2H-2-Benzazepine-2-carboxylic acid, 7-[[[(dimethylamino)carbonyl]oxy]-1,3,4,5-tetrahydro-1-[2-(4-nitrophenoxy)ethyl]-5-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 649722-88-3 CAPLUS

CN 2H-2-Benzazepine-2-carboxylic acid, 7-[[[(dimethylamino)carbonyl]oxy]-1,3,4,5-tetrahydro-5-methylene-1-[2-(4-nitrophenoxy)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 649722-89-4 CAPLUS

CN Carbamic acid, dimethyl-, 2,3,4,5-tetrahydro-2-methyl-5-methylene-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)




RN 649722-91-8 CAPLUS


CN 2H-2-Benzazepine-2-carboxylic acid, 7-[[[(dimethylamino)carbonyl]oxy]-1,3-dihydro-1-[2-(4-nitrophenoxy)ethyl]-5-[[[(trifluoromethyl)sulfonyl]oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 649722-92-9 CAPLUS
 CN 2H-2-Benzazepine-2-carboxylic acid, 7-[[[(dimethylamino)carbonyl]oxy]-
 1,3-
 dihydro-5-methyl-1-[2-(4-nitrophenoxy)ethyl]-, 1,1-dimethylethyl ester
 (9CI) (CA INDEX NAME)




RN 649722-95-2 CAPLUS
 CN 2H-2-Benzazepine-2-carboxylic acid, 7-[[[(dimethylamino)carbonyl]oxy]-
 5-
 ethenyl-1,3-dihydro-1-[2-(4-nitrophenoxy)ethyl]-, 1,1-dimethylethyl
 ester
 (9CI) (CA INDEX NAME)



RN 649722-98-5 CAPLUS


CN 2H-2-Benzazepine-2-carboxylic acid, 7-[[[(dimethylamino)carbonyl]oxy]-1,3-dihydro-1-[2-(4-nitrophenoxy)ethyl]-5-(2-thienyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 649723-01-3 CAPLUS

CN 2H-2-Benzazepine-2-carboxylic acid, 5-(4-chlorophenyl)-7-[[[(dimethylamino)carbonyl]oxy]-1,3-dihydro-1-[2-(4-nitrophenoxy)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 649723-02-4 CAPLUS

CN Carbamic acid, dimethyl-, 5-(4-chlorophenyl)-2,3-dihydro-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)


PAGE 1-A






RN 649723-07-9 CAPLUS

CN Carbamic acid, dimethyl-, 2,3-dihydro-5-methyl-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)




RN 649723-08-0 CAPLUS

CN Carbamic acid, dimethyl-, 5-ethenyl-2,3-dihydro-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)



RN 649723-09-1 CAPLUS

CN Carbamic acid, dimethyl-, 2,3-dihydro-1-[2-(4-nitrophenoxy)ethyl]-5-(2-thienyl)-1H-2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)



IT 474296-02-1P 649722-19-0P 649722-20-3P
 649722-22-5P 649722-24-7P 649722-26-9P
 649722-28-1P 649722-30-5P 649722-32-7P
 649722-34-9P 649722-39-4P 649722-60-1P
 649722-62-3P 649722-64-5P 649722-65-6P
 649722-66-7P 649722-68-9P 649722-70-3P
 649722-72-5P 649722-73-6P 649722-75-8P
 649722-77-0P 649722-79-2P 649722-81-6P
 649722-83-8P 649722-93-0P 649722-96-3P
 649722-99-6P 649723-03-5P


RL: SPN (Synthetic preparation); PREP (Preparation).
 (preparation of dimethylcarbamic acid 2-methyl-1-[2-(4-nitrophenoxy)ethyl]-
 2,3-dihydro-1H-benzo[c]azepin-7-yl ester and related compds. as
 dual

inhibitors of acetylcholinesterase and serotonin transporter)

RN 474296-02-1 CAPLUS


CN Carbamic acid, dimethyl-, (1R)-2,3-dihydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 649722-19-0 CAPLUS

CN Carbamic acid, dimethyl-, 1,2,3,4-tetrahydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-6-isoquinolinyl ester (9CI) (CA INDEX NAME)




RN 649722-20-3 CAPLUS

CN Carbamic acid, dimethyl-, 1-[2-(4-chlorophenoxy)ethyl]-1,2,3,4-tetrahydro-2-methyl-6-isoquinolinyloxy ester (9CI) (CA INDEX NAME)




RN 649722-22-5 CAPLUS

CN Carbamic acid, dimethyl-, 1,2,3,4-tetrahydro-2-methyl-1-[2-(3-methyl-4-nitrophenoxy)ethyl]-6-isoquinolinyloxy ester (9CI) (CA INDEX NAME)




RN 649722-24-7 CAPLUS

CN Carbamic acid, dimethyl-, 1,2,3,4-tetrahydro-2-methyl-1-[2-(3-nitrophenoxy)ethyl]-6-isoquinolinyl ester (9CI) (CA INDEX NAME)




RN 649722-26-9 CAPLUS

CN Carbamic acid, dimethyl-, 1-[2-(4-fluorophenoxy)ethyl]-1,2,3,4-tetrahydro-2-methyl-6-isoquinolinyl ester (9CI) (CA INDEX NAME)




RN 649722-28-1 CAPLUS

CN Carbamic acid, dimethyl-, 1-[2-(4-bromophenoxy)ethyl]-1,2,3,4-tetrahydro-2-methyl-6-isoquinolinyl ester (9CI) (CA INDEX NAME)




RN 649722-30-5 CAPLUS

CN Carbamic acid, dimethyl-, 1,2,3,4-tetrahydro-1-[2-(4-methoxyphenoxy)ethyl]-2-methyl-6-isoquinolinyl ester (9CI) (CA INDEX NAME)




RN 649722-32-7 CAPLUS

CN Carbamic acid, dimethyl-, 1,2,3,4-tetrahydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-7-isoquinolinyl ester (9CI) (CA INDEX NAME)




RN 649722-34-9 CAPLUS

CN Carbamic acid, dimethyl-, 1-[2-(4-chlorophenoxy)ethyl]-1,2,3,4-tetrahydro-2-methyl-7-isoquinolinyl ester (9CI) (CA INDEX NAME)




RN 649722-39-4 CAPLUS

CN Carbamic acid, dimethyl-, 1,2,3,4-tetrahydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-5-isoquinolinyl ester (9CI) (CA INDEX NAME)




RN 649722-60-1 CAPLUS

CN Carbamic acid, dimethyl-, 2,3-dihydro-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)




RN 649722-62-3 CAPLUS

CN Carbamic acid, dimethyl-, 1-[2-(4-chloro-3-methylphenoxy)ethyl]-2,3-dihydro-1H-2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)




RN 649722-64-5 CAPLUS

CN Carbamic acid, dimethyl-, 2,3-dihydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)




RN 649722-65-6 CAPLUS

CN Carbamic acid, dimethyl-, 1-[2-(4-chloro-3-methylphenoxy)ethyl]-2,3-dihydro-2-methyl-1H-2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)




RN 649722-66-7 CAPLUS

CN Carbamic acid, dimethyl-, 1-[2-(4-chlorophenoxy)ethyl]-2,3-dihydro-2-methyl-1H-2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)




RN 649722-68-9 CAPLUS

CN Carbamic acid, dimethyl-, 1-[2-(4-fluorophenoxy)ethyl]-2,3-dihydro-2-methyl-1H-2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)




RN 649722-70-3 CAPLUS

CN Carbamic acid, dimethyl-, 2,3-dihydro-2-methyl-1-[2-[4-(trifluoromethyl)phenoxy]ethyl]-1H-2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)




RN 649722-72-5 CAPLUS

CN Carbamic acid, dimethyl-, 1-[2-(4-chloro-3-methylphenoxy)ethyl]-2,3-dihydro-2-methyl-1H-2-benzazepin-6-yl ester (9CI) (CA INDEX NAME)




RN 649722-73-6 CAPLUS

CN Carbamic acid, dimethyl-, 2,3-dihydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-8-yl ester (9CI) (CA INDEX NAME)




RN 649722-75-8 CAPLUS

CN Carbamic acid, dimethyl-, 1-[2-(4-chlorophenoxy)ethyl]-2,3-dihydro-2-methyl-1H-2-benzazepin-8-yl ester (9CI) (CA INDEX NAME)




RN 649722-77-0 CAPLUS

CN Carbamic acid, dimethyl-, 2,3,4,5-tetrahydro-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)




RN 649722-79-2 CAPLUS


CN Carbamic acid, dimethyl-, 1-[2-(4-chlorophenoxy)ethyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)



RN 649722-81-6 CAPLUS
CN Carbamic acid, dimethyl-, 2,3,4,5-tetrahydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)




RN 649722-83-8 CAPLUS
CN Carbamic acid, dimethyl-, 1-[2-(4-chlorophenoxy)ethyl]-2,3,4,5-tetrahydro-2-methyl-1H-2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)




RN 649722-93-0 CAPLUS

CN Carbamic acid, dimethyl-, 2,3-dihydro-2,5-dimethyl-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)




RN 649722-96-3 CAPLUS

CN Carbamic acid, dimethyl-, 5-ethenyl-2,3-dihydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)




RN 649722-99-6 CAPLUS
 CN Carbamic acid, dimethyl-, 2,3-dihydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-5-(2-thienyl)-1H-2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)



RN 649723-03-5 CAPLUS
 CN Carbamic acid, dimethyl-, 5-(4-chlorophenyl)-2,3-dihydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

NO₂

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d BIB HITSTR L16 2

THE ESTIMATED COST FOR THIS REQUEST IS 2.15 BRITISH POUNDS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L16 ANSWER 2 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:251390 CAPLUS Full-text

DN 139:173164

TI Design, synthesis and structure-Activity relationships of dual
inhibitors
of acetylcholinesterase and serotonin transporter as potential agents
for

Alzheimer's disease

AU Toda, Narihiro; Tago, Keiko; Marumoto, Shinji; Takami, Kazuko; Ori,
Mayuko; Yamada, Naho; Koyama, Kazuo; Naruto, Shunji; Abe, Kazumi;
Yamazaki, Reina; Hara, Takao; Aoyagi, Atsushi; Abe, Yasuyuki; Kaneko,
Tsugio; Kogen, Hiroshi

CS Exploratory Chemistry Research Laboratories, Sankyo Co., Ltd.,
Shinagawa-ku, Tokyo, 140-8710, Japan

SO Bioorganic & Medicinal Chemistry (2003), 11(9), 1935-1955
CODEN: BMECEP; ISSN: 0968-0896

PB Elsevier Science Ltd.

DT Journal

LA English

IT 444644-04-6P 444644-05-7P 444644-06-8P

444644-07-9P 444644-08-0P 444644-13-7P

444644-14-8P 444644-15-9P 444644-26-2P

444644-36-4P 444644-44-4P 444644-49-9P

444644-52-4P 444644-62-6P 444644-63-7P

444644-85-3P 444644-90-0P 444645-11-8P

444645-12-9P 444645-16-3P 444645-31-2P

444645-32-3P 444645-47-0P 444645-58-3P

444667-96-3P 474295-89-1P 578729-98-3P

578729-99-4P 578730-07-1P 578730-08-2P

578730-09-3P 578730-10-6P 578730-16-2P

578730-17-3P 578730-18-4P 578730-19-5P

578730-20-8P 578730-21-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(design, synthesis and structure-Activity relationships of dual
inhibitors of acetylcholinesterase and serotonin transporter as
potential agents for Alzheimer's disease)

RN 444644-04-6 CAPLUS

CN Carbamic acid, dimethyl-, 3-[1-(methylamino)-3-[4-
(trifluoromethyl)phenoxy]propyl]phenyl ester, monohydrochloride (9CI)


(CA
INDEX NAME)



● HCl

RN 444644-05-7 CAPLUS


CN Carbamic acid, dimethyl-, 3-[3-(4-methoxyphenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-06-8 CAPLUS


CN Carbamic acid, dimethyl-, 3-[1-(methylamino)-3-(4-methylphenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-07-9 CAPLUS


CN Carbamic acid, dimethyl-, 3-[3-(4-chlorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 444644-08-0 CAPLUS

CN Carbamic acid, dimethyl-, 3-[3-(4-fluorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444644-13-7 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[3-(4-chlorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444644-14-8 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-[4-(trifluoromethyl)phenoxy]propyl]phenyl ester, monohydrochloride (9CI)
 (CA INDEX NAME)



● HCl


RN 444644-15-9 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[3-(4-methoxyphenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-26-2 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-(4-fluorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-36-4 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-(4-methylphenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-44-4 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-(4-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-49-9 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-(3-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-52-4 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-(4-cyanophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-62-6 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-(2-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-63-7 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-phenoxypropyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-85-3 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(dimethylamino)-3-(4-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-90-0 CAPLUS


CN Carbamic acid, dimethyl-, 3-[1-(methylamino)-3-(4-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-11-8 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-4-(4-nitrophenoxy)butyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-12-9 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-2-(4-nitrophenoxy)ethyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-16-3 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-(4-nitrophenyl)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-31-2 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(ethylamino)-3-(4-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 444645-32-3 CAPLUS

CN Carbamic acid, dimethyl-, 4-[1-(ethylmethylamino)-3-(4-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 444645-47-0 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-[(4-nitrophenyl)thio]propyl]phenyl ester (9CI) (CA INDEX NAME)



● HCl


RN 444645-58-3 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[(1S)-3-(4-chlorophenoxy)-1-(methylamino)propyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444667-96-3 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[(1S)-1-(methylamino)-3-(4-nitrophenoxy)propyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 474295-89-1 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[(1R)-1-(methylamino)-3-(4-nitrophenoxy)propyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 578729-98-3 CAPLUS
 CN Phenol, 4-[1-(methylamino)-3-(4-nitrophenoxy)propyl]-, methylcarbamate (ester), monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 578729-99-4 CAPLUS
 CN Carbamic acid, ethyl-, 4-[1-(methylamino)-3-(4-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 578730-07-1 CAPLUS
 CN Benzenemethanaminium, 4-[[dimethylamino]carbonyloxy]-N,N,N-trimethyl- α -[2-(4-nitrophenoxy)ethyl]-, iodide (9CI) (CA INDEX NAME)




● I⁻

RN 578730-08-2 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[3-(4-nitrophenoxy)-1-(1-


pyrrolidiny]propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




RN 578730-09-3 CAPLUS
CN Carbamic acid, dimethyl-, 4-[3-(4-nitrophenoxy)-1-(1-piperazinyl)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



RN 578730-10-6 CAPLUS
CN Carbamic acid, dimethyl-, 4-[1-(4-morpholinyl)-3-(4-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




RN 578730-16-2 CAPLUS
CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-[(4-nitrophenyl)amino]propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 578730-17-3 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-[acetyl(4-nitrophenyl)amino]-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 578730-18-4 CAPLUS

CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-(4-nitrophenyl)propyl]phenyl ester (9CI) (CA INDEX NAME)



RN 578730-19-5 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-(4-chlorophenoxy)-1-(methylamino)propyl]phenyl ester (9CI) (CA INDEX NAME)




RN 578730-20-8 CAPLUS

CN Carbamic acid, dimethyl-, 4-[(1R)-3-(4-chlorophenoxy)-1-(methylamino)propyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 578730-21-9 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-(4-nitrophenoxy)propyl]phenyl ester (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d BIB HITSTR L16 3-94

THE ESTIMATED COST FOR THIS REQUEST IS 198.03 BRITISH POUNDS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L16 ANSWER 3 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:163990 CAPLUS Full-text
 DN 139:350659
 TI Chemoselective oxidation of 3-acetyl-2,3-dihydrobenzothiazoles by dimethyldioxirane
 AU Levai, Albert; Jeko, Jozsef
 CS Department of Organic Chemistry, University of Debrecen, Debrecen, H-4010, Hung.
 SO ARKIVOC (Gainesville, FL, United States) (2003), (5), 19-27
 CODEN: AGFUAR
 URL: <http://www.arkat-usa.org/ark/journal/2003/Bernath/GB-642J/642J.pdf>
 PB Arkat USA Inc.
 DT Journal; (online computer file)
 LA English
 IT **191017-21-7 191017-23-9**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (ring contraction of dihydrobenzothiazoles by acetic anhydride and oxidation with dimethyldioxirane)
 RN 191017-21-7 CAPLUS
 CN Benzothiazole, 3-acetyl-2-[4-(acetyloxy)phenyl]-2,3-dihydro-2-[(1E)-2-phenylethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 191017-23-9 CAPLUS

CN Benzothiazole, 3-acetyl-2-[2-(acetyloxy)phenyl]-2,3-dihydro-2-[(1E)-2-phenylethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 618113-97-6P 618114-01-5P 618114-02-6P

618114-03-7P 618114-04-8P 618114-05-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT


(Reactant or reagent)

(ring contraction of dihydrobenzothiazoles by acetic anhydride and oxidation with dimethyldioxirane)

RN 618113-97-6 CAPLUS

CN Benzothiazole, 3-acetyl-2-[2-(acetyloxy)phenyl]-2,3-dihydro-2-[(1E)-2-(4-(1-methylethyl)phenyl)ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 618114-01-5 CAPLUS

CN Benzothiazole, 3-acetyl-2-[2-(acetyloxy)phenyl]-2-[(1E)-2-(3-chlorophenyl)ethenyl]-2,3-dihydro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 618114-02-6 CAPLUS

CN Benzothiazole, 3-acetyl-2-[2-(acetyloxy)phenyl]-2-[(1E)-2-(4-chlorophenyl)ethenyl]-2,3-dihydro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 618114-03-7 CAPLUS

CN Benzothiazole, 3-acetyl-2-[2-(acetyloxy)phenyl]-2-[(1E)-2-(2,4-dichlorophenyl)ethenyl]-2,3-dihydro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 618114-04-8 CAPLUS


CN Benzothiazole, 3-acetyl-2-[2-(acetyloxy)phenyl]-2-[(1E)-2-(3,4-dichlorophenyl)ethenyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 618114-05-9 CAPLUS
 CN Benzothiazole, 3-acetyl-2-[4-(acetyloxy)phenyl]-2-[(1E)-2-(4-chlorophenyl)ethenyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 618113-98-7P 618113-99-8P 618114-00-4P
 618114-09-3P 618114-10-6P 618114-12-8P
 618114-13-9P 618114-14-0P 618114-15-1P
 618114-16-2P 618114-17-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (ring contraction of dihydrobenzothiazoles by acetic anhydride and
 oxidation with dimethyldioxirane)
 RN 618113-98-7 CAPLUS
 CN Benzothiazole, 3-acetyl-2-[2-(acetyloxy)phenyl]-2,3-dihydro-2-[(1E)-2-(2-methoxyphenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 618113-99-8 CAPLUS
 CN Benzothiazole, 3-acetyl-2-[2-(acetyloxy)phenyl]-2,3-dihydro-2-[(1E)-2-(3,4,5-trimethoxyphenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 618114-00-4 CAPLUS
CN Benzothiazole, 3-acetyl-2-[2-(acetyloxy)phenyl]-2-[(1E)-2-(2-chlorophenyl)ethenyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 618114-09-3 CAPLUS
CN Benzothiazole, 3-acetyl-2-[2-(acetyloxy)phenyl]-2,3-dihydro-2-[(1E)-2-phenylethenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 618114-10-6 CAPLUS
CN Benzothiazole, 3-acetyl-2-[4-(acetyloxy)phenyl]-2,3-dihydro-2-[(1E)-2-phenylethenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 618114-12-8 CAPLUS
 CN Benzothiazole, 3-acetyl-2-[2-(acetyloxy)phenyl]-2,3-dihydro-2-[(1E)-2-[4-(1-methylethyl)phenyl]ethenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 618114-13-9 CAPLUS
 CN Benzothiazole, 3-acetyl-2-[2-(acetyloxy)phenyl]-2-[(1E)-2-(3-chlorophenyl)ethenyl]-2,3-dihydro-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 618114-14-0 CAPLUS
 CN Benzothiazole, 3-acetyl-2-[2-(acetyloxy)phenyl]-2-[(1E)-2-(4-chlorophenyl)ethenyl]-2,3-dihydro-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 618114-15-1 CAPLUS
 CN Benzothiazole, 3-acetyl-2-[2-(acetyloxy)phenyl]-2-[(1E)-2-(2,4-dichlorophenyl)ethenyl]-2,3-dihydro-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 618114-16-2 CAPLUS
 CN Benzothiazole, 3-acetyl-2-[2-(acetyloxy)phenyl]-2-[(1E)-2-(3,4-dichlorophenyl)ethenyl]-2,3-dihydro-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 618114-17-3 CAPLUS
 CN Benzothiazole, 3-acetyl-2-[4-(acetyloxy)phenyl]-2-[(1E)-2-(4-chlorophenyl)ethenyl]-2,3-dihydro-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:667576 CAPLUS Full-text
DN 137:337771
TI Design and Synthesis of Dual Inhibitors of Acetylcholinesterase and Serotonin Transporter Targeting Potential Agents for Alzheimer's Disease
AU Kogen, Hiroshi; Toda, Narihiro; Tago, Keiko; Marumoto, Shinji; Takami, Kazuko; Ori, Mayuko; Yamada, Naho; Koyama, Kazuo; Naruto, Shunji; Abe, Kazumi; Yamazaki, Reina; Hara, Takao; Aoyagi, Atsushi; Abe, Yasuyuki; Kaneko, Tsugio
CS Research Information Department, Exploratory Chemistry Research Laboratories, Neuroscience and Immunology Research Laboratories, Sankyo Co., Ltd., Shinagawa-ku, Tokyo, 140-8710, Japan
SO Organic Letters (2002), 4(20), 3359-3362
CODEN: ORLEF7; ISSN: 1523-7060
PB American Chemical Society
DT Journal
LA English
IT **474296-05-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
RACT
(Reactant or reagent)
(determination of absolute stereochem. of
(dimethylcarbamoyl)(nitrophenoxyethyl)benzylamine, prepared as dual acetylcholinesterase/serotonin transporter inhibitor for Alzheimer's disease)
RN 474296-05-4 CAPLUS
CN Methanesulfonic acid, trifluoro-, 5-[[[(dimethylamino)carbonyl]oxy]-2-[(1R)-1-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-nitrophenoxy)propyl]phenyl]ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 444644-93-3P 444667-98-5P 474295-89-1P
474296-03-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)
(preparation of chiral
(dimethylcarbamoyl)(nitrophenoxyethyl)benzylamine and
(dimethylcarbamoyl)(nitrophenoxyethyl)dihydrobenzazepine as dual
acetylcholinesterase/serotonin transporter inhibitors for
Alzheimer's
disease)

RN 444644-93-3 CAPLUS

CN Carbamic acid, dimethyl-, 4-[(1S)-1-(methylamino)-3-(4-
nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




● HCl

RN 444667-98-5 CAPLUS

CN Carbamic acid, dimethyl-, (1R)-2,3-dihydro-2-methyl-1-[2-(4-
nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester, monohydrochloride
(9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 474295-89-1 CAPLUS

CN Carbamic acid, dimethyl-, 4-[(1R)-1-(methylamino)-3-(4-
nitrophenoxy)propyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474296-03-2 CAPLUS

CN Carbamic acid, dimethyl-, (1S)-2,3-dihydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 474296-04-3


RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of chiral

(dimethylcarbamoyl)(nitrophenoxyethyl)benzylamine and
(dimethylcarbamoyl)(nitrophenoxyethyl)dihydrobenzazepine as dual
acetylcholinesterase/serotonin transporter inhibitors for
Alzheimer's
disease)

RN 474296-04-3 CAPLUS

CN Carbamic acid, dimethyl-, (1S)-2,3-dihydro-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 444646-39-3P 444646-40-6P 444667-96-3P
474295-88-0P 474295-90-4P 474295-96-0P
474295-97-1P 474295-98-2P 474295-99-3P
474296-00-9P 474296-01-0P 474296-02-1P
474296-07-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT


(Reactant or reagent)
(preparation of chiral

(dimethylcarbamoyl)(nitrophenoxyethyl)benzylamine and
 (dimethylcarbamoyl)(nitrophenoxyethyl)dihydrobenzazepine as dual
 acetylcholinesterase/serotonin transporter inhibitors for
 Alzheimer's
 disease)

RN 444646-39-3 CAPLUS

CN Carbamic acid, dimethyl-, 4-[(1S)-1-[[[(1,1-dimethylethoxy)carbonyl]methylamino]-3-(4-nitrophenoxy)propyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 444646-40-6 CAPLUS

CN Carbamic acid, dimethyl-, 4-[(1R)-1-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-nitrophenoxy)propyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 444667-96-3 CAPLUS

CN Carbamic acid, dimethyl-, 4-[(1S)-1-(methylamino)-3-(4-nitrophenoxy)propyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474295-88-0 CAPLUS


CN Carbamic acid, dimethyl-, 4-[(1S)-1-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-nitrophenoxy)propyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 474295-90-4 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[(1R)-1-[[[(1,1-dimethylethoxy)carbonyl]methylamino]-3-(4-nitrophenoxy)propyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 474295-96-0 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[(1R)-1-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-nitrophenoxy)propyl]-3-(methoxymethoxy)phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474295-97-1 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[(1R)-1-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-nitrophenoxy)propyl]-3-hydroxyphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 474295-98-2 CAPLUS

CN Carbamic acid, dimethyl-, 4-[(1R)-1-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-nitrophenoxy)propyl]-3-ethenylphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 474295-99-3 CAPLUS

CN Carbamic acid, dimethyl-, 4-[(1R)-1-[[[(1,1-dimethylethoxy)carbonyl]-2-propenylamino]-3-(4-nitrophenoxy)propyl]-3-ethenylphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 474296-00-9 CAPLUS

CN 2H-2-Benzazepine-2-carboxylic acid, 7-[[[(dimethylamino)carbonyl]oxy]-1,3-dihydro-1-[2-(4-nitrophenoxy)ethyl]-, 1,1-dimethylethyl ester, (1R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 474296-01-0 CAPLUS

CN Carbamic acid, dimethyl-, (1R)-2,3-dihydro-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 474296-02-1 CAPLUS

CN Carbamic acid, dimethyl-, (1R)-2,3-dihydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 474296-07-6 CAPLUS

CN Carbamic acid, dimethyl-, 4-[(1R)-1-amino-3-(4-nitrophenoxy)propyl]-3-hydroxyphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 5 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:575038 CAPLUS Full-text

DN 137:140527

TI Preparation of alkylcarbamic acid esters as acetylcholinesterase inhibitor

and serotonin reuptake inhibitor

IN Koyama, Kazuo; Marumoto, Shinji; Toda, Narihiro; Kogen, Hiroshi; Suzuki,

Keiko

PA Sankyo Company, Limited, Japan

SO PCT Int. Appl., 300 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002059074	A1	20020801	WO 2002-JP400	20020122
PL,	W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PH,				
	RU, SG, SK, US, VN, ZA				
NL,	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,				
	PT, SE, TR				
PT,	EP 1362844	A1	20031119	EP 2002-716323	20020122
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,				
	IE, FI, CY, TR				
	JP 2003176256	A2	20030624	JP 2002-15136	20020124
PRAI	JP 2001-18386	A	20010126		
	JP 2001-305182	A	20011001		
	WO 2002-JP400	W	20020122		

OS MARPAT 137:140527

IT 444643-92-9P 444644-03-5P 444644-07-9P
444644-26-2P 444644-76-2P 444644-78-4P
444644-93-3P 444645-18-5P 444645-22-1P
444645-29-8P 444645-33-4P 444645-35-6P
444645-37-8P 444645-38-9P 444645-40-3P
444645-41-4P 444645-45-8P 444645-47-0P
444645-49-2P 444645-51-6P 444645-54-9P
444645-56-1P 444645-62-9P 444645-64-1P
444645-66-3P 444645-69-6P 444645-73-2P
444645-78-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(preparation of alkylcarbamic acid esters as acetylcholinesterase inhibitor)

RN 444643-92-9 CAPLUS

CN Carbamic acid, dimethyl-, 3-[3-(4-methoxyphenyl)-1-


(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX

NAME)




● HCl

RN 444644-03-5 CAPLUS
 CN Carbamic acid, ethyl-, 3-[3-(4-methoxyphenyl)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444644-07-9 CAPLUS
 CN Carbamic acid, dimethyl-, 3-[3-(4-chlorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 444644-26-2 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[3-(4-fluorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-76-2 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-(3,4,5-trifluorophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)


INDEX
NAME)



● HCl

RN 444644-78-4 CAPLUS
CN Carbamic acid, dimethyl-, 4-[(1S)-3-(4-chlorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 444644-93-3 CAPLUS
CN Carbamic acid, dimethyl-, 4-[(1S)-1-(methylamino)-3-(4-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 444645-18-5 CAPLUS
CN Carbamic acid, dimethyl-, 4-[3-(2-chloro-4-nitrophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444645-22-1 CAPLUS

CN Carbamic acid, dimethyl-, 3-[(1R)-3-(2-chloro-4-nitrophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 444645-29-8 CAPLUS

CN Carbamic acid, dimethyl-, 3-[(1R)-1-(methylamino)-3-(4-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 444645-33-4 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-(4-chlorophenoxy)-1-(ethylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-35-6 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-(3,4-difluorophenoxy)-1-(ethylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-37-8 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(ethylmethlamino)-3-(4-fluorophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-38-9 CAPLUS


CN Carbamic acid, dimethyl-, 3-[3-(3-chlorophenoxy)-1-(methlamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-40-3 CAPLUS


CN Carbamic acid, dimethyl-, 3-[3-(3-chloro-4-fluorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-41-4 CAPLUS

CN Carbamic acid, dimethyl-, 3-[3-(4-chloro-3-fluorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444645-45-8 CAPLUS

CN Carbamic acid, dimethyl-, 4-[(1R)-3-(3,4-difluorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 444645-47-0 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-[(4-nitrophenyl)thio]propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-49-2 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-[(4-chlorophenyl)thio]-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-51-6 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-[(4-fluorophenyl)thio]-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-54-9 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-[(6-chloro-2-pyridinyl)oxy]-1-(methylamino)propyl]phenyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 444645-56-1 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[(1S)-3-(3,4-difluorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 444645-62-9 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-[(6-nitro-2-pyridinyl)oxy]propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 444645-64-1 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-[[6-(trifluoromethyl)-2-pyridinyl]oxy]propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444645-66-3 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[3-[4-

[[(dimethylamino) carbonyl] oxy] phenyl]-
3-(methylamino)propoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 444645-69-6 CAPLUS
CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-[4-(methylthio)phenoxy]propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-73-2 CAPLUS
CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-(pentafluorophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444645-78-7 CAPLUS
CN Carbamic acid, dimethyl-, 2-methyl-4-[(1S)-1-(methylamino)-3-(4-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

NAME)

Absolute stereochemistry.



IT 444643-93-0P 444644-00-2P 444644-01-3P
 444644-02-4P 444644-04-6P 444644-05-7P
 444644-06-8P 444644-08-0P 444644-09-1P
 444644-10-4P 444644-11-5P 444644-12-6P
 444644-13-7P 444644-14-8P 444644-15-9P
 444644-16-0P 444644-17-1P 444644-18-2P
 444644-19-3P 444644-20-6P 444644-21-7P
 444644-22-8P 444644-23-9P 444644-24-0P
 444644-25-1P 444644-27-3P 444644-28-4P
 444644-29-5P 444644-30-8P 444644-31-9P
 444644-32-0P 444644-33-1P 444644-34-2P
 444644-35-3P 444644-36-4P 444644-37-5P
 444644-38-6P 444644-39-7P 444644-40-0P
 444644-41-1P 444644-42-2P 444644-43-3P
 444644-44-4P 444644-45-5P 444644-46-6P
 444644-47-7P 444644-48-8P 444644-49-9P
 444644-50-2P 444644-51-3P 444644-52-4P
 444644-53-5P 444644-54-6P 444644-55-7P
 444644-56-8P 444644-57-9P 444644-58-0P
 444644-59-1P 444644-60-4P 444644-61-5P
 444644-62-6P 444644-63-7P 444644-64-8P
 444644-65-9P 444644-66-0P 444644-67-1P
 444644-68-2P 444644-69-3P 444644-70-6P
 444644-71-7P 444644-72-8P 444644-73-9P
 444644-74-0P 444644-75-1P 444644-77-3P
 444644-79-5P 444644-80-8P 444644-81-9P
 444644-82-0P 444644-83-1P 444644-84-2P
 444644-85-3P 444644-86-4P 444644-87-5P
 444644-88-6P 444644-89-7P 444644-90-0P
 444644-91-1P 444644-92-2P 444644-94-4P
 444644-95-5P 444644-96-6P 444644-97-7P
 444644-98-8P 444644-99-9P 444645-00-5P
 444645-01-6P 444645-02-7P 444645-03-8P
 444645-04-9P 444645-05-0P 444645-06-1P
 444645-07-2P 444645-08-3P 444645-09-4P
 444645-10-7P 444645-11-8P 444645-12-9P
 444645-13-0P 444645-14-1P 444645-15-2P
 444645-16-3P 444645-17-4P 444645-19-6P
 444645-20-9P 444645-21-0P 444645-23-2P
 444645-24-3P 444645-25-4P 444645-26-5P
 444645-27-6P 444645-28-7P 444645-30-1P
 444645-31-2P 444645-32-3P 444645-34-5P


444645-36-7P 444645-39-0P 444645-42-5P
 444645-43-6P 444645-44-7P 444645-46-9P
 444645-48-1P 444645-50-5P 444645-52-7P
 444645-53-8P 444645-55-0P 444645-57-2P
 444645-59-4P 444645-60-7P 444645-61-8P
 444645-63-0P 444645-65-2P 444645-67-4P
 444645-68-5P 444645-70-9P 444645-71-0P
 444645-72-1P 444645-74-3P 444645-75-4P
 444645-76-5P 444645-77-6P 444645-79-8P
 444645-80-1P 444645-81-2P 444645-82-3P
 444645-83-4P 444645-84-5P 444645-85-6P
 444645-86-7P 444645-87-8P 444645-88-9P
 444645-89-0P 444645-90-3P 444645-91-4P
 444645-92-5P 444645-93-6P 444645-94-7P
 444645-95-8P 444645-96-9P 444645-97-0P
 444646-62-2P 444667-95-2P 444667-97-4P
 444667-98-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of alkylcarbamic acid esters as acetylcholinesterase inhibitor)

RN 444643-93-0 CAPLUS


CN Carbamic acid, dimethyl-, 3-[1-(dimethylamino)-3-(4-methoxyphenyl)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-00-2 CAPLUS


CN Carbamic acid, dimethyl-, 3-[1-(methylamino)-3-[4-(trifluoromethyl)phenyl]propyl]phenyl ester, monohydrochloride (9CI)
 (CA INDEX NAME)



● HCl

RN 444644-01-3 CAPLUS


CN Carbamic acid, dimethyl-, 3-[3-(3,4-dimethoxyphenyl)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-02-4 CAPLUS


CN Carbamic acid, dimethyl-, 3-[3-(1,3-benzodioxol-5-yl)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-04-6 CAPLUS


CN Carbamic acid, dimethyl-, 3-[1-(methylamino)-3-[4-(trifluoromethyl)phenoxy]propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-05-7 CAPLUS


CN Carbamic acid, dimethyl-, 3-[3-(4-methoxyphenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-06-8 CAPLUS


CN Carbamic acid, dimethyl-, 3-[1-(methylamino)-3-(4-methylphenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-08-0 CAPLUS


CN Carbamic acid, dimethyl-, 3-[3-(4-fluorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-09-1 CAPLUS


CN Carbamic acid, ethyl-, 3-[3-(4-fluorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-10-4 CAPLUS


CN Phenol, 3-[3-(4-fluorophenoxy)-1-(methylamino)propyl]-, acetate (ester), hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-11-5 CAPLUS


CN Propanoic acid, 2,2-dimethyl-, 3-[3-(4-fluorophenoxy)-1-(methylamino)propyl]phenyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-12-6 CAPLUS


CN Carbamic acid, dimethyl-, 3-[3-(4-chlorophenyl)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-13-7 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-(4-chlorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 444644-14-8 CAPLUS

CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-[4-(trifluoromethyl)phenoxy]propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444644-15-9 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[3-(4-methoxyphenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444644-16-0 CAPLUS
 CN Carbamic acid, dimethyl-, 3-[1-amino-3-(4-fluorophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 444644-17-1 CAPLUS
 CN Carbamic acid, dimethyl-, 3-[1-(ethylamino)-3-(4-fluorophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-18-2 CAPLUS
 CN Carbamic acid, dimethyl-, 3-[3-(4-fluorophenoxy)-1-(propylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

NAME)




● HCl

RN 444644-19-3 CAPLUS

CN Carbamic acid, dimethyl-, 3-[4-(4-fluorophenyl)-1-(methylamino)butyl]phenyl ester, monohydrochloride (9CI) (CA INDEX

NAME)




● HCl

RN 444644-20-6 CAPLUS

CN Carbamic acid, diethyl-, 3-[3-(4-fluorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX

NAME)




● HCl

RN 444644-21-7 CAPLUS

CN Carbamic acid, dipropyl-, 3-[3-(4-fluorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX


NAME)



● HCl


RN 444644-22-8 CAPLUS

CN 4-Morpholinecarboxylic acid, 3-[3-(4-fluorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444644-23-9 CAPLUS
CN Carbamic acid, dimethyl-, 3-[1-(dimethylamino)-3-[4-(trifluoromethyl)phenoxy]propyl]phenyl ester, monohydrochloride (9CI)
(CA INDEX NAME)




● HCl

RN 444644-24-0 CAPLUS
CN Carbamic acid, dimethyl-, 3-[1-(dimethylamino)-3-(4-fluorophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 444644-25-1 CAPLUS
CN Carbamic acid, dimethyl-, 4-[1-(dimethylamino)-3-[4-(trifluoromethyl)phenoxy]propyl]phenyl ester, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 444644-27-3 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(dimethylamino)-3-(4-fluorophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-28-4 CAPLUS


CN Carbamic acid, dimethyl-, 3-[3-(4-fluorophenyl)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-29-5 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-(4-fluorophenyl)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 444644-30-8 CAPLUS

CN Carbamic acid, dimethyl-, 3-[4-(4-chlorophenyl)-1-(methylamino)butyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444644-31-9 CAPLUS
CN Carbamic acid, dimethyl-, 4-[4-(4-chlorophenyl)-1-(methylamino)butyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444644-32-0 CAPLUS
CN Carbamic acid, dimethyl-, 4-[3-(3-methoxyphenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 444644-33-1 CAPLUS
CN Carbamic acid, dimethyl-, 4-[3-(2-methoxyphenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-34-2 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-(3-chlorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-35-3 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-(2-chlorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 444644-36-4 CAPLUS

CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-(4-methylphenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444644-37-5 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[3-(4-chlorophenoxy)-1-(dimethylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444644-38-6 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[3-(4-chlorophenyl)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444644-39-7 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[3-(2,4-difluorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444644-40-0 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[3-(2-chloro-4-fluorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444644-41-1 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[3-(4-acetylphenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444644-42-2 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[3-(2,4-dichlorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 444644-43-3 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[3-(3,4-dichlorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-44-4 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-(4-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-45-5 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-(4-aminophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-46-6 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-[4-(acetamino)phenoxy]-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-47-7 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-(3-chlorophenoxy)-1-(dimethylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-48-8 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-(2-chlorophenoxy)-1-(dimethylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-49-9 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(methylanino)-3-(3-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-50-2 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-(3,4-difluorophenoxy)-1-(methylanino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-51-3 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-(4-chloro-3-fluorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-52-4 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-(4-cyanophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-53-5 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-(4-bromophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 444644-54-6 CAPLUS

CN Carbamic acid, dimethyl-, 4-[3-(4-fluoro-2-methylphenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444644-55-7 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-(3-methylphenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 444644-56-8 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[3-(3,4-dimethylphenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-57-9 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[(1R)-3-(3-chlorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 444644-58-0 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[(1R)-3-(4-chlorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 444644-59-1 CAPLUS
 CN Carbamic acid, diethyl-, 4-[3-(4-chlorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 444644-60-4 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[3-(3-aminophenoxy)-1-(methylamino)propyl]phenyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 444644-61-5 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-[3-(acetylamino)phenoxy]-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-62-6 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-(2-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-63-7 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-phenoxypropyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-64-8 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-(3-fluorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-65-9 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-(2-fluorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-66-0 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(dimethylamino)-3-(3-fluorophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-67-1 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(dimethylamino)-3-(2-fluorophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-68-2 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-(3-acetylphenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-69-3 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-(4-chloro-3-methylphenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 444644-70-6 CAPLUS

CN Carbamic acid, dimethyl-, 4-[3-(3-chloro-4-fluorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444644-71-7 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[3-(4-acetylphenoxy)-1-(dimethylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444644-72-8 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[3-(3,4-difluorophenoxy)-1-(dimethylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444644-73-9 CAPLUS
 CN Carbamic acid, diethyl-, 4-[3-(3-chlorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 444644-74-0 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[3-(4-chloro-3-fluorophenoxy)-1-(dimethylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-75-1 CAPLUS

CN Carbamic acid, dimethyl-, 4-[3-(3,5-difluorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444644-77-3 CAPLUS

CN Carbamic acid, dimethyl-, 4-[(1S)-3-(3-chlorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 444644-79-5 CAPLUS


CN Carbamic acid, ethylmethyl-, 4-[3-(4-chlorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-80-8 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-(3,5-difluorophenoxy)-1-(dimethylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-81-9 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-(2,4-difluorophenoxy)-1-(dimethylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-82-0 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(dimethylamino)-3-(3-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-83-1 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-[(3-chlorophenyl)amino]-1-(methylamino)propyl]phenyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 444644-84-2 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-(3-fluoro-4-nitrophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444644-85-3 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(dimethylamino)-3-(4-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 444644-86-4 CAPLUS

CN Carbamic acid, dimethyl-, 4-[3-(4-chloro-3-nitrophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444644-87-5 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-(2,3,5-trifluorophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444644-88-6 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[3-[(3-fluorophenyl)amino]-1-(methylamino)propyl]phenyl ester, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 444644-89-7 CAPLUS
 CN Carbamic acid, dimethyl-, 3-[3-(3-fluorophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444644-90-0 CAPLUS
 CN Carbamic acid, dimethyl-, 3-[1-(methylamino)-3-(4-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444644-91-1 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[3-(2-fluoro-4-nitrophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 444644-92-2 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[3-[(4-fluorophenyl)amino]-1-(methylamino)propyl]phenyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 444644-94-4 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[(1S)-1-(dimethylamino)-3-(4-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 444644-95-5 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[(1R)-1-amino-3-(4-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 444644-96-6 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[(1R)-1-(methylamino)-3-(4-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 444644-97-7 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[(1R)-1-(dimethylamino)-3-(4-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 444644-98-8 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[1-(methyldimethylamino)-3-(3-pyridinyloxy)propyl]phenyl ester, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 444644-99-9 CAPLUS
 CN Carbamic acid, dimethyl-, 3-[1-(dimethylamino)-3-(4-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444645-00-5 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[1-(ethylamino)-3-(3-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444645-01-6 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[1-(ethylamino)-3-(4-fluorophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444645-02-7 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[1-(ethylamino)-3-(3-fluorophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444645-03-8 CAPLUS
 CN Carbamic acid, dimethyl-, 3-[1-(methylamino)-3-(3-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 444645-04-9 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[3-[(4-chlorophenyl)amino]-1-(methylamino)propyl]phenyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 444645-05-0 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-[acetyl(3-fluorophenyl)amino]-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-06-1 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-(3-methyl-4-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-07-2 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-(2-methylphenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-08-3 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-(4-chloro-2-methylphenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-09-4 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(dimethylamino)-3-(3,4,5-trifluorophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-10-7 CAPLUS


CN Carbamic acid, dimethyl-, 4-[4-(4-chlorophenoxy)-1-(methylamino)butyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-11-8 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-4-(4-nitrophenoxy)butyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-12-9 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-2-(4-nitrophenoxy)ethyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-13-0 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-[acetyl(4-chlorophenyl)amino]-1-(methylamino)propyl]phenyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 444645-14-1 CAPLUS

CN Carbamic acid, dimethyl-, 4-[3-[acetyl(4-nitrophenyl)amino]-1-(methylamino)propyl]phenyl ester, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 444645-15-2 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-[(4-nitrophenyl)amino]propyl]phenyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 444645-16-3 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-(4-nitrophenyl)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-17-4 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[(1S)-1-amino-3-(4-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 444645-19-6 CAPLUS
 CN Carbamic acid, dimethyl-, 3-[(1S)-1-(methylamino)-3-(4-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 444645-20-9 CAPLUS
 CN Carbamic acid, dimethyl-, 3-[(1S)-1-(dimethylamino)-3-(4-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 444645-21-0 CAPLUS
 CN Carbamic acid, dimethyl-, 3-[(1S)-3-(2-chloro-4-nitrophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 444645-23-2 CAPLUS
 CN Carbamic acid, dimethyl-, 3-[(1S)-3-(2-chloro-4-nitrophenoxy)-1-(dimethylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 444645-24-3 CAPLUS

CN Carbamic acid, dimethyl-, 3-[(1R)-3-(2-chloro-4-nitrophenoxy)-1-(dimethylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 444645-25-4 CAPLUS


CN Carbamic acid, dimethyl-, 3-[3-(2-chloro-4-nitrophenoxy)-1-(dimethylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 444645-26-5 CAPLUS

CN Carbamic acid, dimethyl-, 3-[3-[(5-chloro-3-pyridinyl)oxy]-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444645-27-6 CAPLUS
 CN Carbamic acid, dimethyl-, 3-[1-(methylamino)-3-[(6-methyl-3-pyridinyl)oxy]propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 444645-28-7 CAPLUS
 CN Carbamic acid, dimethyl-, 3-[1-(methylamino)-3-[(2-methyl-3-pyridinyl)oxy]propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-30-1 CAPLUS
 CN Carbamic acid, dimethyl-, 3-[(1R)-1-(dimethylamino)-3-(4-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 444645-31-2 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(ethylamino)-3-(4-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-32-3 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(ethylmethlamino)-3-(4-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-34-5 CAPLUS

CN Carbamic acid, dimethyl-, 4-[3-(4-chlorophenoxy)-1-(ethylmethlamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444645-36-7 CAPLUS

CN Carbamic acid, dimethyl-, 4-[3-(3,4-difluorophenoxy)-1-(ethylmethylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA

INDEX
NAME)




● HCl

RN 444645-39-0 CAPLUS

CN Carbamic acid, dimethyl-, 3-[3-(4-chlorophenoxy)-1-(dimethylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX


NAME)



● HCl

RN 444645-42-5 CAPLUS


CN Carbamic acid, dimethyl-, 3-[3-(3-chlorophenoxy)-1-(dimethylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX
NAME)



● HCl


RN 444645-43-6 CAPLUS

CN Carbamic acid, dimethyl-, 3-[3-(3-chloro-4-fluorophenoxy)-1-(dimethylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX
NAME)



● HCl


RN 444645-44-7 CAPLUS
 CN Carbamic acid, dimethyl-, 3-[3-(4-chloro-3-fluorophenoxy)-1-(dimethylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 444645-46-9 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[(1R)-3-(3,4-difluorophenoxy)-1-(dimethylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 444645-48-1 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[1-(dimethylamino)-3-[(4-nitrophenyl)thio]propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444645-50-5 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[3-[(4-chlorophenyl)thio]-1-(dimethylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444645-52-7 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[1-(dimethylamino)-3-[(4-fluorophenyl)thio]propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444645-53-8 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[1-(dimethylamino)-3-(2-pyridinyloxy)propyl]phenyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 444645-55-0 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[3-[(6-chloro-2-pyridinyl)oxy]-1-(dimethylamino)propyl]phenyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 444645-57-2 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[(1S)-3-(3,4-difluorophenoxy)-1-(dimethylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 444645-59-4 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[(1S)-3-(4-chlorophenoxy)-1-(methylamino)propyl]phenyl ester, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 444645-58-3
 CMF C19 H23 Cl N2 O3

Absolute stereochemistry.




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.




RN 444645-60-7 CAPLUS

CN Benzoic acid, 4-[3-[4-[[(dimethylamino)carbonyl]oxy]phenyl]-3-(methylamino)propoxy]- (9CI) (CA INDEX NAME)




RN 444645-61-8 CAPLUS

CN Benzoic acid, 4-[3-(dimethylamino)-3-[4-[[(dimethylamino)carbonyl]oxy]phenyl]propoxy]- (9CI) (CA INDEX NAME)



RN 444645-63-0 CAPLUS

CN Carbamic acid, dimethyl-, 4-[1-(dimethylamino)-3-[(6-nitro-2-pyridinyl)oxy]propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444645-65-2 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(dimethylamino)-3-[[6-(trifluoromethyl)-2-

pyridinyl]oxy]propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444645-67-4 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[3-(dimethylamino)-3-[4-
[[(dimethylamino) carbonyl]oxy]phenyl]propoxy]-, methyl ester (9CI)
(CA INDEX NAME)




RN 444645-68-5 CAPLUS
CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-[(2-nitro-4-pyridinyl)oxy]propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-70-9 CAPLUS
CN Carbamic acid, dimethyl-, 4-[1-(dimethylamino)-3-[4-


(methylthio)phenoxy]propyl]phenyl ester, monohydrochloride (9CI) (CA
INDEX NAME)



● HCl

RN 444645-71-0 CAPLUS
CN Carbamic acid, dimethyl-, 4-[(1S)-1-(methylamino)-3-[4-(methylthio)phenoxy]propyl]phenyl ester, monohydrochloride (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



● HCl


RN 444645-72-1 CAPLUS
CN Carbamic acid, dimethyl-, 4-[(1R)-1-(methylamino)-3-[4-(methylthio)phenoxy]propyl]phenyl ester, monohydrochloride (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




● HCl


RN 444645-74-3 CAPLUS
CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-(1-naphthalenyloxy)propyl]phenyl ester, monohydrochloride (9CI) (CA
INDEX NAME)




RN 444645-75-4 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[1-(methylamino)-3-(6-quinolinyloxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



RN 444645-76-5 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[1-(dimethylamino)-3-(pentafluorophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



RN 444645-77-6 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[1-(dimethylamino)-3-(4-nitrophenoxy)propyl]-3-methylphenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444645-79-8 CAPLUS

CN Carbamic acid, dimethyl-, 2-methyl-4-[(1R)-1-(methyamino)-3-(4-nitrophenoxy)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 444645-80-1 CAPLUS


CN Carbamic acid, dimethyl-, 4-[3-(4-chlorophenoxy)-1-(dimethylamino)propyl]-2-methylphenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-81-2 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-(dimethylamino)-3-[4-(methylthio)phenoxy]propyl]-2-methylphenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-82-3 CAPLUS


CN Carbamic acid, dimethyl-, 1,2,3,4-tetrahydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-6-isoquinolinyl ester, monohydrochloride (9CI)

(CA
INDEX NAME)

● HCl


RN 444645-83-4 CAPLUS

CN Carbamic acid, dimethyl-, 1-[2-(4-chloro-3-methylphenoxy)ethyl]-1,2,3,4-tetrahydro-2-methyl-6-isoquinolinyl ester, monohydrochloride (9CI)

(CA
INDEX NAME)

● HCl


RN 444645-84-5 CAPLUS
 CN Carbamic acid, dimethyl-, 1-[2-(2-chloro-4-nitrophenoxy)ethyl]-
 1,2,3,4-
 tetrahydro-2-methyl-6-isoquinolinyl ester, monohydrochloride (9CI)
 (CA INDEX NAME)



● HCl


RN 444645-85-6 CAPLUS
 CN Carbamic acid, dimethyl-, (1R)-1-[2-(2-chloro-4-nitrophenoxy)ethyl]-
 1,2,3,4-tetrahydro-2-methyl-6-isoquinolinyl ester, monohydrochloride
 (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 444645-86-7 CAPLUS
 CN Carbamic acid, dimethyl-, 1-[2-(4-chlorophenoxy)ethyl]-1,2,3,4-
 tetrahydro-
 2-methyl-7-isoquinolinyl ester, monohydrochloride (9CI) (CA INDEX
 NAME)



● HCl

RN 444645-87-8 CAPLUS


CN Carbamic acid, dimethyl-, 2,3-dihydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 444645-88-9 CAPLUS


CN Carbamic acid, dimethyl-, 1-[2-(2-chloro-4-nitrophenoxy)ethyl]-2,3,4,5-tetrahydro-2-methyl-1H-2-benzazepin-7-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



RN 444645-89-0 CAPLUS

CN Carbamic acid, dimethyl-, 1-[2-(4-chloro-3-methylphenoxy)ethyl]-2,3-dihydro-2-methyl-1H-2-benzazepin-7-yl ester, monohydrochloride (9CI)


(CA
INDEX NAME)




RN 444645-90-3 CAPLUS

CN Carbamic acid, dimethyl-, 1-[2-(2-chloro-4-fluorophenoxy)ethyl]-2,3-dihydro-2-methyl-1H-2-benzazepin-7-yl ester, monohydrochloride (9CI)

(CA
INDEX NAME)




RN 444645-91-4 CAPLUS
 CN Carbamic acid, dimethyl-, 2,3-dihydro-2-methyl-1-[2-[4-(methylthio)phenoxy]ethyl]-1H-2-benzazepin-7-yl ester, monohydrochloride
 (9CI) (CA INDEX NAME)




RN 444645-92-5 CAPLUS
 CN Carbamic acid, dimethyl-, (1R)-2,3-dihydro-2-methyl-1-[2-[4-(methylthio)phenoxy]ethyl]-1H-2-benzazepin-7-yl ester, monohydrochloride
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444645-93-6 CAPLUS
 CN Carbamic acid, dimethyl-, (1S)-2,3-dihydro-2-methyl-1-[2-[4-(methylthio)phenoxy]ethyl]-1H-2-benzazepin-7-yl ester, monohydrochloride
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 444645-94-7 CAPLUS
 CN Carbamic acid, dimethyl-, (1S)-2,3-dihydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester, monohydrochloride
 (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 444645-95-8 CAPLUS
 CN Carbamic acid, dimethyl-, 1-[2-(4-chloro-3-methylphenoxy)ethyl]-2,3-dihydro-2-methyl-1H-2-benzazepin-8-yl ester, monohydrochloride (9CI)
 (CA INDEX NAME)




● HCl

RN 444645-96-9 CAPLUS

CN Carbamic acid, dimethyl-, 1-[2-(4-chloro-3-methylphenoxy)ethyl]-2,3-dihydro-2-methyl-1H-2-benzazepin-6-yl ester, monohydrochloride (9CI)


(CA INDEX NAME)



● HCl

RN 444645-97-0 CAPLUS


CN Carbamic acid, dimethyl-, 3-[3-(4-chloro-3-nitrophenoxy)-1-(methylamino)propyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444646-62-2 CAPLUS
 CN Carbamic acid, dimethyl-, (1R)-1-[2-(4-chloro-3-methylphenyl)ethyl]-1,2,3,4-tetrahydro-6-isoquinoliny ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444667-95-2 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[2-(4-chlorophenoxy)-1-(methylamino)ethyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 444667-97-4 CAPLUS
 CN Carbamic acid, dimethyl-, 4-[(1S)-1-(methylamino)-3-(4-nitrophenoxy)propyl]phenyl ester, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 444667-96-3
 CMF C19 H23 N3 O5

Absolute stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 444667-98-5 CAPLUS

CN Carbamic acid, dimethyl-, (1R)-2,3-dihydro-2-methyl-1-[2-(4-nitrophenoxy)ethyl]-1H-2-benzazepin-7-yl ester, monohydrochloride

(9CI)

(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

IT 444646-02-0P 444646-04-2P 444646-10-0P
 444646-11-1P 444646-13-3P 444646-16-6P
 444646-17-7P 444646-19-9P 444646-20-2P
 444646-21-3P 444646-22-4P 444646-23-5P
 444646-24-6P 444646-25-7P 444646-26-8P
 444646-29-1P 444646-30-4P 444646-32-6P
 444646-33-7P 444646-35-9P 444646-36-0P
 444646-39-3P 444646-40-6P 444646-49-5P
 444646-61-1P 444646-82-6P 444646-83-7P
 444646-84-8P 444646-85-9P 444646-86-0P
 444646-89-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT


(Reactant or reagent)

(preparation of alkylcarbamic acid esters as acetylcholinesterase inhibitor)

RN 444646-02-0 CAPLUS


CN Carbamic acid, dimethyl-, 3-[1-[[[1,1-dimethylethoxy)carbonyl]methylamino]-

3-(4-methoxyphenyl)propyl]phenyl ester (9CI) (CA INDEX NAME)




RN 444646-04-2 CAPLUS

CN Carbamic acid, [1-[3-[(ethylamino)carbonyloxy]phenyl]-3-(4-methoxyphenyl)propyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 444646-10-0 CAPLUS

CN Carbamic acid, dimethyl-, 3-[1-[[[(1,1-dimethylethoxy)carbonyl]methylamino]-3-[4-(trifluoromethyl)phenoxy]propyl]phenyl ester (9CI) (CA INDEX NAME)




RN 444646-11-1 CAPLUS

CN Carbamic acid, dimethyl-, 3-[1-[[[(1,1-dimethylethoxy)carbonyl]methylamino]-3-(4-fluorophenoxy)propyl]phenyl ester (9CI) (CA INDEX NAME)




RN 444646-13-3 CAPLUS

CN Carbamic acid, [1-[3-(acetyloxy)phenyl]-3-(4-fluorophenoxy)propyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 444646-16-6 CAPLUS

CN Carbamic acid, dimethyl-, 3-[1-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-fluorophenoxy)propyl]phenyl ester (9CI) (CA INDEX NAME)




RN 444646-17-7 CAPLUS

CN Carbamic acid, dimethyl-, 3-[1-[[[(1,1-dimethylethoxy)carbonyl]ethylamino]-3-(4-fluorophenoxy)propyl]phenyl ester (9CI) (CA INDEX NAME)




RN 444646-19-9 CAPLUS

CN Carbamic acid, dimethyl-, 3-[1-[[[(1,1-dimethylethoxy)carbonyl]methylamino]-4-(4-fluorophenyl)-3-butenyl]phenyl ester (9CI) (CA INDEX NAME)




RN 444646-20-2 CAPLUS

CN Carbamic acid, dimethyl-, 3-[1-[[[(1,1-dimethylethoxy)carbonyl]methylamino]-4-(4-fluorophenyl)butyl]phenyl ester (9CI) (CA INDEX NAME)




RN 444646-21-3 CAPLUS

CN Carbamic acid, diethyl-, 3-[1-[[[(1,1-dimethylethoxy)carbonyl]methylamino]-3-(4-fluorophenoxy)propyl]phenyl ester (9CI) (CA INDEX NAME)




RN 444646-22-4 CAPLUS

CN Carbamic acid, [3-(3-chlorophenoxy)-1-[4-[[[(dimethylamino)carbonyl]oxy]phenyl]propyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 444646-23-5 CAPLUS

CN Carbamic acid, dimethyl-, 4-[1-[[[(1,1-dimethylethoxy)carbonyl]methylamino]-3-(4-nitrophenoxy)propyl]phenyl ester (9CI) (CA INDEX NAME)




RN 444646-24-6 CAPLUS

CN Carbamic acid, [3-(4-aminophenoxy)-1-[4-[[[(dimethylamino)carbonyl]oxy]phenyl]propyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 444646-25-7 CAPLUS

CN Carbamic acid, [3-[4-(acetamino)phenoxy]-1-[4-
[[dimethylamino)carbonyl]oxy]phenyl]propylmethyl-, 1,1-dimethylethyl
ester (9CI) (CA INDEX NAME)



RN 444646-26-8 CAPLUS


CN Carbamic acid, dimethyl-, 4-[1-[[1,1-
dimethylethoxy)carbonyl]methylamino]-
3-(3-nitrophenoxy)propyl]phenyl ester (9CI) (CA INDEX NAME)



RN 444646-29-1 CAPLUS

CN Carbamic acid, dimethyl-, 4-[(1R)-3-(3-chlorophenoxy)-1-[[1,1-
dimethylethoxy)carbonyl]amino]propyl]phenyl ester (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 444646-30-4 CAPLUS

CN Carbamic acid, [(1R)-3-(3-chlorophenoxy)-1-[4-
[[dimethylamino)carbonyl]oxy]phenyl]propylmethyl-, 1,1-dimethylethyl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444646-32-6 CAPLUS

CN Carbamic acid, [3-(3-aminophenoxy)-1-[4-

[[dimethylamino]carbonyl]oxy]phen

yl]propyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 444646-33-7 CAPLUS

CN Carbamic acid, [3-[3-(acetylamino)phenoxy]-1-[4-

[[dimethylamino]carbonyl]oxy]phenyl]propyl]methyl-, 1,1-dimethylethyl

ester (9CI) (CA INDEX NAME)




RN 444646-35-9 CAPLUS

CN Carbamic acid, [3-(4-chlorophenoxy)-1-[4-

[[ethylmethylamino]carbonyl]oxy]

phenyl]propyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 444646-36-0 CAPLUS

CN Carbamic acid, [3-[(3-chlorophenyl)amino]-1-[4-

[[dimethylamino]carbonyl]oxy]phenyl]propyl]methyl-, 1,1-dimethylethyl


ester (9CI) (CA INDEX NAME)



RN 444646-39-3 CAPLUS

CN Carbamic acid, dimethyl-, 4-[(1S)-1-[[[(1,1-dimethylethoxy)carbonyl]methylamino]-3-(4-nitrophenoxy)propyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 444646-40-6 CAPLUS


CN Carbamic acid, dimethyl-, 4-[(1R)-1-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-nitrophenoxy)propyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 444646-49-5 CAPLUS

CN Benzoic acid, 4-[3-[4-[[[(dimethylamino)carbonyl]oxy]phenyl]-3-[methyl[(phenylmethoxy)carbonyl]amino]propoxy]- (9CI) (CA INDEX NAME)




RN 444646-61-1 CAPLUS

CN Carbamic acid, dimethyl-, (1R)-1-[2-(4-chloro-3-methylphenyl)ethyl]-1,2,3,4-tetrahydro-2-(trifluoroacetyl)-6-isoquinolinyl ester (9CI)
(CA

INDEX NAME)


Absolute stereochemistry.



RN 444646-82-6 CAPLUS

CN Carbamic acid, dimethyl-, 4-[(1R)-1-amino-3-[4-(methylthio)phenoxy]propyl]-3-hydroxyphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444646-83-7 CAPLUS

CN Carbamic acid, dimethyl-, 4-[(1R)-1-[[[1,1-dimethylethoxy)carbonyl]amino]-3-[4-(methylthio)phenoxy]propyl]-3-hydroxyphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444646-84-8 CAPLUS

CN Carbamic acid, dimethyl-, 4-[(1R)-1-[[[1,1-dimethylethoxy)carbonyl]amino]-3-[4-(methylthio)phenoxy]propyl]-3-ethenylphenyl ester (9CI) (CA INDEX NAME)

NAME)


Absolute stereochemistry.



RN 444646-85-9 CAPLUS

CN Carbamic acid, dimethyl-, 4-[(1R)-1-[[[(1,1-dimethylethoxy)carbonyl]-2-propenylamino]-3-[4-(methylthio)phenoxy]propyl]-3-ethenylphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444646-86-0 CAPLUS

CN 2H-2-Benzazepine-2-carboxylic acid, 7-[[[(dimethylamino)carbonyl]oxy]-1,3-dihydro-1-[2-[4-(methylthio)phenoxy]ethyl]-, 1,1-dimethylethyl ester, (1R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444646-89-3 CAPLUS

CN Methanesulfonic acid, trifluoro-, 5-[[[(dimethylamino)carbonyl]oxy]-2-[(1R)-1-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-[4-(methylthio)phenoxy]propyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L16 ANSWER 6 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:196132 CAPLUS Full-text
DN 135:2935
TI Tetrahydroisoquinoline-monoterpene and iridoid glycosides from
Alangium
lamarckii
AU Itoh, A.; Tanahashi, T.; Tabata, M.; Shikata, M.; Kakite, M.; Nagai,
M.;
Nagakura, N.
CS Kobe Pharmaceutical University, Higashinada-ku, Kobe, 658-8558, Japan
SO Phytochemistry (2001), 56(6), 623-630
CODEN: PYTCAS; ISSN: 0031-9422
PB Elsevier Science Ltd.
DT Journal
LA English
IT **342036-89-9P 342036-90-2P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and properties of)
RN 342036-89-9 CAPLUS
CN 2H-Pyran-5-carboxylic acid, 4-[[[(1S)-2-acetyl-7-(acetyloxy)-1,2,3,4-
tetrahydro-6-methoxy-1-isoquinolinyl]methyl]-3-ethenyl-3,4-dihydro-2-
[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]-, (2S,3R,4S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A




PAGE 2-A




RN 342036-90-2 CAPLUS
 CN 2H-Pyran-5-carboxylic acid, 4-[[[(1S)-2-acetyl-6-(acetyloxy)-1,2,3,4-tetrahydro-7-methoxy-1-isoquinolinyl]methyl]-3-ethenyl-3,4-dihydro-2-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]-, (2S,3R,4S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 7 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:172231 CAPLUS Full-text

DN 132:305767


TI A tetrahydroisoquinoline-monoterpene glucoside and an iridoid

glucoside


from *Alangium kurzii*
 AU Tanahashi, Takao; Kobayashi, Chizu; Itoh, Atsuko; Nagakura, Naotaka;
 Inoue, Kenichiro; Kuwajima, Hiroshi; Wu, Hua-Xin
 CS Kobe Pharmaceutical University, Kobe, 658-8558, Japan
 SO Chemical & Pharmaceutical Bulletin (2000), 48(3), 415-419
 CODEN: CPBTAL; ISSN: 0009-2363
 PB Pharmaceutical Society of Japan
 DT Journal
 LA English
 IT **137318-71-9P 265096-94-4P**
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (preparation and properties of)
 RN 137318-71-9 CAPLUS
 CN 2H-Pyran-5-carboxylic acid, 4-[[[(1R)-2-acetyl-7-(acetyloxy)-1,2,3,4-
 tetrahydro-6-methoxy-1-isoquinolinyl]methyl]-3-ethenyl-3,4-dihydro-2-
 [(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]-, methyl ester,
 (2S,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A




PAGE 2-A




RN 265096-94-4 CAPLUS
 CN 2H-Pyran-5-carboxylic acid, 4-[[[(1R)-2-acetyl-7-(acetyloxy)-1,2,3,4-
 tetrahydro-6-methoxy-1-isoquinolinyl]methyl]-3-ethenyl-3,4-dihydro-2-
 [(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]-, (2S,3R,4S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 8 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1997:303161 CAPLUS Full-text

DN 127:50579

TI Oxazepines and Thiazepines. Part 33. An efficient procedure for the
preparation of 3-acetyl-2,3-dihydrobenzothiazoles by ring contraction
of

2,4-diaryl-2,3-dihydro-1,5-benzothiazepines under acetylating
conditions

AU Toth, Gabor; Levai, Albert; Balazs, Barbara; Simon, Andras

CS Technical Analytical Research Group, Hungarian Academy Sciences,
Budapest,

H-1111, Hung.

SO Liebig's Annalen/Recueil (1997), (5), 995-998

CODEN: LIARFV

PB VCH

DT Journal

LA English

OS CASREACT 127:50579

IT 191017-21-7P 191017-23-9P 191017-24-0P

191017-25-1P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of acetyldihydrobenzothiazoles by ring contraction of
aryldihydrobenzothiazepines under acetylating conditions)

RN 191017-21-7 CAPLUS

CN Benzothiazole, 3-acetyl-2-[4-(acetyloxy)phenyl]-2,3-dihydro-2-[(1E)-2-phenylethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 191017-23-9 CAPLUS

CN Benzothiazole, 3-acetyl-2-[2-(acetyloxy)phenyl]-2,3-dihydro-2-[(1E)-2-phenylethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 191017-24-0 CAPLUS

CN Benzothiazole, 3-acetyl-2-[2-(acetyloxy)-4-methoxyphenyl]-2,3-dihydro-2-[(2-phenylethenyl)-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 191017-25-1 CAPLUS

CN Benzothiazole, 3-acetyl-2-[2-(acetyloxy)phenyl]-2,3-dihydro-2-[2-(4-methoxyphenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L16 ANSWER 9 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1996:582453 CAPLUS Full-text
 DN 125:243101
 TI Berberis alkaloids. XXXIV. Turcomanine, a new alkaloid from Berberis turcomanica
 AU Khamidov, I.; Faskhutdinov, M.; Telezhenetskaya, M. V.; Karimov, A.; Levkovich, M. G.; Abdullaev, N. D.; Shakirov, R. Sh.
 CS Inst. Khim. Rastit. Veshchestv, Tashkent, Uzbekistan
 SO Khimiya Prirodnikh Soedinenii (1996), (1), 74-76
 CODEN: KPSUAR; ISSN: 0023-1150
 PB Fan
 DT Journal
 LA Russian
 IT **182121-11-5P**, Tri-O-acetylturcomanine
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (of Berberis turcomanica)
 RN 182121-11-5 CAPLUS
 CN 1,2-Benzenediol, 4-[[7-(acetyloxy)-6-methoxy-1-isoquinolinyl]methyl]-, diacetate (ester) (9CI) (CA INDEX NAME)



L16 ANSWER 10 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1996:560528 CAPLUS Full-text
 DN 125:195213
 TI Preparation of 2-(aryl or heterocyclyl)-1-phenylethylamine derivatives as δ -opioid receptor agonists
 IN Murase, Masao; Hamada, Kozo; Asaki, Tetsuo
 PA Nippon Shinyaku Co., Ltd., Japan
 SO PCT Int. Appl., 93 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9622276	A1	19960725	WO 1996-JP86	19960119
	W: AU, BR, CA, CN, FI, HU, JP, KR, MX, NO, NZ, RU, UA, US, VN,				
AZ,	BY, KG, KZ, RU, TJ, TM				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9644589	A1	19960807	AU 1996-44589	19960119
PRAI	JP 1995-7670		19950120		
	WO 1996-JP86		19960119		
OS	MARPAT 125:195213				
IT	181069-29-4P 181069-30-7P 181069-31-8P				
	181069-32-9P 181069-33-0P 181069-34-1P				
	181069-35-2P 181069-36-3P 181069-37-4P				
	181069-39-6P 181069-40-9P 181069-41-0P				
	181069-42-1P 181069-43-2P				
	RL: BAC (Biological activity or effector, except adverse); BSU				
	(Biological				
	study, unclassified); SPN (Synthetic preparation); THU (Therapeutic				
	use);				
	BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of (phenylethyl)amine derivs. as δ -opioid receptor				
	agonists as analgesics and immunostimulants and for treating				
	frequent				
	urination and urinary incontinence)				
RN	181069-29-4 CAPLUS				
CN	Phenol, 3-[1-(dimethylamino)-2-(2-naphthalenyl)ethyl]-, acetate				
	(ester),				
	hydrochloride, (+)- (9CI) (CA INDEX NAME)				


Rotation (+).



● HCl


RN 181069-30-7 CAPLUS
 CN Phenol, 3-[1-(dimethylamino)-2-(2-naphthalenyl)ethyl]-, acetate
 (ester),
 (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 181069-31-8 CAPLUS

CN Benzoic acid, 4-[2-[3-(acetyloxy)phenyl]-2-(dimethylamino)ethyl]-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 181069-32-9 CAPLUS
CN 1-Propanone, 1-[4-[2-[3-(acetyloxy)phenyl]-2-(dimethylamino)ethyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 181069-33-0 CAPLUS
CN Phenol, 3-[1-(dimethylamino)-2-[4-(methoxymethyl)phenyl]ethyl]-, acetate (ester), hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 181069-34-1 CAPLUS
CN Phenol, 3-[1-(dimethylamino)-2-[4-(ethoxymethyl)phenyl]ethyl]-, acetate (ester), hydrochloride, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



● HCl

RN 181069-35-2 CAPLUS
 CN Propanoic acid, 2,2-dimethyl-, 3-[1-(dimethylamino)-2-(2-naphthalenyl)ethyl]phenyl ester, hydrochloride, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



● HCl

RN 181069-36-3 CAPLUS
 CN Propanoic acid, 2,2-dimethyl-, 3-[1-(dimethylamino)-2-[4-(methoxymethyl)phenyl]ethyl]phenyl ester, hydrochloride, (+)- (9CI)
 (CA INDEX NAME)


Rotation (+).



● HCl

RN 181069-37-4 CAPLUS
 CN Propanoic acid, 2,2-dimethyl-, 3-[1-(dimethylamino)-2-[4-(ethoxymethyl)phenyl]ethyl]phenyl ester, hydrochloride, (+)- (9CI)
 (CA INDEX NAME)


Rotation (+).



● HCl

RN 181069-39-6 CAPLUS
 CN Carbamic acid, propyl-, 3-[1-(dimethylamino)-2-[4-(ethoxymethyl)phenyl]ethyl]phenyl ester, monohydrochloride, (+)- (9CI)
 (CA INDEX NAME)


Rotation (+).



● HCl


RN 181069-40-9 CAPLUS
 CN Carbamic acid, propyl-, 3-[1-(dimethylamino)-2-[4-(ethoxymethyl)phenyl]ethyl]phenyl ester, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 181069-41-0 CAPLUS
 CN Carbamic acid, dimethyl-, 3-[1-(dimethylamino)-2-[4-(ethoxymethyl)phenyl]ethyl]phenyl ester, monohydrochloride, (+)- (9CI)
 (CA INDEX NAME)


Rotation (+).



● HCl


RN 181069-42-1 CAPLUS
 CN Carbamic acid, dimethyl-, 3-[1-(dimethylamino)-2-[4-(ethoxymethyl)phenyl]ethyl]phenyl ester, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 181069-43-2 CAPLUS
 CN Carbamic acid, dimethyl-, 3-[1-(dimethylamino)-2-[4-(methoxymethyl)phenyl]ethyl]phenyl ester, monohydrochloride, (+)- (9CI)
 (CA INDEX NAME)


Rotation (+).



● HCl

L16 ANSWER 11 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1995:982327 CAPLUS Full-text
 DN 124:55796
 TI Preparation of nonpeptide heterocyclic amides as neurokinin A antagonists
 IN Shenvi, Ashokkumar Bhikkappa; Jacobs, Robert Toms; Miller, Scott Carson;
 Ohnmacht, Cyrus John, Jr.; Veale, Chris Allan
 PA Zeneca Ltd., UK
 SO PCT Int. Appl., 157 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9516682	A1	19950622	WO 1994-GB2726	19941213
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5589489	A	19961231	US 1994-353767	19941212
ZA 9409934	A	19950615	ZA 1994-9934	19941213
CA 2176036	AA	19950622	CA 1994-2176036	19941213
AU 9512471	A1	19950703	AU 1995-12471	19941213
AU 690951	B2	19980507		
EP 734383	A1	19961002	EP 1995-903415	19941213
EP 734383	B1	20020724		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1142822	A	19970212	CN 1994-194944	19941213
HU 76275	A2	19970728	HU 1996-1568	19941213
BR 9408325	A	19970819	BR 1994-8325	19941213
IL 111970	A1	19990312	IL 1994-111970	19941213
AT 221064	E	20020815	AT 1995-903415	19941213
ES 2179094	T3	20030116	ES 1995-903415	19941213
FI 9602418	A	19960611	FI 1996-2418	19960611
NO 9602543	A	19960814	NO 1996-2543	19960614
US 5705505	A	19980106	US 1996-717999	19960926
US 5965576	A	19991012	US 1997-980399	19971126
PRAI GB 1993-25654	A	19931215		
GB 1994-23248	A	19941117		
US 1994-353767	A3	19941212		
WO 1994-GB2726	W	19941213		
US 1996-717999	A3	19960926		
OS MARPAT 124:55796				
IT 171426-11-2P				
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
(preparation of nonpeptide heterocyclic amides as neurokinin A antagonists)				
RN 171426-11-2	CAPLUS			
CN 1H-Isindol-1-one, 6-(acetyloxy)-3-[1-(3,4-dichlorophenyl)-3-butenyl]-2,3-dihydro-2-methyl-, (R*,S*)- (9CI) (CA INDEX NAME)				
Relative stereochemistry.				



L16 ANSWER 12 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1995:451708 CAPLUS Full-text

DN 122:214056

TI preparation of 1,2-benzisoxazole derivatives and salts as brain protective

agents

IN Takeda, Kenji; Terashima, Nobuo; Nakano, Joji; Minami, Hisashi; Kobayashi,

Toyokazu; Furuhata, Kunikazu; Takakura, Tadakazu; Takata, Makoto; Kawafuchi, Hiroyo; Hiraiwa, Toru

PA Toyama Chemical Co., Ltd., Japan

SO PCT Int. Appl., 173 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9410158	A1	19940511	WO 1993-JP1549	19931027
	W: AU, CA, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9453442	A1	19940524	AU 1994-53442	19931027
	AU 674358	B2	19961219		
	EP 665226	A1	19950802	EP 1993-923647	19931027
	R: BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, SE				
	JP 3457669	B2	20031020	JP 1994-510885	19931027
	US 5578627	A	19961126	US 1995-411667	19950412
PRAI	JP 1992-312743	A	19921028		
	JP 1993-238688	A	19930702		
	JP 1993-197776	A	19930715		
	WO 1993-JP1549	W	19931027		

OS MARPAT 122:214056

IT 162035-09-8P 162035-11-2P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological


study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1,2-benzisoxazole derivs. and salts as brain protective agents)

RN 162035-09-8 CAPLUS


CN Phenol, 3-[1-amino-2-[(5-chloro-1,2-benzisoxazol-3-yl)oxy]ethyl]-, carbamate (ester), monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 162035-11-2 CAPLUS

CN Phenol, 4-[1-amino-2-[(5-chloro-1,2-benzisoxazol-3-yl)oxy]ethyl]-, carbamate (ester), monohydrochloride (9CI) (CA INDEX NAME)



● HCl


L16 ANSWER 13 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1994:478365 CAPLUS Full-text
 DN 121:78365
 TI Tetrahydroisoquinoline-monoterpene glucosides from *Alangium lamarckii*
 and
Cephaelis ipecacuanha
 AU Itoh, Atsuko; Tanahashi, Takao; Nagakura, Naotaka; Nayeshiro, Hidekazu
 CS Kobe Women's Coll. Pharm., Kobe, 658, Japan
 SO Phytochemistry (1994), 36(2), 383-7
 CODEN: PYTCAS; ISSN: 0031-9422
 DT Journal
 LA English
 IT **156366-69-7P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 156366-69-7 CAPLUS
 CN 2H-Pyran-5-carboxylic acid, 4-[[2-acetyl-6-(acetyloxy)-1,2,3,4-
 tetrahydro-
 7-methoxy-1-isoquinolinyl]methyl]-3-ethenyl-3,4-dihydro-2-[(2,3,4,6-
 tetra-
 O-acetyl-β-D-glucopyranosyl)oxy]-, methyl ester, [2S-
 [2α,3β,4β(S*)]]- (9CI) (CA INDEX NAME)



L16 ANSWER 14 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1994:245566 CAPLUS Full-text
 DN 120:245566
 TI General asymmetric synthesis of isoquinoline alkaloids.
 Enantioselective
 hydrogenation of enamides catalyzed by BINAP-ruthenium(II) complexes
 AU Kitamura, Masato; Hsiao, Yi; Ohta, Masako; Tsukamoto, Masaki; Ohta,
 Tetsuo; Takaya, Hidemasa; Noyori, Ryoji


CS Dep. Chem., Nagoya Univ., Chikusa, 464-01, Japan
 SO Journal of Organic Chemistry (1994), 59(2), 297-310
 CODEN: JOCEAH; ISSN: 0022-3263
 DT Journal
 LA English
 OS CASREACT 120:245566
 IT **104621-45-6 104621-46-7**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (intermediate, synthesis of isoquinoline alkaloid)
 RN 104621-45-6 CAPLUS
 CN 7-Isoquinolinol, 2-acetyl-1-[[3-(acetyloxy)-4-methoxyphenyl]methyl]-
 1,2,3,4-tetrahydro-6-methoxy-, acetate (ester), (R)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




RN 104621-46-7 CAPLUS
 CN 7-Isoquinolinol, 2-acetyl-1-[[3-(acetyloxy)-4-methoxyphenyl]methyl]-
 1,2,3,4-tetrahydro-6-methoxy-, acetate (ester), (S)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




L16 ANSWER 15 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1994:106723 CAPLUS Full-text
 DN 120:106723
 TI Enzymic resolution of acylates of prochiral phenolic 1-aryl- and
 1-arylalkyl-1,2,3,4-tetrahydroisoquinolinols, which possess a
 guaiacol-type moiety, by use of immobilized lipase in organic solvent
 AU Hoshino, Osamu; Tanahashi, Ruka; Okada, Mitsuhiro; Akita, Hiroyuki;
 Oishi,
 Takeshi
 CS Fac. Pharm. Sci., Sci. Univ. Tokyo, Tokyo, 162, Japan
 SO Tetrahedron: Asymmetry (1993), 4(5), 933-42
 CODEN: TASYE3; ISSN: 0957-4166
 DT Journal


LA English
 OS CASREACT 120:106723
 IT 152561-05-2 152561-06-3 152561-07-4
 152561-08-5 152561-09-6 152561-10-9
 152561-18-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (enzymic resolution of)
 RN 152561-05-2 CAPLUS
 CN 5-Isoquinolinol, 1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6-methoxy-2-methyl-, acetate (ester) (9CI) (CA INDEX NAME)




RN 152561-06-3 CAPLUS
 CN 6-Isoquinolinol, 1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-7-methoxy-2-methyl-, acetate (ester) (9CI) (CA INDEX NAME)




RN 152561-07-4 CAPLUS
 CN 7-Isoquinolinol, 1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6-methoxy-2-methyl-, acetate (ester) (9CI) (CA INDEX NAME)




RN 152561-08-5 CAPLUS
 CN 5-Isoquinolinol, 1-[2-(3,4-dimethoxyphenyl)ethyl]-1,2,3,4-tetrahydro-
 6-methoxy-2-methyl-, acetate (ester) (9CI) (CA INDEX NAME)



RN 152561-09-6 CAPLUS
 CN 6-Isoquinolinol, 1-[2-(3,4-dimethoxyphenyl)ethyl]-1,2,3,4-tetrahydro-
 7-methoxy-2-methyl-, acetate (ester) (9CI) (CA INDEX NAME)




RN 152561-10-9 CAPLUS
 CN 7-Isoquinolinol, 1-[2-(3,4-dimethoxyphenyl)ethyl]-1,2,3,4-tetrahydro-
 6-methoxy-2-methyl-, acetate (ester) (9CI) (CA INDEX NAME)



RN 152561-18-7 CAPLUS

CN 6-Isoquinolinol, 1-[(1,3-benzodioxol-5-ylmethyl)-1,2,3,4-tetrahydro-7-methoxy-2-methyl-, acetate (ester) (9CI) (CA INDEX NAME)



IT 152693-96-4P 152693-97-5P 152693-98-6P

152693-99-7P 152694-00-3P 152694-01-4P

152694-02-5P 152694-03-6P 152694-04-7P

152694-05-8P 152694-06-9P 152694-07-0P

152694-18-3P 152694-19-4P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 152693-96-4 CAPLUS

CN 5-Isoquinolinol, 1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6-methoxy-2-methyl-, acetate (ester), (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152693-97-5 CAPLUS


CN 5-Isoquinolinol, 1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6-methoxy-2-methyl-, acetate (ester), (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 152693-98-6 CAPLUS
 CN 6-Isoquinolinol, 1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-7-methoxy-2-methyl-, acetate (ester), (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 152693-99-7 CAPLUS
 CN 6-Isoquinolinol, 1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-7-methoxy-2-methyl-, acetate (ester), (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 152694-00-3 CAPLUS
 CN 7-Isoquinolinol, 1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6-methoxy-2-methyl-, acetate (ester), (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 152694-01-4 CAPLUS
 CN 7-Isoquinolinol, 1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6-methoxy-2-methyl-, acetate (ester), (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 152694-02-5 CAPLUS
 CN 5-Isoquinolinol, 1-[2-(3,4-dimethoxyphenyl)ethyl]-1,2,3,4-tetrahydro-
 6-
 methoxy-2-methyl-, acetate (ester), (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 152694-03-6 CAPLUS
 CN 5-Isoquinolinol, 1-[2-(3,4-dimethoxyphenyl)ethyl]-1,2,3,4-tetrahydro-
 6-
 methoxy-2-methyl-, acetate (ester), (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152694-04-7 CAPLUS
 CN 6-Isoquinolinol, 1-[2-(3,4-dimethoxyphenyl)ethyl]-1,2,3,4-tetrahydro-
 7-

methoxy-2-methyl-, acetate (ester), (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 152694-05-8 CAPLUS

CN 6-Isoquinolinol, 1-[2-(3,4-dimethoxyphenyl)ethyl]-1,2,3,4-tetrahydro-7-

methoxy-2-methyl-, acetate (ester), (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 152694-06-9 CAPLUS

CN 7-Isoquinolinol, 1-[2-(3,4-dimethoxyphenyl)ethyl]-1,2,3,4-tetrahydro-6-


methoxy-2-methyl-, acetate (ester), (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 152694-07-0 CAPLUS
 CN 7-Isoquinolinol, 1-[2-(3,4-dimethoxyphenyl)ethyl]-1,2,3,4-tetrahydro-6-methoxy-2-methyl-, acetate (ester), (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 152694-18-3 CAPLUS
 CN 6-Isoquinolinol, 1-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4-tetrahydro-7-methoxy-2-methyl-, acetate (ester), (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 152694-19-4 CAPLUS
 CN 6-Isoquinolinol, 1-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4-tetrahydro-7-methoxy-2-methyl-, acetate (ester), (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L16 ANSWER 16 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1993:445228 CAPLUS Full-text
 DN 119:45228
 TI Four tetrahydroisoquinoline-monoterpene glucosides from *Cephaelis*
ipecacuanha
 AU Nagakura, Naotaka; Itoh, Atsuko; Tanahashi, Takao
 CS Kobe Women's Coll. Pharm., Kobe, 658, Japan
 SO Phytochemistry (1993), 32(3), 761-5
 CODEN: PYTCAS; ISSN: 0031-9422
 DT Journal
 LA English
 IT **21104-39-2**, Ipecoside hexaacetate
 RL: BIOL (Biological study)
 (cephaloside heptaacetate preparation from)
 RN 21104-39-2 CAPLUS
 CN 2H-Pyran-5-carboxylic acid, 4-[[2-acetyl-6,7-bis(acetyloxy)-1,2,3,4-
 tetrahydro-1-isoquinolinyl]methyl]-3-ethenyl-3,4-dihydro-2-[(2,3,4,6-
 tetra-
 O-acetyl- β -D-glucopyranosyl)oxy]-, methyl ester, [2S-
 [2 α ,3 β ,4 β (S*)]]- (9CI) (CA INDEX NAME)




IT **147677-06-3P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
 RACT
 (Reactant or reagent)
 (preparation and condensation reaction of)
 RN 147677-06-3 CAPLUS
 CN 2H-Pyran-5-carboxylic acid, 4-[[6,7-bis(acetyloxy)-1,2,3,4-tetrahydro-
 1-
 isoquinolinyl]methyl]-3-ethenyl-3,4-dihydro-2-[(2,3,4,6-tetra-O-
 acetyl-
 β -D-glucopyranosyl)oxy]-, methyl ester, [2S-
 [2 α ,3 β ,4 β (S*)]]- (9CI) (CA INDEX NAME)




L16 ANSWER 17 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1992:105914 CAPLUS Full-text
 DN 116:105914
 TI Reactions of flavonoid thiosemicarbazones under acetylating conditions
 AU Somogyi, Laszlo
 CS Res. Group Antibiot., Hung. Acad. Sci., Debrecen, H-4010, Hung.
 SO Tetrahedron (1991), 47(44), 9305-16
 CODEN: TETRAB; ISSN: 0040-4020
 DT Journal
 LA English
 IT **139061-57-7P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, from thiosemicarbazone)
 RN 139061-57-7 CAPLUS
 CN Acetamide, N-[4-acetyl-5-[2-(acetyloxy)phenyl]-4,5-dihydro-5-(2-phenylethenyl)-1,3,4-thiadiazol-2-yl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L16 ANSWER 18 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1991:652125 CAPLUS Full-text
 DN 115:252125
 TI Six tetrahydroisoquinoline-monoterpene glucosides from Cephaelis
 ipecacuanha
 AU Itoh, Atsuko; Tanahashi, Takao; Nagakura, Naotaka
 CS Kobe Women's Coll. Pharm., Kobe, 658, Japan
 SO Phytochemistry (1991), 30(9), 3117-23
 CODEN: PYTCAS; ISSN: 0031-9422
 DT Journal
 LA English
 IT **21104-39-2**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (cyclization of)
 RN 21104-39-2 CAPLUS
 CN 2H-Pyran-5-carboxylic acid, 4-[[2-acetyl-6,7-bis(acetyloxy)-1,2,3,4-

tetrahydro-1-isoquinoliny]methyl]-3-ethenyl-3,4-dihydro-2-[(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyl)oxy]-, methyl ester, [2S-[2 α ,3 β ,4 β (S*)]]- (9CI) (CA INDEX NAME)



IT 122587-80-8P 137318-71-9P 137318-72-0P
137318-75-3P

RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation of, by acetylation of alkaloidal glycoside from
Cephaelis
ippecacuanha)

RN 122587-80-8 CAPLUS

CN 2H-Pyran-5-carboxylic acid, 4-[[2-acetyl-8-(acetyloxy)-1,2,3,4-tetrahydro-

7-methoxy-1-isoquinoliny]methyl]-3-ethenyl-3,4-dihydro-2-[(2,3,4,6-tetra-

O-acetyl- β -D-glucopyranosyl)oxy]-, methyl ester, [2S-[2 α ,3 β ,4 β (S*)]]- (9CI) (CA INDEX NAME)




RN 137318-71-9 CAPLUS


CN 2H-Pyran-5-carboxylic acid, 4-[[[(1R)-2-acetyl-7-(acetyloxy)-1,2,3,4-tetrahydro-6-methoxy-1-isoquinoliny]methyl]-3-ethenyl-3,4-dihydro-2-[(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyl)oxy]-, methyl ester, (2S,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A




PAGE 2-A



RN 137318-72-0 CAPLUS

CN 2H-Pyran-5-carboxylic acid, 4-[[2-acetyl-6,7-bis(acetyloxy)-1,2,3,4-tetrahydro-1-isoquinolinyl]methyl]-3-ethenyl-3,4-dihydro-2-[(2,3,4,6-tetra-

O-acetyl-β-D-glucopyranosyl)oxy]-, [2S-[2α,3β,4β(S*)]]
]- (9CI) (CA INDEX NAME)




RN 137318-75-3 CAPLUS

CN 2H-Pyran-5-carboxylic acid, 4-[[2-acetyl-7,8-bis(acetyloxy)-1,2-dihydro-1-isoquinolinyl]methyl]-3-ethenyl-3,4-dihydro-2-[(2,3,4,6-tetra-O-acetyl-

β-D-glucopyranosyl)oxy]-, methyl ester, [2S-

[2 α , 3 β , 4 β (S*)]]- (9CI) (CA INDEX NAME)



IT 122587-78-4P

RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation of, by acetylation of alkaloidal glycoside from
Cephaelis

ipecacuanha, and cyclization of)

RN 122587-78-4 CAPLUS

CN 2H-Pyran-5-carboxylic acid, 4-[[2-acetyl-7,8-bis(acetyloxy)-1,2,3,4-tetrahydro-1-isoquinolinyl]methyl]-3-ethenyl-3,4-dihydro-2-[(2,3,4,6-tetra-

O-acetyl- β -D-glucopyranosyl)oxy]-, methyl ester, [2S-[2 α , 3 β , 4 β (S*)]]- (9CI) (CA INDEX NAME)



L16 ANSWER 19 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1991:450035 CAPLUS Full-text

DN 115:50035

TI Revised stereostructure for (+)-roemecarine and synthesis of (\pm)-, (+)-, and (-)-roemecarine and (\pm)-epiroemecarine

AU Hoshino, Osamu; Itoh, Katsuhiko; Tanahashi, Ruka; Umezawa, Bunsuke; Akita,

Hiroyuki; Oishi, Takeshi

CS Fac. Pharm. Sci., Sci. Univ. Tokyo, Tokyo, 162, Japan

SO Chemical & Pharmaceutical Bulletin (1990), 38(12), 3277-9

CODEN: CPBTAL; ISSN: 0009-2363

DT Journal


LA English

OS CASREACT 115:50035

IT 96012-67-8


RL: PROC (Process)
 (enzymic kinetic resolution of)
 RN 96012-67-8 CAPLUS
 CN 4,6-Isoquinolinediol, 1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-
 tetrahydro-7-
 methoxy-2-methyl-, diacetate (ester), trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L16 ANSWER 20 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1991:229209 CAPLUS Full-text
 DN 114:229209
 TI The structure and partial synthesis of imbricatine, a
 benzyltetrahydroisoquinoline alkaloid from the starfish *Dermasterias*
imbricata
 AU Burgoyne, David L.; Miao, Shichang; Pathirana, Charles; Andersen,
 Raymond
 J.; Ayer, William A.; Singer, Peter P.; Kokke, William C. M. C.; Ross,
 Donald M.
 CS Dep. Chem., Univ. British Columbia, Vancouver, BC, V6T 1W5, Can.
 SO Canadian Journal of Chemistry (1991), 69(1), 20-7
 CODEN: CJCHAG; ISSN: 0008-4042
 DT Journal
 LA English
 OS CASREACT 114:229209
 IT **105372-71-2P 133761-47-4P 133761-48-5P**
133761-56-5P 133761-57-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 105372-71-2 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-acetyl-5-[[5-[2-(acetylamino)-3-
 methoxy-3-
 oxopropyl]-1-methyl-1H-imidazol-4-yl]thio]-6,8-bis(acetyloxy)-1-[[4-
 (acetyloxy)phenyl]methyl]-1,2,3,4-tetrahydro-, methyl ester,
 [1R-[1 α ,3 α ,5(S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 133761-47-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-acetyl-6,7-bis(acetyloxy)-1,2,3,4-tetrahydro-1-[(4-methoxyphenyl)methyl]-, methyl ester, (1S-cis)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 133761-48-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-acetyl-6,7-bis(acetyloxy)-1,2,3,4-tetrahydro-1-[(4-methoxyphenyl)methyl]-, methyl ester, (1R-trans)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 133761-56-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-acetyl-6,8-bis(acetyloxy)-1-[[4-(acetyloxy)phenyl]methyl]-1,2,3,4-tetrahydro-, methyl ester, cis-


(9CI)
(CA INDEX NAME)

Relative stereochemistry.




RN 133761-57-6 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 2-acetyl-6,8-bis(acetyloxy)-1-[[4-(acetyloxy)phenyl]methyl]-1,2,3,4-tetrahydro-, methyl ester, trans-
(9CI)
(CA INDEX NAME)

Relative stereochemistry.




IT **133761-54-3P 133761-55-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
RACT
(Reactant or reagent)
(preparation, hydrogenolysis, and acetylation of)
RN 133761-54-3 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 2-acetyl-6,8-bis(acetyloxy)-1,2,3,4-tetrahydro-1-[[4-(phenylmethoxy)phenyl]methyl]-, methyl ester, cis-
(9CI)
(CA INDEX NAME)

Relative stereochemistry.




RN 133761-55-4 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-acetyl-6,8-bis(acetyloxy)-1,2,3,4-tetrahydro-1-[[4-(phenylmethoxy)phenyl]methyl]-, methyl ester, trans-(9CI) (CA INDEX NAME)

Relative stereochemistry.



L16 ANSWER 21 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1991:98333 CAPLUS Full-text
 DN 114:98333
 TI The biosynthesis of the phenethylisoquinoline alkaloid colchicine.
 Early
 and intermediate stages
 AU Herbert, Richard B.; Kattah, Abdullah E.; Knagg, Eric
 CS Sch. Chem., Univ. Leeds, Leeds, LS2 9JT, UK
 SO Tetrahedron (1990), 46(20), 7119-38
 CODEN: TETRAB; ISSN: 0040-4020
 DT Journal
 LA English
 IT **131946-66-2P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 131946-66-2 CAPLUS
 CN 6,7-Isoquinolinediol, 1-[2-[4-(acetyloxy)phenyl]ethyl]-1,2,3,4-tetrahydro-
 , diacetate (ester) (9CI) (CA INDEX NAME)




L16 ANSWER 22 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1990:156714 CAPLUS Full-text
 DN 112:156714
 TI Enzymic resolution of isoquinoline alkaloids
 IN Oishi, Takeshi; Umezawa, Fumisuke; Hoshino, Osamu; Akita, Hiroyuki;
 Machida, Haruo
 PA Institute of Physical and Chemical Research, Japan; Meito Sangyo Co.,
 Ltd.
 SO Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 01228964	A2	19890912	JP 1988-56887	19880310
PRAI	JP 1988-56887		19880310		
IT	96012-67-8P				

 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
 RACT
 (Reactant or reagent)
 (preparation and enzymic resolution of)
 RN 96012-67-8 CAPLUS
 CN 4,6-Isoquinolinediol, 1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-
 tetrahydro-7-
 methoxy-2-methyl-, diacetate (ester), trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.




IT **125942-07-6P**
 RL: PREP (Preparation)
 (preparation of, via enzymic resolution)

RN 125942-07-6 CAPLUS
 CN 4,6-Isoquinolinediol, 1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-7-methoxy-2-methyl-, diacetate (ester), trans-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



L16 ANSWER 23 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1990:18869 CAPLUS Full-text
 DN 112:18869
 TI Neoipecoside and 7-methylneoipecoside, new unusually-cyclized tetrahydroisoquinoline-monoterpene glucosides from *Cephaelis ipecacuanha*
 [Erratum to document cited in CA111(15):130718m]
 AU Itoh, Atsuko; Tanahashi, Takao; Nagakura, Naotaka
 CS Kobe Women's Coll. Pharm., Kobe, 658, Japan
 SO Chemical & Pharmaceutical Bulletin (1989), 37(6), 1684
 CODEN: CPBTAL; ISSN: 0009-2363
 DT Journal
 LA English
 IT **122587-78-4P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
 RACT
 (Reactant or reagent)
 (preparation and deacetylation of (Erratum))
 RN 122587-78-4 CAPLUS
 CN 2H-Pyran-5-carboxylic acid, 4-[[2-acetyl-7,8-bis(acetyloxy)-1,2,3,4-tetrahydro-1-isoquinolinyl]methyl]-3-ethenyl-3,4-dihydro-2-[(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyl)oxy]-, methyl ester, [2S-[2 α ,3 β ,4 β (S*)]]- (9CI) (CA INDEX NAME)




IT 122587-80-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of (Erratum))

RN 122587-80-8 CAPLUS

CN 2H-Pyran-5-carboxylic acid, 4-[[2-acetyl-8-(acetyloxy)-1,2,3,4-tetrahydro-7-methoxy-1-isoquinolinyl]methyl]-3-ethenyl-3,4-dihydro-2-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]-, methyl ester, [2S-[2α,3β,4β(S*)]]- (9CI) (CA INDEX NAME)



L16 ANSWER 24 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1989:530718 CAPLUS Full-text

DN 111:130718

TI Neoipecoside and 7-methylneoipecoside, new unusually-cyclized tetrahydroisoquinoline-monoterpene glucosides from *Cephaelis ipecacuanha*

AU Itoh, Atsuko; Tanahashi, Takao; Nagakura, Naotaka

CS Kobe Women's Coll. Pharm., Kobe, 658, Japan

SO Chemical & Pharmaceutical Bulletin (1989), 37(4), 1137-9
CODEN: CPBTAL; ISSN: 0009-2363

DT Journal

LA English

IT 122587-78-4P, Neoipecoside hexaacetate

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);


RACT

(Reactant or reagent)
(preparation and deacetylation of)


RN 122587-78-4 CAPLUS

CN 2H-Pyran-5-carboxylic acid, 4-[[2-acetyl-7,8-bis(acetyloxy)-1,2,3,4-tetrahydro-1-isoquinolinyl]methyl]-3-ethenyl-3,4-dihydro-2-[(2,3,4,6-tetra-

O-acetyl-β-D-glucopyranosyl)oxy]-, methyl ester, [2S-[2α,3β,4β(S*)]]- (9CI) (CA INDEX NAME)




IT **122587-80-8P**, 7-Methylneoipecoside pentaacetate
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 122587-80-8 CAPLUS
 CN 2H-Pyran-5-carboxylic acid, 4-[[2-acetyl-8-(acetyloxy)-1,2,3,4-tetrahydro-7-methoxy-1-isoquinolinyl]methyl]-3-ethenyl-3,4-dihydro-2-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]-, methyl ester, [2S-[2α,3β,4β(S*)]]- (9CI) (CA INDEX NAME)




L16 ANSWER 25 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1989:169041 CAPLUS Full-text
 DN 110:169041
 TI Mammalian alkaloids: O-methylation of (S)- and (R)-dideoxynorlaudanoline-1-carboxylic acid by catechol O-methyltransferase and identification of a yellow pigment obtained at physiological pH
 AU Rozwadowska, Maria Danuta; Chrzanowska, Maria; Brossi, Arnold; Creveling, Cyrus R.; Bembenek, Michael E.; Abell, Creed W.
 CS Lab. Anal. Chem., NIDDK, Bethesda, MD, 20892, USA
 SO Helvetica Chimica Acta (1988), 71(7), 1598-607
 CODEN: HCACAV; ISSN: 0018-019X
 DT Journal
 LA English
 OS CASREACT 110:169041
 IT **119995-28-7P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 119995-28-7 CAPLUS
 CN 6,7-Isoquinolinediol, 2-acetyl-1,2,3,4-tetrahydro-1-(phenylmethyl)-, diacetate (ester) (9CI) (CA INDEX NAME)




L16 ANSWER 26 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1989:74990 CAPLUS Full-text
 DN 110:74990
 TI On the selectivity of O-demethylation of tetramethoxylated 1,2-diarylethylamides
 AU Villa, M. J.; Lete, E.; Dominguez, E.
 CS Fac. Cienc., Univ. Pais Vasco, Bilbao, 48080, Spain
 SO Chemica Scripta (1988), 28(2), 145-8
 CODEN: CSRPB9; ISSN: 0004-2056
 DT Journal
 LA English
 OS CASREACT 110:74990
 IT **118647-44-2P 118647-45-3P 118647-46-4P 118647-47-5P**


RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 118647-44-2 CAPLUS
 CN Acetamide, N-[2-[5-(acetyloxy)-2-bromo-4-methoxyphenyl]-1-[3-(acetyloxy)-4-methoxyphenyl]ethyl]-N-formyl- (9CI) (CA INDEX NAME)



RN 118647-45-3 CAPLUS
 CN Acetamide, N-[2-[5-(acetyloxy)-2-bromo-4-methoxyphenyl]-1-[4-(acetyloxy)-3-methoxyphenyl]ethyl]-N-formyl- (9CI) (CA INDEX NAME)




RN 118647-46-4 CAPLUS
 CN Acetamide, N-[2-[4-(acetyloxy)-2-bromo-5-methoxyphenyl]-1-[3-(acetyloxy)-4-methoxyphenyl]ethyl]-N-formyl- (9CI) (CA INDEX NAME)



RN 118647-47-5 CAPLUS

CN Acetamide, N-[2-[4-(acetyloxy)-2-bromo-5-methoxyphenyl]-1-[4-(acetyloxy)-3-methoxyphenyl]ethyl]-N-formyl- (9CI) (CA INDEX NAME)



L16 ANSWER 27 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1988:504068 CAPLUS Full-text

DN 109:104068

TI Studies on intestinal lymphatic absorption of drugs. I. Lymphatic absorption of alkyl ester derivatives and α -monoglyceride derivatives of drugs

AU Sugihara, Juko; Furuuchi, Satoshi; Nakano, Kouzaburo; Harigaya, Shoichi

CS Biol. Res. Lab., Tanabe Seiyaku Co. Ltd., Toda, 335, Japan

SO Journal of Pharmacobio-Dynamics (1988), 11(5), 369-76

CODEN: JOPHDQ; ISSN: 0386-846X

DT Journal

LA English

IT **116048-70-5P**

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of radiolabeled and intestinal lymphatic absorption


of)

RN 116048-70-5 CAPLUS

CN Butanoic acid, 1,2,3,4-tetrahydro-1-[(3,4,5-trimethoxyphenyl)methyl]-6,7-

isoquinolinediyl ester, hydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L16 ANSWER 28 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1988:406430 CAPLUS Full-text

DN 109:6430

TI Preparation of optically pure N-acyltetrahydroisoquinolines as pharmaceutical intermediates

IN Noyori, Ryoji; Kitamura, Masato; Takaya, Hidemasa; Kumobayashi, Hidenori;

Akutagawa, Susumu

PA Takasago Perfumery Co., Ltd., Japan

SO Eur. Pat. Appl., 12 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 245960	A2	19871119	EP 1987-303217	19870413
	EP 245960	A3	19881221		
	EP 245960	B1	19920729		
	R: CH, DE, FR, GB, LI, NL				
	JP 62265266	A2	19871118	JP 1986-108889	19860513
	JP 03068022	B4	19911025		
	US 4851537	A	19890725	US 1987-38571	19870415
PRAI	JP 1986-108889		19860513		

OS CASREACT 109:6430

IT 104621-45-6P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as pharmaceutical intermediate)

RN 104621-45-6 CAPLUS


CN 7-Isoquinolinol, 2-acetyl-1-[[3-(acetyloxy)-4-methoxyphenyl]methyl]-1,2,3,4-tetrahydro-6-methoxy-, acetate (ester), (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L16 ANSWER 29 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1988:112803 CAPLUS Full-text
 DN 108:112803
 TI Synthesis of (±)-roemecarine and (±)-epiroemecarine. Revised stereostructure for (+)-roemecarine
 AU Hoshino, Osamu; Itoh, Katsuhiko; Umezawa, Bunsuke; Akita, Hiroyuki; Oishi, Takeshi
 CS Fac. Pharm. Sci., Sci. Univ. Tokyo, Tokyo, 162, Japan
 SO Heterocycles (1987), 26(8), 2099-100
 CODEN: HTCYAM; ISSN: 0385-5414
 DT Journal
 LA English
 OS CASREACT 108:112803
 IT **96012-67-8P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 96012-67-8 CAPLUS
 CN 4,6-Isoquinolinediol, 1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-7-methoxy-2-methyl-, diacetate (ester), trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L16 ANSWER 30 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1987:156744 CAPLUS Full-text
 DN 106:156744
 TI Studies on tetrahydroisoquinolines. XXVI. A biomimetic synthesis of 5-oxygenated 1,2,3,4-tetrahydroisoquinolines
 AU Hara, Hiroshi; Tsunashima, Akira; Shinoki, Hiroshi; Akiba, Toshifumi; Hoshino, Osamu; Umezawa, Bunsuke
 CS Fac. Pharm. Sci., Sci. Univ. Tokyo, Tokyo, 162, Japan
 SO Chemical & Pharmaceutical Bulletin (1986), 34(1), 66-70

CODEN: CPBTAL; ISSN: 0009-2363
 DT Journal
 LA English
 OS CASREACT 106:156744
 IT **81451-72-1P 107503-19-5P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
 RACT
 (Reactant or reagent)
 (preparation and hydrolysis-methylation of)
 RN 81451-72-1 CAPLUS
 CN 5,6-Isoquinolinediol, 1,2,3,4-tetrahydro-7-methoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-, diacetate (ester) (9CI) (CA INDEX NAME)




RN 107503-19-5 CAPLUS
 CN 5,6-Isoquinolinediol, 1,2,3,4-tetrahydro-7-methoxy-2-methyl-1-(phenylmethyl)-, diacetate (ester) (9CI) (CA INDEX NAME)



L16 ANSWER 31 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1987:153047 CAPLUS Full-text
 DN 106:153047
 TI Alkaloids of the Annonaceae. Part 67. Luxandrine, a quaternary benzylisoquinoline from *Pseudoxandra sclerocarpa*
 AU Cortes, Diego; Wannigama, G. Percy; Saez, Jairo; Cave, Andre
 CS Lab. Pharmacogn., Fac. Pharm., Chatenay-Malabry, 92296, Fr.
 SO Phytochemistry (1986), 25(11), 2693-5
 CODEN: PYTCAS; ISSN: 0031-9422
 DT Journal
 LA English
 IT **107584-93-0P**, O,O-Diacetylluxandrine chloride
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 107584-93-0 CAPLUS
 CN Isoquinolinium, 6,7-bis(acetyloxy)-1,2,3,4-tetrahydro-1-[(4-methoxyphenyl)methyl]-2,2-dimethyl-, chloride, (R)- (9CI) (CA INDEX


NAME)

Absolute stereochemistry.

● Cl⁻


L16 ANSWER 32 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1987:3059 CAPLUS Full-text
 DN 106:3059
 TI Imbricatine, an unusual benzyltetrahydroisoquinoline alkaloid isolated from the starfish *Dermasterias imbricata*
 AU Pathirana, Charles; Andersen, Raymond J.
 CS Dep. Chem., Univ. British Columbia, Vancouver, BC, V6T 1W5, Can.
 SO Journal of the American Chemical Society (1986), 108(26), 8288-9
 CODEN: JACSAT; ISSN: 0002-7863
 DT Journal
 LA English
 IT **105372-71-2P**
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation and mass spectrum of)
 RN 105372-71-2 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-acetyl-5-[[5-[2-(acetylamino)-3-methoxy-3-oxopropyl]-1-methyl-1H-imidazol-4-yl]thio]-6,8-bis(acetyloxy)-1-[[4-(acetyloxy)phenyl]methyl]-1,2,3,4-tetrahydro-, methyl ester, [1R-[1 α ,3 α ,5(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L16 ANSWER 33 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1987:2899 CAPLUS Full-text
 DN 106:2899
 TI Isolation and identification of N-nororientaline from Erythrina herbacea
 Linn
 AU Saqib, Qazi Najmus; Usmanghani, K.; Ahmad, V. U.
 CS Dep. Pharm., Gomul Univ., Dera Ismail Khan, Pak.
 SO Journal of Pharmacy (University of Karachi) (1985), 4(1), 39-42
 CODEN: JPUKDX; ISSN: 0257-3865
 DT Journal
 LA English
 IT **105701-93-7P**, N-Nororientaline triacetate
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 105701-93-7 CAPLUS
 CN 7-Isoquinolinol, 2-acetyl-1-[[4-(acetyloxy)-3-methoxyphenyl]methyl]-1,2,3,4-tetrahydro-6-methoxy-, acetate (ester), (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 34 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1986:591459 CAPLUS Full-text
 DN 105:191459
 TI Asymmetric synthesis of isoquinoline alkaloids by homogeneous catalysis
 AU Noyori, Ryoji; Ohta, Masako; Hsiao, Yi; Kitamura, Masato; Ohta, Tetsuo;
 Takaya, Hidemasa
 CS Dep. Chem., Nagoya Univ., Nagoya, 464, Japan
 SO Journal of the American Chemical Society (1986), 108(22), 7117-19
 CODEN: JACSAT; ISSN: 0002-7863
 DT Journal
 LA English
 OS CASREACT 105:191459
 IT **104621-46-7P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
 RACT
 (Reactant or reagent)
 (preparation and deacetylation of)
 RN 104621-46-7 CAPLUS
 CN 7-Isoquinolinol, 2-acetyl-1-[[3-(acetyloxy)-4-methoxyphenyl]methyl]-1,2,3,4-tetrahydro-6-methoxy-, acetate (ester), (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 104621-45-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 104621-45-6 CAPLUS

CN 7-Isoquinolinol, 2-acetyl-1-[[3-(acetyloxy)-4-methoxyphenyl]methyl]-
1,2,3,4-tetrahydro-6-methoxy-, acetate (ester), (R)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.



L16 ANSWER 35 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1986:533730 CAPLUS Full-text

DN 105:133730

TI Syntheses and β -adrenergic agonist and antiaggregatory properties of
N-substituted trimetoquinol analogues

AU Adejare, Adeboye; Miller, Duane D.; Fedyna, Joanne S.; Ahn, Chang Ho;
Feller, Dennis R.

CS Coll. Pharm., Ohio State Univ., Columbus, OH, 43210, USA

SO Journal of Medicinal Chemistry (1986), 29(9), 1603-9

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

OS CASREACT 105:133730

IT 102920-96-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);


RACT

(Reactant or reagent)

(preparation and deacetylation of)

RN 102920-96-7 CAPLUS

CN 6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-2-(phenylmethyl)-1-[(3,4,5-
trimethoxyphenyl)methyl]-, diacetate (ester), hydrochloride (9CI) (CA
INDEX NAME)




● HCl

IT 102920-97-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 102920-97-8 CAPLUS

CN 6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-2-(phenylmethyl)-1-[(3,4,5-trimethoxyphenyl)methyl]-, diacetate (ester) (9CI) (CA INDEX NAME)



L16 ANSWER 36 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1985:166036 CAPLUS Full-text

DN 102:166036

TI Studies on tetrahydroisoquinolines. XXIII. Reactions of
(±)-7-acetoxy-7-methoxy-1-(3,4-dimethoxy- or 3,4-methylenedioxybenzyl)-

2-methyl-6-oxo-8a,5,8,8a-hexahydroisoquinoline (o-quinol acetate)

AU Hoshino, Osamu; Ohtani, Minoru; Umezawa, Bunsuke; Iitaka, Yoichi

CS Fac. Pharm. Sci., Sci. Univ. Tokyo, Tokyo, 162, Japan

SO Chemical & Pharmaceutical Bulletin (1984), 32(12), 4873-82

CODEN: CPBTAL; ISSN: 0009-2363

DT Journal

LA English

OS CASREACT 102:166036

IT 96012-66-7P 96012-67-8P 96012-68-9P

96012-71-4P 96012-72-5P 96012-73-6P

96012-74-7P 96022-25-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 96012-66-7 CAPLUS

CN Isoquinolinium, 4,6-bis(acetyloxy)-1-[(3,4-dimethoxyphenyl)methyl]-
1,2,3,4-

tetrahydro-7-methoxy-2,2-dimethyl-, cis-, salt with 2,4,6-trinitrophenol


(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 96012-65-6

CMF C25 H32 N O7


Relative stereochemistry.



CM 2

CRN 14798-26-6

CMF C6 H2 N3 O7




RN 96012-67-8 CAPLUS

CN 4,6-Isoquinolinediol, 1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-7-


methoxy-2-methyl-, diacetate (ester), trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 96012-68-9 CAPLUS
 CN Isoquinolinium, 4,6-bis(acetyloxy)-1-[(3,4-dimethoxyphenyl)methyl]-
 1,2,3,4-
 tetrahydro-7-methoxy-2,2-dimethyl-, iodide, trans- (9CI) (CA INDEX
 NAME)


Relative stereochemistry.



● I⁻

RN 96012-71-4 CAPLUS
 CN 4,6-Isoquinolinediol, 1-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4-
 tetrahydro-7-
 methoxy-2-methyl-, diacetate (ester), cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 96012-72-5 CAPLUS
 CN 4,6-Isoquinolinediol, 1-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4-
 tetrahydro-7-
 methoxy-2-methyl-, diacetate (ester), cis-, compd. with
 2,4,6-trinitrophenol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 96012-71-4
 CMF C23 H25 N O7

Relative stereochemistry.






CM 2

CRN 88-89-1

CMF C6 H3 N3 O7




RN 96012-73-6 CAPLUS

CN 4,6-Isoquinolinediol, 1-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4-tetrahydro-7-

methoxy-2-methyl-, diacetate (ester), trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 96012-74-7 CAPLUS

CN Isoquinolinium, 4,6-bis(acetyloxy)-1-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4-

tetrahydro-7-methoxy-2,2-dimethyl-, iodide, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● I-

RN 96022-25-2 CAPLUS

CN 4,6-Isoquinolinediol, 1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-7-methoxy-2-methyl-, diacetate (ester), cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L16 ANSWER 37 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1984:175104 CAPLUS Full-text

DN 100:175104

TI Studies on tetrahydroisoquinolines. XXI. A synthesis of (±)-1-hydroxy-2-methoxyhomoproaporphine and stereochemistry of 4-oxygenated 1,2,3,4-tetrahydroisoquinolines

AU Hara, Hiroshi; Shirai, Ryuichi; Hoshino, Osamu; Umezawa, Bunsuke; Iitaka, Yoichi

CS Fac. Pharm. Sci., Sci. Univ. Tokyo, Tokyo, 162, Japan

SO Chemical & Pharmaceutical Bulletin (1983), 31(12), 4236-46
CODEN: CPBTAL; ISSN: 0009-2363

DT Journal

LA English


IT 89758-71-4P 89758-83-8P 89758-88-3P
89758-89-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 89758-71-4 CAPLUS

CN 4,7-Isoquinolinediol, 1,2,3,4-tetrahydro-6-methoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-, diacetate (ester), trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 89758-83-8 CAPLUS

CN 4,7-Isoquinolinediol, 1,2,3,4-tetrahydro-6-methoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-, diacetate (ester), cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 89758-88-3 CAPLUS

CN Isoquinolinium, 4,7-bis(acetyloxy)-1,2,3,4-tetrahydro-6-methoxy-1-[(4-methoxyphenyl)methyl]-2,2-dimethyl-, iodide, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● I⁻

RN 89758-89-4 CAPLUS

CN Isoquinolinium, 4,7-bis(acetyloxy)-1,2,3,4-tetrahydro-6-methoxy-1-[(4-methoxyphenyl)methyl]-2,2-dimethyl-, iodide, cis- (9CI) (CA INDEX NAME)

NAME)

Relative stereochemistry.

● I⁻

L16 ANSWER 38 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1984:139411 CAPLUS Full-text

DN 100:139411

TI Synthesis of 6'-methylated reticulines and tetrahydropapaverolines

AU Sharma, Padam N.; Rice, Kenner C.; Brossi, Arnold

CS Lab. Chem., Natl. Inst. Arthritis, Metab. Dig. Kidney Dis., Bethesda, MD,

20205, USA

SO Heterocycles (1983), 20(12), 2417-24

CODEN: HTCYAM; ISSN: 0385-5414

DT Journal

LA English


IT 89300-66-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(dechlorination of)

RN 89300-66-3 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 7-(acetyloxy)-1-[[5-(acetyloxy)-2-(chloromethyl)-4-methoxyphenyl]methyl]-3,4-dihydro-6-methoxy-, ethyl ester

(9CI) (CA INDEX NAME)



IT 89240-92-6P 89240-93-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT


(Reactant or reagent)

(preparation and dechlorination of)

RN 89240-92-6 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 7-(acetyloxy)-1-[[5-(acetyloxy)-2-(chloromethyl)-4-methoxyphenyl]methyl]-3,4-dihydro-6-methoxy-, ethyl ester, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 89240-93-7 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 7-(acetyloxy)-1-[[5-(acetyloxy)-2-(chloromethyl)-4-methoxyphenyl]methyl]-3,4-dihydro-6-methoxy-, ethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 89300-67-4P 89300-68-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT


(Reactant or reagent)
(preparation and hydrazinolysis of)

RN 89300-67-4 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 7-(acetyloxy)-1-[[5-(acetyloxy)-4-methoxy-2-methylphenyl]methyl]-3,4-dihydro-6-methoxy-, ethyl ester, (S)-


(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 89300-68-5 CAPLUS
 CN 2(1H)-Isoquinolinecarboxylic acid, 7-(acetyloxy)-1-[[5-(acetyloxy)-4-methoxy-2-methylphenyl]methyl]-3,4-dihydro-6-methoxy-, ethyl ester,
 (R)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 89240-94-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
 RACT
 (Reactant or reagent)
 (preparation, reduction, and hydrazinolysis of)
 RN 89240-94-8 CAPLUS
 CN 2(1H)-Isoquinolinecarboxylic acid, 7-(acetyloxy)-1-[[5-(acetyloxy)-4-methoxy-2-methylphenyl]methyl]-3,4-dihydro-6-methoxy-, ethyl ester
 (9CI)
 (CA INDEX NAME)



L16 ANSWER 39 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1983:89195 CAPLUS Full-text
 DN 98:89195
 TI Isoquinoline derivatives
 PA Fujisawa Pharmaceutical Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 26 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 57139066	A2	19820827	JP 1981-24812	19810220

PRAI JP 1981-24812 19810220

OS CASREACT 98:89195

IT 84641-18-9P 84641-20-3P 84641-35-0P

84641-41-8P 84641-42-9P 84641-43-0P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological

study, unclassified); SPN (Synthetic preparation); BIOL (Biological

study); PREP (Preparation)


(preparation and antiulcer activity of)

RN 84641-18-9 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 6,7-bis(2,2-dimethyl-1-oxopropoxy)-3,4-

dihydro-1-[[[(1-methyl-1H-tetrazol-5-yl)amino]methyl]-, phenylmethyl ester

(9CI) (CA INDEX NAME)




RN 84641-20-3 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 1,2,3,4-tetrahydro-1-[[[(1-methyl-1H-tetrazol-5-yl)amino]methyl]-6,7-isoquinolinediyl ester, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 84641-19-0

CMF C22 H32 N6 O4




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.




RN 84641-35-0 CAPLUS

CN 6,7-Isoquinolinediol, 2-[[4-(aminomethyl)cyclohexyl]carbonyl]-1,2,3,4-tetrahydro-1-[[1-methyl-1H-tetrazol-5-yl]amino]methyl]-, 7-acetate (9CI)
(CA INDEX NAME)




RN 84641-41-8 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 6-(2,2-dimethyl-1-oxopropoxy)-3,4-dihydro-1-[[1-methyl-1H-tetrazol-5-yl]amino]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 84641-42-9 CAPLUS


CN Propanoic acid, 2,2-dimethyl-, 1,2,3,4-tetrahydro-1-[[1-methyl-1H-tetrazol-5-yl]amino]methyl]-6-isoquinolinyl ester (9CI) (CA INDEX NAME)



RN 84641-43-0 CAPLUS
 CN Propanoic acid, 2,2-dimethyl-, 1,2,3,4-tetrahydro-1-[[1-methyl-1H-tetrazol-5-yl)amino]methyl]-6-isoquinolinyl ester, ethanedioate (2:1) (9CI) (CA INDEX NAME)


CM 1

CRN 84641-42-9
 CMF C17 H24 N6 O2




CM 2

CRN 144-62-7
 CMF C2 H2 O4




L16 ANSWER 40 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1983:34820 CAPLUS Full-text
 DN 98:34820
 TI Synthesis of benzo[5,6]cyclohept[1,2,3,ij]isoquinolines as rigid congeners of tetrahydropapaveroline
 AU Sharma, Padam N.; Rice, Kenner C.; Brossi, Arnold
 CS Lab. Chem., Natl. Inst. Arthritis, Diabetes, Dig. Kidney Dis., Bethesda, MD, 20205, USA
 SO Heterocycles (1982), 19(10), 1895-901

CODEN: HTCYAM; ISSN: 0385-5414
 DT Journal
 LA English
 IT **83607-55-0P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
 RACT
 (Reactant or reagent)
 (preparation and cyclization of)
 RN 83607-55-0 CAPLUS
 CN 2(1H)-Isoquinolinecarboxylic acid, 6-(acetyloxy)-1-[[4-(acetyloxy)-2-(chloromethyl)-5-methoxyphenyl)methyl]-3,4-dihydro-7-methoxy-, ethyl ester
 (9CI) (CA INDEX NAME)



L16 ANSWER 41 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1982:162995 CAPLUS Full-text
 DN 96:162995
 TI A biomimetic synthesis of (±)-tetrahydrotakatonine, (±)-O-methylgigantine, and tehaunine
 AU Hara, Hirohi; Tsunashima, Akira; Shinoki, Hiroshi; Hoshino, Osamu; Umezawa, Bunsuke
 CS Fac. Pharm. Sci., Sci. Univ. Tokyo, Tokyo, 162, Japan
 SO Heterocycles (1982), 17(Spec. Issue), 293-6
 CODEN: HTCYAM; ISSN: 0385-5414
 DT Journal
 LA English
 IT **81451-72-1P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
 RACT
 (Reactant or reagent)
 (preparation and hydrolysis of)
 RN 81451-72-1 CAPLUS
 CN 5,6-Isoquinolinediol, 1,2,3,4-tetrahydro-7-methoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-, diacetate (ester) (9CI) (CA INDEX NAME)



L16 ANSWER 42 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1982:6609 CAPLUS Full-text

DN 96:6609

TI 1,2,3,4-Tetrahydroisoquinoline derivatives

IN Kishimoto, Teiji; Kochi, Hiromu; Kaneda, Yoshiyuki

PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO U.S., 16 pp. Cont. of U.S. Ser. No. 695,975, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 4292320	A	19810929	US 1979-67393	19790817
	JP 50035174	A2	19750403	JP 1973-85987	19730730
	JP 57034275	B4	19820722		
	US 3978063	A	19760831	US 1974-489993	19740719
	CH 615162	A	19800115	CH 1977-16303	19771230
	CH 619695	A	19801015	CH 1977-16304	19771230
	US 4370332	A	19830125	US 1980-201997	19801029
PRAI	JP 1973-85987		19730730		
	US 1974-489993		19740719		
	US 1976-695975		19760614		
	JP 1973-4882004		19730720		
	CH 1974-9936		19740717		
	US 1979-67393		19790817		

OS CASREACT 96:6609

IT **80128-82-1P 80128-84-3P 80128-86-5P**

80128-89-8P 80128-91-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT

(Reactant or reagent)

(preparation and deblocking of)


RN 80128-82-1 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 6,7-bis(acetyloxy)-3,4-dihydro-1-

[(2-

thienylthio)methyl]-, 2,2,2-trichloroethyl ester (9CI) (CA INDEX


NAME)



RN 80128-84-3 CAPLUS


CN 2(1H)-Isoquinolinecarboxylic acid, 6,7-bis(acetyloxy)-1-[(2-benzothiazolylthio)methyl]-3,4-dihydro-, 2,2,2-trichloroethyl ester (9CI)

(CA INDEX NAME)



RN 80128-86-5 CAPLUS


CN 2(1H)-Isoquinolinecarboxylic acid, 6,7-bis(acetyloxy)-3,4-dihydro-1-[[5-methyl-1,3,4-thiadiazol-2-yl]thio]methyl]-, 2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)



RN 80128-89-8 CAPLUS


CN 2(1H)-Isoquinolinecarboxylic acid, 6,7-bis(acetyloxy)-3,4-dihydro-1-[[1-methyl-1H-tetrazol-5-yl]thio]methyl]-, 2,2,2-trichloroethyl ester (9CI)

(CA INDEX NAME)



RN 80128-91-2 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-6,7-bis(2-methyl-1-oxopropoxy)-1-[[1-methyl-1H-tetrazol-5-yl]thio]methyl]-, 2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)



IT 80128-93-4P 80128-95-6P 80128-97-8P

80129-00-6P 80129-09-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 80128-93-4 CAPLUS

CN 6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-[(2-thienylthio)methyl]-, diacetate (ester), (2E)-2-butenedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 80128-92-3


CMF C18 H19 N O4 S2



CM 2

CRN 110-17-8
CMF C4 H4 O4


Double bond geometry as shown.



RN 80128-95-6 CAPLUS
CN 6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-[[1-methyl-1H-tetrazol-5-yl]thio]methyl]-, diacetate (ester), (2E)-2-butenedioate (salt) (9CI)
(CA INDEX NAME)

CM 1


CRN 80128-94-5
CMF C16 H19 N5 O4 S



CM 2

CRN 110-17-8
CMF C4 H4 O4


Double bond geometry as shown.



RN 80128-97-8 CAPLUS
CN 6,7-Isoquinolinediol, 1-[(2-benzothiazolylthio)methyl]-1,2,3,4-tetrahydro-, diacetate (ester), (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 80128-96-7
CMF C21 H20 N2 O4 S2




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 80129-00-6 CAPLUS

CN 6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-, diacetate (ester), (2R,3R)-2,3-dihydroxybutanedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 80128-99-0

CMF C17 H19 N3 O4 S2




CM 2

CRN 87-69-4

CMF C4 H6 O6


Absolute stereochemistry.



RN 80129-09-5 CAPLUS
 CN Propanoic acid, 2-methyl-, 1,2,3,4-tetrahydro-1-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-6,7-isoquinolinediyl ester, (2E)-2-butenedioate (9CI)
 (CA INDEX NAME)

CM 1


CRN 80129-08-4
 CMF C20 H27 N5 O4 S



CM 2

CRN 110-17-8
 CMF C4 H4 O4


Double bond geometry as shown.




L16 ANSWER 43 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1981:565576 CAPLUS Full-text
 DN 95:165576
 TI Alkaloids and olefinic acids from *Cryptocarya amygdalina*
 AU Borthakur, N.; Mahanta, P. K.; Rastogi, R. C.
 CS Reg. Res. Lab., Assam, 785006, India
 SO Phytochemistry (Elsevier) (1981), 20(3), 501-4
 CODEN: PYTCAS; ISSN: 0031-9422
 DT Journal
 LA English
 IT **78405-24-0P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 78405-24-0 CAPLUS
 CN 7-Isoquinolinol, 1-[[4-(acetyloxy)-3-methoxyphenyl]methyl]-1,2,3,4-tetrahydro-6-methoxy-2-methyl-, acetate (ester), (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L16 ANSWER 44 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1981:550373 CAPLUS Full-text
 DN 95:150373
 TI Studies on 1,2,3,4-tetrahydroisoquinoline derivatives. I. Syntheses and β -adrenoceptor activities of positional isomers of trimetoquinol with respect to its 6,7-dihydroxyl groups
 AU Yamada, Koichiro; Ikezaki, Muneyoshi; Umino, Norihide; Ohtsuka, Hisao; Itoh, Nobuo; Ikezawa, Katsuo; Kiyomoto, Akio; Iwakuma, Takeo
 CS Res. Lab., Tanabe Seiyaku, Co., Ltd., Saitama, 335, Japan
 SO Chemical & Pharmaceutical Bulletin (1981), 29(3), 744-53
 CODEN: CPBTAL; ISSN: 0009-2363
 DT Journal
 LA English
 OS CASREACT 95:150373
 IT **61831-77-4P 64728-80-9P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
 RACT
 (Reactant or reagent)
 (preparation and hydrogenolysis of)
 RN 61831-77-4 CAPLUS
 CN 7,8-Isoquinolinediol, 1-[(3,4,5-trimethoxyphenyl)methyl]-, diacetate (ester) (9CI) (CA INDEX NAME)




RN 64728-80-9 CAPLUS
 CN 5,7-Isoquinolinediol, 1-[(3,4,5-trimethoxyphenyl)methyl]-, diacetate (ester), hydrochloride (9CI) (CA INDEX NAME)




● HCl

IT **60095-77-4P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 60095-77-4 CAPLUS
 CN 5,7-Isoquinolinediol, 1-[(3,4,5-trimethoxyphenyl)methyl]-, diacetate
 (ester) (9CI) (CA INDEX NAME)




L16 ANSWER 45 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1981:171027 CAPLUS Full-text
 DN 94:171027
 TI Isolation of higenamine from Annona squamosa; significance of
 adsorbent
 macromolecular resins in extractive plant chemistry
 AU Leboeuf, Michel; Cave, Andre; Touche, Andre; Provost, Jean; Forgacs,
 Pierre
 CS Lab. Pharmacog., Fac. Pharm., Chatenay-Malabry, F 92290, Fr.
 SO Journal of Natural Products (1981), 44(1), 53-60
 CODEN: JNPRDF; ISSN: 0163-3864
 DT Journal
 LA French
 IT **60941-91-5P 77354-35-9P 77354-36-0P**
77354-37-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 60941-91-5 CAPLUS
 CN 6,7-Isoquinolinediol, 1-[[4-(acetyloxy)phenyl]methyl]-1,2,3,4-
 tetrahydro-,

diacetate (ester) (9CI) (CA INDEX NAME)




RN 77354-35-9 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 1-[[4-(2,2-dimethyl-1-oxopropoxy)phenyl]methyl]-1,2,3,4-tetrahydro-6,7-isoquinolinediyl ester (9CI) (CA INDEX NAME)




RN 77354-36-0 CAPLUS

CN Butanoic acid, 1,2,3,4-tetrahydro-1-[[4-(1-oxobutoxy)phenyl]methyl]-6,7-isoquinolinediyl ester (9CI) (CA INDEX NAME)




RN 77354-37-1 CAPLUS


CN Propanoic acid, 2-methyl-, 1,2,3,4-tetrahydro-1-[[4-(2-methyl-1-oxopropoxy)phenyl]methyl]-6,7-isoquinolinediyl ester (9CI) (CA INDEX NAME)




L16 ANSWER 46 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1980:198704 CAPLUS Full-text
 DN 92:198704
 TI Synthesis and proton and carbon-13 NMR spectroscopic studies of
 monoterpenoid isoquinolines
 AU Hoefle, Gerhard; Nagakura, Naotaka; Zenk, Meinhard H.
 CS Ges. Biotechnol. Forsch. m.b.H., Braunschweig, D-3300, Fed. Rep. Ger.
 SO Chemische Berichte (1980), 113(2), 566-76
 CODEN: CHBEAM; ISSN: 0009-2940
 DT Journal
 LA German
 IT **21104-39-2P 21104-40-5P**
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (preparation and NMR of)
 RN 21104-39-2 CAPLUS
 CN 2H-Pyran-5-carboxylic acid, 4-[[2-acetyl-6,7-bis(acetyloxy)-1,2,3,4-
 tetrahydro-1-isoquinolinyl]methyl]-3-ethenyl-3,4-dihydro-2-[(2,3,4,6-
 tetra-
 O-acetyl- β -D-glucopyranosyl)oxy]-, methyl ester, [2S-
 [2 α ,3 β ,4 β (S*)]]- (9CI) (CA INDEX NAME)



RN 21104-40-5 CAPLUS
 CN 2H-Pyran-5-carboxylic acid, 4-[[2-acetyl-6,7-bis(acetyloxy)-1,2,3,4-
 tetrahydro-1-isoquinolinyl]methyl]-3-ethenyl-3,4-dihydro-2-[(2,3,4,6-
 tetra-
 O-acetyl- β -D-glucopyranosyl)oxy]-, methyl ester, [2S-
 [2 α ,3 β ,4 β (R*)]]- (9CI) (CA INDEX NAME)




L16 ANSWER 47 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1979:100170 CAPLUS Full-text
 DN 90:100170
 TI Deacetylisoipecoside: the key intermediate in the biosynthesis of the alkaloids cephaeline and emetine
 AU Nagakura, Naotaka; Hoefle, Gerhard; Zenk, Meinhard H.
 CS Lehrstuhl Pflanzenphysiol., Ruhr Univ. Bochum, Bochum, Fed. Rep. Ger.
 SO Journal of the Chemical Society, Chemical Communications (1978), (20), 896-8
 CODEN: JCCCAT; ISSN: 0022-4936
 DT Journal
 LA English
 IT **21104-39-2**
 RL: BIOL (Biological study)
 (CD of)
 RN 21104-39-2 CAPLUS
 CN 2H-Pyran-5-carboxylic acid, 4-[[2-acetyl-6,7-bis(acetyloxy)-1,2,3,4-tetrahydro-1-isoquinolinyl]methyl]-3-ethenyl-3,4-dihydro-2-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]-, methyl ester, [2S-[2α,3β,4β(S*)]]- (9CI) (CA INDEX NAME)



L16 ANSWER 48 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1978:439396 CAPLUS Full-text
 DN 89:39396
 TI The alkaloids of *Thalictrum dioicum* L
 AU Shamma, Maurice; Rothenberg, Alan S.
 CS Dep. Chem., Pennsylvania State Univ., University Park, PA, USA

SO Lloydia (1978), 41(2), 169-78
 CODEN: LLOYA2; ISSN: 0024-5461
 DT Journal
 LA English
 IT **32490-10-1P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 32490-10-1 CAPLUS
 CN 7-Isoquinolinol, 1-[[4-(acetyloxy)phenyl]methyl]-1,2,3,4-tetrahydro-6-methoxy-2-methyl-, acetate (ester), (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L16 ANSWER 49 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1977:601342 CAPLUS Full-text
 DN 87:201342
 TI Tetrahydroisoquinolines
 IN Ikezaki, Muneatsu; Irie, Kunihiro; Unno, Tokuei; Ikezawa, Ichiro;
 Sato,
 Masanori
 PA Tanabe Seiyaku Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 5 pp.
 CODEN: JKXXAF

DT Patent
 LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 52102281	A2	19770827	JP 1976-19593	19760224
	JP 56019871	B4	19810509		
PRAI	JP 1976-19593		19760224		
IT	60095-77-4P				

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and conversion to hydrochloride)
 RN 60095-77-4 CAPLUS
 CN 5,7-Isoquinolinediol, 1-[(3,4,5-trimethoxyphenyl)methyl]-, diacetate
 (ester) (9CI) (CA INDEX NAME)



IT **64728-80-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);


RACT

(Reactant or reagent)

(preparation and hydrogenation of)

RN 64728-80-9 CAPLUS

CN 5,7-Isoquinolinediol, 1-[(3,4,5-trimethoxyphenyl)methyl]-, diacetate (ester), hydrochloride (9CI) (CA INDEX NAME)



● HCl

L16 ANSWER 50 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1977:121339 CAPLUS Full-text

DN 86:121339

TI Tetrahydroisoquinolines

IN Kishimoto, Teiji; Kouchi, Hiromu; Kaneda, Yoshiyuki

PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 5 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 51086477	A2	19760729	JP 1975-8187	19750117
	JP 58017472	B4	19830407		
PRAI	JP 1975-8187		19750117		
OS	CASREACT 86:121339				
IT	61809-61-8				

RL: RCT (Reactant); RACT (Reactant or reagent)

(deprotection of)

RN 61809-61-8 CAPLUS

CN 6,7-Isoquinolinediol, 2-acetyl-1,2,3,4-tetrahydro-1-[[1-methyl-1H-tetrazol-5-yl)thio]methyl]-, diacetate (ester) (9CI) (CA INDEX NAME)



L16 ANSWER 51 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1977:106409 CAPLUS Full-text

DN 86:106409

TI Tetrahydroisoquinolines

IN Ikezaki, Muneyoshu; Irie, Kunihiro; Umino, Norihide; Ikezawa, Kazuo; Satoh, Masanori

PA Tanabe Seiyaku Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 11 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 51070774	A2	19760618	JP 1974-140294	19741205
PRAI	JP 1974-140294		19741205		
IT	61831-77-4P				

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);


RACT

(Reactant or reagent)

(preparation and hydrogenation of)

RN 61831-77-4 CAPLUS

CN 7,8-Isoquinolinediol, 1-[(3,4,5-trimethoxyphenyl)methyl]-, diacetate (ester) (9CI) (CA INDEX NAME)

IT **61831-78-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);


RACT

(Reactant or reagent)

(preparation and hydrolysis of)

RN 61831-78-5 CAPLUS

CN 7,8-Isoquinolinediol, 1-[(3,4,5-trimethoxyphenyl)methyl]-, diacetate (ester), hydrochloride (9CI) (CA INDEX NAME)



● HCl

L16 ANSWER 52 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1977:89826 CAPLUS Full-text

DN 86:89826

TI Tetrahydroisoquinolines

IN Kishimoto, Teiji; Kouchi, Hiromu; Kaneda, Yoshiyuki

PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKXXAF

DT Patent

LA Japanese


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 51086478	A2	19760729	JP 1975-8188	19750117
PRAI	JP 1975-8188		19750117		
IT	61809-61-8P				

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 61809-61-8 CAPLUS

CN 6,7-Isoquinolinediol, 2-acetyl-1,2,3,4-tetrahydro-1-[[1-methyl-1H-tetrazol-5-yl)thio]methyl]-, diacetate (ester) (9CI) (CA INDEX NAME)




L16 ANSWER 53 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1977:72465 CAPLUS Full-text
 DN 86:72465
 TI Tetrahydroisoquinolines
 IN Ikezaki, Muneyoshi; Irie, Kunihiko; Umino, Norihide; Ikezawa, Kazuo;
 Satoh, Masanori
 PA Tanabe Seiyaku Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 6 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 51070772	A2	19760618	JP 1974-137166	19741127
PRAI	JP 1974-137166		19741127		
IT	61672-56-8P				

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
 RACT
 (Reactant or reagent)
 (preparation and hydrogenation of)
 RN 61672-56-8 CAPLUS
 CN 5-Isoquinolinol, 1-[(3,4,5-trimethoxyphenyl)methyl]-, acetate (ester),
 hydrochloride (9CI) (CA INDEX NAME)



● HCl

L16 ANSWER 54 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1976:592960 CAPLUS Full-text
 DN 85:192960
 TI O-Acylhigenamines
 IN Okamoto, Toshihiko; Kosuga, Takuo; Yokota, Masami
 PA Hokuriku Pharmaceutical Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 3 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 51048677	A2	19760426	JP 1974-121715	19741022
PRAI	JP 1974-121715		19741022		
IT	60941-90-4P				


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT

(Reactant or reagent)
(preparation and hydrogenation of)

RN 60941-90-4 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 6,7-bis(acetyloxy)-1-[[4-(acetyloxy)phenyl]methyl]-3,4-dihydro-, phenylmethyl ester (9CI) (CA INDEX NAME)




IT 60941-91-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 60941-91-5 CAPLUS

CN 6,7-Isoquinolinediol, 1-[[4-(acetyloxy)phenyl]methyl]-1,2,3,4-tetrahydro-, diacetate (ester) (9CI) (CA INDEX NAME)



L16 ANSWER 55 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN .

AN 1976:478022 CAPLUS Full-text

DN 85:78022

TI 5,7-Dihydroxytetrahydroisoquinoline derivatives

IN Ikezaki, Muneyoshi; Irie, Kunihiro; Umino, Norihide; Ikezawa, Katsuo;
Sato, Masanori

PA Tanabe Seiyaku Co., Ltd., Japan

SO Ger. Offen., 23 pp.

CODEN: GWXXBX


DT Patent

LA German

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DE 2551924	A1	19760526	DE 1975-2551924	19751119
	DE 2551924	B2	19770526		

JP 51070770	A2	19760618	JP 1974-134734	19741120
JP 52047474	B4	19771202		
DK 7504873	A	19760521	DK 1975-4873	19751029
DK 143197	B	19810720		
DK 143197	C	19811123		
GB 1487457	A	19770928	GB 1975-44807	19751030
US 4054659	A	19771018	US 1975-627259	19751030
AU 7586713	A1	19770317	AU 1975-86713	19751118
CA 1032541	A1	19780606	CA 1975-239977	19751118
CS 190503	P	19790531	CS 1975-7781	19751118
BE 835744	A1	19760316	BE 1975-6045258	19751119
SE 7513013	A	19760521	SE 1975-13013	19751119
SE 424638	B	19820802		
SE 424638	C	19821111		
NL 7513517	A	19760524	NL 1975-13517	19751119
NL 166469	B	19810316		
NL 166469	C	19810817		
FR 2291753	A1	19760618	FR 1975-35390	19751119
FR 2291753	B1	19781110		
HU 170648	P	19770728	HU 1975-TA1379	19751119
CH 621341	A	19810130	CH 1975-15048	19751120
CH 623039	A	19810515	CH 1980-6065	19800811
PRAI JP 1974-134734		19741120		
CH 1975-15048		19751120		
IT 60095-77-4P				
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);				
RACT				
(Reactant or reagent)				
(preparation and reduction of)				
RN 60095-77-4 CAPLUS				
CN 5,7-Isoquinolinediol, 1-[(3,4,5-trimethoxyphenyl)methyl]-, diacetate				
(ester) (9CI) (CA INDEX NAME)				




L16 ANSWER 56 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1975:606461 CAPLUS Full-text
 DN 83:206461
 TI Proaporphine and aporphine alkaloids. V. Synthesis of (+)-glaziovine
 by 8,1'-ring closure of 1-benzylisoquinoline derivatives
 AU Casagrande, Cesare; Canonica, Luigi
 CS Lab. Ric. Chim., Simes S.p.A., Milan, Italy
 SO Journal of the Chemical Society, Perkin Transactions 1: Organic and
 Bio-Organic Chemistry (1972-1999) (1975), (17), 1647-52
 CODEN: JCPRB4; ISSN: 0300-922X


DT Journal
 LA English
 IT **58093-40-6P 58093-41-7P 58093-42-8P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 58093-40-6 CAPLUS
 CN Isoquinoline, 7-(acetyloxy)-1-[[4-(acetyloxy)phenyl]methyl]-1,2,3,4-tetrahydro-6-methoxy-2-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 58093-41-7 CAPLUS
 CN Isoquinoline, 7-(acetyloxy)-1-[[4-(acetyloxy)phenyl]methyl]-8-chloro-1,2,3,4-tetrahydro-6-methoxy-2-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 58093-42-8 CAPLUS
 CN Isoquinoline, 4,7-bis(acetyloxy)-1-[[4-(acetyloxy)phenyl]methyl]-8-chloro-1,2,3,4-tetrahydro-6-methoxy-2-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




L16 ANSWER 57 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1975:514235 CAPLUS Full-text
 DN 83:114235
 TI Tetrahydroisoquinoline derivatives
 IN Irie, Kunihiko; Ito, Nobuo; Sugasawa, Shigehiko; Ikezawa, Kazuo; Sato, Masanori
 PA Tanabe Seiyaku Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 50035175	A2	19750403	JP 1973-86072	19730731
	JP 52046232	B4	19771122		
PRAI	JP 1973-86072		19730731		
IT	56629-28-8				

RL: RCT (Reactant); RACT (Reactant or reagent)
 (hydrolysis of)

RN 56629-28-8 CAPLUS

CN 7-Isoquinolinol, 1,2,3,4-tetrahydro-1-[(3,4,5-trimethoxyphenyl)methyl]-,
 acetate (ester), hydrochloride (9CI) (CA INDEX NAME)



● HCl

L16 ANSWER 58 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1975:427935 CAPLUS Full-text
 DN 83:27935
 TI N-[α-(3,4-Diacloxyphenyl)-β-arylethyl]-carbamates
 IN Yamamura, Toshiro; Ohashi, Motoaki; Saito, Seiichi; Iwasawa, Yoshio; Harigaya, Shoichi
 PA Tanabe Seiyaku Co., Ltd.
 SO Jpn. Kokai Tokkyo Koho, 4 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 49135955	A2	19741227	JP 1973-53352	19730514
PRAI	JP 1973-53352		19730514		

IT 56064-56-3P 56064-57-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 56064-56-3 CAPLUS

CN Carbamic acid, [1-[3,4-bis(acetyloxy)phenyl]-2-(3,4-dimethoxyphenyl)ethyl]-
, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 56064-57-4 CAPLUS

CN Carbamic acid, [1-[3,4-bis(acetyloxy)phenyl]-2-(3,4,5-trimethoxyphenyl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



L16 ANSWER 59 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1975:156025 CAPLUS Full-text

DN 82:156025

TI Tetrahydroisoquinolines. VIII. Lead tetraacetate oxidation of
1,2,3,4-tetrahydro-6-hydroxy-7-methoxy-2-methylisoquinoline and its
1-substituted derivatives

AU Hoshino, Osamu; Ohyama, Keiko; Taga, Michinori; Umezawa, Bunsuke

CS Fac. Pharm. Sci., Sci. Univ. Tokyo, Tokyo, Japan

SO Chemical & Pharmaceutical Bulletin (1974), 22(11), 2587-92

CODEN: CPBTAL; ISSN: 0009-2363

DT Journal


LA English

IT 55161-55-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 55161-55-2 CAPLUS

CN Isoquinolinium, 4,6-bis(acetyloxy)-1,2,3,4-tetrahydro-7-methoxy-2,2-dimethyl-1-(phenylmethyl)-, iodide (9CI) (CA INDEX NAME)



● I -

L16 ANSWER 60 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1974:569676 CAPLUS Full-text
 DN 81:169676
 TI 1-Phenethylisoquinoline alkaloids. IV. Isolation, structural elucidation, and synthesis of C-homoaporphines
 AU Battersby, Alan R.; Bradbury, Robert B.; Herbert, Richard B.; Munro, Murray H. G.; Ramage, Robert
 CS Robert Robinson Lab., Univ. Liverpool, Liverpool, UK
 SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1974), (12), 1394-9
 CODEN: JCPRB4; ISSN: 0300-922X
 DT Journal
 LA English
 IT **54370-10-4P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 54370-10-4 CAPLUS
 CN 7-Isoquinolinol, 1-[2-[4-(acetyloxy)-3,5-dimethoxyphenyl]ethyl]-1,2,3,4-tetrahydro-6-methoxy-2-methyl-, acetate (ester) (9CI) (CA INDEX NAME)




L16 ANSWER 61 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1974:505783 CAPLUS Full-text
 DN 81:105783
 TI (+-)-Glaziovine
 IN Casagrande, Cesare; Canonica, Luigi
 PA SIPHAR S. A.
 SO Ger. Offen., 23 pp.
 CODEN: GWXXBX
 DT Patent

LA German

FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2363530	A1	19740627	DE 1973-2363530	19731220
	CH 575930	A	19760531	CH 1972-18784	19721222
	GB 1451377	A	19760929	GB 1973-57205	19731210
	ZA 7309528	A	19741127	ZA 1973-9528	19731218
	FR 2211433	A1	19740719	FR 1973-45942	19731221
	CA 1014158	A1	19770719	CA 1973-188805	19731221
	JP 50004079	A2	19750116	JP 1974-4872	19731222
	ES 421744	A1	19760416	ES 1973-421744	19731222
PRAI	CH 1972-18784		19721222		
IT	54170-07-9P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	54170-07-9 CAPLUS				
CN	7-Isoquinolinol, 8-bromo-1,2,3,4-tetrahydro-6-methoxy-2-methyl-1-[[4-(phenylmethoxy)phenyl]methyl]-, acetate (ester) (9CI) (CA INDEX NAME)				




L16 ANSWER 62 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1974:505313 CAPLUS Full-text
 DN 81:105313
 TI 6,7-Dihydroxy-1,2,3,4-tetrahydroisoquinolines
 IN Kishimoto, Teiji; Kouchi, Hiromu; Kaneda, Yoshiyuki
 PA Fujisawa Pharmaceutical Co., Ltd.
 SO Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 49020187	A2	19740222	JP 1972-61961	19720620
	JP 55000381	B4	19800108		
	CA 990725	A1	19760608	CA 1973-173937	19730613
	CH 592629	A	19771031	CH 1973-8900	19730619
	ES 416095	A1	19760516	ES 1973-416095	19730620
	AT 7502024	A	19760415	AT 1975-2024	19750317
	AT 333762	B	19761210		
PRAI	JP 1972-61960		19720620		
	JP 1972-61961		19720620		
	JP 1972-61962		19720620		
	JP 1972-61963		19720620		
	JP 1972-100210		19721005		
	JP 1972-100211		19721005		


AT 1973-5381 19730619
 IT 53593-12-7 53593-15-0 53593-16-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (hydrolysis of)
 RN 53593-12-7 CAPLUS
 CN 6,7-Isoquinolinediol, 2-acetyl-1-[(4-chlorophenoxy)methyl]-1,2,3,4-tetrahydro-, diacetate (ester) (9CI) (CA INDEX NAME)




RN 53593-15-0 CAPLUS
 CN 6,7-Isoquinolinediol, 2-acetyl-1-[(2-chloro-4-methoxyphenoxy)methyl]-1,2,3,4-tetrahydro-, diacetate (ester) (9CI) (CA INDEX NAME)



RN 53593-16-1 CAPLUS
 CN 6,7-Isoquinolinediol, 2-acetyl-1-[(3,4-dichlorophenoxy)methyl]-1,2,3,4-tetrahydro-, diacetate (ester) (9CI) (CA INDEX NAME)




L16 ANSWER 63 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1974:96187 CAPLUS Full-text
 DN 80:96187
 TI Simple synthesis of an isopavine alkaloid, (+)-O-methylthalisopavine
 and
 (+)-reframine
 AU Hoshino, Osamu; Tata, Michinori; Umezawa, Bunsuke
 CS Fac. Pharm. Sci., Sci. Univ. Tokyo, Tokyo, Japan
 SO Heterocycles (1973), 1(3-4), 223-6
 CODEN: HTCYAM; ISSN: 0385-5414
 DT Journal
 LA English
 IT **51724-65-3P 51724-69-7P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 51724-65-3 CAPLUS
 CN Isoquinolinium, 4,6-bis(acetyloxy)-1-[(3,4-dimethoxyphenyl)methyl]-
 1,2,3,4-
 tetrahydro-7-methoxy-2,2-dimethyl-, iodide (9CI) (CA INDEX NAME)



● I⁻


RN 51724-69-7 CAPLUS
 CN Isoquinolinium, 4,6-bis(acetyloxy)-1-(1,3-benzodioxol-5-ylmethyl)-
 1,2,3,4-
 tetrahydro-7-methoxy-2,2-dimethyl-, iodide (9CI) (CA INDEX NAME)




● I⁻

L16 ANSWER 64 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1973:526676 CAPLUS Full-text
 DN 79:126676
 TI Syntheses of heterocyclic compounds. DXXIII. Enzymic oxidation of homoorientaline with homogenized potato peelings
 AU Kametani, T.; Mizushima, M.; Takano, S.; Fukumoto, K.
 CS Pharm. Inst., Tohoku Univ., Sendai, Japan
 SO Tetrahedron (1973), 29(14), 2031-3
 CODEN: TETRAB; ISSN: 0040-4020
 DT Journal
 LA English
 IT **50678-01-8P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 50678-01-8 CAPLUS
 CN 1,7-Isoquinolinediol, 1-[2-[4-(acetyloxy)-3-methoxyphenyl]ethyl]-
 1,2,3,4-
 tetrahydro-6-methoxy-2-methyl-, diacetate (ester), (S)- (9CI) (CA
 INDEX
 NAME)


Absolute stereochemistry.



L16 ANSWER 65 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1973:442719 CAPLUS Full-text
 DN 79:42719
 TI Intramolecular oxidative coupling of monophenolic benzylisoquinolines. Quinonoid oxoaporphines
 AU Kupchan, S. Morris; Liepa, Andris J.
 CS Dep. Chem., Univ. Virginia, Charlottesville, VA, USA
 SO Journal of the American Chemical Society (1973), 95(12), 4062-4
 CODEN: JACSAT; ISSN: 0002-7863
 DT Journal
 LA English
 IT **42922-19-0P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 42922-19-0 CAPLUS
 CN 7-Isoquinolinol, 1-[(2-amino-4,5-dimethoxyphenyl)methyl]-6-methoxy-, acetate (ester) (9CI) (CA INDEX NAME)




L16 ANSWER 66 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1972:488742 CAPLUS Full-text
 DN 77:88742
 TI Nonaromatic ring D analog of the dibenzopyrrocoline alkaloids
 AU Morrison, Glenn C.; Waite, Ronald O.; Shavel, John, Jr.
 CS Dep. Org. Chem., Warner-Lambert Res. Inst., Morris Plains, NJ, USA
 SO Journal of Heterocyclic Chemistry (1972), 9(3), 683-5
 CODEN: JHTCAD; ISSN: 0022-152X
 DT Journal
 LA English
 IT **31804-77-0P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 31804-77-0 CAPLUS
 CN 6-Isoquinolinol, 2-acetyl-1,2,3,4-tetrahydro-7-methoxy-1-[(4-oxo-2-cyclohexen-1-yl)methyl]-, acetate (ester) (8CI) (CA INDEX NAME)




L16 ANSWER 67 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1972:459392 CAPLUS Full-text
 DN 77:59392
 TI Whole-body autoradiographic studies on the distribution of radioisotopes.
 XXVIII. Distribution of radioactivity in mice after oral administration
 of tritium labeled O-dibutyrylated trimethoquinol (BAQ-509)
 AU Otsuka, Minezo; Sakuma, Mari; Sato, Yoshishige
 CS Biol. Res. Lab., Tanabe Seiyaku Co. Ltd., Toda, Japan
 SO Radioisotopes (1972), 21(2), 102-9
 CODEN: RAISAB; ISSN: 0033-8303
 DT Journal

LA Japanese
 IT 37893-95-1 |
 RL: BPR (Biological process); BSU (Biological study, unclassified);
 BIOL (Biological study); PROC (Process)
 (metabolism of)
 RN 37893-95-1 CAPLUS
 CN Butanoic acid, 1,2,3,4-tetrahydro-1-[(3,4,5-trimethoxyphenyl)methyl]-
 6,7-
 isoquinolinediyl ester, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI)
 (CA
 INDEX NAME)
 CM 1
 CRN 47765-22-0
 CMF C27 H35 N O7




CM 2
 CRN 87-69-4
 CMF C4 H6 O6

Absolute stereochemistry.




L16 ANSWER 68 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1972:448280 CAPLUS Full-text
 DN 77:48280
 TI Tetrahydroisoquinoline derivatives
 IN Watanabe, Toshiro; Hayashi, Kimiaki; Sato, Yoshinori; Iwasawa, Yoshiro
 PA Tanabe Seiyaku Co., Ltd.
 SO Jpn. Tokkyo Koho, 4 pp.
 CODEN: JAXXAD
 DT Patent
 LA Japanese
 FAN.CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE


PI JP 47014108 B4 19720427 JP 1969-53256 19690704
 IT **34202-91-0P 34221-51-7P 34221-52-8P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 34202-91-0 CAPLUS
 CN Butanoic acid, 1,2,3,4-tetrahydro-1-[(3,4,5-trimethoxyphenyl)methyl]-
 6,7-
 isoquinolinediyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)
 CM 1
 CRN 47765-22-0
 CMF C27 H35 N O7



CM 2
 CRN 144-62-7
 CMF C2 H2 O4




RN 34221-51-7 CAPLUS
 CN 6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-[(3,4,5-trimethoxyphenyl)methyl]-, diacetate (ester), ethanedioate (1:1)
 (salt)
 (9CI) (CA INDEX NAME)
 CM 1
 CRN 33300-96-8
 CMF C23 H27 N O7



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 34221-52-8 CAPLUS


CN Propanoic acid, 2-methyl-, 1,2,3,4-tetrahydro-1-[(3,4,5-trimethoxyphenyl)methyl]-6,7-isoquinolinediyl ester, ethanedioate (1:1)

(9CI) (CA INDEX NAME)

CM 1

CRN 34685-11-5


CMF C27 H35 N O7




CM 2

CRN 144-62-7

CMF C2 H2 O4




L16 ANSWER 69 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1972:72378 CAPLUS Full-text
 DN 76:72378
 TI Reaction between isatin and amines
 AU Brouwer, W. G.; Craig, W. A.; Jeffreys, J. A. D.; Munro, A.
 CS Dep. Pure Appl. Chem., Univ. Strathclyde, Glasgow, UK
 SO Journal of the Chemical Society, Perkin Transactions 1: Organic and
 Bio-Organic Chemistry (1972-1999) (1972), (1), 124-9
 CODEN: JCPRB4; ISSN: 0300-922X
 DT Journal
 LA English
 IT **35117-99-8P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 35117-99-8 CAPLUS
 CN 6-Isoquinolinol, 1-[[3-(acetyloxy)-4-methoxyphenyl]methyl]-7-methoxy-,
 acetate (ester) (9CI) (CA INDEX NAME)




L16 ANSWER 70 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1972:34129 CAPLUS Full-text
 DN 76:34129
 TI Tetrahydroisoquinolines
 IN Watanabe, Toshio; Tsukamoto, Goro; Hayashi, Kimiaki; Sato, Tadanori
 PA Tanabe Seiyaku Co., Ltd.
 SO Jpn. Tokkyo Koho, 4 pp.
 CODEN: JAXXAD
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 46039700	B4	19711122	JP	19690313


IT **33300-96-8P 34685-11-5P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 33300-96-8 CAPLUS
 CN 6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-[(3,4,5-trimethoxyphenyl)methyl]-, diacetate (ester) (9CI) (CA INDEX NAME)



RN 34685-11-5 CAPLUS
 CN Propanoic acid, 2-methyl-, 1,2,3,4-tetrahydro-1-[(3,4,5-trimethoxyphenyl)methyl]-6,7-isoquinolinediyl ester (9CI) (CA INDEX NAME)




L16 ANSWER 71 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1972:34077 CAPLUS Full-text
 DN 76:34077
 TI Tetrahydroisoquinolines. I. Formation and acid-catalyzed rearrangement
 of 10-acetoxy-6-methoxy-2-methyl-7-oxo-8,9-hexahydroisoquinolines
 AU Umezawa, Bunsuke; Hoshino, Osamu; Terayama, Yasuo; Ohya, Keiko; Yamanashi, Yasuhiro; Inoue, Tsutomu; Toshioka, Tadashi
 CS Fac. Pharm. Sci., Sci. Univ. Tokyo, Tokyo, Japan
 SO Chemical & Pharmaceutical Bulletin (1971), 19(10), 2138-46
 CODEN: CPBTAL; ISSN: 0009-2363
 DT Journal
 LA English
 IT **35006-05-4P 35006-06-5P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 35006-05-4 CAPLUS
 CN 4,7-Isoquinolinediol, 1,2,3,4-tetrahydro-6-methoxy-2-methyl-1-(phenylmethyl)-, diacetate (ester) (9CI) (CA INDEX NAME)



RN 35006-06-5 CAPLUS
 CN 4,7-Isoquinolinediol, 1,2,3,4-tetrahydro-6-methoxy-2-methyl-1-
 (phenylmethyl)-, diacetate (ester), compd. with 2,4-dihydro-5-methyl-
 4-nitro-2-(4-nitrophenyl)-3H-pyrazol-3-one (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 35006-05-4
 CMF C22 H25 N O5



CM 2


CRN 550-74-3
 CMF C10 H8 N4 O5



L16 ANSWER 72 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1971:488505 CAPLUS Full-text
 DN 75:88505
 TI Tetrahydroisoquinoline derivatives
 IN Watanabe, Toshiro; Tsukamoto, Goro; Hayashi, Kimiaki; Sato, Kuninori;
 Iwasawa, Yoshiro
 PA Tanabe Seiyaku Co., Ltd.
 SO Jpn. Tokkyo Koho, 3 pp.
 CODEN: JAXXAD
 DT Patent
 LA Japanese
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 46023389	B4	19710703	JP	19681210

IT 33300-96-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 33300-96-8 CAPLUS
 CN 6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-[(3,4,5-trimethoxyphenyl)methyl]-, diacetate (ester) (9CI) (CA INDEX NAME)



L16 ANSWER 73 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1971:436410 CAPLUS Full-text
 DN 75:36410
 TI Syntheses of heterocyclic compounds. CMII. Chemical and enzymic phenol oxidation of (R)(-)-N-methylcocclaurine and (S)(+)-reticuline
 AU Kametani, Tetsuji; Fukumoto, Keiichiro; Kigasawa, Kazuo; Wakisaka, Kikuo
 CS Pharm. Inst., Tohoku Univ., Sendai, Japan
 SO Chemical & Pharmaceutical Bulletin (1971), 19(4), 714-17
 CODEN: CPBTAL; ISSN: 0009-2363
 DT Journal
 LA English
 IT 32490-10-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 32490-10-1 CAPLUS
 CN 7-Isoquinolinol, 1-[[4-(acetyloxy)phenyl]methyl]-1,2,3,4-tetrahydro-6-methoxy-2-methyl-, acetate (ester), (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L16 ANSWER 74 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1971:141565 CAPLUS Full-text
 DN 74:141565
 TI Hypotensive 5,6,7a,8,11,11a,12,12a-octahydroindolo[2,1-a]isoquinolin-

9(10H)-ones
 IN Shavel, John, Jr.; Morrison, Glenn Curtis
 PA Warner-Lambert Pharmaceutical Co.
 SO U.S., 5 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3557122	A	19710119	US 1968-766636	19681010
PRAI	US 1968-766636		19681010		
IT	31804-77-0P				

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 31804-77-0 CAPLUS
 CN 6-Isoquinolinol, 2-acetyl-1,2,3,4-tetrahydro-7-methoxy-1-[(4-oxo-2-cyclohexen-1-yl)methyl]-, acetate (ester) (8CI) (CA INDEX NAME)




L16 ANSWER 75 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1970:455982 CAPLUS Full-text
 DN 73:55982
 TI β -Stimulating 6,7-diacyloxy-1-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinolines
 IN Watanabe, Toshio; Tsukamoto, Goro; Hayashi, Kimiaki; Sato, Masanori; Toda, Iwasawa
 PA Tanabe Seiyaku Co., Ltd.
 SO Ger. Offen., 20 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1961947	A	19700618	DE 1969-1961947	19691210
	DE 1961947	B2	19740328		
	DE 1961947	C3	19741031		
	IL 33480	A1	19730330	IL 1969-33480	19691203
	US 3647799	A	19720307	US 1969-882296	19691204
	FI 49166	B	19741231	FI 1969-3512	19691204
	ES 374291	A1	19711216	ES 1969-374291	19691205
	BE 742807	A	19700514	BE 1969-742807	19691208
	GB 1242160	A	19710811	GB 1969-1242160	19691208
	NL 6918454	A	19700612	NL 1969-18454	19691209

FR 2025778	A5	19700910	FR 1969-42467	19691209
FR 2025778	B1	19731221		
AT 294095	B	19711110	AT 1969-11438	19691209
SE 347744	B	19720814	SE 1969-17003	19691209
NO 126320	B	19730122	NO 1969-4860	19691209
BR 6914920	A0	19730308	BR 1969-214920	19691209
DK 129994	B	19741209	DK 1969-6498	19691209
CH 523250	A	19720531	CH 1969-523250	19691210
CS 156504	P	19740724	CS 1969-8138	19691210
PRAI JP 1968-90741		19681210		
IT		28940-86-5P 28940-88-7P 28940-89-8P		
		28940-90-1P 28940-91-2P 28954-28-1P		
		28954-29-2P 29051-20-5P 34202-91-0P		
		34221-51-7P 34221-52-8P		
		RL: SPN (Synthetic preparation); PREP (Preparation)		
		(preparation of)		
RN		28940-86-5 CAPLUS		
CN		6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-(3,4,5-trimethoxybenzyl)-, diacetate (ester), oxalate (1:1), (-)- (8CI) (CA INDEX NAME)		
CM	1			
CRN	47685-00-7			
CMF	C23 H27 N O7			


Rotation (-).



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 28940-88-7 CAPLUS


CN Butyric acid, 1,2,3,4-tetrahydro-1-(3,4,5-trimethoxybenzyl)-6,7-isoquinolinediyl ester oxalate (1:1), (S)-(-)- (8CI) (CA INDEX NAME)

CM 1

CRN 39772-42-4

CMF C27 H35 N O7


Absolute stereochemistry.



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 28940-89-8 CAPLUS


CN Butyric acid, 1,2,3,4-tetrahydro-1-(3,4,5-trimethoxybenzyl)-6,7-isoquinolinediyl ester tartrate (1:1), (S)-(-)- (8CI) (CA INDEX NAME)

CM 1

CRN 39772-42-4

CMF C27 H35 N O7

Absolute stereochemistry.




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.




RN 28940-90-1 CAPLUS
 CN Butyric acid, 1,2,3,4-tetrahydro-1-(3,4,5-trimethoxybenzyl)-6,7-
 isoquinolinediyl ester succinate (1:1), (S)-(-)- (8CI) (CA INDEX
 NAME)

CM 1


CRN 39772-42-4
 CMF C27 H35 N O7

Absolute stereochemistry.



CM 2

CRN 110-15-6
 CMF C4 H6 O4




RN 28940-91-2 CAPLUS
 CN Isobutyric acid, 1,2,3,4-tetrahydro-1-(3,4,5-trimethoxybenzyl)-6,7-
 isoquinolinediyl ester oxalate (1:1), (-)- (8CI) (CA INDEX NAME)

CM 1

CRN 47765-21-9
 CMF C27 H35 N O7


Rotation (-).



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 28954-28-1 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-6,7-dihydroxy-1-(3,4,5-trimethoxybenzyl)-, benzyl ester, diacetate (ester), (-)- (8CI) (CA

INDEX
NAME)

Rotation (-).



RN 28954-29-2 CAPLUS


CN 6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-(3,4,5-trimethoxybenzyl)-, dipropionate (ester), oxalate (1:1), (-)- (8CI) (CA INDEX NAME)

CM 1

CRN 47730-19-8

CMF C25 H31 N O7


Rotation (-).



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 29051-20-5 CAPLUS


CN Butyric acid, 1,2,3,4-tetrahydro-1-(3,4,5-trimethoxybenzyl)-6,7-isoquinolinediyl ester maleate (1:1), (S)-(-)-(8CI) (CA INDEX NAME)

CM 1

CRN 39772-42-4

CMF C27 H35 N O7

Absolute stereochemistry.




CM 2


CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.




RN 34202-91-0 CAPLUS
 CN Butanoic acid, 1,2,3,4-tetrahydro-1-[(3,4,5-trimethoxyphenyl)methyl]-
 6,7-
 isoquinolinediyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)
 CM 1
 CRN 47765-22-0
 CMF C27 H35 N O7



CM 2
 CRN 144-62-7
 CMF C2 H2 O4




RN 34221-51-7 CAPLUS
 CN 6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-[(3,4,5-
 trimethoxyphenyl)methyl]-, diacetate (ester), ethanedioate (1:1)
 (salt)
 (9CI) (CA INDEX NAME)
 CM 1
 CRN 33300-96-8
 CMF C23 H27 N O7



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 34221-52-8 CAPLUS


CN Propanoic acid, 2-methyl-, 1,2,3,4-tetrahydro-1-[(3,4,5-trimethoxyphenyl)methyl]-6,7-isoquinolinediyl ester, ethanedioate (1:1)

(9CI) (CA INDEX NAME)

CM 1

CRN 34685-11-5


CMF C27 H35 N O7




CM 2

CRN 144-62-7


CMF C2 H2 O4




L16 ANSWER 76 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1970:121744 CAPLUS Full-text
 DN 72:121744
 TI Synthetic studies of curare alkaloids. XIV. Synthesis of
 1-(4'-benzyloxybenzyl)6-methoxy-7-(2''-methoxy-5''-
 methoxycarbonylmethylphenoxy)-N-methyl-1,2,3,4-tetrahydroisoquinoline
 AU Tolkachev, O. N.; Volkova, L. V.; Vasil'ev, G. S.; Prokhorov, A. B.;
 Kulachkina, N. S.; Preobrazhenskii, N. A.
 CS Mosk. Inst. Tonkoi Khim. Tekhnol. im. Lomonosova, Moscow, USSR
 SO Khimiya Geterotsiklicheskikh Soedinenii (1969), (5), 831-7
 CODEN: KGSSAQ; ISSN: 0132-6244
 DT Journal
 LA Russian
 IT **26626-00-6P 26626-03-9P 26648-66-8P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 26626-00-6 CAPLUS
 CN 7-Isoquinolinol, 1-[p-(benzyloxy)benzyl]-1,2,3,4-tetrahydro-6-methoxy-
 ' acetate (ester), oxalate (1:1), (±)- (8CI) (CA INDEX NAME)
 CM 1
 CRN 96808-23-0
 CMF C26 H27 N O4



CM 2
 CRN 144-62-7
 CMF C2 H2 O4



RN 26626-03-9 CAPLUS
 CN 7-Isoquinolinol, 1-[p-(benzyloxy)benzyl]-1,2,3,4-tetrahydro-6-methoxy-
 2- methyl-, acetate (ester), hydrochloride, (±)- (8CI) (CA INDEX NAME)




● HCl

RN 26648-66-8 CAPLUS
 CN 7-Isoquinolinol, 1-[p-(benzyloxy)benzyl]-1,2,3,4-tetrahydro-6-methoxy-
 2-methyl-, acetate (ester), oxalate (1:1), (±)- (8CI) (CA INDEX NAME)


CM 1

CRN 4119-55-5
 CMF C27 H29 N O4




CM 2

CRN 144-62-7
 CMF C2 H2 O4




L16 ANSWER 77 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1970:43387 CAPLUS Full-text
 DN 72:43387
 TI Enzymic phenol oxidation. III. Head-to-head coupling of
 1,2,3,4-tetrahydro-7-hydroxy-1-(4-hydroxyphenethyl)-6-methoxy-2-
 methylisoquinoline with homogenized Wasabia japonica and hydrogen
 peroxide
 AU Kametani, Tetsuji; Takano, Seiichi; Kobari, Takashi
 CS Pharm. Inst., Tohoku Univ., Sendai, Japan


SO Journal of the Chemical Society [Section] C: Organic (1969), (19),
2770-3
CODEN: JSOOAX; ISSN: 0022-4952
DT Journal
LA English
IT **25888-72-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 25888-72-6 CAPLUS
CN 7-Isoquinolinol, 1,2,3,4-tetrahydro-1-(p-hydroxyphenethyl)-6-methoxy-
2-
methyl-, diacetate (ester) (8CI) (CA INDEX NAME)



L16 ANSWER 78 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1969:413241 CAPLUS Full-text
DN 71:13241
TI Alkaloid biosynthesis. XIV. Secologanin: its conversion into
ipecoside
and its role as biological precursor of the indole alkaloids
AU Battersby, Alan R.; Burnett, Alan R.; Parsons, P. G.
CS Univ. Liverpool, Liverpool, UK
SO Journal of the Chemical Society [Section] C: Organic (1969), (8),
1187-92
CODEN: JSOOAX; ISSN: 0022-4952
DT Journal
LA English
IT **21104-39-2P 21104-40-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 21104-39-2 CAPLUS
CN 2H-Pyran-5-carboxylic acid, 4-[[2-acetyl-6,7-bis(acetyloxy)-1,2,3,4-
tetrahydro-1-isoquinolinyl]methyl]-3-ethenyl-3,4-dihydro-2-[(2,3,4,6-
tetra-
O-acetyl- β -D-glucopyranosyl)oxy]-, methyl ester, [2S-
[2 α , 3 β , 4 β (S*)]]- (9CI) (CA INDEX NAME)




RN 21104-40-5 CAPLUS
 CN 2H-Pyran-5-carboxylic acid, 4-[[2-acetyl-6,7-bis(acetyloxy)-1,2,3,4-tetrahydro-1-isoquinolinyl]methyl]-3-ethenyl-3,4-dihydro-2-[(2,3,4,6-O-acetyl-beta-D-glucopyranosyl)oxy]-, methyl ester, [2S-[2alpha,3beta,4beta(R*)]]- (9CI) (CA INDEX NAME)



L16 ANSWER 79 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1969:403289 CAPLUS Full-text
 DN 71:3289
 TI 1-Benzyl-6,7-di(lower-alkanoyloxy)-1,2,3,4-tetrahydroisoquinolines
 IN Yamato, Eisaku; Kasuya, Shoichi
 PA Tanabe Seiyaku Co., Ltd.
 SO Jpn. Tokkyo Koho, 2 pp.
 CODEN: JAXXAD
 DT Patent
 LA Japanese
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 43018547	B4	19680809	JP	19651202
IT	22655-30-7P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	22655-30-7	CAPLUS			
CN	6,7-Isoquinolinediol, 1-benzyl-1,2,3,4-tetrahydro-, diacetate (ester), sulfate (1:1) (8CI) (CA INDEX NAME)				
CM	1				

CRN 47446-88-8
CMF C20 H21 N O4




CM 2


CRN 7664-93-9
CMF H2 O4 S



L16 ANSWER 80 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1969:20259 CAPLUS Full-text
DN 70:20259
TI Preparation of secologanin: its conversion into ipecoside and its
role in
indole alkaloid biosynthesis
AU Battersby, Alan R.; Burnett, Alan R.; Parsons, P. G.
CS Univ. Liverpool, Liverpool, UK
SO Chemical Communications (London) (1968), (21), 1280-1
CODEN: CCOMA8; ISSN: 0009-241X
DT Journal
LA English
IT **21104-39-2P 21104-40-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 21104-39-2 CAPLUS
CN 2H-Pyran-5-carboxylic acid, 4-[[2-acetyl-6,7-bis(acetyloxy)-1,2,3,4-
tetrahydro-1-isoquinolinyl]methyl]-3-ethenyl-3,4-dihydro-2-[(2,3,4,6-
tetra-
O-acetyl-β-D-glucopyranosyl)oxy]-, methyl ester, [2S-
[2α,3β,4β(S*)]]- (9CI) (CA INDEX NAME)




RN 21104-40-5 CAPLUS
 CN 2H-Pyran-5-carboxylic acid, 4-[[2-acetyl-6,7-bis(acetyloxy)-1,2,3,4-tetrahydro-1-isoquinolinyl]methyl]-3-ethenyl-3,4-dihydro-2-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]-, methyl ester, [2S-[2α,3β,4β(R*)]]- (9CI) (CA INDEX NAME)




L16 ANSWER 81 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1968:459456 CAPLUS Full-text
 DN 69:59456
 TI Alkaloids of *Xylopiapapua*
 AU Johns, S. R.; Lamberton, J. A.; Sioumis, A. A.
 CS Div. Appl. Chem., C.S.I.R.O., Melbourne, Australia
 SO Australian Journal of Chemistry (1968), 21(5), 1383-6
 CODEN: AJCHAS; ISSN: 0004-9425
 DT Journal
 LA English
 IT **14199-49-6P 19894-20-3P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 14199-49-6 CAPLUS
 CN Reticuline, diacetate (ester) (8CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 19894-20-3 CAPLUS
 CN 7-Isoquinolinol, 2-acetyl-1-[[4-(4-acetyloxy)phenyl]methyl]-1,2-dihydro-6-methoxy-, acetate (ester), (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 82 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1968:427560 CAPLUS Full-text
 DN 69:27560
 TI Studies on the syntheses of heterocyclic compounds. CCIX. Total syntheses of (+-)-isococclaurine and (-)-lotusine
 AU Kametani, Tetsuji; Takano, Seiichi; Sasaki, Fujinori; Yamaki, Kazuya
 CS Tohoku Univ. Sch. Med., Sendai, Japan
 SO Chemical & Pharmaceutical Bulletin (1968), 16(1), 20-4
 CODEN: CPBTAL; ISSN: 0009-2363
 DT Journal
 LA English
 IT **19442-72-9P**
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 19442-72-9 CAPLUS
 CN Butanedioic acid, 2,3-bis(benzoyloxy)-, [S-(R*,R*)]-, compd. with 1-[[4-(4-acetyloxy)phenyl]methyl]-1,2,3,4-tetrahydro-7-methoxy-2-methyl-6-isoquinolinyl acetate (ester) (9CI) (CA INDEX NAME)
 CM 1
 CRN 47581-12-4
 CMF C22 H25 N O5




CM 2


CRN 17026-42-5

CMF C18 H14 O8


Absolute stereochemistry. Rotation (+).



L16 ANSWER 83 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1968:104952 CAPLUS Full-text
 DN 68:104952
 TI Synthesis of 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline derivatives
 AU Yamato, Eisaku; Mashimo, Kiyohiko; Hirakura, Minoru; Yamagata, Osamu;
 Kurihara, Sumio
 CS Tanabe Seiyaku Co., Ltd., Osaka, Japan
 SO Yakugaku Zasshi (1967), 87(9), 1083-8
 CODEN: YKKZAJ; ISSN: 0031-6903
 DT Journal
 LA Japanese
 IT **18063-81-5P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 18063-81-5 CAPLUS
 CN Isoquinoline, 2-acetyl-1,2,3,4-tetrahydro-6,7-dihydroxy-1-(3,4,5-trimethoxybenzyl)-, diacetate (ester) (8CI) (CA INDEX NAME)



L16 ANSWER 84 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1968:29924 CAPLUS Full-text
 DN 68:29924
 TI 1-Phenethylisoquinoline alkaloids. I. Structure and synthesis of
 (-)-melanthioidine, a bisphenethylisoquinoline alkaloid
 AU Battersby, Alan R.; Herbert, Richard B.; Mo, Lucy; Santavy, Frantisek
 CS Univ. Liverpool, Liverpool, UK
 SO Journal of the Chemical Society [Section] C: Organic (1967), (18),
 1739-44
 CODEN: JSOOAX; ISSN: 0022-4952
 DT Journal
 LA English
 OS CASREACT 68:29924
 IT **17801-29-5P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 17801-29-5 CAPLUS
 CN 7-Isoquinolinol, 1-[4-(benzyloxy)-3-bromophenethyl]-1,2,3,4-
 tetrahydro-6-
 methoxy-2-methyl-, acetate (ester), hydrochloride, (±)- (8CI) (CA
 INDEX NAME)




● HCl

L16 ANSWER 85 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1967:490969 CAPLUS Full-text
 DN 67:90969
 TI 1-Benzyl-1,2,3,4-tetrahydroisoquinoline alkaloids from Alseodaphne
 archboldiana
 AU Johns, Stanley R.; Lamberton, John A.; Sioumis, A. A.


CS Div. Appl. Chem., C.S.I.R.O., Melbourne, Australia
 SO Australian Journal of Chemistry (1967), 20(8), 1729-35
 CODEN: AJCHAS; ISSN: 0004-9425
 DT Journal
 LA English
 IT **3422-43-3P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 3422-43-3 CAPLUS
 CN 7-Isoquinolinol, 2-acetyl-1-[[4-(acetyloxy)phenyl]methyl]-1,2,3,4-
 tetrahydro-6-methoxy-, acetate (ester), (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 86 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1967:454293 CAPLUS Full-text
 DN 67:54293
 TI Cassytha alkaloids. IV. Alkaloids of Cassytha racemosa
 AU Johns, Stanley R.; Lamberton, John A.; Sioumis, A. A.
 CS Div. Appl. Chem., C.S.I.R.O., Melbourne, Australia
 SO Australian Journal of Chemistry (1967), 20(7), 1457-62
 CODEN: AJCHAS; ISSN: 0004-9425
 DT Journal
 LA English
 IT **3422-43-3P**
 RL: PREP (Preparation)
 (from Cassytha racemosa)
 RN 3422-43-3 CAPLUS
 CN 7-Isoquinolinol, 2-acetyl-1-[[4-(acetyloxy)phenyl]methyl]-1,2,3,4-
 tetrahydro-6-methoxy-, acetate (ester), (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L16 ANSWER 87 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1967:2672 CAPLUS Full-text

DN 66:2672
 TI Phenol oxidation. I. The synthesis of isoboldine and glaucine
 AU Jackson, Anthony Hugh; Martin, Joseph Armstrong
 CS Univ. Liverpool, Liverpool, UK
 SO Journal of the Chemical Society [Section] C: Organic (1966), (22),
 2061-9
 CODEN: JSOAX; ISSN: 0022-4952
 DT Journal
 LA English
 OS CASREACT 66:2672
 IT **13261-09-1P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 13261-09-1 CAPLUS
 CN 7-Isoquinolinol, 1,2,3,4-tetrahydro-6-methoxy-2-methyl-1-vanillyl-,
 diacetate (ester), monopicrate (8CI) (CA INDEX NAME)


 CM 1

 CRN 47653-34-9
 CMF C23 H27 N O6




CM 2

 CRN 88-89-1
 CMF C6 H3 N3 O7




L16 ANSWER 88 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1965:480864 CAPLUS Full-text
 DN 63:80864
 OREF 63:14929e-h
 TI Constitution of thalsimine
 AU Maekh, S. Kh.; Yunusov, S. Yu.
 CS Inst. Chem. Vegetable Compounds, Tashkent
 SO Khim. Prirodn. Soedin., Akad. Nauk Uz. SSR (1965), (3), 188-94
 DT Journal

LA Russian
 IT **96370-47-7**, 7-Isoquinolinol, 2-acetyl-1,2,3,4-tetrahydro-1-(p-hydroxybenzyl)-6-methoxy-, diacetate
 (preparation of)
 RN 96370-47-7 CAPLUS
 CN 7-Isoquinolinol, 2-acetyl-1,2,3,4-tetrahydro-1-(p-hydroxybenzyl)-6-methoxy-, diacetate (7CI) (CA INDEX NAME)




L16 ANSWER 89 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1965:51864 CAPLUS Full-text
 DN 62:51864
 OREF 62:9184b-d
 TI Alkaloids of Nelumbo nucifera. IV. Total synthesis of liensinine
 AU Hsieh, Yu-Yuan; Pan, Pei-Chuan; Chen, Wen-Chi; Kao, Yee-Sheng
 SO Scientia Sinica (English Edition) (1964), 12(12), 2020-5
 CODEN: SSINAV; ISSN: 0582-236X
 DT Journal
 LA English
 IT **1857-42-7**, 7-Isoquinolinol, 1-[p-(benzyloxy)benzyl]-1,2,3,4-tetrahydro-6-methoxy-, acetate (ester), (+)- **1857-43-8**, 7-Isoquinolinol, 1-[p-(benzyloxy)benzyl]-1,2,3,4-tetrahydro-6-methoxy-, acetate (ester), (-)- **4119-55-5**, 7-Isoquinolinol, 1-[p-(benzyloxy)benzyl]-1,2,3,4-tetrahydro-6-methoxy-2-methyl-, acetate (ester), (+)- (8CI) (CA INDEX NAME)

Rotation (+).




RN 1857-43-8 CAPLUS
 CN 7-Isoquinolinol, 1-[p-(benzyloxy)benzyl]-1,2,3,4-tetrahydro-6-methoxy-
 ,
 acetate (ester), (-)- (8CI) (CA INDEX NAME)


Rotation (-).



RN 4119-55-5 CAPLUS
 CN 7-Isoquinolinol, 1-[p-(benzyloxy)benzyl]-1,2,3,4-tetrahydro-6-methoxy-
 2-
 methyl-, acetate (ester) (8CI) (CA INDEX NAME)




L16 ANSWER 90 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1965:36788 CAPLUS Full-text
 DN 62:36788
 OREF 62:6471a-f
 TI Reaction of flavanone with hydrazine
 AU Kallay, F.; Janzo, G.; Koczor, I.
 CS Res. Inst. Org. Chem. Ind., Budapest, Hung.
 SO Tetrahedron (1965), 21(1), 19-24
 CODEN: TETRAB; ISSN: 0040-4020
 DT Journal
 LA Unavailable
 OS CASREACT 62:36788
 IT 1692-42-8, Acetamide, N-(α -phenethylsalicyl)-, acetate
 (preparation of)
 RN 1692-42-8 CAPLUS
 CN Acetamide, N-(α -phenethylsalicyl)-, acetate (7CI, 8CI) (CA INDEX
 NAME)




L16 ANSWER 91 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1964:45659 CAPLUS Full-text
 DN 60:45659
 OREF 60:8004a-e
 TI 6(or 7)-Hydroxy-1,2,3,4-tetrahydroisoquinolines
 PA F. Hoffmann-La Roche & Co., A.-G.
 SO 19 pp.
 DT Patent
 LA Unavailable

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	BE 627177		19630716	BE	
	FR 1344709			FR	
	FR M2303			FR	
	GB 995369			GB	
	GB 995370			GB	
	US 3217007		1965	US	
PRAI	CH		19620119		
IT	94760-32-4, 7-Isoquinolinol, 1-(p-chlorophenethyl)-1,2,3,4-tetrahydro-6-methoxy-2-methyl-, acetate (preparation of)				
RN	94760-32-4 CAPLUS				
CN	7-Isoquinolinol, 1-(p-chlorophenethyl)-1,2,3,4-tetrahydro-6-methoxy-2-methyl-, acetate (7CI) (CA INDEX NAME)				




L16 ANSWER 92 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1963:403691 CAPLUS Full-text
 DN 59:3691
 OREF 59:691g-h,692a-d
 TI (-)-N-Methylcoclaurine from *Phyllica rogersii*
 AU Arndt, R. R.
 CS S. African Council Sci. Ind. Res., Pretoria
 SO Journal of the Chemical Society, Abstracts (1963) 2547-9
 CODEN: JCSAAZ; ISSN: 0590-9791
 DT Journal
 LA Unavailable

IT 95133-86-1, 7-Isoquinolinol, 1,2,3,4-tetrahydro-1-(p-hydroxybenzyl)-6-methoxy-2-methyl-, diacetate, hydrochloride
 95133-87-2, 7-Isoquinolinol, 1,2,3,4-tetrahydro-1-(p-hydroxybenzyl)-6-methoxy-2-methyl-, diacetate
 (preparation of)
 RN 95133-86-1 CAPLUS
 CN 7-Isoquinolinol, 1,2,3,4-tetrahydro-1-(p-hydroxybenzyl)-6-methoxy-2-methyl-, diacetate, hydrochloride (7CI) (CA INDEX NAME)



● HCl

RN 95133-87-2 CAPLUS
 CN 7-Isoquinolinol, 1,2,3,4-tetrahydro-1-(p-hydroxybenzyl)-6-methoxy-2-methyl-, diacetate (7CI) (CA INDEX NAME)




L16 ANSWER 93 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1961:67220 CAPLUS Full-text
 DN 55:67220
 OREF 55:12781b-d
 TI Recovery of a glucoside from ipecac
 IN Bellet, Paul
 PA U C L A F
 DT Patent
 LA Unavailable
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1060089		19590625	DE	
IT	21104-39-2,	Ipecoside,	hexaacetate		

(isolation from ipecac)

RN 21104-39-2 CAPLUS

CN 2H-Pyran-5-carboxylic acid, 4-[[2-acetyl-6,7-bis(acetyloxy)-1,2,3,4-tetrahydro-1-isoquinolinyl]methyl]-3-ethenyl-3,4-dihydro-2-[(2,3,4,6-tetra-

O-acetyl- β -D-glucopyranosyl)oxy]-, methyl ester, [2S-[2 α ,3 β ,4 β (S*)]]- (9CI) (CA INDEX NAME)

L16 ANSWER 94 OF 94 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1955:21606 CAPLUS Full-text

DN 49:21606

OREF 49:4233i,4234a-b

TI Ipecoside

AU Bellet, Paul

CS Roussel-Uclaf, Paris-Romainville

SO Annales Pharmaceutiques Francaises (1954), 12, 466-70

CODEN: APFRAD; ISSN: 0003-4509


DT Journal

LA Unavailable

IT 21104-39-2, Ipecoside, hexaacetate
(preparation of)

RN 21104-39-2 CAPLUS

CN 2H-Pyran-5-carboxylic acid, 4-[[2-acetyl-6,7-bis(acetyloxy)-1,2,3,4-tetrahydro-1-isoquinolinyl]methyl]-3-ethenyl-3,4-dihydro-2-[(2,3,4,6-tetra-

O-acetyl- β -D-glucopyranosyl)oxy]-, methyl ester, [2S-[2 α ,3 β ,4 β (S*)]]- (9CI) (CA INDEX NAME)


=> logoff hold

SEARCH 2 CAS REGISTRY

=> fil reg

=>

Uploading E:\express6\Queries\rogers2005\metX1OX2S.sfr



chain nodes :

7 8 12 13 14 15 16 17 18 19 26 27 28 29 30 34 35 36 37 38 39
45 47 48 49 52 54 55

ring nodes :

1 2 3 4 5 6

ring/chain nodes :

25 53

chain bonds :

2-13 13-15 14-15 15-16 25-26 26-45 28-29 28-30 34-35 36-37 38-39 38-52
47-48 48-49 54-55

ring/chain bonds :

6-25 25-53

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

2-13 6-25 13-15 14-15 15-16 25-26 25-53 26-45 28-29 28-30 34-35 36-37
38-39 38-52 47-48 48-49 54-55

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:[*1],[*2]

G4:[*3],[*4],[*5],[*6],[*7]

G9:[*8],[*9],[*10],[*11]

G10:H,[*12]

Connectivity :

7:1 E exact RC ring/chain 17:1 E exact RC ring/chain 26:2 E exact RC ring/chain
29:1 E exact RC ring/chain 30:1 E exact RC ring/chain 49:1 E exact RC
ring/chain 55:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 12:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom 24:CLASS
25:CLASS 26:CLASS 27:Atom 28:CLASS 29:CLASS 30:CLASS 34:CLASS 35:Atom
36:CLASS 37:Atom 38:CLASS 39:Atom 45:CLASS 47:CLASS 48:CLASS 49:CLASS
52:CLASS 53:CLASS 54:CLASS 55:CLASS

Generic attributes :

7:

Number of Carbon Atoms : less than 7

17:

Number of Carbon Atoms : less than 7

19:

Saturation : Saturated

26:

Number of Carbon Atoms : less than 7
 27:
 Saturation : Unsaturated
 29:
 Number of Carbon Atoms : less than 7
 30:
 Number of Carbon Atoms : less than 7
 35:
 Saturation : Unsaturated
 37:
 Saturation : Unsaturated
 39:
 Saturation : Unsaturated
 49:
 Number of Carbon Atoms : less than 7
 55:
 Number of Carbon Atoms : less than 7

Element Count :
 Node 19: Limited
 N,N1

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS


L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=>

Uploading E:\express6\Queries\rogers2005\metX1SX20.str



chain nodes :

7 8 12 13 14 15 16 17 18 19 26 27 28 29 30 34 35 36 37 38 39
 45 47 48 49 52 54 55

ring nodes :

1 2 3 4 5 6

ring/chain nodes :

25 53

chain bonds :

2-13 13-15 14-15 15-16 25-26 26-45 28-29 28-30 34-35 36-37 38-39 38-52
 47-48 48-49 54-55

ring/chain bonds :

6-25 25-53
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 exact/norm bonds :
 2-13 6-25 13-15 14-15 15-16 25-26 25-53 26-45 28-29 28-30 34-35 36-37
 38-39 38-52 47-48 48-49 54-55
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6

G1:[*1],[*2]

G4:[*3],[*4],[*5],[*6],[*7]

G9:[*8],[*9],[*10],[*11]

G10:H,[*12]

Connectivity :
 7:1 E exact RC ring/chain 17:1 E exact RC ring/chain 26:2 E exact RC ring/chain
 29:1 E exact RC ring/chain 30:1 E exact RC ring/chain 49:1 E exact RC
 ring/chain 55:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 12:CLASS
 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom 24:CLASS
 25:CLASS 26:CLASS 27:Atom 28:CLASS 29:CLASS 30:CLASS 34:CLASS 35:Atom
 36:CLASS 37:Atom 38:CLASS 39:Atom 45:CLASS 47:CLASS 48:CLASS 49:CLASS
 52:CLASS 53:CLASS 54:CLASS 55:CLASS

Generic attributes :

7:

Number of Carbon Atoms : less than 7

17:

Number of Carbon Atoms : less than 7

19:

Saturation : Saturated

26:

Number of Carbon Atoms : less than 7

27:

Saturation : Unsaturated

29:

Number of Carbon Atoms : less than 7

30:

Number of Carbon Atoms : less than 7

35:

Saturation : Unsaturated

37:

Saturation : Unsaturated

39:

Saturation : Unsaturated

49:

Number of Carbon Atoms : less than 7

55:

Number of Carbon Atoms : less than 7


Element Count :

Node 19: Limited

N,N1

=>

Uploading E:\express6\Queries\rogers2005\metX1SX2S.str



chain nodes :

7 8 12 13 14 15 16 17 18 19 26 27 28 29 30 34 35 36 37 38 39
45 47 48 49 52 54 55

ring nodes :

1 2 3 4 5 6

ring/chain nodes :

25 53

chain bonds :

2-13 13-15 14-15 15-16 25-26 26-45 28-29 28-30 34-35 36-37 38-39 38-52
47-48 48-49 54-55

ring/chain bonds :

6-25 25-53

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

2-13 6-25 13-15 14-15 15-16 25-26 25-53 26-45 28-29 28-30 34-35 36-37
38-39 38-52 47-48 48-49 54-55

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:[*1],[*2]

G4:[*3],[*4],[*5],[*6],[*7]

G9:[*8],[*9],[*10],[*11]

G10:H,[*12]

Connectivity :

7:1 E exact RC ring/chain 17:1 E exact RC ring/chain 26:2 E exact RC ring/chain
29:1 E exact RC ring/chain 30:1 E exact RC ring/chain 49:1 E exact RC
ring/chain 55:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 12:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom 24:CLASS
25:CLASS 26:CLASS 27:Atom 28:CLASS 29:CLASS 30:CLASS 34:CLASS 35:Atom
36:CLASS 37:Atom 38:CLASS 39:Atom 45:CLASS 47:CLASS 48:CLASS 49:CLASS
52:CLASS 53:CLASS 54:CLASS 55:CLASS

Generic attributes :

7:

Number of Carbon Atoms : less than 7

17:

Number of Carbon Atoms : less than 7

19:

Saturation : Saturated

26:

Number of Carbon Atoms : less than 7


27:
 Saturation : Unsaturated
 29:
 Number of Carbon Atoms : less than 7
 30:
 Number of Carbon Atoms : less than 7
 35:
 Saturation : Unsaturated
 37:
 Saturation : Unsaturated
 39:
 Saturation : Unsaturated
 49:
 Number of Carbon Atoms : less than 7
 55:
 Number of Carbon Atoms : less than 7

Element Count :
 Node 19: Limited
 N,N1

L3 STRUCTURE UPLOADED

=>

Uploading E:\express6\Queries\rogers2005\ortX10X2S.str



chain nodes :

7 8 12 13 14 15 16 17 18 19 26 27 28 29 30 34 35 36 37 38 39
 45 48 49 50 53 55 56

ring nodes :

1 2 3 4 5 6

ring/chain nodes :

25 54

chain bonds :

2-13 13-15 14-15 15-16 25-26 26-45 28-29 28-30 34-35 36-37 38-39 38-53
 48-49 49-50 55-56

ring/chain bonds :

1-25 25-54

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

1-25 2-13 13-15 14-15 15-16 25-26 25-54 26-45 28-29 28-30 34-35 36-37
 38-39 38-53 48-49 49-50 55-56

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:[*1],[*2]

G4:[*3],[*4],[*5],[*6],[*7]

G9:[*8],[*9],[*10],[*11]

G10:H,[*12]

Connectivity :

7:1 E exact RC ring/chain 17:1 E exact RC ring/chain 26:2 E exact RC ring/chain
29:1 E exact RC ring/chain 30:1 E exact RC ring/chain 50:1 E exact RC
ring/chain 56:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 12:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom 24:CLASS
25:CLASS 26:CLASS 27:Atom 28:CLASS 29:CLASS 30:CLASS 34:CLASS 35:Atom
36:CLASS 37:Atom 38:CLASS 39:Atom 45:CLASS 48:CLASS 49:CLASS 50:CLASS
53:CLASS 54:CLASS 55:CLASS 56:CLASS

Generic attributes :

7:

Number of Carbon Atoms : less than 7

17:

Number of Carbon Atoms : less than 7

19:

Saturation : Saturated

26:

Number of Carbon Atoms : less than 7

27:

Saturation : Unsaturated

29:

Number of Carbon Atoms : less than 7

30:

Number of Carbon Atoms : less than 7

35:

Saturation : Unsaturated

37:

Saturation : Unsaturated

39:

Saturation : Unsaturated

50:

Number of Carbon Atoms : less than 7

56:

Number of Carbon Atoms : less than 7

Element Count :


Node 19: Limited

N,N1

L4 STRUCTURE UPLOADED

=>

Uploading E:\express6\Queries\rogers2005\ortX1SX20.str



chain nodes :

7 8 12 13 14 15 16 17 18 19 26 27 28 29 30 34 35 36 37 38 39
45 48 49 50 53 55 56

ring nodes :

1 2 3 4 5 6

ring/chain nodes :

25 54

chain bonds :

2-13 13-15 14-15 15-16 25-26 26-45 28-29 28-30 34-35 36-37 38-39 38-53
48-49 49-50 55-56

ring/chain bonds :

1-25 25-54

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

1-25 2-13 13-15 14-15 15-16 25-26 25-54 26-45 28-29 28-30 34-35 36-37
38-39 38-53 48-49 49-50 55-56

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:[*1],[*2]

G4:[*3],[*4],[*5],[*6],[*7]

G9:[*8],[*9],[*10],[*11]

G10:H,[*12]

Connectivity :

7:1 E exact RC ring/chain 17:1 E exact RC ring/chain 26:2 E exact RC ring/chain
29:1 E exact RC ring/chain 30:1 E exact RC ring/chain 50:1 E exact RC
ring/chain 56:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 12:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom 24:CLASS
25:CLASS 26:CLASS 27:Atom 28:CLASS 29:CLASS 30:CLASS 34:CLASS 35:Atom
36:CLASS 37:Atom 38:CLASS 39:Atom 45:CLASS 48:CLASS 49:CLASS 50:CLASS
53:CLASS 54:CLASS 55:CLASS 56:CLASS

Generic attributes :

7:

Number of Carbon Atoms : less than 7

17:

Number of Carbon Atoms : less than 7

19:

Saturation : Saturated

26:

Number of Carbon Atoms : less than 7

27:

Saturation : Unsaturated

29:


Number of Carbon Atoms : less than 7
 30:
 Number of Carbon Atoms : less than 7
 35:
 Saturation : Unsaturated
 37:
 Saturation : Unsaturated
 39:
 Saturation : Unsaturated
 50:
 Number of Carbon Atoms : less than 7
 56:
 Number of Carbon Atoms : less than 7

Element Count :
 Node 19: Limited
 N,N1

L5 STRUCTURE UPLOADED

=>

Uploading E:\express6\Queries\rogers2005\ortX1SX2S.str



chain nodes :
 7 8 12 13 14 15 16 17 18 19 26 27 28 29 30 34 35 36 37 38 39
 45 48 49 50 53 55 56
 ring nodes :
 1 2 3 4 5 6
 ring/chain nodes :
 25 54
 chain bonds :
 2-13 13-15 14-15 15-16 25-26 26-45 28-29 28-30 34-35 36-37 38-39 38-53
 48-49 49-50 55-56
 ring/chain bonds :
 1-25 25-54
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 exact/norm bonds :
 1-25 2-13 13-15 14-15 15-16 25-26 25-54 26-45 28-29 28-30 34-35 36-37
 38-39 38-53 48-49 49-50 55-56
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6

G1:[*1],[*2]

G4:[*3],[*4],[*5],[*6],[*7]

G9:[*8],[*9],[*10],[*11]

G10:H,[*12]

Connectivity :

7:1 E exact RC ring/chain 17:1 E exact RC ring/chain 26:2 E exact RC ring/chain
29:1 E exact RC ring/chain 30:1 E exact RC ring/chain 50:1 E exact RC
ring/chain 56:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 12:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom 24:CLASS
25:CLASS 26:CLASS 27:Atom 28:CLASS 29:CLASS 30:CLASS 34:CLASS 35:Atom
36:CLASS 37:Atom 38:CLASS 39:Atom 45:CLASS 48:CLASS 49:CLASS 50:CLASS
53:CLASS 54:CLASS 55:CLASS 56:CLASS

Generic attributes :

7:

Number of Carbon Atoms : less than 7

17:

Number of Carbon Atoms : less than 7

19:

Saturation : Saturated

26:

Number of Carbon Atoms : less than 7

27:

Saturation : Unsaturated

29:

Number of Carbon Atoms : less than 7

30:

Number of Carbon Atoms : less than 7

35:

Saturation : Unsaturated

37:

Saturation : Unsaturated

39:

Saturation : Unsaturated

50:

Number of Carbon Atoms : less than 7

56:

Number of Carbon Atoms : less than 7

Element Count :


Node 19: Limited

N,N1

L6 STRUCTURE UPLOADED

=>

Uploading E:\express6\Queries\rogers2005\parX10X2S.str



chain nodes :

7 8 12 13 14 15 16 17 18 19 26 27 28 29 30 34 35 36 37 38 39
45 48 49 50 53 55 56

ring nodes :

1 2 3 4 5 6

ring/chain nodes :

25 54

chain bonds :

2-13 13-15 14-15 15-16 25-26 26-45 28-29 28-30 34-35 36-37 38-39 38-53
48-49 49-50 55-56

ring/chain bonds :

5-25 25-54

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

2-13 5-25 13-15 14-15 15-16 25-26 25-54 26-45 28-29 28-30 34-35 36-37
38-39 38-53 48-49 49-50 55-56

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:[*1],[*2]

G4:[*3],[*4],[*5],[*6],[*7]

G9:[*8],[*9],[*10],[*11]

G10:H,[*12]

Connectivity :

7:1 E exact RC ring/chain 17:1 E exact RC ring/chain 26:2 E exact RC ring/chain
29:1 E exact RC ring/chain 30:1 E exact RC ring/chain 50:1 E exact RC
ring/chain 56:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 12:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom 24:CLASS
25:CLASS 26:CLASS 27:Atom 28:CLASS 29:CLASS 30:CLASS 34:CLASS 35:Atom
36:CLASS 37:Atom 38:CLASS 39:Atom 45:CLASS 48:CLASS 49:CLASS 50:CLASS
53:CLASS 54:CLASS 55:CLASS 56:CLASS

Generic attributes :

7:

Number of Carbon Atoms : less than 7

17:

Number of Carbon Atoms : less than 7

19:

Saturation : Saturated

26:

Number of Carbon Atoms : less than 7

27:

Saturation : Unsaturated

29:


Number of Carbon Atoms : less than 7
 30:
 Number of Carbon Atoms : less than 7
 35:
 Saturation : Unsaturated
 37:
 Saturation : Unsaturated
 39:
 Saturation : Unsaturated
 50:
 Number of Carbon Atoms : less than 7
 56:
 Number of Carbon Atoms : less than 7

Element Count :
 Node 19: Limited
 N,N1

L7 STRUCTURE UPLOADED

=>

Uploading E:\express6\Queries\rogers2005\parX1SX20.str



chain nodes :

7 8 12 13 14 15 16 17 18 19 26 27 28 29 30 34 35 36 37 38 39
45 48 49 50 53 55 56

ring nodes :

1 2 3 4 5 6

ring/chain nodes :

25 54

chain bonds :

2-13 13-15 14-15 15-16 25-26 26-45 28-29 28-30 34-35 36-37 38-39 38-53
48-49 49-50 55-56

ring/chain bonds :

5-25 25-54

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

2-13 5-25 13-15 14-15 15-16 25-26 25-54 26-45 28-29 28-30 34-35 36-37
38-39 38-53 48-49 49-50 55-56

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:[*1],[*2]

G4:[*3],[*4],[*5],[*6],[*7]

G9:[*8],[*9],[*10],[*11]

G10:H,[*12]

Connectivity :

7:1 E exact RC ring/chain 17:1 E exact RC ring/chain 26:2 E exact RC ring/chain
29:1 E exact RC ring/chain 30:1 E exact RC ring/chain 50:1 E exact RC
ring/chain 56:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 12:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom 24:CLASS
25:CLASS 26:CLASS 27:Atom 28:CLASS 29:CLASS 30:CLASS 34:CLASS 35:Atom
36:CLASS 37:Atom 38:CLASS 39:Atom 45:CLASS 48:CLASS 49:CLASS 50:CLASS
53:CLASS 54:CLASS 55:CLASS 56:CLASS

Generic attributes :

7:

Number of Carbon Atoms : less than 7

17:

Number of Carbon Atoms : less than 7

19:

Saturation : Saturated

26:

Number of Carbon Atoms : less than 7

27:

Saturation : Unsaturated

29:

Number of Carbon Atoms : less than 7

30:

Number of Carbon Atoms : less than 7

35:

Saturation : Unsaturated

37:

Saturation : Unsaturated

39:

Saturation : Unsaturated

50:

Number of Carbon Atoms : less than 7

56:

Number of Carbon Atoms : less than 7

Element Count :


Node 19: Limited

N,N1

L8 STRUCTURE UPLOADED

=>

Uploading E:\express6\Queries\rogers2005\parX1SX2S.str



chain nodes :

7 8 12 13 14 15 16 17 18 19 26 27 28 29 30 34 35 36 37 38 39
45 48 49 50 53 55 56

ring nodes :

1 2 3 4 5 6

ring/chain nodes :

25 54

chain bonds :

2-13 13-15 14-15 15-16 25-26 26-45 28-29 28-30 34-35 36-37 38-39 38-53
48-49 49-50 55-56

ring/chain bonds :

5-25 25-54

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

2-13 5-25 13-15 14-15 15-16 25-26 25-54 26-45 28-29 28-30 34-35 36-37
38-39 38-53 48-49 49-50 55-56

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:[*1],[*2]

G4:[*3],[*4],[*5],[*6],[*7]

G9:[*8],[*9],[*10],[*11]

G10:H,[*12]

Connectivity :

7:1 E exact RC ring/chain 17:1 E exact RC ring/chain 26:2 E exact RC ring/chain
29:1 E exact RC ring/chain 30:1 E exact RC ring/chain 50:1 E exact RC
ring/chain 56:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 12:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom 24:CLASS
25:CLASS 26:CLASS 27:Atom 28:CLASS 29:CLASS 30:CLASS 34:CLASS 35:Atom
36:CLASS 37:Atom 38:CLASS 39:Atom 45:CLASS 48:CLASS 49:CLASS 50:CLASS
53:CLASS 54:CLASS 55:CLASS 56:CLASS

Generic attributes :

7:

Number of Carbon Atoms : less than 7

17:

Number of Carbon Atoms : less than 7

19:

Saturation : Saturated

26:

Number of Carbon Atoms : less than 7

27:

Saturation : Unsaturated

29:

Number of Carbon Atoms : less than 7
30:
Number of Carbon Atoms : less than 7
35:
Saturation : Unsaturated
37:
Saturation : Unsaturated
39:
Saturation : Unsaturated
50:
Number of Carbon Atoms : less than 7
56:
Number of Carbon Atoms : less than 7

Element Count :
Node 19: Limited
N,N1

L9 STRUCTURE UPLOADED

=> s (11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19) sss sam
SAMPLE SEARCH INITIATED 18:13:21 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3199 TO ITERATE

62.5% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 60588 TO 67372
PROJECTED ANSWERS: 0 TO 0

L10 0 SEA SSS SAM (L1 OR L2 OR L3 OR L4 OR L5 OR L6 OR L7 OR L8 OR L9

=> s (11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19) sss full
FULL SEARCH INITIATED 18:13:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 62536 TO ITERATE

100.0% PROCESSED 62536 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.03

L11 0 SEA SSS FUL (L1 OR L2 OR L3 OR L4 OR L5 OR L6 OR L7 OR L8 OR L9


=> log h

SEARCH2 MARPAT

=> fil marpat.

=>

Uploading E:\express6\Queries\rogers2005\metX1OX2Smar.str



chain nodes :

7 8 12 13 14 15 16 17 18 19 26 27 28 29 30 34 35 36 37 38 39
45 47 48 49 52 54 55

ring nodes :

1 2 3 4 5 6

ring/chain nodes :

25 53

chain bonds :

2-13 6-25 13-15 14-15 15-16 25-26 25-53 26-45 28-29 28-30 34-35 36-37
38-39 38-52 47-48 48-49 54-55

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

2-13 6-25 13-15 14-15 15-16 25-26 25-53 26-45 28-29 28-30 34-35 36-37
38-39 38-52 47-48 48-49 54-55

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:[*1],[*2]

G4:[*3],[*4],[*5],[*6],[*7]

G9:[*8],[*9],[*10],[*11]

G10:H,[*12]

Connectivity :

7:1 E exact RC ring/chain 17:1 E exact RC ring/chain 26:2 E exact RC ring/chain
29:1 E exact RC ring/chain 30:1 E exact RC ring/chain 49:1 E exact RC
ring/chain 55:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 12:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom 24:CLASS
25:CLASS 26:CLASS 27:Atom 28:CLASS 29:CLASS 30:CLASS 34:CLASS 35:Atom
36:CLASS 37:Atom 38:CLASS 39:Atom 45:CLASS 47:CLASS 48:CLASS 49:CLASS
52:CLASS 53:CLASS 54:CLASS 55:CLASS

Generic attributes :

7:

Number of Carbon Atoms : less than 7

17:

Number of Carbon Atoms : less than 7

19:

Saturation : Saturated

26:

Number of Carbon Atoms : less than 7

27:

Saturation : Unsaturated
 29:
 Number of Carbon Atoms : less than 7
 30:
 Number of Carbon Atoms : less than 7
 35:
 Saturation : Unsaturated
 37:
 Saturation : Unsaturated
 39:
 Saturation : Unsaturated
 49:
 Number of Carbon Atoms : less than 7
 55:
 Number of Carbon Atoms : less than 7

Element Count :
 Node 19: Limited
 N,N1

L1 STRUCTURE UPLOADED

=> s l1 sss sam
 SAMPLE SEARCH INITIATED 12:52:18 FILE 'MARPAT'
 SAMPLE SCREEN SEARCH COMPLETED - 1448 TO ITERATE

49.2% PROCESSED	712 ITERATIONS	0 ANSWERS
65.7% PROCESSED	952 ITERATIONS	8 ANSWERS
67.7% PROCESSED	980 ITERATIONS	8 ANSWERS
69.1% PROCESSED	1000 ITERATIONS (9 INCOMPLETE)	10 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)		
SEARCH TIME: 00.01.07		

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 26832 TO 31088
 PROJECTED ANSWERS: 61 TO 517

L2 10 SEA SSS SAM L1

=> s l1 sss ful
 FULL SEARCH INITIATED 12:53:53 FILE 'MARPAT'
 FULL SCREEN SEARCH COMPLETED - 29062 TO ITERATE

7.2% PROCESSED	2089 ITERATIONS (1 INCOMPLETE)	1 ANSWERS
13.4% PROCESSED	3903 ITERATIONS (2 INCOMPLETE)	4 ANSWERS
19.9% PROCESSED	5774 ITERATIONS (6 INCOMPLETE)	9 ANSWERS
26.7% PROCESSED	7762 ITERATIONS (18 INCOMPLETE)	24 ANSWERS
33.1% PROCESSED	9630 ITERATIONS (25 INCOMPLETE)	33 ANSWERS
40.3% PROCESSED	11723 ITERATIONS (36 INCOMPLETE)	44 ANSWERS

44.7%	PROCESSED	12981	ITERATIONS	(44	INCOMPLETE)	52	ANSWERS
47.8%	PROCESSED	13896	ITERATIONS	(53	INCOMPLETE)	63	ANSWERS
51.9%	PROCESSED	15076	ITERATIONS	(66	INCOMPLETE)	76	ANSWERS
56.2%	PROCESSED	16327	ITERATIONS	(77	INCOMPLETE)	89	ANSWERS
60.5%	PROCESSED	17573	ITERATIONS	(91	INCOMPLETE)	103	ANSWERS
65.3%	PROCESSED	18966	ITERATIONS	(108	INCOMPLETE)	121	ANSWERS
69.9%	PROCESSED	20306	ITERATIONS	(121	INCOMPLETE)	134	ANSWERS
73.5%	PROCESSED	21366	ITERATIONS	(135	INCOMPLETE)	150	ANSWERS
76.4%	PROCESSED	22194	ITERATIONS	(146	INCOMPLETE)	162	ANSWERS
79.3%	PROCESSED	23044	ITERATIONS	(157	INCOMPLETE)	173	ANSWERS
82.4%	PROCESSED	23948	ITERATIONS	(165	INCOMPLETE)	181	ANSWERS
85.0%	PROCESSED	24709	ITERATIONS	(176	INCOMPLETE)	192	ANSWERS
86.7%	PROCESSED	25188	ITERATIONS	(185	INCOMPLETE)	201	ANSWERS
88.9%	PROCESSED	25832	ITERATIONS	(202	INCOMPLETE)	218	ANSWERS
91.0%	PROCESSED	26435	ITERATIONS	(211	INCOMPLETE)	227	ANSWERS
92.7%	PROCESSED	26945	ITERATIONS	(219	INCOMPLETE)	235	ANSWERS
94.4%	PROCESSED	27445	ITERATIONS	(225	INCOMPLETE)	241	ANSWERS
95.0%	PROCESSED	27597	ITERATIONS	(230	INCOMPLETE)	246	ANSWERS
96.1%	PROCESSED	27936	ITERATIONS	(235	INCOMPLETE)	251	ANSWERS
96.7%	PROCESSED	28091	ITERATIONS	(238	INCOMPLETE)	254	ANSWERS
97.2%	PROCESSED	28239	ITERATIONS	(239	INCOMPLETE)	255	ANSWERS
97.3%	PROCESSED	28263	ITERATIONS	(240	INCOMPLETE)	256	ANSWERS
97.5%	PROCESSED	28321	ITERATIONS	(240	INCOMPLETE)	256	ANSWERS
97.7%	PROCESSED	28408	ITERATIONS	(241	INCOMPLETE)	257	ANSWERS
98.0%	PROCESSED	28479	ITERATIONS	(243	INCOMPLETE)	259	ANSWERS
98.3%	PROCESSED	28559	ITERATIONS	(245	INCOMPLETE)	261	ANSWERS
98.4%	PROCESSED	28603	ITERATIONS	(247	INCOMPLETE)	264	ANSWERS
98.5%	PROCESSED	28616	ITERATIONS	(249	INCOMPLETE)	266	ANSWERS
98.8%	PROCESSED	28710	ITERATIONS	(251	INCOMPLETE)	268	ANSWERS
99.0%	PROCESSED	28774	ITERATIONS	(252	INCOMPLETE)	269	ANSWERS
99.1%	PROCESSED	28803	ITERATIONS	(252	INCOMPLETE)	269	ANSWERS
99.2%	PROCESSED	28816	ITERATIONS	(252	INCOMPLETE)	269	ANSWERS

99.3% PROCESSED 28853 ITERATIONS (253 INCOMPLETE) 270 ANSWERS
 99.4% PROCESSED 28884 ITERATIONS (253 INCOMPLETE) 270 ANSWERS
 99.4% PROCESSED 28893 ITERATIONS (253 INCOMPLETE) 270 ANSWERS
 99.7% PROCESSED 28961 ITERATIONS (253 INCOMPLETE) 270 ANSWERS
 99.7% PROCESSED 28977 ITERATIONS (253 INCOMPLETE) 270 ANSWERS
 99.8% PROCESSED 28991 ITERATIONS (253 INCOMPLETE) 270 ANSWERS
 99.9% PROCESSED 29042 ITERATIONS (253 INCOMPLETE) 270 ANSWERS
 100.0% PROCESSED 29062 ITERATIONS (253 INCOMPLETE) 270 ANSWERS
 SEARCH TIME: 00.13.13

L3 270 SEA SSS FUL L1

=> s l3/com

L4 17 L3/COM

=> d his

L1 STRUCTURE UPLOADED


L2 10 S L1 SSS SAM

L3 270 S L1 SSS FUL

L4 17 S L3/COM

=>

Uploading E:\express6\Queries\rogers2005\metX1SX2Omar.str



chain nodes :

7 8 12 13 14 15 16 17 18 19 26 27 28 29 30 34 35 36 37 38 39
45 47 48 49 52 54 55

ring nodes :

1 2 3 4 5 6

ring/chain nodes :

25 53

chain bonds :

2-13 6-25 13-15 14-15 15-16 25-26 25-53 26-45 28-29 28-30 34-35 36-37
38-39 38-52 47-48 48-49 54-55

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

2-13 6-25 13-15 14-15 15-16 25-26 25-53 26-45 28-29 28-30 34-35 36-37
38-39 38-52 47-48 48-49 54-55

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:[*1],[*2]

G4:[*3],[*4],[*5],[*6],[*7]

G9:[*8],[*9],[*10],[*11]

G10:H,[*12]

Connectivity :

7:1 E exact RC ring/chain 17:1 E exact RC ring/chain 26:2 E exact RC ring/chain
29:1 E exact RC ring/chain 30:1 E exact RC ring/chain 49:1 E exact RC
ring/chain 55:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 12:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom 24:CLASS
25:CLASS 26:CLASS 27:Atom 28:CLASS 29:CLASS 30:CLASS 34:CLASS 35:Atom
36:CLASS 37:Atom 38:CLASS 39:Atom 45:CLASS 47:CLASS 48:CLASS 49:CLASS
52:CLASS 53:CLASS 54:CLASS 55:CLASS

Generic attributes :

7:

Number of Carbon Atoms : less than 7

17:

Number of Carbon Atoms : less than 7

19:

Saturation : Saturated

26:

Number of Carbon Atoms : less than 7

27:

Saturation : Unsaturated

29:

Number of Carbon Atoms : less than 7

30:

Number of Carbon Atoms : less than 7

35:

Saturation : Unsaturated

37:

Saturation : Unsaturated

39:

Saturation : Unsaturated

49:

Number of Carbon Atoms : less than 7

55:

Number of Carbon Atoms : less than 7

Element Count :

Node 19: Limited

N,N1

L5 STRUCTURE UPLOADED

=> s 15 sss sam

SAMPLE SEARCH INITIATED 13:12:58 FILE 'MARPAT'

SAMPLE SCREEN SEARCH COMPLETED - 1634 TO ITERATE

61.2% PROCESSED 1000 ITERATIONS

0 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

=> s 15 sss ful

FULL SEARCH INITIATED 13:13:16 FILE 'MARPAT'

```
77.3% PROCESSED      25864 ITERATIONS                                3 ANSWERS
```

=> d his

L1 STRUCTURE UPLOADED

L2 10 S L1 SSS SAM

L3 270 S L1 SSS FUL


L4 17 S L3/COM

L5 STRUCTURE UPLOADED

L6 O S L5 SSS SAM

L7 12 S L5 SSS FUL

Uploading E:\express6\Queries\rogers2005\metX1SX2Smar.str

[illegible]

1	2	3	4	5	6
---	---	---	---	---	---

25 53

2-13 6-25 13-15 14-15 15-16 25-26 25-53 26-45 28-29 28-30 34-35 36-37
38-39 38-52 47-48 48-49 54-55

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :
2-13 6-25 13-15 14-15 15-16 25-26 25-53 26-45 28-29 28-30 34-35 36-37
38-39 38-52 47-48 48-49 54-55
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:[*1],[*2]

G4:[*3],[*4],[*5],[*6],[*7]

G9:[*8],[*9],[*10],[*11]

G10:H,[*12]

Connectivity :
7:1 E exact RC ring/chain 17:1 E exact RC ring/chain 26:2 E exact RC ring/chain
29:1 E exact RC ring/chain 30:1 E exact RC ring/chain 49:1 E exact RC
ring/chain 55:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 12:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom 24:CLASS
25:CLASS 26:CLASS 27:Atom 28:CLASS 29:CLASS 30:CLASS 34:CLASS 35:Atom
36:CLASS 37:Atom 38:CLASS 39:Atom 45:CLASS 47:CLASS 48:CLASS 49:CLASS
52:CLASS 53:CLASS 54:CLASS 55:CLASS

Generic attributes :

7:

Number of Carbon Atoms : less than 7

17:

Number of Carbon Atoms : less than 7

19:

Saturation : Saturated

26:

Number of Carbon Atoms : less than 7

27:

Saturation : Unsaturated

29:

Number of Carbon Atoms : less than 7

30:

Number of Carbon Atoms : less than 7

35:

Saturation : Unsaturated

37:

Saturation : Unsaturated

39:

Saturation : Unsaturated

49:

Number of Carbon Atoms : less than 7

55:

Number of Carbon Atoms : less than 7

Element Count :

Node 19: Limited

N,N1

L9 STRUCTURE UPLOADED

=> s 19 sss sam

SAMPLE SEARCH INITIATED 13:17:02 FILE 'MARPAT'

SAMPLE SCREEN SEARCH COMPLETED - 1245 TO ITERATE

80.3% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.03

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 22905 TO 26895
PROJECTED ANSWERS: 0 TO 0

L10 0 SEA SSS SAM L9


=> s 19 sss ful
FULL SEARCH INITIATED 13:17:15 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 24029 TO ITERATE

93.3% PROCESSED 22409 ITERATIONS 4 ANSWERS
99.3% PROCESSED 23870 ITERATIONS 4 ANSWERS
99.3% PROCESSED 23870 ITERATIONS 4 ANSWERS
100.0% PROCESSED 24029 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.01.03

L11 4 SEA SSS FUL L9

=> s l11/com
L12 4 L11/COM

=>
Uploading E:\express6\Queries\rogers2005\ortX1OX2Smar.str



chain nodes :
7 8 12 13 14 15 16 17 18 19 26 27 28 29 30 34 35 36 37 38 39
45 48 49 50 53 55 56
ring nodes :
1 2 3 4 5 6
ring/chain nodes :
25 54
chain bonds :
1-25 2-13 13-15 14-15 15-16 25-26 25-54 26-45 28-29 28-30 34-35 36-37
38-39 38-53 48-49 49-50 55-56
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-25 2-13 13-15 14-15 15-16 25-26 25-54 26-45 28-29 28-30 34-35 36-37
38-39 38-53 48-49 49-50 55-56
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:[*1],[*2]

G4:[*3],[*4],[*5],[*6],[*7]

G9:[*8],[*9],[*10],[*11]

G10:H,[*12]

Connectivity :

7:1 E exact RC ring/chain 17:1 E exact RC ring/chain 26:2 E exact RC ring/chain
29:1 E exact RC ring/chain 30:1 E exact RC ring/chain 50:1 E exact RC
ring/chain 56:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 12:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom 24:CLASS
25:CLASS 26:CLASS 27:Atom 28:CLASS 29:CLASS 30:CLASS 34:CLASS 35:Atom
36:CLASS 37:Atom 38:CLASS 39:Atom 45:CLASS 48:CLASS 49:CLASS 50:CLASS
53:CLASS 54:CLASS 55:CLASS 56:CLASS

Generic attributes :

7:

Number of Carbon Atoms : less than 7

17:

Number of Carbon Atoms : less than 7

19:

Saturation : Saturated

26:

Number of Carbon Atoms : less than 7

27:

Saturation : Unsaturated

29:

Number of Carbon Atoms : less than 7

30:

Number of Carbon Atoms : less than 7

35:

Saturation : Unsaturated

37:

Saturation : Unsaturated

39:

Saturation : Unsaturated

50:

Number of Carbon Atoms : less than 7

56:

Number of Carbon Atoms : less than 7

Element Count :

Node 19: Limited

N,N1

L13 STRUCTURE UPLOADED

=> d his

L1 STRUCTURE UPLOADED

L2 10 S L1 SSS SAM

L3 270 S L1 SSS FUL

L4 17 S L3/COM

L5 STRUCTURE UPLOADED

L6 0 S L5 SSS SAM
L7 12 S L5 SSS FUL
L8 4 S L7/COM
L9 STRUCTURE UPLOADED
L10 0 S L9 SSS SAM
L11 4 S L9 SSS FUL
L12 4 S L11/COM
L13 STRUCTURE UPLOADED

=> s 113 sss sam

SAMPLE SEARCH INITIATED 13:20:16 FILE 'MARPAT'
SAMPLE SCREEN SEARCH COMPLETED - 1448 TO ITERATE

52.1% PROCESSED	754 ITERATIONS	0 ANSWERS
66.6% PROCESSED	965 ITERATIONS	6 ANSWERS
68.2% PROCESSED	987 ITERATIONS	8 ANSWERS

69.1% PROCESSED 1000 ITERATIONS (9 INCOMPLETE) 10 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.01.09

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 26832 TO 31088
PROJECTED ANSWERS: 61 TO 517

L14 10 SEA SSS SAM L13

=> s 113 sss sam

SAMPLE SEARCH INITIATED 13:22:04 FILE 'MARPAT'
SAMPLE SCREEN SEARCH COMPLETED - 1448 TO ITERATE

49.4% PROCESSED	716 ITERATIONS	0 ANSWERS
64.7% PROCESSED	937 ITERATIONS	6 ANSWERS
67.7% PROCESSED	980 ITERATIONS	8 ANSWERS
68.9% PROCESSED	997 ITERATIONS	9 ANSWERS

69.1% PROCESSED 1000 ITERATIONS (9 INCOMPLETE) 10 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.01.10

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 26832 TO 31088
PROJECTED ANSWERS: 61 TO 517

L15 10 SEA SSS SAM L13

=> s 113 sss ful

FULL SEARCH INITIATED 13:23:43 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 29062 TO ITERATE

6.5% PROCESSED	1901 ITERATIONS (1 INCOMPLETE)	1 ANSWERS
13.2% PROCESSED	3827 ITERATIONS (2 INCOMPLETE)	4 ANSWERS
19.4% PROCESSED	5634 ITERATIONS (14 INCOMPLETE)	17 ANSWERS
24.9% PROCESSED	7227 ITERATIONS (24 INCOMPLETE)	29 ANSWERS

31.0%	PROCESSED	9011	ITERATIONS	(34	INCOMPLETE)	40	ANSWERS
37.9%	PROCESSED	11020	ITERATIONS	(44	INCOMPLETE)	51	ANSWERS
43.0%	PROCESSED	12492	ITERATIONS	(53	INCOMPLETE)	60	ANSWERS
46.0%	PROCESSED	13368	ITERATIONS	(61	INCOMPLETE)	68	ANSWERS
49.2%	PROCESSED	14301	ITERATIONS	(75	INCOMPLETE)	84	ANSWERS
52.4%	PROCESSED	15217	ITERATIONS	(84	INCOMPLETE)	93	ANSWERS
55.3%	PROCESSED	16085	ITERATIONS	(96	INCOMPLETE)	107	ANSWERS
58.0%	PROCESSED	16867	ITERATIONS	(103	INCOMPLETE)	115	ANSWERS
60.5%	PROCESSED	17593	ITERATIONS	(114	INCOMPLETE)	126	ANSWERS
62.7%	PROCESSED	18222	ITERATIONS	(127	INCOMPLETE)	139	ANSWERS
65.4%	PROCESSED	19001	ITERATIONS	(137	INCOMPLETE)	149	ANSWERS
66.9%	PROCESSED	19433	ITERATIONS	(145	INCOMPLETE)	157	ANSWERS
69.5%	PROCESSED	20191	ITERATIONS	(153	INCOMPLETE)	167	ANSWERS
72.1%	PROCESSED	20940	ITERATIONS	(161	INCOMPLETE)	177	ANSWERS
74.5%	PROCESSED	21656	ITERATIONS	(173	INCOMPLETE)	190	ANSWERS
76.4%	PROCESSED	22194	ITERATIONS	(177	INCOMPLETE)	194	ANSWERS
78.8%	PROCESSED	22909	ITERATIONS	(186	INCOMPLETE)	204	ANSWERS
80.9%	PROCESSED	23498	ITERATIONS	(197	INCOMPLETE)	215	ANSWERS
82.9%	PROCESSED	24093	ITERATIONS	(210	INCOMPLETE)	228	ANSWERS
84.4%	PROCESSED	24530	ITERATIONS	(222	INCOMPLETE)	240	ANSWERS
86.5%	PROCESSED	25132	ITERATIONS	(234	INCOMPLETE)	252	ANSWERS
88.0%	PROCESSED	25578	ITERATIONS	(240	INCOMPLETE)	259	ANSWERS
89.7%	PROCESSED	26077	ITERATIONS	(246	INCOMPLETE)	265	ANSWERS
90.7%	PROCESSED	26370	ITERATIONS	(254	INCOMPLETE)	273	ANSWERS
92.9%	PROCESSED	26991	ITERATIONS	(261	INCOMPLETE)	280	ANSWERS
94.2%	PROCESSED	27389	ITERATIONS	(267	INCOMPLETE)	286	ANSWERS
95.3%	PROCESSED	27693	ITERATIONS	(272	INCOMPLETE)	291	ANSWERS
96.1%	PROCESSED	27925	ITERATIONS	(276	INCOMPLETE)	295	ANSWERS
96.5%	PROCESSED	28037	ITERATIONS	(278	INCOMPLETE)	297	ANSWERS
96.9%	PROCESSED	28147	ITERATIONS	(283	INCOMPLETE)	302	ANSWERS
97.4%	PROCESSED	28316	ITERATIONS	(285	INCOMPLETE)	304	ANSWERS
97.5%	PROCESSED	28334	ITERATIONS	(286	INCOMPLETE)	305	ANSWERS

97.8% PROCESSED	28427 ITERATIONS	(287 INCOMPLETE)	306 ANSWERS
98.0% PROCESSED	28470 ITERATIONS	(288 INCOMPLETE)	307 ANSWERS
98.1% PROCESSED	28499 ITERATIONS	(289 INCOMPLETE)	308 ANSWERS
98.3% PROCESSED	28573 ITERATIONS	(292 INCOMPLETE)	311 ANSWERS
98.4% PROCESSED	28606 ITERATIONS	(294 INCOMPLETE)	314 ANSWERS
98.6% PROCESSED	28658 ITERATIONS	(296 INCOMPLETE)	316 ANSWERS
98.7% PROCESSED	28687 ITERATIONS	(296 INCOMPLETE)	316 ANSWERS
98.9% PROCESSED	28732 ITERATIONS	(297 INCOMPLETE)	317 ANSWERS
99.1% PROCESSED	28799 ITERATIONS	(298 INCOMPLETE)	318 ANSWERS
99.1% PROCESSED	28812 ITERATIONS	(298 INCOMPLETE)	318 ANSWERS
99.2% PROCESSED	28816 ITERATIONS	(298 INCOMPLETE)	318 ANSWERS
99.3% PROCESSED	28853 ITERATIONS	(299 INCOMPLETE)	319 ANSWERS
99.4% PROCESSED	28882 ITERATIONS	(299 INCOMPLETE)	319 ANSWERS
99.4% PROCESSED	28884 ITERATIONS	(299 INCOMPLETE)	319 ANSWERS
99.4% PROCESSED	28901 ITERATIONS	(299 INCOMPLETE)	319 ANSWERS
99.7% PROCESSED	28977 ITERATIONS	(299 INCOMPLETE)	319 ANSWERS
99.8% PROCESSED	28991 ITERATIONS	(299 INCOMPLETE)	319 ANSWERS
99.9% PROCESSED	29024 ITERATIONS	(299 INCOMPLETE)	319 ANSWERS
100.0% PROCESSED	29062 ITERATIONS	(299 INCOMPLETE)	319 ANSWERS

SEARCH TIME: 00.15.18


L15 319 SEA SSS FUL L13

=> s l15/com

L16 20 L15/COM

=>

Uploading E:\express6\Queries\rogers2005\ortX1SX2Omar.str



chain nodes :

7 8 12 13 14 15 16 17 18 19 26 27 28 29 30 34 35 36 37 38 39
45 48 49 50 53 55 56

ring nodes :


```

1  2  3  4  5  6
ring/chain nodes :
25  54
chain bonds :
1-25  2-13  13-15  14-15  15-16  25-26  25-54  26-45  28-29  28-30  34-35  36-37
38-39  38-53  48-49  49-50  55-56
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
1-25  2-13  13-15  14-15  15-16  25-26  25-54  26-45  28-29  28-30  34-35  36-37
38-39  38-53  48-49  49-50  55-56
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6

```

G1:[*1],[*2]

G4:[*3],[*4],[*5],[*6],[*7]

G9:[*8],[*9],[*10],[*11]

G10:H,[*12]

Connectivity :
7:1 E exact RC ring/chain 17:1 E exact RC ring/chain 26:2 E exact RC ring/chain
29:1 E exact RC ring/chain 30:1 E exact RC ring/chain 50:1 E exact RC
ring/chain 56:1 E exact RC ring/chain

Match level :

```

1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS 12:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom 24:CLASS
25:CLASS 26:CLASS 27:Atom 28:CLASS 29:CLASS 30:CLASS 34:CLASS 35:Atom
36:CLASS 37:Atom 38:CLASS 39:Atom 45:CLASS 48:CLASS 49:CLASS 50:CLASS
53:CLASS 54:CLASS 55:CLASS 56:CLASS

```

Generic attributes :

7:

Number of Carbon Atoms : less than 7

17:

Number of Carbon Atoms : less than 7

19:

Saturation : Saturated

26:

Number of Carbon Atoms : less than 7

27:

Saturation : Unsaturated

29:

Number of Carbon Atoms : less than 7

30:

Number of Carbon Atoms : less than 7

35:

Saturation : Unsaturated

37:

Saturation : Unsaturated

39:

Saturation : Unsaturated

50:

Number of Carbon Atoms : less than 7

56:

Number of Carbon Atoms : less than 7

Element Count :

Node 19: Limited

N,N1

=> s 117 sss sam

```

61.2% PROCESSED      1000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.02

```

L18 0 SEA SSS SAM L17

=> s 117 sss ful

74.2% PROCESSED	24821 ITERATIONS		2 ANSWERS
88.6% PROCESSED	29654 ITERATIONS	(4 INCOMPLETE)	7 ANSWERS
97.6% PROCESSED	32654 ITERATIONS	(11 INCOMPLETE)	14 ANSWERS
98.8% PROCESSED	33053 ITERATIONS	(13 INCOMPLETE)	16 ANSWERS
99.4% PROCESSED	33253 ITERATIONS	(14 INCOMPLETE)	17 ANSWERS
100.0% PROCESSED	33458 ITERATIONS	(15 INCOMPLETE)	18 ANSWERS
SEARCH TIME: 00.01.36			


L19 18 SEA SSS FUL L17

=> s 119/com

L20 3 L19/COM

 \Rightarrow

Uploading E:\express6\Queries\rogers2005\ortX1SX2Smar.str



chain nodes :

[illegible]

ring nodes :

1	2	3	4	5	6
---	---	---	---	---	---

```
ring/chain nodes :
```

25 54
chain bonds :
1-25 2-13 13-15 14-15 15-16 25-26 25-54 26-45 28-29 28-30 34-35 36-37
38-39 38-53 48-49 49-50 55-56
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-25 2-13 13-15 14-15 15-16 25-26 25-54 26-45 28-29 28-30 34-35 36-37
38-39 38-53 48-49 49-50 55-56
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:[*1],[*2]

G4:[*3],[*4],[*5],[*6],[*7]

G9:[*8],[*9],[*10],[*11]

G10:H,[*12]

Connectivity :
7:1 E exact RC ring/chain 17:1 E exact RC ring/chain 26:2 E exact RC ring/chain
29:1 E exact RC ring/chain 30:1 E exact RC ring/chain 50:1 E exact RC
ring/chain 56:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 12:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom 24:CLASS
25:CLASS 26:CLASS 27:Atom 28:CLASS 29:CLASS 30:CLASS 34:CLASS 35:Atom
36:CLASS 37:Atom 38:CLASS 39:Atom 45:CLASS 48:CLASS 49:CLASS 50:CLASS
53:CLASS 54:CLASS 55:CLASS 56:CLASS

Generic attributes :

7:

Number of Carbon Atoms : less than 7

17:

Number of Carbon Atoms : less than 7

19:

Saturation : Saturated

26:

Number of Carbon Atoms : less than 7

27:

Saturation : Unsaturated

29:

Number of Carbon Atoms : less than 7

30:

Number of Carbon Atoms : less than 7

35:

Saturation : Unsaturated

37:

Saturation : Unsaturated

39:

Saturation : Unsaturated

50:

Number of Carbon Atoms : less than 7

56:

Number of Carbon Atoms : less than 7

Element Count :

Node 19: Limited

N,N1

L21 STRUCTURE UPLOADED

=> s l21 sss sam
SAMPLE SEARCH INITIATED 13:44:00 FILE 'MARPAT'
SAMPLE SCREEN SEARCH COMPLETED - 1245 TO ITERATE

80.3% PROCESSED 1000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
PROJECTED ITERATIONS: 22905 TO 26895
PROJECTED ANSWERS: 0 TO 0

L22 0 SEA SSS SAM L21

=> s l21 sss ful
FULL SEARCH INITIATED 13:44:22 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 24029 TO ITERATE

84.2% PROCESSED 20236 ITERATIONS 3 ANSWERS
97.8% PROCESSED 23493 ITERATIONS 3 ANSWERS
97.8% PROCESSED 23493 ITERATIONS 3 ANSWERS
99.3% PROCESSED 23870 ITERATIONS (2 INCOMPLETE) 5 ANSWERS
100.0% PROCESSED 24029 ITERATIONS (2 INCOMPLETE) 5 ANSWERS
SEARCH TIME: 00.01.25


L23 5 SEA SSS FUL L21

=> s l23/com

L24 3 L23/COM

=>

Uploading E:\express6\Queries\rogers2005\parX1OX2Smar.str



chain nodes :

7 8 12 13 14 15 16 17 18 19 26 27 28 29 30 34 35 36 37 38 39
45 48 49 50 53 55 56

ring nodes :

1 2 3 4 5 6

ring/chain nodes :

25 54

chain bonds :

2-13 5-25 13-15 14-15 15-16 25-26 25-54 26-45 28-29 28-30 34-35 36-37
38-39 38-53 48-49 49-50 55-56

```

ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
2-13  5-25  13-15  14-15  15-16  25-26  25-54  26-45  28-29  28-30  34-35  36-37
38-39  38-53  48-49  49-50  55-56
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6

G1:[*1],[*2]

G4:[*3],[*4],[*5],[*6],[*7]

G9:[*8],[*9],[*10],[*11]

G10:H,[*12]

Connectivity :
7:1 E exact RC ring/chain  17:1 E exact RC ring/chain  26:2 E exact RC ring/chain
29:1 E exact RC ring/chain  30:1 E exact RC ring/chain  50:1 E exact RC
ring/chain  56:1 E exact RC ring/chain
Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  12:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom 24:CLASS
25:CLASS 26:CLASS 27:Atom 28:CLASS 29:CLASS 30:CLASS 34:CLASS 35:Atom
36:CLASS 37:Atom 38:CLASS 39:Atom 45:CLASS 48:CLASS 49:CLASS 50:CLASS
53:CLASS 54:CLASS 55:CLASS 56:CLASS
Generic attributes :
7:
Number of Carbon Atoms : less than 7
17:
Number of Carbon Atoms : less than 7
19:
Saturation                : Saturated
26:
Number of Carbon Atoms : less than 7
27:
Saturation                : Unsaturated
29:
Number of Carbon Atoms : less than 7
30:
Number of Carbon Atoms : less than 7
35:
Saturation                : Unsaturated
37:
Saturation                : Unsaturated
39:
Saturation                : Unsaturated
50:
Number of Carbon Atoms : less than 7
56:
Number of Carbon Atoms : less than 7

Element Count :
Node 19: Limited
      N,N1

```

```
=> s l25 sss sam
SAMPLE SEARCH INITIATED 13:47:25 FILE 'MARPAT'
SAMPLE SCREEN SEARCH COMPLETED - 1448 TO ITERATE
```

45.5% PROCESSED	659 ITERATIONS	1 ANSWERS
61.9% PROCESSED	897 ITERATIONS	8 ANSWERS
67.7% PROCESSED	980 ITERATIONS	17 ANSWERS
68.2% PROCESSED	987 ITERATIONS	18 ANSWERS
69.1% PROCESSED	1000 ITERATIONS (20 INCOMPLETE)	21 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.01.17

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:    26832 TO 31088
PROJECTED ANSWERS:       277 TO 939
```

L26 21 SEA SSS SAM L25

```
=> s l25 sss ful
FULL SEARCH INITIATED 13:49:01 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 29062 TO ITERATE
```

5.0% PROCESSED	1450 ITERATIONS (1 INCOMPLETE)	2 ANSWERS
9.7% PROCESSED	2829 ITERATIONS (4 INCOMPLETE)	6 ANSWERS
11.8% PROCESSED	3438 ITERATIONS (12 INCOMPLETE)	17 ANSWERS
14.4% PROCESSED	4191 ITERATIONS (20 INCOMPLETE)	27 ANSWERS
17.1% PROCESSED	4975 ITERATIONS (27 INCOMPLETE)	34 ANSWERS
21.2% PROCESSED	6160 ITERATIONS (41 INCOMPLETE)	48 ANSWERS
24.5% PROCESSED	7106 ITERATIONS (51 INCOMPLETE)	58 ANSWERS
29.2% PROCESSED	8497 ITERATIONS (64 INCOMPLETE)	71 ANSWERS
33.8% PROCESSED	9829 ITERATIONS (87 INCOMPLETE)	96 ANSWERS
38.5% PROCESSED	11182 ITERATIONS (97 INCOMPLETE)	107 ANSWERS
42.0% PROCESSED	12206 ITERATIONS (107 INCOMPLETE)	117 ANSWERS
45.7% PROCESSED	13267 ITERATIONS (119 INCOMPLETE)	129 ANSWERS
47.5% PROCESSED	13800 ITERATIONS (130 INCOMPLETE)	141 ANSWERS
50.1% PROCESSED	14555 ITERATIONS (144 INCOMPLETE)	156 ANSWERS
51.9% PROCESSED	15071 ITERATIONS (154 INCOMPLETE)	166 ANSWERS
53.3% PROCESSED	15501 ITERATIONS (160 INCOMPLETE)	172 ANSWERS
55.4% PROCESSED	16114 ITERATIONS (172 INCOMPLETE)	185 ANSWERS
57.0% PROCESSED	16560 ITERATIONS (181 INCOMPLETE)	195 ANSWERS
58.1% PROCESSED	16873 ITERATIONS (187 INCOMPLETE)	202 ANSWERS

59.3%	PROCESSED	17239	ITERATIONS	(195	INCOMPLETE)	210	ANSWERS
60.9%	PROCESSED	17706	ITERATIONS	(204	INCOMPLETE)	219	ANSWERS
63.0%	PROCESSED	18320	ITERATIONS	(221	INCOMPLETE)	236	ANSWERS
65.9%	PROCESSED	19166	ITERATIONS	(229	INCOMPLETE)	244	ANSWERS
68.6%	PROCESSED	19951	ITERATIONS	(241	INCOMPLETE)	257	ANSWERS
70.9%	PROCESSED	20596	ITERATIONS	(260	INCOMPLETE)	276	ANSWERS
73.5%	PROCESSED	21366	ITERATIONS	(272	INCOMPLETE)	288	ANSWERS
75.4%	PROCESSED	21920	ITERATIONS	(279	INCOMPLETE)	296	ANSWERS
77.0%	PROCESSED	22369	ITERATIONS	(290	INCOMPLETE)	307	ANSWERS
79.2%	PROCESSED	23016	ITERATIONS	(309	INCOMPLETE)	326	ANSWERS
81.0%	PROCESSED	23532	ITERATIONS	(324	INCOMPLETE)	341	ANSWERS
82.6%	PROCESSED	24014	ITERATIONS	(336	INCOMPLETE)	353	ANSWERS
84.3%	PROCESSED	24499	ITERATIONS	(348	INCOMPLETE)	366	ANSWERS
86.2%	PROCESSED	25038	ITERATIONS	(364	INCOMPLETE)	382	ANSWERS
87.6%	PROCESSED	25465	ITERATIONS	(369	INCOMPLETE)	387	ANSWERS
88.8%	PROCESSED	25806	ITERATIONS	(375	INCOMPLETE)	393	ANSWERS
89.7%	PROCESSED	26066	ITERATIONS	(386	INCOMPLETE)	404	ANSWERS
90.7%	PROCESSED	26371	ITERATIONS	(391	INCOMPLETE)	409	ANSWERS
91.9%	PROCESSED	26700	ITERATIONS	(397	INCOMPLETE)	415	ANSWERS
92.8%	PROCESSED	26969	ITERATIONS	(401	INCOMPLETE)	419	ANSWERS
93.3%	PROCESSED	27128	ITERATIONS	(404	INCOMPLETE)	422	ANSWERS
94.4%	PROCESSED	27443	ITERATIONS	(408	INCOMPLETE)	426	ANSWERS
94.9%	PROCESSED	27583	ITERATIONS	(415	INCOMPLETE)	433	ANSWERS
95.6%	PROCESSED	27789	ITERATIONS	(417	INCOMPLETE)	435	ANSWERS
96.1%	PROCESSED	27941	ITERATIONS	(419	INCOMPLETE)	437	ANSWERS
96.4%	PROCESSED	28019	ITERATIONS	(422	INCOMPLETE)	440	ANSWERS
96.7%	PROCESSED	28117	ITERATIONS	(424	INCOMPLETE)	442	ANSWERS
97.1%	PROCESSED	28218	ITERATIONS	(426	INCOMPLETE)	444	ANSWERS
97.4%	PROCESSED	28303	ITERATIONS	(427	INCOMPLETE)	445	ANSWERS
97.5%	PROCESSED	28348	ITERATIONS	(429	INCOMPLETE)	447	ANSWERS
97.6%	PROCESSED	28372	ITERATIONS	(430	INCOMPLETE)	448	ANSWERS
97.7%	PROCESSED	28385	ITERATIONS	(431	INCOMPLETE)	449	ANSWERS

97.9% PROCESSED	28455 ITERATIONS	(433 INCOMPLETE)	451 ANSWERS
98.1% PROCESSED	28500 ITERATIONS	(435 INCOMPLETE)	453 ANSWERS
98.2% PROCESSED	28537 ITERATIONS	(435 INCOMPLETE)	453 ANSWERS
98.4% PROCESSED	28587 ITERATIONS	(437 INCOMPLETE)	455 ANSWERS
98.5% PROCESSED	28618 ITERATIONS	(439 INCOMPLETE)	457 ANSWERS
98.6% PROCESSED	28644 ITERATIONS	(440 INCOMPLETE)	458 ANSWERS
98.7% PROCESSED	28695 ITERATIONS	(441 INCOMPLETE)	459 ANSWERS
98.9% PROCESSED	28743 ITERATIONS	(442 INCOMPLETE)	460 ANSWERS
99.1% PROCESSED	28806 ITERATIONS	(444 INCOMPLETE)	462 ANSWERS
99.3% PROCESSED	28852 ITERATIONS	(444 INCOMPLETE)	462 ANSWERS
99.4% PROCESSED	28884 ITERATIONS	(445 INCOMPLETE)	463 ANSWERS
99.4% PROCESSED	28890 ITERATIONS	(445 INCOMPLETE)	463 ANSWERS
99.4% PROCESSED	28893 ITERATIONS	(445 INCOMPLETE)	463 ANSWERS
99.5% PROCESSED	28914 ITERATIONS	(445 INCOMPLETE)	463 ANSWERS
99.6% PROCESSED	28939 ITERATIONS	(446 INCOMPLETE)	464 ANSWERS
99.6% PROCESSED	28939 ITERATIONS	(446 INCOMPLETE)	464 ANSWERS
99.7% PROCESSED	28968 ITERATIONS	(446 INCOMPLETE)	464 ANSWERS
99.7% PROCESSED	28989 ITERATIONS	(447 INCOMPLETE)	465 ANSWERS
99.8% PROCESSED	29000 ITERATIONS	(447 INCOMPLETE)	465 ANSWERS
99.9% PROCESSED	29024 ITERATIONS	(447 INCOMPLETE)	465 ANSWERS
99.9% PROCESSED	29044 ITERATIONS	(447 INCOMPLETE)	465 ANSWERS
100.0% PROCESSED	29062 ITERATIONS	(447 INCOMPLETE)	465 ANSWERS

SEARCH TIME: 00.21.04


L27 465 SEA SSS FUL L25

=> s 127/com

L28 18 L27/COM

=>

Uploading E:\express6\Queries\rogers2005\parX1sX2Omar.str



chain nodes :

7 8 12 13 14 15 16 17 18 19 26 27 28 29 30 34 35 36 37 38 39
45 48 49 50 53 55 56

ring nodes :

1 2 3 4 5 6

ring/chain nodes :

25 54

chain bonds :

2-13 5-25 13-15 14-15 15-16 25-26 25-54 26-45 28-29 28-30 34-35 36-37
38-39 38-53 48-49 49-50 55-56

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

2-13 5-25 13-15 14-15 15-16 25-26 25-54 26-45 28-29 28-30 34-35 36-37
38-39 38-53 48-49 49-50 55-56

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:[*1],[*2]

G4:[*3],[*4],[*5],[*6],[*7]

G9:[*8],[*9],[*10],[*11]

G10:H,[*12]

Connectivity :

7:1 E exact RC ring/chain 17:1 E exact RC ring/chain 26:2 E exact RC ring/chain
29:1 E exact RC ring/chain 30:1 E exact RC ring/chain 50:1 E exact RC
ring/chain 56:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 12:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom 24:CLASS
25:CLASS 26:CLASS 27:Atom 28:CLASS 29:CLASS 30:CLASS 34:CLASS 35:Atom
36:CLASS 37:Atom 38:CLASS 39:Atom 45:CLASS 48:CLASS 49:CLASS 50:CLASS
53:CLASS 54:CLASS 55:CLASS 56:CLASS

Generic attributes :

7:

Number of Carbon Atoms : less than 7

17:

Number of Carbon Atoms : less than 7

19:

Saturation : Saturated

26:

Number of Carbon Atoms : less than 7

27:

Saturation : Unsaturated

29:

Number of Carbon Atoms : less than 7

30:

Number of Carbon Atoms : less than 7
 35:
 Saturation : Unsaturated
 37:
 Saturation : Unsaturated
 39:
 Saturation : Unsaturated
 50:
 Number of Carbon Atoms : less than 7
 56:
 Number of Carbon Atoms : less than 7

 Element Count :
 Node 19: Limited
 N,N1

L29 STRUCTURE UPLOADED

=> s 129 sss sam
 SAMPLE SEARCH INITIATED 14:11:43 FILE 'MARPAT'
 SAMPLE SCREEN SEARCH COMPLETED - 1634 TO ITERATE

61.2% PROCESSED 1000 ITERATIONS 0 ANSWERS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.04

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 30443 TO 34917
 PROJECTED ANSWERS: 0 TO 0

L30 0 SEA SSS SAM L29


=> s 129 sss ful
 FULL SEARCH INITIATED 14:12:16 FILE 'MARPAT'
 FULL SCREEN SEARCH COMPLETED - 33458 TO ITERATE

66.5% PROCESSED 22260 ITERATIONS 2 ANSWERS
 86.5% PROCESSED 28932 ITERATIONS 3 ANSWERS
 95.3% PROCESSED 31902 ITERATIONS (8 INCOMPLETE) 11 ANSWERS
 97.9% PROCESSED 32770 ITERATIONS (12 INCOMPLETE) 15 ANSWERS
 99.4% PROCESSED 33253 ITERATIONS (13 INCOMPLETE) 16 ANSWERS
 100.0% PROCESSED 33458 ITERATIONS (13 INCOMPLETE) 16 ANSWERS
 SEARCH TIME: 00.01.27

L31 16 SEA SSS FUL L29

=> s 131/com
 L32 3 L31/COM

=>
 Uploading E:\express6\Queries\rogers2005\parX1SX2Smar.str



chain nodes :
 7 8 12 13 14 15 16 17 18 19 26 27 28 29 30 34 35 36 37 38 39
 45 48 49 50 53 55 56
 ring nodes :
 1 2 3 4 5 6
 ring/chain nodes :
 25 54
 chain bonds :
 2-13 5-25 13-15 14-15 15-16 25-26 25-54 26-45 28-29 28-30 34-35 36-37
 38-39 38-53 48-49 49-50 55-56
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 exact/norm bonds :
 2-13 5-25 13-15 14-15 15-16 25-26 25-54 26-45 28-29 28-30 34-35 36-37
 38-39 38-53 48-49 49-50 55-56
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6

G1: [*1], [*2]

G4: [*3], [*4], [*5], [*6], [*7]

G9: [*8], [*9], [*10], [*11]

G10: H, [*12]

Connectivity :

7:1 E exact RC ring/chain 17:1 E exact RC ring/chain 26:2 E exact RC ring/chain
 29:1 E exact RC ring/chain 30:1 E exact RC ring/chain 50:1 E exact RC
 ring/chain 56:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 12:CLASS
 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom 24:CLASS
 25:CLASS 26:CLASS 27:Atom 28:CLASS 29:CLASS 30:CLASS 34:CLASS 35:Atom
 36:CLASS 37:Atom 38:CLASS 39:Atom 45:CLASS 48:CLASS 49:CLASS 50:CLASS
 53:CLASS 54:CLASS 55:CLASS 56:CLASS

Generic attributes :

7:

Number of Carbon Atoms : less than 7

17:

Number of Carbon Atoms : less than 7

19:

Saturation : Saturated

26:

Number of Carbon Atoms : less than 7

27:

Saturation : Unsaturated

29:

Number of Carbon Atoms : less than 7

30:

Number of Carbon Atoms : less than 7
35:
Saturation : Unsaturated
37:
Saturation : Unsaturated
39:
Saturation : Unsaturated
50:
Number of Carbon Atoms : less than 7
56:
Number of Carbon Atoms : less than 7

Element Count :
Node 19: Limited
N,N1

L33 STRUCTURE UPLOADED

=> s l33 sss sam
SAMPLE SEARCH INITIATED 14:14:51 FILE 'MARPAT'
SAMPLE SCREEN SEARCH COMPLETED - 1245 TO ITERATE

80.3% PROCESSED 1000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.06

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 22905 TO 26895
PROJECTED ANSWERS: 0 TO 0

L34 0 SEA SSS SAM L33

=> s l33 sss ful
FULL SEARCH INITIATED 14:15:09 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 24029 TO ITERATE

80.9% PROCESSED 19445 ITERATIONS 2 ANSWERS
97.8% PROCESSED 23493 ITERATIONS (1 INCOMPLETE) 4 ANSWERS
99.3% PROCESSED 23870 ITERATIONS (3 INCOMPLETE) 6 ANSWERS
99.3% PROCESSED 23870 ITERATIONS (3 INCOMPLETE) 6 ANSWERS
99.3% PROCESSED 23870 ITERATIONS (3 INCOMPLETE) 6 ANSWERS
100.0% PROCESSED 24029 ITERATIONS (4 INCOMPLETE) 7 ANSWERS
SEARCH TIME: 00.01.35

L35 7 SEA SSS FUL L33

=> s l35/com
L36 3 L35/COM

=> d his

L1 STRUCTURE UPLOADED
L2 10 S L1 SSS SAM

L3 270 S L1 SSS FUL
 L4 17 S L3/COM
 L5 STRUCTURE UPLOADED
 L6 0 S L5 SSS SAM
 L7 12 S L5 SSS FUL
 L8 4 S L7/COM
 L9 STRUCTURE UPLOADED
 L10 0 S L9 SSS SAM
 L11 4 S L9 SSS FUL
 L12 4 S L11/COM
 L13 STRUCTURE UPLOADED
 L14 10 S L13 SSS SAM
 L15 319 S L13 SSS FUL
 L16 20 S L15/COM
 L17 STRUCTURE UPLOADED
 L18 0 S L17 SSS SAM
 L19 18 S L17 SSS FUL
 L20 3 S L19/COM
 L21 STRUCTURE UPLOADED
 L22 0 S L21 SSS SAM
 L23 5 S L21 SSS FUL
 L24 3 S L23/COM
 L25 STRUCTURE UPLOADED
 L26 21 S L25 SSS SAM
 L27 465 S L25 SSS FUL
 L28 18 S L27/COM
 L29 STRUCTURE UPLOADED
 L30 0 S L29 SSS SAM
 L31 16 S L29 SSS FUL
 L32 3 S L31/COM
 L33 STRUCTURE UPLOADED
 L34 0 S L33 SSS SAM
 L35 7 S L33 SSS FUL
 L36 3 S L35/COM

=> s l4 or l8 or l12 or l16 or l20 or l24 or l28 or l32 or l36
 L37 25 L4 OR L8 OR L12 OR L16 OR L20 OR L24 OR L28 OR L32 OR L36

=> d bib fhit 1-

L37 ANSWER 1 OF 25 MARPAT COPYRIGHT 2005 ACS on STN
 AN 142:279952 MARPAT Full-text
 TI Preparation of aralkanoates as inhibitors of prostaglandin and leukotriene
 production.
 IN Shoda, Motoshi; Kuriyama, Hiroshi
 PA Asahi Kasei Pharma Corporation, Japan
 SO PCT Int. Appl., 687 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2005016862	A1	20050224	WO 2004-JP11952	20040813
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,				

SN, TD, TG


WO 2005016862	A1	20050224	WO 2004-XA11952	20040813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

WO 2005016862	A1	20050224	WO 2004-XB11952	20040813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				





WO 2005016862	A1	20050224	WO 2004-XC11952	20040813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				





PRAI JP 2003-293590 20030814
US 2003-495734P 20030818
WO 2004-JP11952 20040813

MSTR 1






G1 = Cy<EC (0-4) Q (0-) N (0-) O (0-) S (0) OTHERQ,
RC (2)> (SO G34) / Cl / Br / I / OSO2Me / 64 /
arylsulfonyloxy / (EX benzothienyl / benzofuranyl /
naphthyl / indazolyl / indolyl / benzothiazolyl /
quinolinyl / isoquinolinyl / benzotriazolyl / 111 /
benzoxazolyl / 120 / 137 / 147 / 157 / 166 / 170 / 187 /
197 / 207 / 216 / 227 / 238 / 247 / 256 / 265 / 276 / 286)





G2 = 9-1 8-3 5-81 6-83 7-84 /
 15-1 13-3 11-81 12-83 14-84 / 21-1 18-3 17-81 19-83 20-84 /
 27-1 23-3 24-81 25-83 26-84 / 32-1 33-3 29-81 30-83 31-84 /
 38-1 37-3 35-81 36-83 39-84 / 44-1 42-3 41-81 43-83 45-84 /
 50-1 47-3 48-81 49-83 51-84 / 55-1 54-3 53-81 56-83 57-84 /
 61-1 59-3 60-81 62-83 63-84 / 90-1 85-3 86-81 87-83 88-84 /
 96-1 92-3 91-81 93-83 94-84 / 102-1 99-3 97-81 98-83 100-84



G3 = 67 / CHO

$$6G4-C(O)-G5$$

G4 = Ak<(1-3)> / (SC G44)
G5 = OH / 331

391-G37

G6 = H / alkyl<(1-4)> / F / Cl / Br / NO2 / OH (SO) /
70 / NH2 / 75 / 76 / Hy<EC (3-6) A (1-) N, AN (1) N>
(SO alkyl<(1-4)>) / morpholino / G7 / 106 / 108

$$\begin{array}{ccccccc} 70 & \text{---} & G9 & & H5 & \text{---} & G10 \\ & & & & | & & \\ & & & & G10 & & \\ & & & & & & C(=O) - G7 \\ & & & & & & | \\ & & & & & & G8 & \text{---} & G35 \end{array}$$

G7 = alkyl<(3-8)> / 293 / Cy<EC (0-) N (0-) O (0-) S,
RC (1-2)> / 295 / 297 / 301 / 309

2G15—G16 2G17—G18 2G20—G18 3G17—G20—G18 3G22—G23

G8 = O / S / S(O) / SO2 / 322

322—G35

G9 = alkyl<(1-4)> / Ph / CH₂Ph
G10 = alkyl<(1-4)> / 77 / 79

77(0)-G11 O₂S—G12


```
G11      = H / alkyl<(1-4)> / alkoxy<(1-4)> / OPh / OCH2Ph /
          NH2 / alkylamino<(1-4)> / dialkylamino<(1-4)> /
          Hy<EC (3-6) A (1-) N, AN (1) N> / morpholino
G12      = alkyl<(1-4)> / NH2 / alkylamino<(1-4)> /
          dialkylamino<(1-4)>
G13      = O / S
G14      = O / S / NMe
G15      = alkylene<EC (1-3) C, DC (0) M3>
G16      = Cb<(3-8)> (SO alkyl<(1-4)>)
G17      = alkylene<(1-3)> (SO G19) / G15
G18      = Cy<EC (0-) N (0-) O (0-) S, RC (1-2)>
G19      = alkyl<(1-4)> / Ph
G20      = O / S / S(O) / SO2 / NH / 299
```

299-G21

```
G21      = alkyl<(1-4)>
G22      = alkylene<EC (2-4) C, DC (0) M3>
G23      = NH2 / 307
```


~~367~~³⁶⁴-G24


G24 = 313 / 317



G25 = alkylene<EC (1-2) C, DC (0) M3>
G26 = Cy<RC (1-2)> / H / alkyl<(1-8)>
G27 = NH / 308

~~308~~³⁰⁸-G33


G28 = O / S
G29 = Cy<RC (1-2)> / alkyl<(1-8)> / 315 / 320 / OH (SO) /
SH (SO) / NH2 (SO) / Hy<EC (1-) N, AN (1) N> / morpholino




G30 = Cy<RC (1-2)>
G31 = alkylene<EC (1-3) C, DC (0) M3>
G32 = OH / alkoxy<(1-4)> / CO2H /
dialkylaminocarbonyl<(1-4)>
G33 = Cy<RC (1-2)> / alkyl<(1-8)> / 311

~~365~~³⁶²-G26


G34 = R / (EX Me)
G35 = G7 / Me / Et / G24 / alkyl<(1-8)> / Ph / CH2Ph
G36 = alkyl<(1-4)> / F / Cl / Br / NO2 / OH (SO) / 329 /
NH2 / 325 / 328 / Hy<EC (3-6) A (1-) N, AN (1) N> /
morpholino



G37 = alkyl<(1-4)> / 333 / 338



G38 = alkylene<EC (2-3) C, DC (0) M3>
G39 = 337 / Hy<EC (3-6) A (1-) N, AN (1) N> / morpholino




G40 = Me / Et / Pr-n
 G41 = H / Me / Et / Pr-n
 G42 = NULL / O
 G43 = alkyl<(1-4)> / cycloalkyl<(3-6)> / Ph
 G44 = (1-3) CH2
 MPL: claim 1
 NTE: additional substitution also claimed
 NTE: additional ring formation also claimed
 NTE: and protected derivatives and salts
 NTE: also incorporates claim 29

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 2 OF 25 MARPAT COPYRIGHT 2005 ACS on STN
 AN 141:366254 MARPAT Full-text
 TI Preparation of novel triazine compounds for inhibiting smooth muscle cell proliferation
 IN Timmer, Richard T.; Alexander, Christopher W.; Pillarisetti, Sivaram; Saxena, Uday; Yeleswarapu, Koteswar Rao; Pal, Manojit; Reddy, Jangalgar Tirupathy; Krishma, Reddy Velagala Venkata Rama Murali; Sesila, Sridevi Bhatlapenumarthy; Kumar, Potlapally Rajender; Reddy, Gaddam Om
 PA USA
 SO U.S. Pat. Appl. Publ., 422 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004209882	A1	20041021	US 2003-400169	20030326
	US 2005124619	A1	20050609	US 2004-951120	20040927
PRAI	US 2001-324147P		20010921		
	US 2002-253388		20020923		
	US 2003-390485		20030317		
	US 2003-400169		20030326		


MSTR 1




G1 = O / 178 / 180-1 181-9




G2 = O / 20






G3 = 25 / Cy<EC (10) A (0-2) N (0-2) O (0) OTHERQ (7-)
C, AR (1-), BD (6-) N, RC (2), RS (2) E6> (SO G5)




G4 = 29-8 30-22 26-24 27-23 28-32 /
36-8 38-22 33-24 34-23 35-32 / 42-8 43-22 39-24 40-23 41-32




G5 = G10 / 46 / OCF3 / F / Cl / Br / I / CF3 / CN / NO2 /
48 / 51 / 54 / 56 / 59 / 70 / 71 / 73 / 86 / 93 / 101



G6 = Li / Na / K / Mg / Ca
G7 = C(O) / SO2
G8 = O / S / 62




G9 = O / NH
G10 = H / alkyl<(1-10)> / Cb<EC (-10) C, BD (0) T> / 10 /
13 / 15 / aryl / 18




G11 = H / alkyl<(1-10)>
G12 = Ph / OH / NH2
G13 = OH / SH


G14 = (0-3) CH2
 G15 = 76 / 78 / 81 / 87





G16 = O / S / S(O) / SO2
 G17 = NULL / alkylene<EC (1-3) C, DC (0) M3>
 G18 = O / NULL
 G19 = (0-6) 98-94 100-97




G20 = (0-6) 108-101 110-103




G21 = H / R
 G22 = 106 / F / Cl / Br / I / 113 / 123 / 133 / 142 /
 150 / 159 / 161 / 168





G23 = (3-5) CH2
 G24 = NH / CH2 / S
 G25 = O / 170







G26 = G10 / CF3 / G29 / 172 / 174 / 176 / 228 / 352 /
 365 / 381 / 448 / 466 / G58 / 481 / 454 / 458 / 462 / 483 /
 490 / 501







G27 = alkylene<EC (1-3) C, DC (0) M3> (SO G10)
 G28 = (1-3) CH2
 G29 = 184 / 187 / 194 / 199 / 232 / 237 / 244 / 251 /
 258 / 263 / 268 / 271 / 278 / 284 / 290 / 301 / 310 / 318 /
 369 / 378 / 438 / Ph / cyclopentyl / cyclohexyl / cycloheptyl





G30 = alkylene<EC (1-3) C, DC (0) M3> (SO G10) / G28
 G31 = 202 / O / S / 204




G32 = O / 206




G34 = H / R
 G35 = 210 / 213 / 220 / 225 / 321 / 326 / 331 / 336 /





G36 = (1-2) CH₂
 G37 = N / CH
 G38 = 357 / 362




G39 = O / 374



G41 = Cl / Br / I / 392 / 399 / 406




G42 = R / COMe
 G43 = chloride / bromide / iodide / 419 / 426 / 433



G44 = CH / N
 G45 = O / 442 / S / SO₂ / 444




G46 = H / R / OH
 G47 = OH (SO)
 G48 = alkyl<(1-10)>
 G49 = H / 446




G50 = CO₂H / 451

~~4952~~-G53


G51 = cyclohexyl / Ph
G52 = alkylene<EC (1-6) C, DC (0) M3> (SO)
G53 = NH₂ (SO)
G54 = 382 / 410




G55 = OH / R / H
G56 = H / R
G57 = C(O) / alkylene<EC (1-6) C, DC (0) M3> (SO)
G58 = NH₂ (SO) / 470 / 479



G59 = alkylene<EC (1-3) C, DC (0) M3> (SO G10) / G28
G60 = H / NH₂ (SO)
G61 = (0-6) 498-503 500-508



G62 = (0-6) 498-495 500-497



MPL: claim 1
NTE: substitution is restricted
NTE: additional derivatization also claimed

L37 ANSWER 3 OF 25 MARPAT COPYRIGHT 2005 ACS on STN

AN 141:106367 MARPAT Full-text

TI Preparation of substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists

IN Lee, Taekyu; Chen, Wenting; Deng, Wei; Robichaud, Albert; Wexler, Ruth

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 256 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004056324	A2	20040708	WO 2003-US41447	20031219

WO 2004056324 A3 20040902


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004180875 A1 20040916 US 2003-743449 20031219
PRAI US 2002-434760P 20021219

MSTR 1




G1 = H / CHO / 15 / 18 / 23 / 20 / cycloalkyl<(3-6)> /
Ak<EC (1-) C, BD (0-) D (0-) T> (SO (1-) G4) /
aryl<(6-10)> (SO) / Cb<(3-10)> (SO) /
Hy<EC (5-6) A (1-4) Q (0-) N (0-) O (0-) S (0) OTHERQ,
RC (1), RS (1) M5 (1) X6> (SO) / 27 / (SC Me / Et)



G2 = alkyl<(1-4)> (SO (1-) aryl<(6-10)>) /
alkyl<(1-4)> (SR cycloalkyl<(3-6)>)
G3 = C(O) / S(O) / SO2
G4 = F / Cl / Br / I / alkoxy<(1-4)> /
cycloalkyl<(3-6)> / aryl<(6-10)> (SO) / Cb<(3-10)> (SO) /
Hy<EC (5-6) A (1-4) Q (0-) N (0-) O (0-) S (0) OTHERQ,
RC (1), RS (1) M5 (1) X6> (SO) / 25



G5 = Cb<(3-10)> (SO) / Hy<EC (5-6) A (1-4) Q (0-) N (0-)
O (0-) S (0) OTHERQ, RC (1), RS (1) M5 (1) X6> (SO)
G6 = (1-2) 33



G7 = H / alkyl<(1-4)>
G8 = H / alkyl<(1-4)> (SO (1-2) G10) /
alkylcarbonyl<(1-4)> / alkoxycarbonyl<(1-4)> /
alkyl<(1-4)> (SR (1-) G9) / (SC Me / Et)
G9 = F / Cl / Br / I
G10 = F / Cl / Br / I / OH / CF3 / CN / NO2 / CO2H /

alkylsulfonyl<(1-4)> / alkylsulfinyl<(1-4)> /
 alkylthio<(1-4)> / 36 / 41 / 44 / NH2 /
 alkyl<(1-4)> (SO (1-) G9) / alkenyl<(2-6)> / alkynyl<(2-6)> /
 alkoxy<(1-4)> / Cb<(3-10)> (SO) / aryl<(6-10)> (SO) /
 Hy<EC (5-10) A (1-4) Q (0-) N (0-) O (0-) S (0) OTHERQ>
 (SO) / 46

${}^3_8\text{G11-SO}_2\text{-G12}$ ${}^4_1\text{G11-C(O)-G12}$ ${}^4_4\text{G11-G13}$ ${}^4_6\text{G14=O}$

G11 = NH / 39

${}^3_8\text{N-G12}$

G12 = alkyl<(1-4)>
 G13 = alkyl<(1-4)> / alkylaminocarbonyl<(1-4)> /
 alkylsulfonyl<(1-4)> / alkoxycarbonyl<(1-4)> /
 alkylcarbonyl<(1-4)> / CHO
 G14 = Cb<(3-10)> (SO) / Hy<EC (5-10) A (1-4) Q (0-) N (0-)
 O (0-) S (0) OTHERQ> (SO)
 G15 = F / Cl / Br / I / CF3 / OCF3 / CN / NO2 / OMe /
 SMe / 49 / 51 / 59 / 62 / 65 / 66 / 71 /
 Hy<EC (5-6) A (1-) N (0-) O (0) OTHERQ, AN (1-) N, RC (1),
 RS (1) M5 (1) X6> (SO alkyl<(1-4)>) /
 Hy<EC (9-10) A (1-4) Q (1-) N (0-) O (0-) S (0) OTHERQ,
 AN (1-) N, RC (2)> (SO) / 74 / alkyl<(1-4)> (SR (1-) G9) /
 alkoxy<(1-4)> (SR (1-) G9) / Ak<EC (1-) C, BD (0-) D (0-) T>
 (SO) / Cb<(3-6)> (SO) / 76 / (SC OEt / SEt / S(O)Me / SO2Me /
 Me / Et / Pr-n / Pr-i / Bu-n / Bu-i / Bu-s)

$\text{F}_2\text{C-G17}$ ${}^5_1\text{G17-G16}$ ${}^5_3\text{G-GF2-CF3}$ ${}^6_2\text{G-GF2-H}$ ${}^6_3\text{G-GF2-Me}$

${}^6_8\text{G19-G18-G16}$ $\text{H}_2\text{C-G17-G16}$ ${}^7_4\text{G20-G21}$ ${}^7_6\text{G22=O}$

G16 = Ak<(1-)> (SO) / Cb<(3-10)> (SO) /
 aryl<(6-10)> (SO) / Hy<EC (5-10) A (1-4) Q (0-) N (0-) O (0-)
 S (0) OTHERQ> (SO) / 53

${}^5_3\text{G14=O}$

G17 = O / S / S(O) / SO2 / NH / 55

${}^5_8\text{N-G12}$

G18 = NH / 69



${}^6_8\text{N-G12}$

G19 = S(O) / SO2 / C(O)


G20 = S(O) / SO2 / CH2 / C(O)
 G21 = Hy<EC (5-6) A (1-) N (0-) O (0) OTHERQ, AN (1-) N,
 RC (1), RS (1) M5 (1) X6> (SO alkyl<(1-4)>) /
 Hy<EC (9-10) A (1-4) Q (1-) N (0-) O (0-) S (0) OTHERQ,
 AN (1-) N, RC (2)> (SO)
 G22 = Cb<(3-6)> (SO)
 G23 = (1) G25 / (-2) G24 / (-2) H
 G24 = F / Cl / Br / CF3 / OCF3 / OH / CN / NO2 / 81 /
 alkyl<(1-4)> (SO (1-) G9) / alkenyl<(2-4)> / alkynyl<(2-4)> /
 alkoxy<(1-4)> (SO (1-) G9)



G25 = F / Cl / Br / I / CF3 / OCF3 / OH / CN / NO2 / OMe /
 SMe / 83 / OH / SH / NH2 / 85 /
 Hy<EC (5-6) A (1-) N (0-) O (0) OTHERQ, AN (1-) N, RC (1),
 RS (1) M5 (1) X6> (SO alkyl<(1-4)>) /
 Hy<EC (9-10) A (1-4) Q (1-) N (0-) O (0-) S (0) OTHERQ,
 AN (1-) N, RC (2)> (SO) / 91 / 93 / 99 / 106 / 111 / 113 /
 116 / 122 / 133 / Ak<EC (1-) C, BD (0-) D (0-) T>
 (SO (1-) G43) / cycloalkyl<(3-6)> (SO (1-) G44) /
 Cb<(3-10)> (SO (1-) G45)




G26 = O / S / NH / 87 / S(O) / SO2



G27 = Ak<EC (1-) C, BD (0-) D (0-) T> (SO) / 89 /
 cycloalkyl<(3-6)> (SO) / aryl<(6-10)> (SO) /
 Cb<(3-10)> (SO) / Hy<EC (5-10) A (1-4) Q (0-) N (0-) O (0-)
 S (0) OTHERQ> (SO)



G28 = alkyl<(1-4)> / alkenyl<(2-4)> / alkynyl<(2-4)>
 G29 = Ak<EC (1-) C, BD (0-) D (0-) T> (SO)
 G30 = NH2 / 95 / Hy<EC (5-6) A (1-) N (0-) O (0) OTHERQ,
 AN (1-) N, RC (1), RS (1) M5 (1) X6> (SO alkyl<(1-4)>) /
 Hy<EC (9-10) A (1-4) Q (1-) N (0-) O (0-) S (0) OTHERQ,
 AN (1-) N, RC (2)> (SO) / OH



G31 = O / NH / 97

9N—G28

G32 = NH / 102 / O

102—G12

G33 = H / Ak<EC (1-) C, BD (0-) D (0-) T> (SO) / 104 /
cycloalkyl<(3-6)> (SO) / aryl<(6-10)> (SO) /
Cb<(3-10)> (SO) / Hy<EC (5-10) A (1-4) Q (0-) N (0-) O (0-)
S (0) OTHERQ> (SO)

104²⁹=O

G34 = OH / 109

109—G27

G35 = S(O) / SO2

G36 = NH2 / 118 / Hy<EC (5-6) A (1-) N (0-) O (0) OTHERQ,
AN (1-) N, RC (1), RS (1) M5 (1) X6> (SO alkyl<(1-4)>) /
Hy<EC (9-10) A (1-4) Q (1-) N (0-) O (0-) S (0) OTHERQ,
AN (1-) N, RC (2)> (SO)

118³⁷—G27


G37 = NH / 120 / (SC NMe / NEt)

120—G28

G38 = NH / 124

124—G12


G39 = 126 / 128 / 131




G40 = NH / 135

135—G27


G41 = CHO / CO2H / 137 / CONH2 / 140 / 142 / 145




G42 = O / NH
 G43 = R / (SC OH / OMe / OEt / OPr-n / OPr-i / F / OCF3 /
 CN / NO2 / SMe / SEt / SO2Me / NH2 / NHMe / NMe2 / COMe /
 CO2Me / NHCOMe / CONH2 / CHO / Ph (SO) / pyridyl (SO))
 G44 = R / (SC F / Cl / Br / Me / Et / Pr-n / Pr-i / Bu-n /
 Bu-i / Bu-s / Bu-t / OH / OMe / OEt / OPr-n / OPr-i / CF3 /
 OCF3 / CN / NO2 / 147 / SMe / SEt / SO2Me / NH2 / 149 / 152 /
 NHMe / NMe2 / COMe / CO2Me / NHCOMe / CONH2 / CHO /
 CH(OH)Me / CH2OH / CH2CH2OH / CH2OMe / 156 / 159 / Ph (SO) /
 pyridyl (SO))






G45 = R / (SC F / Cl / Br / Me / Et / Pr-n / Pr-i / Bu-n /
 Bu-i / Bu-s / Bu-t / OH / OMe / OEt / OPr-n / OPr-i / CF3 /
 OCF3 / CN / NO2 / 161 / SMe / SEt / SO2Me / NH2 / 163 / 166 /
 NHMe / NMe2 / COMe / CO2Me / NHCOMe / CONH2 / CHO /
 CH(OH)Me / CH2OH / CH2CH2OH / CH2OMe / 170 / 173)



G46 = Ak<EC (1-) C, BD (0-) D (0-) T> (SO (1-) G47) /
 273 / cycloalkyl<(3-6)> (SO (1-) G45) /
 aryl<(6-10)> (SO (1-) G45) / Cb<(3-10)> (SO (1-) G45) /
 Hy<EC (5-10) A (1-4) Q (0-) N (0-) O (0-) S (0) OTHERQ>
 (SO (1-) G45) / (SC cyclopropyl / cyclobutyl / cyclopentyl /
 cyclohexyl / 229 / 235 / 240 / 246 / 254 / 262 / 272 / Ph /
 pyridyl / Me / Et / Pr-n / Bu-n / pentyl / hexyl)



G47 = R / (SC F / Cl / OH / cyclopropyl / cyclobutyl /
 cyclopentyl / cyclohexyl / 177 / 185 / 195 / 201 / 207 /
 212 / 218 / Ph)




MPL: claim 1
 NTE: or pharmaceutically acceptable salts
 NTE: substitution is restricted
 STE: or stereoisomers

L37 ANSWER 4 OF 25 MARPAT COPYRIGHT 2005 ACS on STN
 AN 140:315087 MARPAT Full-text
 TI Pharmaceuticals containing (hydroxybenzyl)amines as acetylcholine esterase inhibitors and selective serotonin reuptake inhibitors
 IN Koyama, Kazuo; Marumoto, Masashi; Toda, Seihiro; Suzuki, Keiko; Furumoto, Hiroshi
 PA BTG International Ltd., UK
 SO Jpn. Kokai Tokkyo Koho, 141 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2004107322	A2	20040408	JP 2003-200434	20030723
PRAI	JP 2002-214641		20020724		


MSTR 1




G1 = alkyl<(1-6)> / NH2 / alkylamino<(1-6)> /
 dialkylamino<(1-6)> / Hy<EC (1-4) Q (1-) N (0-) O (0-) S (0)
 OTHERQ, BD (ALL) SE, RS (0-) E5 (0-) E6 (0-) E7 (0) OTHER> /
 (SC 19) / (EX morpholino)



G2 = 13-3 14-6 / 16 / (EX 63-3 70-6)



G3 = aryl<(-14)> (SO (1-3) G4) /
heteroaryl<EC (5-10) A (1-3) Q (0-) N (0-) O (0-) S (0)
OTHERQ> (SO (1-3) G4) / (SC Ph (SO (1-3) G18) /
pyridyl (SO (-1) G4) / 35 / 43) / (EX 49 / naphthyl / 57)




G4 = F / Cl / Br / I / alkyl<(1-6)> (SO (1-) G5) /
alkoxy<(1-6)> / alkylthio<(1-6)> / CHO /
alkylcarbonyl<(1-6)> / alkoxycarbonyl<(1-6)> / NH2 / NHCHO /
alkylcarbonylamino<(1-6)> / OH / SH / CN / NO2 / CO2H
G5 = F / Cl / Br / I
G6 = alkylene<(1-6)> / 9-4 10-7 / (SC CH2 / CH2CH2)



G7 = alkylene<(1-6)> / (SC CH2 / CH2CH2)
G8 = O / S / NH / 11




G9 = CHO / alkylcarbonyl<(1-6)>
G10 = phenylene
G12 = NH2 / 22 / 24



G13 = Hy<EC (1) N (8-10) C, AN (1) N, BD (60) D, RC (2-),
RS (1-) E6>
G14 = H / alkyl<(1-6)> / (SC Me / Et)
G15 = O / S
G16 = Me / Et
G17 = alkyl<(1-6)> / (SC Me / Et)
G18 = F / Cl / Br / I / alkyl<(1-6)> (SO (1-) G5) /
alkoxy<(1-6)> / alkylthio<(1-6)> / CHO /
alkylcarbonyl<(1-6)> / alkoxycarbonyl<(1-6)> / NH2 / NHCHO /
alkylcarbonylamino<(1-6)> / OH / SH / CN / NO2 / CO2H / Me /
CF3 / OMe / SMe / COMe

G19 = alkylene<(1-3)> / (SC CH2 / CH2CH2)
 G20 = G22 / 72-65 74-69



G21 = H / Me
 G22 = (1-3) CH2
 G23 = alkylene<(1-3)> / (SC CH2 / CH2CH2)
 MPL: claim 1
 NTE: additional ring formation also claimed
 NTE: or pharmacologically acceptable salts or esters

L37 ANSWER 5 OF 25 MARPAT COPYRIGHT 2005 ACS on STN

AN 139:268384 MARPAT Full-text

TI Preparation of quaterphenyls and related compounds via combinatorial chemistry for use as liquid crystals

IN Pauluth, Detlef; Kirsch, Peer; Baeuerle, Peter; Deeg, Oliver

PA Merck Patent G.m.b.H., Germany

SO Eur. Pat. Appl., 48 pp.

CODEN: EPXXDW


DT Patent

LA German


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1346995	A1	20030924	EP 2003-3811	20030220
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	DE 10211597	A1	20031002	DE 2002-10211597	20020315
	JP 2003286208	A2	20031010	JP 2003-69260	20030314
	US 2004006235	A1	20040108	US 2003-388607	20030317
PRAI	DE 2002-10211597		20020315		


MSTR 1



G1 = NULL / p-C6H4 (SO (1-) G2) /
 Hy<EC (6) A (1-2) N (4-5) C (0) OTHERQ, AR (1-),
 AN (0) N (2-) C, BD (ALL) N, RC (1), RS (1) E6> (SO (1-) G2)
 G2 = alkyl<(1-12)> / alkenyl<(2-12)> / 7 /
 Ph (SO alkyl<(1-12)>) / F / Cl / Br / I / OH / SH / 9 / CN /
 NO2 / 14 / CF3 / NH2 / 22




G3 = H / Ak<(1-11)> (SO) / R / OH / 18 / NH2



G4 = O / S
 G5 = alkyl<(1-12)> / alkenyl<(2-12)> / 12 /

Ph (SO alkyl<(1-12)>)



G6 = O / NH / 20






G7 = NH / 24



G8 = p-C6H4 / Cb<EC (6) C, AR (1-), BD (ALL) N, RC (1),
RS (1) E6> (SO (1-) G2) / Hy<EC (6) A (1-2) N (4-5) C (0)
OTHERQ, AR (1-), AN (0) N (2-) C, BD (ALL) N, RC (1),
RS (1) E6> (SO (1-) G2)

G9 = H / F / Cl / CN / NCS / alkyl<(1-12)> (SO (1-) F) /
alkoxy<(1-12)> (SO (1-) F) / alkenyl<(2-8)> (SO (1-) F) /
alkynyl<(2-8)> (SO (1-) F)

G10 = 26-2 28-4 / 29-2 30-4 / 31-2 42-4 / 53-2 64-4 /
75-2 86-4 / Hy<EC (13-14) A (1-2) N (11-13) C (0) OTHERQ,
AN (0) N, AR (1-), BD (12) N (-1) D, FA (4) C (0) N, RC (3),
RS (-1) E5 (-3) E6 (0) OTHER> (SO (1-) G2)



G11 = p-C6H4 / Cb<EC (6) C, AR (1-), BD (ALL) N, RC (1),
RS (1) E6> (SO (1-) G2) / Hy<EC (6) A (1-2) N (4-5) C (0)
OTHERQ, AR (1-), AN (0) N (2-) C, BD (ALL) N, RC (1),
RS (1) E6> (SO (1-) G2)

G12 = p-C6H4 / Cb<EC (6) C, AR (1-), BD (ALL) N, RC (1),
RS (1) E6> (SO (1-) G2) / Hy<EC (6) A (1-2) N (4-5) C (0)
OTHERQ, AR (1-), AN (0) N (2-) C, BD (ALL) N, RC (1),
RS (1) E6> (SO (1-) G2)

G13 = CH2CH2 / CH=CH / ethynylene / p-C6H4 /
Cb<EC (6) C, AR (1-), BD (ALL) N, RC (1), RS (1) E6>
(SO (1-) G2) / Hy<EC (6) A (1-2) N (4-5) C (0) OTHERQ,
AR (1-), AN (0) N (2-) C, BD (ALL) N, RC (1), RS (1) E6>
(SO (1-) G2)

G14 = H / Ak<(1-11)> (SO) / R

G15 = p-C6H4 / Cb<EC (6) C, AR (1-), BD (ALL) N, RC (1),


RS (1) E6> (SO (1-) G2) / Hy<EC (6) A (1-2) N (4-5) C (0)
 OTHERQ, AR (1-), AN (0) N (2-) C, BD (ALL) N, RC (1),
 RS (1) E6> (SO (1-) G2)
 G16 = p-C6H4 / Cb<EC (6) C, AR (1-), BD (ALL) N, RC (1),
 RS (1) E6> (SO (1-) G2) / Hy<EC (6) A (1-2) N (4-5) C (0)
 OTHERQ, AR (1-), AN (0) N (2-) C, BD (ALL) N, RC (1),
 RS (1) E6> (SO (1-) G2)
 G17 = H / R
 MPL: claim 1
 NTE: additional interruptions of alkyl, alkoxy, alkenyl, and alkynyl in G9
 also claimed
 NTE: substitution is restricted

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L37 ANSWER 6 OF 25 MARPAT COPYRIGHT 2005 ACS on STN
 AN 139:100974 MARPAT Full-text
 TI Preparation of 4-dedimethylamino (substituted) tetracycline compounds for
 treating tetracycline responsive states
 IN Nelson, Mark L.; Ohemeng, Kwasi
 PA Paratek Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 181 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003057169	A2	20030717	WO 2003-US336	20030106
	WO 2003057169	A3	20031204		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	US 2004157806	A1	20040812	US 2003-337914	20030106
	EP 1474380	A2	20041110	EP 2003-729351	20030106
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK		
	JP 2005514410	T2	20050519	JP 2003-557528	20030106
PRAI	US 2002-346929P		20020108		
	US 2002-346930P		20020108		
	US 2002-346956P		20020108		
	US 2002-347065P		20020108		
	US 2002-367049P		20020321		
	WO 2003-US336		20030106		

MSTR 1



G1 = 21 / 25 / 245 / S / 28 / O




G2 = Me / Ak<EC (1-) C, BD (0-) D (0-) T> (SO (1-) G3)
 G3 = OH / Cb<BD (0-) D (0-) T> (SO G6) / F / Cl / Br /
 I / CN / SH / NH2 / 30 / Cb<EC (6-) C, AR (1-),
 BD (6-) N (0-) D, RC (1-), RS (0-) E5 (0-) E6> (SO G6) /
 Hy<EC (5-) A (1-4) Q (0-) N (0-) O (0-) S (0-) P, AR (1-),
 BD (2-) D, RC (1-), RS (0-) E5 (0-) E6> (SO G6)

$\text{3G4} - \text{G5}$

G4 = O / S / S(O) / SO2 / NH
 G5 = alkyl (SO) / cycloalkyl (SO)
 G6 = alkyl (SO) / cycloalkyl (SO) / R
 G7 = H / OH / F / Cl / Br / I / SH /
 Ak<BD (0-) D (0-) T> (SO) / Cb<BD (0-) D (0-) T> (SO) /
 Cb<EC (6-) C, AR (1-), BD (6-) N (0-) D, RC (1-),
 RS (0-) E5 (0-) E6> (SO G6) / Hy<EC (5-) A (1-4) Q (0-)
 N (0-) O (0-) S (0-) P, AR (1-), BD (2-) D, RC (1-),
 RS (0-) E5 (0-) E6> (SO G6) / 32 / 34

$\text{3G4} - \text{G5} \quad \text{H}_3\text{C} - \text{R}$


G8 = NH2 / 39 / 41



G9 = Ak<BD (0-) D (0-) T> (SO) /
 Cb<BD (0-) D (0-) T> (SO) / 44 /
 Cb<EC (6-) C, AR (1-), BD (6-) N (0-) D, RC (1-),
 RS (0-) E5 (0-) E6> (SO G6) / Hy<EC (5-) A (1-4) Q (0-)
 N (0-) O (0-) S (0-) P, AR (1-), BD (2-) D, RC (1-),
 RS (0-) E5 (0-) E6> (SO G6) / Hy<EC (0-) N (0-) O (0-) S (0-)
 P, AR (0)> (SO) / R<TX "prodrug moiety">

$\text{4G4} - \text{G5}$

G10 = 260 / C(O)



G11 = OH / 56

$\text{5G} - \text{G12}$

G12 = R<TX "prodrug moiety">
 G14 = OH / H / SH / 63 / Cb<EC (6-) C, AR (1-),
 BD (6-) N (0-) D, RC (1-), RS (0-) E5 (0-) E6> (SO G6) /
 Hy<EC (5-) A (1-4) Q (0-) N (0-) O (0-) S (0-) P, AR (1-),
 BD (2-) D, RC (1-), RS (0-) E5 (0-) E6> (SO G6) /
 Ak<BD (0-) D (0-) T> (SO) / Cb<BD (0-) D (0-) T> (SO) / 65 /
 67

${}_{63}^{G12}(O)-G15$ ${}_{63}^{G14}-G5$ ${}_{69}-C(O)-G17$

G15 = Ak<BD (0-) D (0-) T> (SO (1-) G16) /
 Cb<BD (0-) D (0-) T> (SO G16) /
 Cb<EC (6-) C, AR (1-), BD (6-) N (0-) D, RC (1-),
 RS (0-) E5 (0-) E6> (SO) / Hy<EC (5-) A (1-4) Q (0-) N (0-)
 O (0-) S (0-) P, AR (1-), BD (2-) D, RC (1-),
 RS (0-) E5 (0-) E6> (SO)
 G16 = Cb<EC (6-) C, AR (1-), BD (6-) N (0-) D, RC (1-),
 RS (0-) E5 (0-) E6> (SO) / Hy<EC (5-) A (1-4) Q (0-) N (0-)
 O (0-) S (0-) P, AR (1-), BD (2-) D, RC (1-),
 RS (0-) E5 (0-) E6> (SO)
 G17 = Ak<BD (0-) D (0-) T> (SO) /
 Cb<BD (0-) D (0-) T> (SO) / Cb<EC (6-) C, AR (1-),
 BD (6-) N (0-) D, RC (1-), RS (0-) E5 (0-) E6> (SO) /
 Hy<EC (5-) A (1-4) Q (0-) N (0-) O (0-) S (0-) P, AR (1-),
 BD (2-) D, RC (1-), RS (0-) E5 (0-) E6> (SO)
 G18 = NO2 / Ak<BD (0-) D (0-) T> (SO (1-) G42) /
 Cb<BD (0-) D (0-) T> (SO) / Cb<EC (6-) C, AR (1-),
 BD (6-) N (0-) D, RC (1-), RS (0-) E5 (0-) E6> (SO G20) /
 Hy<EC (5-) A (1-4) Q (0-) N (0-) O (0-) S (0-) P, AR (1-),
 BD (2-) D, RC (1-), RS (0-) E5 (0-) E6> (SO G20) / 71 /
 NH2 (SO) / 73 / 103 / (SC Ph (SO (1-) G29) / naphthyl (SO) /
 thiazolyl / thienyl / furyl / Me / Et / Pr-i / Pr-n / Bu-n /
 Bu-i / Bu-t / pentyl / hexyl / cyclopentyl / cyclohexyl /
 cyclopropyl / cyclobutyl / alkylcarbonyl (SO (1-) G43) /
 267 / 269 / SO2NH2 (SO) / 273 / COMe / loweralkylamino /
 diloweralkylamino)

${}_{71}^{G19}-G5$ ${}_{73}^{G21}-G22-\overset{G22}{\parallel}C-G23$ ${}_{103}^{G22}-\overset{G22}{\parallel}C-G23$ ${}_{267}^{HN}-G44$ ${}_{269}^{HN}-C(O)-O-G45$

${}_{273}^{HN}-SO_2-R$

G19 = O / S / S(O) / SO2
 G20 = Ak<BD (0-) D (0-) T> (SO) /
 Cb<BD (0-) D (0-) T> (SO) / R
 G21 = (1-3) CH2
 G22 = O / NH / 77 / S

${}_{77}^{HN}-G24$

G23 = SH / NH2 / OH / 79 / Me /
 Ak<BD (0-) D (0-) T> (SO (1-) G25)

7G22-G24

G24 = acyl / Ak<BD (0-) D (0-) T> (SO) /
 Cb<BD (0-) D (0-) T> (SO) / 83 /
 Cb<EC (6-) C, AR (1-), BD (6-) N (0-) D, RC (1-),
 RS (0-) E5 (0-) E6> (SO G6) / Hy<EC (5-) A (1-4) Q (0-)
 N (0-) O (0-) S (0-) P, AR (1-), BD (2-) D, RC (1-),
 RS (0-) E5 (0-) E6> (SO G6) / Hy<EC (0-) N (0-) O (0-) S (0-)
 P, AR (0)> (SO) / R<TX "prodrug moiety"> / (SC Ph (SO))


8G4-G5

G25 = acyl / Cb<BD (0-) D (0-) T> (SO) / 85 /
 Cb<EC (6-) C, AR (1-), BD (6-) N (0-) D, RC (1-),
 RS (0-) E5 (0-) E6> (SO G6) / Hy<EC (5-) A (1-4) Q (0-)
 N (0-) O (0-) S (0-) P, AR (1-), BD (2-) D, RC (1-),
 RS (0-) E5 (0-) E6> (SO G6) / Hy<EC (0-) N (0-) O (0-) S (0-)
 P, AR (0)> (SO) / R<TX "prodrug moiety">

8G4-G5

G26 = H / NO2 / Ak<BD (0-) D (0-) T> (SO G47) /
 Cb<BD (0-) D (0-) T> (SO) / Cb<EC (6-) C, AR (1-),
 BD (6-) N (0-) D, RC (1-), RS (0-) E5 (0-) E6> (SO G20) /
 Hy<EC (5-) A (1-4) Q (0-) N (0-) O (0-) S (0-) P, AR (1-),
 BD (2-) D, RC (1-), RS (0-) E5 (0-) E6> (SO G20) / 88 / NH2 /
 90 / 95 / 108 / (SC Ph (SO (1-) G46) / Me / Et / Pr-i /
 Pr-n / Bu-i / Bu-t / Bu-n / pentyl / hexyl / COMe)

8G19-G5



G27 = H / OH / F / Cl / Br / I / SH /
 Ak<BD (0-) D (0-) T> (SO) / Cb<BD (0-) D (0-) T> (SO) /
 Cb<EC (6-) C, AR (1-), BD (6-) N (0-) D, RC (1-),
 RS (0-) E5 (0-) E6> (SO G6) / Hy<EC (5-) A (1-4) Q (0-)
 N (0-) O (0-) S (0-) P, AR (1-), BD (2-) D, RC (1-),
 RS (0-) E5 (0-) E6> (SO G6) / 98

9G4-G5

G29 = R / (SC alkyl (SO) / NH2 (SO) / alkoxy (SO) / 263 /
 NO2 / F / Cl / Br / I / OMe)


$\frac{H}{2}\text{N}_3\text{---C(O)-O---G}^{41}$

G30 = H / OH / F / Cl / Br / I / SH /
 Ak<BD (0-) D (0-) T> (SO) / Cb<BD (0-) D (0-) T> (SO) /
 Cb<EC (6-) C, AR (1-), BD (6-) N (0-) D, RC (1-),


RS (0-) E5 (0-) E6> (SO G6) / Hy<EC (5-) A (1-4) Q (0-)
 N (0-) O (0-) S (0-) P, AR (1-), BD (2-) D, RC (1-),
 RS (0-) E5 (0-) E6> (SO G6) / 112 / 114



G37 = 247 / 250 / 253



G38 = H / OH / F / Cl / Br / I / SH /
 Cb<BD (0-) D (0-) T> (SO) / Cb<EC (6-) C, AR (1-),
 BD (6-) N (0-) D, RC (1-), RS (0-) E5 (0-) E6> (SO G6) /
 Hy<EC (5-) A (1-4) Q (0-) N (0-) O (0-) S (0-) P, AR (1-),
 BD (2-) D, RC (1-), RS (0-) E5 (0-) E6> (SO G6) / 258



G39 = Ak<BD (0-) D (0-) T> (SO) / 256



G40 = Ak<BD (0-) D (0-) T> (SO) / OH / F / Cl / Br / I / H
 G41 = alkyl
 G42 = R / (SC NH2 / OH / CO2H / acyl / aryl / Ph (SO) /
 heteroaryl / CONH2 / alkoxy carbonyl / dialkylaminocarbonyl /
 F / Cl / Br / I / OH)
 G43 = R / (SC aryl / heteroaryl)
 G44 = OH / alkoxy
 G45 = Ph (SO)
 G46 = R / (SC Ak (SO) / NO2 / F / Cl / Br / I / NH2 (SO) /
 alkoxy (SO) / CO2H (SO) / aryl (SO) / Hy (SO) / CN /
 alkoxy carbonyl (SO) / CONH2 (SO) / alkyl carbonyl (SO))
 G47 = R / (SC NH2 (SO) / aryl carbonylamino /
 alkyl carbonylamino)
 MPL: claim 1
 NTE: and pharmaceutically acceptable salts
 NTE: substitution is restricted
 NTE: additional substitution and ring formation also claimed
 NTE: also incorporates later claims

L37 ANSWER 7 OF 25 MARPAT COPYRIGHT 2005 ACS on STN
 AN 137:375233 MARPAT Full-text
 TI Metal substituted non centrosymmetrical phthalocyanine analogues, their
 preparation and use in photodynamic therapy and in vivo diagnostic
 IN Roncucci, Gabrio; Dei, Donata; De Filippis, Maria Paola; Fantetti, Lia;
 Nistri, Daniele
 PA L. Molteni & C. Dei Fratelli Alitti Societa' di Esercizio S.P.A., Italy
 SO PCT Int. Appl., 36 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.

KIND DATE





APPLICATION NO. DATE














PI	WO 2002090361	A1	20021114	WO 2002-EP3108	20020320
	WO 2002090361	C1	20040521		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2441386	AA	20021114	CA 2002-2441386	20020320
	EP 1381611	A1	20040121	EP 2002-750855	20020320
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004529171	T2	20040924	JP 2002-587440	20020320
	ZA 2003008093	A	20040708	ZA 2003-8093	20031017
	US 2004156787	A1	20040812	US 2004-472882	20040401
PRAI	EP 2001-106411	20010321			
	WO 2002-EP3108	20020320			

MSTR 1A

$9G12-G15-9G14$

G1 = H / G7 / 58 / 60 / (SC 843 / pyridyl / 495 / 502 /
510 / 518 / 521 / 533 / 552 / 565 / 2-imidazolyl / 569 /
578 / 591 / 609 / 94 / 132 / 640 / 142 / 204 / 176 / 199 /
653 / 662 / NMe2 / 675 / 679 / 710 / 772)







G2 = O / CH2




G3 = Me / decyl

G4 = NH2 / NMe2 / NEt2 / 524 / 529






G5 = O / NH (SO) / S


G6 = NMe2 / 536 / 626 / 631





G7 = Hy<EC (-2) Q (0-) N (0-) O (0-) S (0) OTHERQ> (SO) /
 368 / 373 / 380 / 382 / 404 / 411 / 418 / (EX morpholino /
 piperidino / pyridyl / pyrimidinyl / piperazino /
 pyrrolidino / 422 / 427 / imidazolyl / NHPH / 432 / 444 /
 456 / 481 / 493)





G8 = Zn
 G9 = NMe2 / NEt2 / 644 / 649




G10 = O / CH2
 G11 = 681 / pyridyl / 690 / 696 / 709 / 717 / 729 / 730 /
 736 / 753 / 756 / 771 / 782







G12 = 351 / 352 / 357







G13 = A1
 G14 = H / alkyl<(1-15)>
 G15 = 26-942 25-944 / 971-942 968-944 /
 1017-942 1018-944 / 1083-942 1080-944




G16 = H / R
 G17 = 863 / SH / OH / NH2 / 858 / 788 / 876 /


R<TX "imide or biotine"> / 873 / Ph (SR OH) / OPh (SO) /
(SC 898 / 899 / 910 / 929 / 939 / 940)




G19 = H / alkyl<(1-15)> / Ph
G20 = alkylene<(1-10)> (SO (-2) G22)
G21 = 385 / 390 / 397



G22 = R / (-2) G21
G23 = R / (SC 889)



G27 = NMe2 / 853



MPL: claim 1
NTE: additional ring formation also claimed
NTE: substitution is restricted
NTE: and pharmaceutically acceptable salts


RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 8 OF 25 MARPAT COPYRIGHT 2005 ACS on STN
 AN 137:140527 MARPAT Full-text
 TI Preparation of alkylcarbamic acid esters as acetylcholinesterase inhibitor
 and serotonin reuptake inhibitor
 IN Koyama, Kazuo; Marumoto, Shinji; Toda, Narihiro; Kogen, Hiroshi; Suzuki,
 Keiko
 PA Sankyo Company, Limited, Japan
 SO PCT Int. Appl., 300 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002059074	A1	20020801	WO 2002-JP400	20020122
	W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PH, PL, RU, SG, SK, US, VN, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	CA 2435883	AA	20020801	CA 2002-2435883	20020122
	EP 1362844	A1	20031119	EP 2002-716323	20020122
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	JP 2003176256	A2	20030624	JP 2002-15136	20020124
	US 2004067981	A1	20040408	US 2003-629108	20030728
PRAI	JP 2001-18386		20010126		
	JP 2001-305182		20011001		
	WO 2002-JP400		20020122		


MSTR 1




G1 = alkyl<(1-6)> / NH2 / alkylamino<(1-6)> /
 dialkylamino<(1-6)> / Hy<EC (1-4) Q (1-) N (0-) O (0-) S (0)
 OTHERQ, BD (ALL) SE, RS (0-) E5 (0-) E6 (0-) E7 (0) OTHER> /
 (SC 19) / (EX morpholino)



G2 = 13-3 14-6 / 16 / (EX 63-3 70-6)



G3 = aryl<(-14)> (SO (1-5) G4) /
 heteroaryl<EC (5-10) A (1-3) Q (0-) N (0-) O (0-) S (0)
 OTHERQ> (SO (1-3) G4) / (SC Ph (SO (1-3) G18) /
 pyridyl (SO (-1) G4) / 35 / 43) / (EX 49 / naphthyl / 57)




G4 = F / Cl / Br / I / alkyl<(1-6)> (SO (1-) G5) /
 alkoxy<(1-6)> / alkylthio<(1-6)> / CHO /
 alkylcarbonyl<(1-6)> / alkoxycarbonyl<(1-6)> / NH2 / NHCHO /
 alkylcarbonylamino<(1-6)> / OH / SH / CN / NO2 / CO2H
 G5 = F / Cl / Br / I
 G6 = alkylene<(1-6)> / 9-4 10-7 / (SC CH2 / CH2CH2)

G7—G8

G7 = alkylene<(1-6)> / (SC CH2 / CH2CH2)
 G8 = O / S / NH / 11

11—G9

G9 = CHO / alkylcarbonyl<(1-6)>
 G10 = phenylene (SO (-1) G11)
 G11 = alkyl<(1-6)> / alkenyl<(2-6)> / (SC Me)
 G12 = NH2 / 22 / 24



G13 = Hy<EC (1) N (8-10) C, AN (1) N, BD (60) D, RC (2-),
 RS (1-) E6>
 G14 = H / alkyl<(1-6)> / (SC Me / Et)
 G15 = O / S
 G16 = Me / Et
 G17 = alkyl<(1-6)> / (SC Me / Et)
 G18 = F / Cl / Br / I / alkyl<(1-6)> (SO (1-) G5) /
 alkoxy<(1-6)> / alkylthio<(1-6)> / CHO /
 alkylcarbonyl<(1-6)> / alkoxycarbonyl<(1-6)> / NH2 / NHCHO /
 alkylcarbonylamino<(1-6)> / OH / SH / CN / NO2 / CO2H / Me /
 CF3 / OMe / SMe / COMe
 G19 = alkylene<(1-3)>
 G20 = G22 / 72-65 74-69



G21 = H / Me
 G22 = (1-3) CH2
 MPL: claim 1
 NTE: additional ring formation also claimed
 NTE: or pharmacologically acceptable salts or esters


RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 9 OF 25 MARPAT COPYRIGHT 2005 ACS on STN
 AN 136:232317 MARPAT Full-text
 TI Preparation of heterocyclylbenzenes as herbicides and defoliants.


IN Gupta, Sandeep; Wu, Shao-Yong; Tsukamoto, Masamitsu; Pulman, David A.;
Ying, Bai-Ping
PA ISK Americas Incorporated, USA
SO U.S., 74 pp., Cont.-in-part of U.S. Ser. No. 958,313.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6355799	B1	20020312	US 2000-530373	20000427
	WO 9921837	A1	19990506	WO 1998-US17197	19980821
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002133007	A1	20020919	US 2001-930149	20010816
	US 6545161	B2	20030408		
PRAI	US 1997-958313		19971027		
	WO 1998-US17197		19980821		
	US 2000-530373		20000427		

MSTR 1



G1 = H / F / Cl / Br / I / NO2 / NH2 / 8 / 10 / CONH2 /
CSNH2 / CN / alkylcarbonyl<(1-8)> / alkoxy carbonyl<(1-8)> /
alkylaminosulfonyl<(1-8)> / alkyl<(1-8)> (SO (1-) G3) /
alkoxy<(1-8)> (SO (1-) G3) / alkoxy<(1-8)>
(SR alkoxy carbonyl<(1-8)> (SO)) / OCH2Ph (SO) /
aryloxy<(6-10)> (SO) / heteroaryloxy<EC (1-4) Q (0-) N (0-)
O (0-) S (0) OTHERQ> (SO)



G2 = alkyl<(1-8)> (SO) / alkenyl<(2-8)> (SO) /
alkynyl<(2-8)> (SO) / Cb<EC (3-8) C, AR (0)> (SO) /
aryl<(6-10)> (SO) / heteroaryl<EC (1-4) Q (0-) N (0-) O (0-)
S (0) OTHERQ> (SO) / 13 / alkylsulfonyl<(1-8)> (SO) /
CH2Ph (SO) / alkylcarbonyl<(1-8)> (SO) /
alkenylcarbonyl<(2-8)> (SO) / alkynylcarbonyl<(2-8)> (SO) /
arylcarbonyl<(6-10)> (SO) / heteroarylcarbonyl<EC (1-4)
Q (0-) N (0-) O (0-) S (0) OTHERQ> (SO) /
alkoxy carbonyl<(1-8)> (SO) / aryloxy carbonyl<(6-10)> (SO) /
heteroaryloxy carbonyl<EC (1-4) Q (0-) N (0-) O (0-) S (0)
OTHERQ> (SO)

G3 = F / Cl / Br / I / R
 G4 = F / Cl / Br / I
 G5 = alkyl<(1-8)> (SO) / Cb<EC (3-8) C, AR (0)> (SO) /
 aryl<(6-10)> (SO) / heteroaryl<EC (1-4) Q (0-) N (0-) O (0-)
 S (0) OTHERQ> (SO)
 G6 = H / F / Cl / Br / I / NO2
 G7 = H / OH / SH / NH2 / 17 / Me /
 Ak<EC (1-) C, BD (0-) D (0-) T> (SO (1-3) G9) / F / Cl / Br /
 I / NO2 / CN / (SC 303 / OMe)

$1\text{q}8\text{---}G2$ $3\text{q}3\text{---}G27$










G8 = O / S / NH / 19


$1\text{N}\text{---}G2$

G9 = R / Cb<EC (3-8) C, AR (0)> (SO) /
 aryl<(6-10)> (SO) / heteroaryl<EC (1-4) Q (0-) N (0-) O (0-)
 S (0) OTHERQ> (SO) / 21 / alkylsulfonyl<(1-8)> (SO) /
 CH2Ph (SO) / alkylcarbonyl<(1-8)> (SO) /
 alkenylcarbonyl<(2-8)> (SO) / alkynylcarbonyl<(2-8)> (SO) /
 arylcarbonyl<(6-10)> (SO) / heteroarylcarbonyl<EC (1-4)
 Q (0-) N (0-) O (0-) S (0) OTHERQ> (SO) /
 alkoxycarbonyl<(1-8)> (SO) / aryloxycarbonyl<(6-10)> (SO) /
 heteroaryloxycarbonyl<EC (1-4) Q (0-) N (0-) O (0-) S (0)
 OTHERQ> (SO)


$2\text{q}\text{---}G5$

G10 = 25 / 202 / 212 / (EX Hy (SO) / 37 / 46 / 55 / 62 /
 71 / 82 / 93 / 104 / 122 / 133 / 144 / 155 / 166 / 169 /
 179 / 190 / 272 / 283 / 294 / phthalimido / 222 / 231)






G11 = H / alkyl<(1-8)> (SO (1-) G4) / alkenyl<(2-8)> /
 alkynyl<(2-8)> / NH2 / alkyl<(1-8)> (SR alkoxy<(1-8)>) /
 COMe / alkoxycarbonylamino<(1-8)> /
 alkylcarbonylamino<(1-8)> / alkoxycarbonyl<(1-8)> / (SC Me)
 G12 = alkyl<(1-8)> (SO (1-) G4) / (SC CF3)
 G13 = H / F / Cl / Br / I / NO2 / NH2 /
 alkylamino<(1-8)> (SO (1-) G4) / CN / CONH2
 G14 = O / S / NH
 G15 = N / CH
 G16 = NH2 / OH / SH / CHO / CO2H / CN /
 alkylcarbonyl<(1-8)> / arylcarbonyl<(6-10)> / N3 / 242 /
 Hy<EC (4-8) A (1-) Q (1-) N, AN (1) N> / 258 /
 Ak<EC (1-) C, BD (0-) D (0-) T> (SO (1-) G25) / NO2 /
 (SC 305)



G17 = NH / 244 / O / S




G18 = alkyl<(1-8)> (SO) / alkenyl<(2-8)> (SO) /
 alkynyl<(2-8)> (SO) / NH2 (SO) /
 Cb<EC (3-8) C, AR (0)> (SO) / Hy<EC (3-8) A (1-4) Q (0-)
 N (0-) O (0-) S (0) OTHERQ, AR (0)> (SO) /
 alkylsulfonyl<(1-8)> (SO) / arylsulfonyl<(6-10)> (SO) /
 CH2Ph (SO) / aryl<(6-10)> (SO) /
 heteroaryl<EC (1-4) Q (0-) N (0-) O (0-) S (0) OTHERQ> (SO) /
 alkylcarbonyl<(1-8)> (SO) / alkenylcarbonyl<(2-8)> (SO) /
 alkynylcarbonyl<(2-8)> (SO) / 246 / 250 / 255




G19 = Cb<EC (3-8) C, AR (0)> (SO) / aryl<(6-10)> (SO) /
 heteroaryl<EC (1-4) Q (0-) N (0-) O (0-) S (0) OTHERQ> (SO) /
 248 / alkylthio<(1-8)> (SO) / arylthio<(6-10)> (SO) /
 NH2 (SO) / 253



G20 = aryl<(6-10)> (SO)
 G21 = alkyl<(1-8)> (SO) / aryl<(6-10)> (SO) /
 heteroaryl<EC (1-4) Q (0-) N (0-) O (0-) S (0) OTHERQ> (SO)
 G22 = alkoxy<(1-8)> (SO) / aryl<(6-10)> (SO)
 G23 = alkyl<(1-8)> (SO (1-) G4) / dialkylamino<(1-8)> /
 aryl<(6-10)> (SO) / heteroaryl<EC (1-4) Q (0-) N (0-) O (0-)
 S (0) OTHERQ> (SO)
 G24 = H / F / Cl / Br / I / alkyl<(1-8)> (SO (1-) G4) /
 dialkylamino<(1-8)> / aryl<(6-10)> (SO) /
 heteroaryl<EC (1-4) Q (0-) N (0-) O (0-) S (0) OTHERQ> (SO)
 G25 = CO2H / R / NH2 (SO) / Cb<EC (3-8) C, AR (0)> (SO) /
 Hy<EC (3-8) A (1-4) Q (0-) N (0-) O (0-) S (0) OTHERQ,
 AR (0)> (SO) / alkylsulfonyl<(1-8)> (SO) /
 arylsulfonyl<(6-10)> (SO) / CH2Ph (SO) / aryl<(6-10)> (SO) /
 heteroaryl<EC (1-4) Q (0-) N (0-) O (0-) S (0) OTHERQ> (SO) /
 alkylcarbonyl<(1-8)> (SO) / alkenylcarbonyl<(2-8)> (SO) /
 alkynylcarbonyl<(2-8)> (SO) / 262 / 264 / 267



G26 = O / S / (EX NH)
 G27 = alkyl<(1-8)> (SO (1-) G28) /
 alkenyl<(2-8)> (SO (1-) G28) / alkynyl<(2-8)> (SO (1-) G28)
 G28 = F / Cl / Br / I / CN / NO2 / NH2 / CO2H
 G29 = CO2H / alkyl<(1-8)> (SO) / alkenyl<(2-8)> (SO) /
 alkynyl<(2-8)> (SO) / NH2 (SO) /
 Cb<EC (3-8) C, AR (0)> (SO) / Hy<EC (3-8) A (1-4) Q (0-)
 N (0-) O (0-) S (0) OTHERQ, AR (0)> (SO) /
 alkylsulfonyl<(1-8)> (SO) / arylsulfonyl<(6-10)> (SO) /
 CH2Ph (SO) / aryl<(6-10)> (SO) /
 heteroaryl<EC (1-4) Q (0-) N (0-) O (0-) S (0) OTHERQ> (SO) /
 alkylcarbonyl<(1-8)> (SO) / alkenylcarbonyl<(2-8)> (SO) /
 alkynylcarbonyl<(2-8)> (SO) / 307 / 309 / 312



DER: or salts
MPL: claim 1
NTE: additional ring formation also claimed
NTE: substitution is restricted
NTE: also incorporates claim 9 and broader disclosure

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT






L37 ANSWER 10 OF 25 MARPAT COPYRIGHT 2005 ACS on STN
AN 135:132442 MARPAT Full-text
TI Compounds exhibiting thrombopoietin receptor agonism
IN Takemoto, Hiroshi; Shiota, Takeshi; Takayama, Masami
PA Shionogi & Co., Ltd., Japan
SO PCT Int. Appl., 352 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001053267	A1	20010726	WO 2001-JP411	20010123
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				
	HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU,				
	LV, MZ, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,				
	SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,				
	ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2397018	AA	20010726	CA 2001-2397018	20010123
	AU 2001027089	A5	20010731	AU 2001-27089	20010123
	AU 777777	B2	20041028		
	EP 1253142	A1	20021030	EP 2001-901511	20010123
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003195231	A1	20031016	US 2002-169362	20020702
PRAI	JP 2000-13770	20000124			
	JP 2000-30593	20000208			
	WO 2001-JP411	20010123			

MSTR 1A

G1—G3—G15—G12


G1 = aryl (SO) / heteroaryl<EC (0-) N (0-) O (0-) S>
(SO) / (SC pyridyl (SO (-2) G17) / 256 /
2-thienyl (SO (-2) G17) / 281 / 286 / 291 / 500 / 507 /
536) / (EX 640)


$$\begin{array}{ccccccc} \text{G}_4 & & & \text{G}_4 & & \text{G}_4 & \text{G}_4 \\ | & & | & | & & | & | \\ \text{N} - \text{C}(\text{O}) - \text{G}_5 & , & {}^1_6\text{G}_7 - \text{G}_8 - \text{N} - \text{C}(\text{O}) - \text{T}_4\text{G}_6 & , & {}^2_9\text{G}_7 - \text{G}_8 - \text{C}(\text{O}) - \text{N} - \text{T}_8\text{G}_6 & , & {}^2_4\text{C}(\text{O}) - \text{N} - \text{T}_6\text{G}_6 \\ | & & & & & & | \\ \text{S} & & & & & & \end{array}$$




G4 = H / loweralkyl (SO)
 G5 = NULL / alkylene<(1-)> (SO) / O / S / 9-6 10-3 /
 CH=CH (SO)

~~G6~~—G7

G6 = alkylene<EC (1-2) C, DC (0) M3>
 G7 = O / S
 G8 = alkylene<EC (1-5) C, DC (0) M3>
 G10 = 29-28 30-31 / 36-28 35-31





G11 = O / S
 G12 = SH / loweralkylthio (SO)
 G14 = C(S) / CH2 / CH2CH2
 G15 = phenylene (SO (-2) G49) /
 heteroarylene<EC (0-) N (0-) O (0-) S, RC (1)> (SO) /
 Hy<EC (0-) N (0-) O (0-) S, AR (0), RC (1),
 RS (0-) E5 (0-) E6 (0-) E7 (0) OTHER> (SO) /
 cycloalkylene<RC (1)> (SO) / (SC 620-2 617-541 /
 626-2 623-541 / 628-2 630-541) / (EX 673-2 670-541 /
 681-2 678-541)




G16 = H / loweralkyl (SO) / CO2H / loweralkoxycarbonyl /
 F / Cl / Br / I / CONH2 (SO) / heteroaryl<EC (0-) N (0-)
 O (0-) S> (SO) / aryl (SO)
 G17 = loweralkyl (SO) / CO2H / loweralkoxycarbonyl / F /
 Cl / Br / I / CONH2 (SO) / heteroaryl<EC (0-) N (0-) O (0-)
 S> (SO) / aryl (SO)
 G18 = H / Ph
 G19 = S / 485

~~485~~—G20


G20 = H / loweralkyl
 G22 = 542 / 601 / 603 / 605 / 607 / aryl (SO) /
 heteroaryl<EC (0-) N (0-) O (0-) S> (SO) / 612



- G23 = Ak<(2-)> (SO (-2) G24) / ethynylene
 G24 = F / Cl / Br / I / loweralkoxy (SO) /
 loweralkylthio (SO) / aryl (SO) /
 heteroaryl<EC (0-) N (0-) O (0-) S> (SO) / cycloalkyl (SO) /
 Hy<EC (0-) N (0-) O (0-) S, AR (0)> / NH2 (SO)
 G25 = H / loweralkyl (SO) / CO2H / loweralkoxycarbonyl /
 F / Cl / Br / I / CONH2 (SO)
 G26 = aryl (SO) / heteroaryl<EC (0-) N (0-) O (0-) S>
 (SO) / R
 G27 = 652 / 654 / 656 / 658 / aryl (SO) /
 heteroaryl<EC (0-) N (0-) O (0-) S> (SO) / (EX 663)




- G28 = H / alkyl (SO) / cycloalkyl / alkoxy (SO) /
 alkylthio / F / Cl / Br / I / Ph (SO) /
 heteroaryl<EC (0-) N (0-) O (0-) S> (SO) /
 Hy<EC (0-) N (0-) O (0-) S, AR (0)> (SO)
 G29 = H / loweralkyl (SO) / CO2H / loweralkoxycarbonyl /
 F / Cl / Br / I / CONH2 (SO) / CF3
 G30 = H / alkyl (SO) / cycloalkyl / alkoxy (SO) /
 alkylthio / F / Cl / Br / I / Ph (SO) /
 heteroaryl<EC (0-) N (0-) O (0-) S> (SO) /
 Hy<EC (0-) N (0-) O (0-) S, AR (0)> (SO)
 G31 = H / alkyl (SO) / cycloalkyl / alkoxy (SO) /
 alkylthio / F / Cl / Br / I / Ph (SO) /
 heteroaryl<EC (0-) N (0-) O (0-) S> (SO) /
 Hy<EC (0-) N (0-) O (0-) S, AR (0)> (SO)
 G34 = O / S
 G36 = (1) Ph (SO (1-) G37) / H / loweralkyl (SO) / CO2H /
 loweralkoxycarbonyl / F / Cl / Br / I / CONH2 (SO)
 G37 = alkyl (SO) / cycloalkyl / alkoxy (SO) / alkylthio /
 F / Cl / Br / I / Ph (SO) / heteroaryl<EC (0-) N (0-) O (0-)
 S> (SO) / Hy<EC (0-) N (0-) O (0-) S, AR (0)> (SO)
 G39 = 632 / OH / 635




- G40 = H / F / Cl / Br / I / loweralkyl (SO) /
 loweralkoxy (SO) / loweralkylthio (SO) / loweralkenyl (SO) /
 loweralkynyl (SO) / aryl (SO) /
 heteroaryl<EC (0-) N (0-) O (0-) S> (SO) / cycloalkyl (SO) /
 alkyl (SR G26) / Hy<EC (0-) N (0-) O (0-) S, AR (0)> /
 NH2 (SO)
 G41 = loweralkyl (SO) / loweralkenyl (SO) /
 loweralkynyl (SO) / aryl (SO) /

heteroaryl<EC (0-) N (0-) O (0-) S> (SO) / cycloalkyl (SO) /
 alkyl (SR G26) / Hy<EC (0-) N (0-) O (0-) S, AR (0)> (SO)
 G42 = loweralkyl (SO) / loweralkenyl (SO) /
 loweralkynyl (SO) / alkyl (SR G26)
 G43 = H / aryl (SO) / heteroaryl<EC (0-) N (0-) O (0-) S>
 (SO) / cycloalkyl (SO) / Hy<EC (0-) N (0-) O (0-) S, AR (0)>
 (SO) / (EX morpholino)
 G46 = Ak<(3-)> (SO (-3) G24)
 G47 = 2-furyl / 649



G48 = O / CH2
 G49 = R / (SC loweralkyl (SO (1-) G50) / F / Cl / Br / I /
 loweralkoxy (SO (1-) G50) / OH)
 G50 = F / Cl / Br / I
 G29+G30= alkylene<(1-3)> / 521-505 520-510 / 523-505 522-510



MPL: claim 1
 NTE: or prodrugs, pharmaceutically acceptable salts or solvates

RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 11 OF 25 MARPAT COPYRIGHT 2005 ACS on STN

AN 134:353257 MARPAT Full-text

TI 4-Phenyltetrahydroisoquinolines and use thereof to block reuptake of
 norepinephrine, dopamine and serotonin

IN Beck, James P.; Smith, Mark A.

PA Du Pont Pharmaceuticals Company, USA

SO PCT Int. Appl., 79 pp.

CODEN: PIXXD2


DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001032624	A1	20010510	WO 2000-US30328	20001103
	W: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	CA 2389300	AA	20010510	CA 2000-2389300	20001103
	BR 2000015307	A	20020709	BR 2000-15307	20001103
	EP 1246805	A1	20021009	EP 2000-976884	20001103
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR				
	JP 2004501860	T2	20040122	JP 2001-534776	20001103
	NZ 519146	A	20040227	NZ 2000-519146	20001103
PRAI	US 1999-163270P		19991103		
	WO 2000-US30328		20001103		



MSTR 1




G1 = alkyl<(1-6)> (SO (1-3) G2) / alkenyl<(2-6)> (SO) /
alkynyl<(2-6)> (SO) / cycloalkyl<(3-6)> (SO) /
alkyl<(1-6)> (SR G3) / (SC Me / CF3)
G2 = alkyl<(1-3)> / F / Cl / Br / I / Ph (SO) / CN / OH /
25 / 28 / piperidino / pyrrolidino / piperazino / 132 /
morpholino / thiomorpholino




G3 = (1-) cycloalkyl<(3-7)> (SO) / R
G4 = H / alkyl<(1-6)> / alkenyl<(2-6)> / alkynyl<(2-6)> /
cycloalkyl<(3-6)> / alkyl<(1-6)> (SR cycloalkyl<(3-7)>) /
alkyl<(1-6)> (SR (1-) G22) / (SC Me)
G5 = H / F / Cl / Br / I / OH / 38 / SH / 142 / 145 /
40 / 42 / CN / 46 / 50 / alkyl<(1-6)> (SO (1-3) G2) /
alkenyl<(2-6)> (SO) / alkynyl<(2-6)> (SO) /
cycloalkyl<(3-6)> (SO) / alkyl<(1-6)> (SR G3) /
OPh (SO (1-3) G6) / 35 / (SC Me / Et / Pr-n / Pr-i / OMe /
CF3 / 189 / 192)





G6 = F / Cl / Br / I / CN / alkyl<(1-4)> /
alkyl<(1-4)> (SR (1-) G22) / alkoxy<(1-4)>
G7 = Ph (SO)
G8 = S / S(O) / SO2
G9 = H / F / Cl / Br / I / OH / 52 / SH / 147 / 150 /
54 / 56 / CN / 60 / 64 / 66 / piperidino / pyrrolidino /
piperazino / 178 / morpholino / thiomorpholino /
alkyl<(1-6)> (SO (1-3) G2) / alkenyl<(2-6)> (SO) /
alkynyl<(2-6)> (SO) / cycloalkyl<(3-6)> (SO) /
alkyl<(1-6)> (SR G3) / OPh (SO (1-3) G6) / 69 / (SC Me / Et /
Pr-n / Pr-i / CF3 / 195 / CH2OH)







G10 = H / F / Cl / Br / I / OH / 72 / SH / 152 / 155 /
 74 / CN / 76 / 78 / piperidino / pyrrolidino / piperazino /
 185 / morpholino / thiomorpholino / 83 / 86 / 89 /
 alkyl<(1-6)> (SO) / alkenyl<(2-6)> (SO) /
 alkynyl<(2-6)> (SO) / cycloalkyl<(3-6)> (SO) /
 alkyl<(1-6)> (SR cycloalkyl<(3-7)> (SO)) / F / Cl / Me /
 (SC OMe / CF3)



G11 = 11 / 93 / 102



G12 = H / F / Cl / Br / I / OH / 115



G13 = H / alkyl<(1-4)> / alkyl<(1-4)> (SR (1-) G22) /
 alkyl<(1-4)> (SR alkoxy<(1-4)>) / cycloalkyl<(3-6)> /
 alkyl<(1-6)> (SR cycloalkyl<(3-7)>) / 136 / Ph (SO) / 117



G14 = alkyl<(1-4)> / alkyl<(1-4)> (SR (1-) G22) /
 alkyl<(1-4)> (SR alkoxy<(1-4)>) / cycloalkyl<(3-6)> /
 alkyl<(1-6)> (SR cycloalkyl<(3-7)>) / 138 / Ph (SO) / 119



G15 = H / NH2 / alkyl<(1-4)> /
 alkyl<(1-4)> (SR (1-) G22) / alkyl<(1-4)> (SR alkoxy<(1-4)>)

) / cycloalkyl<(3-6)> / alkyl<(1-6)> (SR cycloalkyl<(3-7)>) /
159 / Ph (SO) / 163

$\text{G19} \text{ } \text{H}_2\text{C} \text{---} \text{G7}$


G16 = NH2 / alkyl<(1-4)> / alkyl<(1-4)> (SR (1-) G22) /
alkyl<(1-4)> (SR alkoxy<(1-4)>) / cycloalkyl<(3-6)> /
alkyl<(1-6)> (SR cycloalkyl<(3-7)>) / 161 / Ph (SO) / 165

$\text{G19} \text{ } \text{H}_2\text{C} \text{---} \text{G7}$

G17 = OH / 157

G16

G18 = 43 / piperidino / pyrrolidino / piperazino / 170 /
morpholino / thiomorpholino



G19 = alkyl<(1-4)> (SO (1-) G22) / Ph
G20 = NHMe / NMe2
G21 = H / R
G22 = F / Cl / Br / I
MPL: claim 1
NTE: substitution is restricted
NTE: or oxides, pharmaceutically acceptable salts, solvates, or prodrugs
STE: 7 - R or S

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 12 OF 25 MARPAT COPYRIGHT 2005 ACS on STN

AN 134:296229 MARPAT Full-text

TI Polymerizable mesogenic tolans

IN Farrand, Louise Diane

PA Merck Patent GmbH, Germany

SO Brit. UK Pat. Appl., 34 pp.

CODEN: BAXXDU


DT Patent

LA English



FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2351734	A1	20010110	GB 2000-16160	20000630
	GB 2351734	B2	20040901		
	US 6514578	B1	20030204	US 2000-598449	20000622
PRAI	EP 1999-112455		19990630		



MSTR 1B





G1 = 19 / 24 / 27 / 29 / 34 / 39



G2 = H / Me / Cl
 G3 = phenylene
 G4 = phenylene
 G5 = O / S / C(O) / 40-38 41-1139 / 42-38 43-1139 /
 44-38 45-1139 / 46-38 47-1139 / CH2CH2 / CH=CH / ethynylene /
 48-38 51-1139 / 55-38 52-1139




G6 = O / NH
 G7 = O / S
 G8 = R<TX "spacer group", EC (1-25) C> /
 (SC alkylene<(1-12)>)
 G9 = 59 / 64 / 67 / 69 / 73




G10 = phenylene
 G11 = phenylene
 G13 = F / Cl / CN / OH / NO2 /
 alkyl<(1-7)> (SO (1-) G14) / alkoxy<(1-7)> (SO (1-) G14) /
 alkylcarbonyl<(1-7)> (SO (1-) G14) / CHO
 G14 = F / Cl
 G15 = H / F / Cl / CN / OH / NO2 /
 alkyl<(1-7)> (SO (1-) G14) / alkoxy<(1-7)> (SO (1-) G14) /
 alkylcarbonyl<(1-7)> (SO (1-) G14) / CHO

G16 = 621-15 226-81 / 371-15 372-81






G17 = 227-622 228-81 / 229-622 230-81 / CH₂CH₂ / CH=CH /
231-622 234-81 / 238-622 235-81 / ethynylene






G18 = C(O) / CH₂

G20 = p-C₆H₄ (SO (1-) G13) /
Hy<EC (1-) Q (1-) N (0) OTHERQ (-5) C, AN (0) N, AR (1-),
BD (6) N, RC (1), RS (1) E6> (SO (1-) G13) /
Hy<EC (1-2) Q (0-2) O (0-2) S (0) OTHERQ (4-5) C, AN (2) C,
AR (0), BD (ALL) SE, RC (1), RS (1) E6> (SO (1-) G13) /
378-15 375-372 / 384-15 381-372 / 390-15 387-372 /
396-15 393-372 / 404-15 401-372 / 410-15 407-372 /
412-15 419-372 / 422-15 429-372 / 432-15 439-372 /
442-15 449-372 / 529-15 530-372






G21 = p-C₆H₄ (SO (1-) G13) /
Hy<EC (1-) Q (1-) N (0) OTHERQ (-5) C, AN (0) N, AR (1-),
BD (6) N, RC (1), RS (1) E6> (SO (1-) G13) /
Hy<EC (1-2) Q (0-2) O (0-2) S (0) OTHERQ (4-5) C, AN (2) C,
AR (0), BD (ALL) SE, RC (1), RS (1) E6> (SO (1-) G13) /
456-371 453-81 / 462-371 459-81 / 468-371 465-81 /
474-371 471-81 / 482-371 479-81 / 488-371 485-81 /
490-371 497-81 / 500-371 507-81 / 510-371 517-81 /
520-371 527-81









G22 = p-C6H4 (SO (1-) G13) /
 Hy<EC (1-) Q (1-) N (0) OTHERQ (-5) C, AN (0) N, AR (1-),
 BD (6) N, RC (1), RS (1) E6> (SO (1-) G13) /
 Hy<EC (1-2) Q (0-2) O (0-2) S (0) OTHERQ (4-5) C, AN (2) C,
 AR (0), BD (ALL) SE, RC (1), RS (1) E6> (SO (1-) G13) /
 536-15 533-530 / 542-15 539-530 / 548-15 545-530 /
 554-15 551-530 / 562-15 559-530 / 568-15 565-530 /
 570-15 577-530 / 580-15 587-530 / 590-15 597-530 /
 600-15 607-530






G23 = 609-529 610-372 / 611-529 612-372 /
 613-529 616-372 / 617-529 620-372 / CH2CH2 / CH=CH /
 ethynylene




G24 = p-C6H4 (SO (1-) G13) /
 Hy<EC (1-) Q (1-) N (0) OTHERQ (-5) C, AN (0) N, AR (1-),
 BD (6) N, RC (1), RS (1) E6> (SO (1-) G13) /
 Hy<EC (1-2) Q (0-2) O (0-2) S (0) OTHERQ (4-5) C, AN (2) C,
 AR (0), BD (ALL) SE, RC (1), RS (1) E6> (SO (1-) G13) /
 628-15 625-622 / 634-15 631-622 / 640-15 637-622 /
 646-15 643-622 / 654-15 651-622 / 660-15 657-622 /
 662-15 669-622 / 672-15 679-622 / 682-15 689-622 /
 692-15 699-622 / 779-15 780-622





G25 = p-C6H4 (SO (1-) G13) /
 Hy<EC (1-) Q (1-) N (0) OTHERQ (-5) C, AN (0) N, AR (1-),
 BD (6) N, RC (1), RS (1) E6> (SO (1-) G13) /
 Hy<EC (1-2) Q (0-2) O (0-2) S (0) OTHERQ (4-5) C, AN (2) C,
 AR (0), BD (ALL) SE, RC (1), RS (1) E6> (SO (1-) G13) /
 706-621 703-226 / 712-621 709-226 / 718-621 715-226 /
 724-621 721-226 / 732-621 729-226 / 738-621 735-226 /
 740-621 747-226 / 750-621 757-226 / 760-621 767-226 /
 770-621 777-226




G26 = p-C6H4 (SO (1-) G13) /
 Hy<EC (1-) Q (1-) N (0) OTHERQ (-5) C, AN (0) N, AR (1-),
 BD (6) N, RC (1), RS (1) E6> (SO (1-) G13) /
 Hy<EC (1-2) Q (0-2) O (0-2) S (0) OTHERQ (4-5) C, AN (2) C,
 AR (0), BD (ALL) SE, RC (1), RS (1) E6> (SO (1-) G13) /
 786-15 783-780 / 792-15 789-780 / 798-15 795-780 /
 804-15 801-780 / 812-15 809-780 / 818-15 815-780 /
 820-15 827-780 / 830-15 837-780 / 840-15 847-780 /
 850-15 857-780









G27 = 859-779 860-622 / 861-779 862-622 /
863-779 866-622 / 867-779 870-622 / CH₂CH₂ / CH=CH /
ethynylene



G28 = H / CN / X / Ak<EC (1-) C, BD (0) D (0-) T>
(SO (1-) G29) / 873 / 875 / 879 / 882 / 883 / 886 / 889 /
893 / 900 / 905 / 908 / 910 / 914 / 919




G29 = X / CN
G30 = O / S / NH / NMe / OCO₂
G31 = alkyl<(-25)> (SO)
G32 = O / S
G33 = alkylene<(-23)> (SO)
G34 = O / S / NH / NMe / OCO₂
G35 = alkyl<(-23)> (SO)
G37 = phenylene
G38 = phenylene
G39 = O / S / C(O) / 920-86 921-918 / 922-86 923-918 /
924-86 925-918 / 926-86 927-918 / CH₂CH₂ / CH=CH /
ethynylene / 928-86 931-918 / 935-86 932-918

926-929 922-923 924-925 926-927 928-C(=O)-CH=CH

H₃C=CH-C(=O)O₂

G40 = 939 / 944 / 947 / 949 / 953



H₂C=CH-G₄₂


G41 = phenylene
 G42 = phenylene
 MPL: claim 1
 NTE: substitution is restricted
 NTE: additional interruptions of ak in G28 also claimed

L37 ANSWER 13 OF 25 MARPAT COPYRIGHT 2005 ACS on STN
 AN 130:338118 MARPAT Full-text
 TI Preparation of heterocyclylbenzenes as herbicides and defoliants.
 IN Gupta, Sandeep; Tsukamoto, Masamitsu; Pulman, David A.; Ying, Bai-ping;
 Wu, Shao-yong
 PA ISK Americas Incorporated, USA
 SO PCT Int. Appl., 139 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9921837	A1	19990506	WO 1998-US17197	19980821
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2307815	AA	19990506	CA 1998-2307815	19980821
	AU 9895650	A1	19990517	AU 1998-95650	19980821
	AU 749237	B2	20020620		
	EP 1030843	A1	20000830	EP 1998-949302	19980821
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	JP 2001521027	T2	20011106	JP 2000-517949	19980821
	BR 9814104	A	20011226	BR 1998-14104	19980821
	ZA 9809639	A	19990426	ZA 1998-9639	19981022
	TW 533200	B	20030521	TW 1998-87117635	19981023
	EG 22047	A	20020630	EG 1998-1309	19981027
	US 6355799	B1	20020312	US 2000-530373	20000427

US 2002133007	A1	20020919	US 2001-930149	20010816
US 6545161	B2	20030408		
PRAI US 1997-958313		19971027		
WO 1998-US17197		19980821		
US 2000-530373		20000427		

MSTR 1



G1 = H / F / Cl / Br / I / NO2 / NH2 / 8 / 10 / CONH2 /
 CSNH2 / CN / alkylcarbonyl<(1-8)> / alkoxy carbonyl<(1-8)> /
 alkylaminosulfonyl<(1-8)> / alkyl<(1-8)> (SO (1-) G3) /
 alkoxy<(1-8)> (SO (1-) G3) / alkoxy<(1-8)>
 (SR alkoxy carbonyl<(1-8)> (SO)) / OCH2Ph (SO) /
 aryloxy<(6-10)> (SO) / heteroaryloxy<EC (1-4) Q (0-) N (0-)
 O (0-) S (0) OTHERQ> (SO)



G2 = alkyl<(1-8)> (SO) / alkenyl<(2-8)> (SO) /
 alkynyl<(2-8)> (SO) / Cb<EC (3-8) C, AR (0)> (SO) /
 aryl<(6-10)> (SO) / heteroaryl<EC (1-4) Q (0-) N (0-) O (0-)
 S (0) OTHERQ> (SO) / 13 / alkylsulfonyl<(1-8)> (SO) /
 CH2Ph (SO) / alkylcarbonyl<(1-8)> (SO) /
 alkenylcarbonyl<(2-8)> (SO) / alkynylcarbonyl<(2-8)> (SO) /
 arylcarbonyl<(6-10)> (SO) / heteroarylcarbonyl<EC (1-4)
 Q (0-) N (0-) O (0-) S (0) OTHERQ> (SO) /
 alkoxy carbonyl<(1-8)> (SO) / aryloxy carbonyl<(6-10)> (SO) /
 heteroaryloxy carbonyl<EC (1-4) Q (0-) N (0-) O (0-) S (0)
 OTHERQ> (SO)



G3 = F / Cl / Br / I / R
 G4 = F / Cl / Br / I
 G5 = alkyl<(1-8)> (SO) / Cb<EC (3-8) C, AR (0)> (SO) /
 aryl<(6-10)> (SO) / heteroaryl<EC (1-4) Q (0-) N (0-) O (0-)
 S (0) OTHERQ> (SO)
 G6 = H / F / Cl / Br / I / NO2
 G7 = H / OH / SH / NH2 / 17 / Me /
 Ak<EC (1-) C, BD (0-) D (0-) T> (SO (1-3) G9) / F / Cl / Br /
 I / NO2 / CN / (SC 303 / OMe)




















G8 = O / S / NH / 19



1⁹—G2

G9 = R / Cb<EC (3-8) C, AR (0)> (SO) /
 aryl<(6-10)> (SO) / heteroaryl<EC (1-4) Q (0-) N (0-) O (0-)
 S (0) OTHERQ> (SO) / 21 / alkylsulfonyl<(1-8)> (SO) /
 CH2Ph (SO) / alkylcarbonyl<(1-8)> (SO) /
 alkenylcarbonyl<(2-8)> (SO) / alkynylcarbonyl<(2-8)> (SO) /
 arylcarbonyl<(6-10)> (SO) / heteroarylcarbonyl<EC (1-4)
 Q (0-) N (0-) O (0-) S (0) OTHERQ> (SO) /
 alkoxy carbonyl<(1-8)> (SO) / aryloxy carbonyl<(6-10)> (SO) /
 heteroaryloxy carbonyl<EC (1-4) Q (0-) N (0-) O (0-) S (0)
 OTHERQ> (SO)


2⁹—G5

G10 = Hy (SO) / 25 / 37 / 46 / 55 / 62 / 71 / 82 / 93 /
 104 / 122 / 133 / 144 / 155 / 166 / 169 / 179 / 190 / 272 /
 283 / 294 / phthalimido / 202 / 212 / 222 / 231







G11 = H / alkyl<(1-8)> (SO (1-) G4) / alkenyl<(2-8)> /
 alkynyl<(2-8)> / NH2 / alkyl<(1-8)> (SR alkoxy<(1-8)>) /
 COMe / alkoxycarbonylamino<(1-8)> /
 alkylcarbonylamino<(1-8)> / alkoxycarbonyl<(1-8)> / (SC Me)
 G12 = alkyl<(1-8)> (SO (1-) G4) / (SC CF3)
 G13 = H / F / Cl / Br / I / NO2 / NH2 /
 alkylamino<(1-8)> (SO (1-) G4) / CN / CONH2
 G14 = O / S / NH
 G15 = N / CH
 G16 = NH2 / OH / SH / CHO / CO2H / CN /
 alkylcarbonyl<(1-8)> / arylcarbonyl<(6-10)> / N3 / 242 /
 Hy<EC (4-8) A (1-) Q (1-) N, AN (1) N> / 258 /
 Ak<BD (0-) D (0-) T> (SO (1-) G25) / NO2 / (SC 305)



G17 = NH / 244 / O / S




G18 = alkyl<(1-8)> (SO) / alkenyl<(2-8)> (SO) /
 alkynyl<(2-8)> (SO) / NH2 (SO) /
 Cb<EC (3-8) C, AR (0)> (SO) / Hy<EC (3-8) A (1-4) Q (0-)
 N (0-) O (0-) S (0) OTHERQ, AR (0)> (SO) /
 alkylsulfonyl<(1-8)> (SO) / arylsulfonyl<(6-10)> (SO) /
 CH2Ph (SO) / aryl<(6-10)> (SO) /
 heteroaryl<EC (1-4) Q (0-) N (0-) O (0-) S (0) OTHERQ> (SO) /
 alkylcarbonyl<(1-8)> (SO) / alkenylcarbonyl<(2-8)> (SO) /
 alkynylcarbonyl<(2-8)> (SO) / 246 / 250 / 255




G19 = Cb<EC (3-8) C, AR (0)> (SO) / aryl<(6-10)> (SO) /
 heteroaryl<EC (1-4) Q (0-) N (0-) O (0-) S (0) OTHERQ> (SO) /
 248 / alkylthio<(1-8)> (SO) / arylthio<(6-10)> (SO) /
 NH2 (SO) / 253

G20 = aryl<(6-10)> (SO)
 G21 = alkyl<(1-8)> (SO) / aryl<(6-10)> (SO) /
 heteroaryl<EC (1-4) Q (0-) N (0-) O (0-) S (0) OTHERQ> (SO)
 G22 = alkoxy<(1-8)> (SO) / aryl<(6-10)> (SO)
 G23 = alkyl<(1-8)> (SO (1-) G4) / dialkylamino<(1-8)> /
 aryl<(6-10)> (SO) / heteroaryl<EC (1-4) Q (0-) N (0-) O (0-)
 S (0) OTHERQ> (SO)
 G24 = H / F / Cl / Br / I / alkyl<(1-8)> (SO (1-) G4) /
 dialkylamino<(1-8)> / aryl<(6-10)> (SO) /
 heteroaryl<EC (1-4) Q (0-) N (0-) O (0-) S (0) OTHERQ> (SO)
 G25 = CO2H / R / NH2 (SO) / Cb<EC (3-8) C, AR (0)> (SO) /
 Hy<EC (3-8) A (1-4) Q (0-) N (0-) O (0-) S (0) OTHERQ,
 AR (0)> (SO) / alkylsulfonyl<(1-8)> (SO) /
 arylsulfonyl<(6-10)> (SO) / CH2Ph (SO) / aryl<(6-10)> (SO) /
 heteroaryl<EC (1-4) Q (0-) N (0-) O (0-) S (0) OTHERQ> (SO) /
 alkylcarbonyl<(1-8)> (SO) / alkenylcarbonyl<(2-8)> (SO) /
 alkynylcarbonyl<(2-8)> (SO) / 262 / 264 / 267



G27 = alkyl<(1-8)> (SO (1-) G28) /
 alkenyl<(2-8)> (SO (1-) G28) / alkynyl<(2-8)> (SO (1-) G28)
 G28 = F / Cl / Br / I / CN / NO2 / NH2 / CO2H
 G29 = CO2H / alkyl<(1-8)> (SO) / alkenyl<(2-8)> (SO) /
 alkynyl<(2-8)> (SO) / NH2 (SO) /
 Cb<EC (3-8) C, AR (0)> (SO) / Hy<EC (3-8) A (1-4) Q (0-)
 N (0-) O (0-) S (0) OTHERQ, AR (0)> (SO) /
 alkylsulfonyl<(1-8)> (SO) / arylsulfonyl<(6-10)> (SO) /
 CH2Ph (SO) / aryl<(6-10)> (SO) /
 heteroaryl<EC (1-4) Q (0-) N (0-) O (0-) S (0) OTHERQ> (SO) /
 alkylcarbonyl<(1-8)> (SO) / alkenylcarbonyl<(2-8)> (SO) /
 alkynylcarbonyl<(2-8)> (SO) / 307 / 309 / 312



DER: or salts
 MPL: claim 1
 NTE: additional ring formation also claimed
 NTE: substitution is restricted
 NTE: also incorporates claim 14

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L37 ANSWER 14 OF 25 MARPAT COPYRIGHT 2005 ACS on STN
 AN 129:100056 MARPAT Full-text
 TI Anti-amyloidogenic agents
 IN De Guzman Mirov, Greta J.; Kelly, Jeffery W.; Lai, Zhihong; Lashuel, Hilal
 A.; Peterson, Scott A.
 PA Texas A & M University, USA
 SO PCT Int. Appl., 68 pp.

CODEN: PIXXD2


DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9827972	A2	19980702	WO 1997-US24181	19971223
	WO 9827972	A3	19990218		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9857277	A1	19980717	AU 1998-57277	19971223
PRAI	US 1996-771938		19961223		
	WO 1997-US24181		19971223		


MSTR 1



G1 = OH / SH / NH2 / 11 / 56 / 79




G5 = alkylene<(1-6)> (SO (1-) G19)
 G6 = Hy<EC (0-) N (0-) O (0-) S (2-8) C> / CO2H / OH /
 SH / NH2 / 15 / 18




G7 = alkyl<(1-8)> / Hy<EC (0-) N (0-) O (0-) S (2-8) C> /
 Ph / alkyl<(1-4)> (SR Ph)
 G8 = O / S / NH / 20




G9 = alkyl<(1-3)>
 G10 = F / Cl / Br / I
 G11 = NH2 / 24 / 26





G12 = alkyl<(1-10)>
 G13 = alkylene<(1-4)>
 G14 = SO3H / PO3H2
 G15 = alkylene<(1-10)>
 G16 = C(O) / R<TX "heteroatom">
 G17 = H / alkyl<(1-10)>
 G18 = F / Cl / Br / I / OH / alkyl<(1-8)> (SR (1-) OH) /
 alkyl<(1-14)> (SO Ph) / Hy<EC (0-) N (0-) O (0-) S (2-8) C> /
 Ph / alkylcarbonyl<(1-13)> (SO Ph) / 43 /
 alkyl<(1-6)> (SR (1-) G10) / CH2Ph / alkenyl<(2-8)> /
 cycloalkyl<(4-10)> / 45 / 47 / SO3H / PO3H2 / 51 / 53



G19 = NH2 (SO)
 G20 = NH / 58 / O / S / CH2 / 60 / 62 / 65



G21 = H / alkyl<(1-6)>
 G22 = (0-2) CH2
 G23 = N / 103-1 102-80 103-91 / 105-1 106-80 105-91 /
 108-1 107-80 109-91 / 111-1 112-80 113-91 /
 114-1 115-91 114-80 / 116-1 118-91 116-80 /
 119-1 121-80 120-91 / 122-1 124-80 125-91



G24 = (1-2) CH2

MPL: claim 1

NTE: alkyl and alkenyl moieties may also be cyclic; substitution is restricted

L37 ANSWER 15 OF 25 MARPAT COPYRIGHT 2005 ACS on STN

AN 129:69033 MARPAT Full-text

TI Multicomponent system for altering, degrading, or bleaching lignin, lignin-containing materials, or similar substances, and method for its use

IN Freudenreich, Johannes; Stohrer, Juergen; Amann, Manfred; Mueller, Robert

PA Consortium fuer Elektrochemische Industrie G.m.b.H., Germany

SO Ger. Offen., 12 pp.

CODEN: GWXXBX


DT Patent

LA German


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19651099	A1	19980610	DE 1996-19651099	19961209
	CA 2271937	AA	19980618	CA 1997-2271937	19971205
	WO 9826127	A1	19980618	WO 1997-EP6802	19971205
	W: AU, BR, CA, CN, JP, KR, NO, PL, RU, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9855603	A1	19980703	AU 1998-55603	19971205
	AU 719140	B2	20000504		
	EP 943032	A1	19990922	EP 1997-952038	19971205
	EP 943032	B1	20000913		
	R: AT, DE, ES, SE, PT, FI				
	CN 1240008	A	19991229	CN 1997-180387	19971205
	BR 9714387	A	20000516	BR 1997-14387	19971205
	JP 2000505844	T2	20000516	JP 1998-526185	19971205
	RU 2154704	C1	20000820	RU 1999-114460	19971205
	AT 196331	E	20000915	AT 1997-952038	19971205
	ES 2150797	T3	20001201	ES 1997-952038	19971205
	PT 943032	T	20001229	PT 1997-952038	19971205
PRAI	DE 1996-19651099		19961209		
	WO 1997-EP6802		19971205		

MSTR 2



G1 = (2-) G2 / H / X / OH / SH / 36 / CHO / CN / 25 /
 CO2H / SO3H / 29 / NO2 / 14 / 31 / Ph (SO (1-) G4) /
 Ak<(1-5)> (SR (1-) G7) / Ak<(1-12)> (SO (1-) G4) / 38 / 16 /
 19 / PO3H2 / OPO3H2



G2 = OH / 12 / SH / NH2



G3 = H / OH / CHO / CN / CO2H / CONH2 / SO3H / SO2NH2 /
 NO2 / 34 / NH2 / Ph / alkyl<(1-5)> / alkoxy<(1-5)> /
 alkylcarbonyl<(1-5)>



G4 = OH / CHO / CN / CO2H / CONH2 / SO3H / SO2NH2 / NO2 /
 42 / NH2 / Ph / alkyl<(1-5)> / alkoxy<(1-5)> /
 alkylcarbonyl<(1-5)>



G5 = Ak<(1-5)> (SO (1-) G4)
 G6 = Ak<(1-10)> (SO (1-) G4) / R
 G7 = (1-) aryl (SO (1-) G4) / OH / CHO / CN / CO2H /
 CONH2 / SO3H / SO2NH2 / NO2 / 40 / NH2 / Ph /
 alkyl<(1-5)> /
 alkoxy<(1-5)> / alkylcarbonyl<(1-5)>



DER: and tautomers, salts, ethers or esters
 MPL: claim 1
 NTE: additional ring formation also claimed

L37 ANSWER 16 OF 25 MARPAT COPYRIGHT 2005 ACS on STN

AN 128:295176 MARPAT Full-text

TI Preparation of monomers useful in the production of liquid-crystalline polymers

IN Gailberger, Michael; Strelzyk, Katja; Grundig, Petra; Barth, Anne;
 Dannenhauer, Fritz; Strohmriegl, Peter; Stohr, Andreas

PA Daimler-Benz A.-G., Germany

SO Ger. Offen., 10 pp.

CODEN: GWXXBX


DT Patent

LA German

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19643048	A1	19980423	DE 1996-19643048	19961018
	EP 837054	A2	19980422	EP 1997-116765	19970926
	EP 837054	A3	19990414		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 10182556	A2	19980707	JP 1997-320232	19971017
	US 6049000	A	20000411	US 1997-953976	19971020
	US 6423865	B1	20020723	US 2000-516511	20000301
	US 6313326	B1	20011106	US 2000-526756	20000316
PRAI	DE 1996-19643048		19961018		
	US 1997-953976		19971020		

MSTR 1




G1 = H / Me

G2 = 13 / 16 / N3 / H / CN / 80



G3 = NULL / alkylene<EC (1-20) C, DC (0) M3>


G4 = O / 20-4 21-6 / 22-4 23-6 / C(O) / S / ethynylene / 25-4 26-6 / 27-4 28-6 / CH2 / R<TX "linking group">




G5 = CH / N / 29




G6 = O / 32-7 33-9 / 34-7 35-9 / C(O) / S / ethynylene / 37-7 38-9 / 39-7 40-9 / CH2 / R<TX "linking group">




G7 = p-C6H4 (SO) / 46-5 43-7 / arylene (SO (1-3) G15) /
heteroarylene (SO (1-3) G15) / cycloalkylene<(3-10)>
(SO (1-3) G15) / (EX 133-5 136-7)




G8 = NULL / p-C6H4 / 56-6 53-8 / arylene (SO) /
heteroarylene (SO (1-3) G15) / cycloalkylene<(3-10)>
(SO (1-3) G15) / 57-6 61-8



G9 = O / NH
G10 = p-C6H4 / 67-6 64-58 / arylene (SO (1-3) G15) /
heteroarylene (SO (1-3) G15) / cycloalkylene<(3-10)>
(SO (1-3) G15)




G11 = p-C6H4 / 73-58 70-60 / arylene (SO (1-3) G15) /
heteroarylene (SO (1-3) G15) / cycloalkylene<(3-10)>
(SO (1-3) G15)




G12 = p-C6H4 / 79-60 76-8 / arylene (SO (1-3) G15) /
heteroarylene (SO (1-3) G15) / cycloalkylene<(3-10)>
(SO (1-3) G15)




G13 = O / 108-57 109-59 / 110-57 111-59 / C(O) / S /
ethynylene / 113-57 114-59 / 115-57 116-59 / CH2 /
R<TX "linking group">



G14 = O / 118-59 119-61 / 120-59 121-61 / C(O) / S /
ethynylene / 123-59 124-61 / 125-59 126-61 / CH2 /
R<TX "linking group">



G15 = alkyl<(1-20)> (SO) / alkoxy<(1-20)> (SO) /
alkylthio<(1-20)> (SO) / alkylcarbonyl<(1-20)> /
alkoxycarbonyl<(1-20)> / 128 / OH / F / Cl / Br / I / CN /
NO2 / cycloalkyl / CHO / COMe




G16 = alkyl<(1-20)>
MPL: claim 16
NTE: alkylene in G3 may be interrupted by oxygen atoms

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 17 OF 25 MARPAT COPYRIGHT 2005 ACS on STN
AN 128:154351 MARPAT Full-text
TI Preparation of 3'-, 4'-, and 5'-C-branched deoxyribonucleosides and their
use for synthesis of oligonucleotides
IN Wang, Guangyi
PA ICN Pharmaceuticals, USA
SO U.S., 30 pp., Cont.-in-part of U.S. 5,681,940.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2



	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5712378	A	19980127	US 1995-552363	19951102
	US 5681940	A	19971028	US 1994-333545	19941102
	CA 2202280	AA	19960517	CA 1995-2202280	19951102
	CA 2202280	C	20000815		
	CA 2307311	AA	19960517	CA 1995-2307311	19951102
	CN 1170412	A	19980114	CN 1995-196962	19951102
	CN 1122040	B	20030924		
	HU 77516	A2	19980528	HU 1997-2445	19951102
	US 6191266	B1	20010220	US 1996-766991	19961216
	US 6743902	B1	20040601	US 2000-697545	20001025
PRAI	US 1994-333545		19941102		
	CA 1995-2202280		19951102		
	US 1995-552363		19951102		
	US 1996-766991		19961216		

MSTR 1



G1 = Ak<(1-10)> (SO (1-) G2) / Ph (SO (1-) G13) /


aryl<RC (2-)> (SO (1-) G13) / heteroaryl (SO (1-) G13)
 G2 = Ph (SO (1-) G13) / aryl<RC (2-)> (SO (1-) G13) /
 heteroaryl (SO (1-) G13) / R / (SC NH2 / 66 / 69 / 72 / CN /
 NO2 / N3 / X / 75 / SH / 77 / OH) / (EX CO2Et /
 alkylaminocarbonyl / dialkylaminocarbonyl / OCOMe / NHCOMe /
 NMe2 / 101 / alkoxy / alkylthio / SO2Me / CF3 / F / Cl / Br /
 I / OSO2C6H4Me-p / 105 / 108 / 111)




G3 = H / OH / 8



G4 = Ak<(1-10)> (SO (1-) G2) / Ph (SO (1-) G13) /
 aryl<RC (2-)> (SO (1-) G13) / heteroaryl (SO (1-) G13)
 G5 = OH / R<TX "internucleotide linkage"> / 13




G6 = R<TX "blocking group"> / (EX 128)



G7 = O / CH2


G8 = 24 / 34 / 43 / 51 / 60





G9 = loweralkyl / loweralkylcarbonyl

G10 = O / S

G11 = OH / 78 / NH2 / 84 / 86



G12 = loweralkyl (SO (1-) aryl) / aryl
 G13 = R / (SC NH2 / 89 / 91 / 94 / CN / NO2 / N3 / X /
 97 / SH / 99 / OH) / (EX CO2Et / alkylaminocarbonyl /
 dialkylaminocarbonyl / OCOMe / NHCOMe / NMe2 / 114 / alkoxy /
 alkylthio / SO2Me / CF3 / F / Cl / Br / I / OSO2C6H4Me-p /
 118 / 121 / 124)




G14 = alkyl
 MPL: claim 1
 NTE: substitution is restricted

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 18 OF 25 MARPAT COPYRIGHT 2005 ACS on STN
 AN 126:47223 MARPAT Full-text
 TI Preparation of imidazopyridine and benzimidazole derivatives as dual
 histamine H1 and platelet activating factor antagonists.
 IN Martin, Fiona Mitchell; Floyd, Christopher David; Spavold, Zoe Marie;
 Ayscough, Andrew Paul; Whittaker, Mark
 PA British Biotech Pharmaceuticals Limited, UK; Martin, Fiona Mitchell;
 Floyd, Christopher David; Spavold, Zoe Marie; Ayscough, Andrew Paul;
 Whittaker, Mark
 SO PCT Int. Appl., 55 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9633997	A1	19961031	WO 1996-GB680	19960322
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	GB 1995-8748		19950428		

MSTR 6




G1 = N / 10

16—G2

G2 = H / alkyl<(1-6)> / alkenyl<(2-6)> / F / Cl / Br /
I / CN / CO2H / alkoxycarbonyl<(1-6)> / CONH2 / CHO / CH2OH /
CF3 / alkoxy<(1-6)> / alkylthio<(1-6)> /
alkylsulfinyl<(1-6)> / alkylsulfonyl / NH2 / NHCOMe / NO2
G3 = H / Me
G4 = alkyl<(1-6)> / alkenyl<(2-6)> / F / Cl / Br / I /
alkoxy<(1-6)>
G5 = p-C6H4 (SO (1) G4)
G6 = H / alkyl<(1-6)> / alkenyl<(2-6)> / alkoxy<(1-6)> /
alkylthio<(1-6)> / cyclopropyl / alkyl<(1-6)> (SR OH) /
dialkylamino<(1-6)> / alkyl<(1-6)> (SR dialkylamino<(1-6)>) /
CF3 / (SC Me)
G7 = NULL / 17

HG—G8

G8 = H / alkyl<(1-6)> / alkenyl<(2-6)> / alkynyl<(2-6)> /
alkoxycarbonyl<(1-6)> / alkoxy<(1-6)> / alkylthio<(1-6)> /
alkyl<(1-6)> (SR alkoxy<(1-6)>) /
alkyl<(1-6)> (SR alkylthio<(1-6)>) / alkyl<(1-6)> (SR Ph) /
SPh
G9 = 25-15 27-20 / 38-15 45-20 / 43-15 44-20



G10 = O / S / NH / 23

2N—G11

G11 = alkyl<(1-6)> / alkenyl<(2-6)> /
cycloalkyl<(3-8)> (SO (1-) alkyl<(1-6)>) /
alkyl<(1-6)> (SR G13) / alkyl<(1-6)> (SR OH) /
alkyl<(1-6)> (SR alkoxy<(1-6)>) / (SC Me / cyclohexyl)
G12 = C(O) / SO2
G13 = CO2H (SO) / CONH2 (SO)
G14 = H / alkyl<(1-6)> / (SC Me)
G15 = Hy<AN (1) C, RC (1), RS (1) M3 (1) X8> /
Cb<AN (1) C, RC (1), RS (1) M3 (1) X8>
CVA = IF G1 = 10 THEN G3 = H
MPL: claim 18

L37 ANSWER 19 OF 25 MARPAT COPYRIGHT 2005 ACS on STN

AN 125:275910 MARPAT Full-text

TI Preparation of benzylpiperidines and -piperazines as muscarinic
antagonists

IN Lowe, Derek; Chang, Wei; Kozlowski, Joseph; Berger, Joel G.; Mcquade,
Robert; Barnett, Allen; Scherlock, Margaret; Tom, Wing; Dugar, Sundeep; et
al.

PA Schering Corporation, USA

SO PCT Int. Appl., 152 pp.

CODEN: PIXXD2


DT Patent

LA English


FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9626196	A2	19960829	WO 1996-US1532	19960216
	WO 9626196	A3	19961003		
	W:	AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, AZ, BY, KG, KZ, MD, RU			
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	CA 2212895	AA	19960829	CA 1996-2212895	19960216
	AU 9649717	A1	19960911	AU 1996-49717	19960216
	AU 701452	B2	19990128		
	EP 811002	A2	19971210	EP 1996-906286	19960216
	EP 811002	B1	20040121		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV			
	JP 11501014	T2	19990126	JP 1996-525703	19960216
	TW 464646	B	20011121	TW 1996-85101945	19960216
	AT 258170	E	20040215	AT 1996-906286	19960216
	ES 2215190	T3	20041001	ES 1996-906286	19960216
	ZA 9601293	A	19960819	ZA 1996-1293	19960219
	FI 9703446	A	19971022	FI 1997-3446	19970822
PRAI	US 1995-392697		19950223		
	US 1995-457712		19950602		
	WO 1996-US1532		19960216		

MSTR 1



G1 = 15-7 12-9 / 21-7 18-9




G2 = N / 22





G3 = H / alkyl<(1-20)>


G4 = 26 / 186 / 188 / CH2OH / R<TX "1-5 amino acid">





G5 = O / S / S(O) / SO2 / 28 / 49 / 69 / 30 / 61 / 35 /
67 / 40-6 41-27 / 44-6 43-27 / 46 / 54 / CH=CH / ethynylene /
NHCONH






G6 = alkyl<(1-20)>
 G7 = C(O) / SO2
 G8 = H / Ph / alkyl<(1-20)>
 G9 = H / alkyl<(1-20)> / CHO /
 alkylcarbonyl<(1-20)> (SO OH)
 G10 = O / S / 51




G11 = H / alkyl<(1-20)> / alkylcarbonyl<(1-20)>
 G12 = H / alkyl<(1-20)> / OH
 G13 = (0-2) CH2
 G14 = H / alkyl<(1-20)> (SO Cb<EC (6-10) C, AR (1-),
 BD (ALL) N, RC (1-2), RS (1-2) E6 (0) OTHER>) /
 cycloalkyl<(3-12)> / Cb<EC (6-10) C, AR (1-), BD (ALL) N,
 RC (1-2), RS (1-2) E6 (0) OTHER> (SO)
 G15 = H / OH / alkoxy<(1-20)>
 G16 = 77 / 86 / 95 / 104 / furyl / 116 / 118 / 125 / 132 /
 Ph (SO) / pyridyl (SO) / pyridazinyl (SO) /
 pyrimidinyl (SO) / 148 / 157 / 162 / 171 / benzoxazolyl /
 thienyl (SO) / 174 / 181 / 238 / oxazolyl (SO) /
 thiazolyl (SO) / pyrazinyl (SO) / 251 / 258 / 264 / 285 /
 299 / 313 / 327 / 336 / naphthyl / H /
 cycloalkyl<(3-12)> (SO (1-2) alkyl<(1-20)>) /
 cycloalkenyl<(5-8)> / cycloalkyl<EC (5-12) C, RC (2)> / 353 /
 (SC 760)








G17 = (1-2) CH2
 G18 = H / Me
 G19 = H / R
 G20 = 147 / alkynyl<(3-)> (SO (1-2) G23) /
 alkenyl (SO (1-2) G24) / 241 / alkyl<(1-20)> (SO G32) / 350
 /
 CH2Ph (SO) / alkylcarbonyl<(1-20)> (SR (2-) G31) /
 alkenylcarbonyl<(2-15)>




G21 = O / S / S(O) / SO2 / 190 / 206 / 217 /
 218-6 219-187 / 225-6 224-187 / NHCONH





G22 = 192 / 194 / 196 / 207 / 222-6 221-189 / 227 / 230 /
 CH=CH / ethynylene




G23 = cycloalkyl<(3-12)> / Cb<EC (6-10) C, AR (1-),
BD (ALL) N, RC (1-2), RS (1-2) E6 (0) OTHER> (SO) / OH
G24 = cycloalkyl<(3-12)> / Cb<EC (6-10) C, AR (1-),
BD (ALL) N, RC (1-2), RS (1-2) E6 (0) OTHER> (SO) / OH
G25 = CH2 / O / 239


 G14

G26 = H / alkyl<(1-20)> (SO OH)
G27 = phenylene
G28 = alkyl<(1-20)> / alkylcarbonyl<(1-20)>
G29 = alkylene<(1-20)>
G30 = H / alkoxy carbonylamino<(1-20)>
G31 = F / Cl / Br / I
G32 = cycloalkyl<(3-12)> / OCH2Ph / OH
G33 = Cb<EC (6-10) C, AR (1-), BD (ALL) N, RC (1-2),
RS (1-2) E6 (0) OTHER> (SO alkyl<(1-20)>) / alkyl<(1-20)>
G34 = Ak<BD (0-) D (0-) T> (SO G35) / 466 / 470 /
cycloalkylene<EC (3-21) C, AN (1) C> / C(O) / 473 / 477 /
Hy<EC (1) Q (0-) N (0-) O (0-) S (0) OTHERQ (3-7) C,
AN (1) C, AR (0), BD (ALL) SE> / (SC 741 / 757)



G35 = cycloalkyl<(3-12)> / cycloalkenyl<(5-8)> /
cycloalkyl<EC (5-12) C, RC (2)> / CN / NH2 / 397 / 355 /
Ph (SO) / alkylcarbonyloxy<(1-20)> / pyridyl (SO) /
pyridazinyl (SO) / pyrimidinyl (SO) / pyrazinyl (SO) / 359 /
368 / 373 / 382 / thienyl (SO) / 385 / 392 / 414 / 424 /
425 / 432 / 439 / OH / alkylcarbonyl<(1-20)> / 463
















G36 = alkoxy<(1-20)> / NH2 / 399 / H /
 Cb<EC (6-10) C, AR (1-), BD (ALL) N, RC (1-2),
 RS (1-2) E6 (0) OTHER>





G37 = CH (SO) / N
 G38 = OH / alkoxy<(1-20)> / CN / NH2 /
 alkylamino<(1-20)> / dialkylamino<(1-20)>
 G39 = H / alkyl<(1-20)> (SO G40) / alkenyl<(2-15)> /
 cycloalkyl<(3-12)> (SO) / cycloalkenyl<(5-8)> /
 alkynyl<(2-10)> / alkylaminocarbonyl<(1-20)> /
 cycloalkyl<EC (5-12) C, RC (2)> /
 Hy<EC (1-) N (4-8) C, RC (2)> / alkylcarbonyl<(1-20)> /
 dialkylamino<(1-20)> / 493 / 498 / 509 / 514 / 535 / 549 /
 563 / 577 / 586 / pyrimidinyl / Ph (SO) / 605 / 622 / 635 /
 645 / 661 / 667 / 679 / 691 / 700 / 708 / 711 / C(NH)NH2 /
 719 / 725 / 737 / alkoxycarbonyl<(1-20)> / CH2OH / 715 /
 (SC cyclohexyl)







G40 = OH / cycloalkyl<(3-12)> /
Cb<EC (6-10) C, AR (1-), BD (ALL) N, RC (1-2),
RS (1-2) E6 (0) OTHER> (SO OH) / 488 /
alkoxy<(1-20)> (SO OH) / CONH2 / 483 /
alkylcarbonyloxy<(1-20)>




G41 = O / S / S(O) / SO2
G42 = H / alkyl<(1-20)> / alkylcarbonyl<(1-20)> /
alkoxycarbonyl<(1-20)> / CONH2 / alkylaminocarbonyl<(1-20)> /
dialkylaminocarbonyl<(1-20)> / alkylsulfonyl<(1-20)> / 611



G43 = Cb<EC (6-10) C, AR (1-), BD (ALL) N, RC (1-2),
RS (1-2) E6 (0) OTHER>
G44 = Cb<EC (5-8) C, AN (2) C, AR (0), BD (ALL) SE,
RC (1), RS (1) M5 (1) X8> / Hy<EC (1) Q (1) O (4-6) C,
AN (2) C, AR (0), BD (ALL) SE, RC (1), RS (1) M5 (1) X7>
G46 = O / 739



G47 = OH / alkoxy<(1-20)>
G48 = cycloalkyl<(3-12)> / alkyl<(1-20)> / CN /
cyclohexyl / Me / CO2Me / Pr-i / 751




G49 = H / alkyl<(1-20)> (SO) / alkylthio<(1-20)> / (SC Me)
G50 = CN / CO2Me
G51 = alkoxy<(1-20)> / OMe

DER: and pharmaceutically acceptable salts, esters and solvates
MPL: claim 1
NTE: substitution is restricted
NTE: additional ring formation is allowed
STE: or isomers

L37 ANSWER 20 OF 25 MARPAT COPYRIGHT 2005 ACS on STN
AN 125:115097 MARPAT Full-text
TI Preparation of sugar-modified nucleosides and their use for synthesis of oligodeoxyribonucleotides
IN Wang, Guangyi; Ramasamy, Kandasamy; Seifert, Wilfried
PA Icn Pharmaceuticals, USA
SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9614329	A1	19960517	WO 1995-US14600	19951102
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5681940	A	19971028	US 1994-333545	19941102
	CA 2202280	AA	19960517	CA 1995-2202280	19951102
	CA 2202280	C	20000815		
	CA 2307311	AA	19960517	CA 1995-2307311	19951102
	AU 9641525	A1	19960531	AU 1996-41525	19951102
	AU 690394	B2	19980423		
	EP 789706	A1	19970820	EP 1995-939864	19951102
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1170412	A	19980114	CN 1995-196962	19951102
	CN 1122040	B	20030924		
	HU 77516	A2	19980528	HU 1997-2445	19951102
	JP 10506915	T2	19980707	JP 1996-515519	19951102
	JP 3633626	B2	20050330		
	RU 2145964	C1	20000227	RU 1997-108591	19951102
	PL 184378	B1	20021031	PL 1995-319944	19951102
	CZ 293731	B6	20040714	CZ 1997-1291	19951102
	HK 1007881	A1	20040604	HK 1998-109044	19980709
PRAI	US 1994-333545		19941102		
	CA 1995-2202280		19951102		
	WO 1995-US14600		19951102		

MSTR 1








G1 = alkyl<(1-10)> (SO G10) /
alkyl<(1-10)> (SR (1-) G7) / Ph (SO G10) / Hy (SO G10) /
(SC alkenyl<(2-10)> (SO (1-) G8) / CN / NO2 / N3 / CF3)
G2 = H / OH / alkoxy<(1-10)> (SO (1-) G9) / 17

G3 = OH / R<TX "oligonucleotide"> / 49 / 15











G4 = R<TX "blocking group">

G5 = R<TX "nucleoside base"> / (EX 67 / 74 / 85 / 93 / 102)



G6 = O / S / NH / CH2









G7 = Ph (SO G10) / Hy (SO G10) / R / (SC CN / NO2 / 20 / OH / alkoxy (SO (1-) G9) / 26 / SH / 30 / 42 / CO2H / 46 / F / Cl / Br / I / SO2C6H4Me-p / N3) / (EX CO2Et / OCOMe / NHCOMe / NMe2 / 129 / SO2Me / CF3 / 108 / 113 / 116)



G8 = Ph / Hy

G9 = Ph / Hy

G10 = R / (SC CN / NO2 / 24 / OH / alkoxy (SO (1-) G9) / 28 / SH / 32 / 38 / CO2H / 43 / F / Cl / Br / I / SO2C6H4Me-p / N3) / (EX CO2Et / OCOMe / NHCOMe / NMe2 / 132 / SO2Me / CF3 / 120 / 123 / 126)



G11 = H / Me / Et / COMe / COCF3

G12 = COMe / COCF3 / alkyl / Ph / Hy / alkyl (SR (1-) G8)

G13 = H / alkyl

G14 = H / alkyl (SO (1-) G8) / Hy / Ph

G15 = alkyl
G16 = OH / R<TX "oligonucleotide"> / 135

~~135~~—G4

MPL: claim 1

L37 ANSWER 21 OF 25 MARPAT COPYRIGHT 2005 ACS on STN

AN 124:307619 MARPAT Full-text

TI Nitric oxide synthase inhibitors for prevention and treatment of shock, hypotension, chronic rheumatism, ulcerative colitis, cerebral ischemia, tumor, and insulin-dependent diabetes

IN Taniguchi, Naoyuki

PA Ono Pharmaceutical Co, Japan

SO Jpn. Kokai Tokkyo Koho, 32 pp.

CODEN: JKXXAF

DT Patent

LA Japanese


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 08041008	A2	19960213	JP 1994-197203	19940729
PRAI	JP 1994-197203		19940729		

MSTR 2

G2=G1

G1 = 3 / 11



G2 = NH / 9

~~8~~—G3

G3 = alkyl<(1-4)> / alkenyl<(2-4)> / Ph /
alkyl<(1-4)> (SO G4)

G4 = OH / Ph

G5 = NH2 / 7

~~92~~—G3

G6 = alkylene<(2-3)> / (EX CH2CH2 / CH2CH2CH2)

G7 = cycloalkyl<(4-7)> / 16 / 18 /

Hy<EC (-2) N (-1) O (-1) S, RS (0-) E4 (0-) E5 (0-) E6 (0-)
E7 (0) OTHER> (SO (1-4) G12)

$1\text{G}^9\text{---G10}$ $1\text{G}^{\text{(O)}}\text{---G11---G10}$


G8 = OH / CO2H / alkoxyacetyl<(1-4)> / SO3H / NH2 /
alkylamino<(1-4)> / dialkylamino<(1-4)> / alkylthio<(1-4)>
G9 = phenylene
G10 = H / X / NO2 / CO2H / alkoxyacetyl<(1-4)> / OH /
alkoxy<(1-4)> / alkylcarbonyloxy<(1-4)> / SH /
alkylthio<(1-4)> / 37 / Ph (SR (1-) X) / alkyl<(1-4)>

$3\text{S}\text{---C(O)---G23}$

G11 = phenylene
G12 = X / NO2 / alkyl<(1-4)> / CO2H /
alkoxyacetyl<(1-4)> / OH / alkoxy<(1-4)> /
alkylcarbonyloxy<(1-4)> / SH / alkylthio<(1-4)> / 40 / Ph /
Hy<EC (6-) C, BD (6-) N, RC (2-), RS (1-) E6>

$4\text{S}\text{---C(O)---G23}$

G13 = alkyl<(1-2)> / 48 / 21 / 23



G14 = NULL / alkylene<(1-4)> (SO (1) G25)
G15 = NULL / alkylene<(1-8)> / 26-4 28-24

$2\text{G}^{16}\text{---G17}\text{---G16}$

G16 = alkylene<(1-4)>
G17 = phenylene (SR (1-2) alkyl<(1-4)>)
G18 = NH / 30

$3\text{S}\text{---G19}$

G19 = alkyl<(1-4)> / alkenyl<(2-4)> / Ph /
alkyl<(1-4)> (SO G20)
G20 = OH / Ph
G21 = NH2 / 33

$3\text{G}^{22}\text{---G19}$

G22 = NH / 35

$3\text{S}\text{---G19}$

G23 = alkyl<(1-4)>
 G24 = H / alkyl<(1-4)> / alkenyl<(2-4)> / Ph /
 alkyl<(1-4)> (SO G4)
 G25 = cycloalkyl<(4-7)> / 43 / 45 /
 Hy<EC (-2) N (-1) O (-1) S, RS (0-) E4 (0-) E5 (0-) E6 (0-)
 E7 (0) OTHER> (SO (1-4) G12)


4526-G10 45(0)-G27-G10

G26 = phenylene
 G27 = phenylene
 G28 = alkylene<(1-12)>
 MPL: claim 1
 NTE: substitution is restricted

L37 ANSWER 22 OF 25 MARPAT COPYRIGHT 2005 ACS on STN
 AN 121:255405 MARPAT Full-text
 TI Catechol diethers as selective phosphodiesterase IV inhibitors
 IN Duplantier, Allen J.; Eggler, James F.; Marfat, Anthony; Masamune, Hiroko
 PA Pfizer Inc., USA
 SO PCT Int. Appl., 159 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9412461	A1	19940609	WO 1993-US10228	19931029
	W: AU, BR, CA, CZ, JP, KR, NO, NZ, PL, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2150812	AA	19940609	CA 1993-2150812	19931029
	CA 2150812	C	20021224		
	CA 2400368	AA	19940609	CA 1993-2400368	19931029
	AU 9455396	A1	19940622	AU 1994-55396	19931029
	AU 673569	B2	19961114		
	EP 672031	A1	19950920	EP 1994-900390	19931029
	EP 672031	B1	20030312		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 08501318	T2	19960213	JP 1994-513129	19931029
	JP 3100984	B2	20001023		
	BR 9307570	A	19990525	BR 1993-7570	19931029
	AT 234270	E	20030315	AT 1994-900390	19931029
	PT 672031	T	20030630	PT 1994-900390	19931029
	ES 2192192	T3	20031001	ES 1994-900390	19931029
	IL 107758	A1	19971120	IL 1993-107758	19931125
	FI 9305379	A	19940603	FI 1993-5379	19931201
	ZA 9308978	A	19950601	ZA 1993-8978	19931201
	HU 65928	A2	19940728	HU 1993-3423	19931202
	CN 1094028	A	19941026	CN 1993-112776	19931202
	NO 9502178	A	19950801	NO 1995-2178	19950601
	US 5814651	A	19980929	US 1997-872686	19970610
PRAI	US 1992-984408		19921202		
	CA 1993-2150812		19931029		
	WO 1993-US10228		19931029		
	US 1993-142328		19931126		

MSTR 1






G1 = Me / Et / 9

F2G—G2

G2 = H / F

G3 = alkyl<(1-6)> (SO (1-) G4) /
 alkyl<(2-4)> (SR alkoxy<(3-7)>) / alkyl<(2-6)> (SR (1-) G5) /
 cycloalkyl<(3-7)> (SO (1-) G4) /
 cycloalkyl<EC (6-9) C, RC (2-)> (SO (1-) G4) /
 alkyl<(1-8)> (SR (1-) G7) / alkyl<(2-6)> (SR 13) / 18 / 28 /
 43 / 51



G4 = F / OH / alkoxy<(1-4)>
 G5 = F / OH / alkoxy<(1-4)> / (1) OPh (SO (1-) G6)
 G6 = alkyl<(1-4)> / alkoxy<(1-4)> / X
 G7 = F / OH / alkoxy<(1-4)> / (1) Ph (SO (1-) G6)
 G8 = NH / 15

1N—G9

G9 = alkyl<(1-4)>
 G10 = H / alkyl<(1-4)> / alkoxy<(1-4)> / X
 G11 = NULL / alkylene<(1-10)> (SO (1-2) G12) / 81 / 89 /
 alkenylene<(2-10)> (SO (1-2) G12) / phenylene (SO (1) G12) /
 O / NH / 83 / S / 85-5 86-80 / 94-5 95-80 / 98-5 100-80

8G13=O 8N—G9 8G14—8G18 O=8G15=O 9G19—9G20 9G21—G23—G22

G12 = alkoxy<(1-4)> / CO2H / alkoxy carbonyl<(1-4)> / OH
 G13 = Ak<EC (1-10) C, BD (0-) D> (SO (1) G12)
 G14 = alkylene<(1-5)> (SO (1) G12) / 87 /
 alkenylene<(2-5)> (SO (1) G17) / phenylene (SO (1) G12)

8G16=O

G15 = Ak<EC (6-10) C, BD (ALL) SE>
 G16 = Ak<EC (1-5) C, BD (ALL) SE>
 G17 = alkoxy<(1-4)> / CO2H / alkoxy carbonyl<(1-4)>
 G18 = O / NH / 92 / S / phenylene (SO (1) G12)

9N—G9

G19 = O / NH / 107 / S / phenylene (SO (1) G12)

1N—G9

G20 = alkylene<(1-5)> (SO (1) G12) / 96 /
 alkenylene<(2-5)> (SO (1) G17) / phenylene (SO (1) G12)

9G16=O

G21 = alkylene<(1-5)> (SO (1) G12) / 101 /
 alkenylene<(2-5)> (SO (1) G17) / phenylene (SO (1) G12)

1G16=O

G22 = alkylene<(1-5)> (SO (1) G12) / 103 /
 alkenylene<(2-5)> (SO (1) G17) / phenylene (SO (1) G12)


1G16=O

G23 = O / NH / 105 / S


1N—G9

G24 = Hy<EC (1-4) Q (-4) N (-1) O (-1) S (0) OTHERQ (1-4)
 C, AR (1-), BD (2) D, RC (1), RS (1) E5> (SO (1-3) G25) /
 159 / 163 / Hy<EC (1-4) Q (1-) N (-1) O (-1) S (0)
 OTHERQ (5-8) C, AR (1-), BD (4) D, RC (2),
 RS (1) E5 (1) E6 (0) OTHER> (SO (1-4) G25) / 126 / 176 /
 pyridyl / pyrimidinyl / Hy<EC (1-2) Q (1-2) N (0)
 OTHERQ (4-5) C, AR (1-), BD (ALL) N, RC (1), RS (1) E6>
 (SO (1-4) G25) / 183 / 194 / Ph (SO (1-5) G25) /

naphthyl (SO (1-7) G25) / Cb<EC (10) C, AR (1-), BD (6) N,
 RC (2), RS (2) E6 (0) OTHER> (SO (1-4) G25) /
 Hy<EC (1-4) Q (0-) N (0-) O (0-) S (0) OTHERQ (6-9) C,
 AR (1-), BD (6) N, RC (2), RS (2) E6 (0) OTHER>
 (SO (1-4) G25) / 212 / 204 / (SC 215 / 225 / 234 / 242 / 252)




G25 = X / alkyl<(1-6)> / 109 / alkoxy<(1-4)> / 114 / 116 /
 NH2 (SO) / Hy<EC (1-2) Q (1-) N (0-) O (0-) S (0) OTHERQ,
 AN (1-) N, RC (1-2), RS (0-) E5 (0-) E6 (0) OTHER> (SO) /
 NO2 / OH / CN / SO3H / alkyl<(1-4)> (SR Ph) / 118 / 123




G26 = H / R
 G27 = H / alkyl<(1-4)>
 G28 = OH (SO) / NHOH
 G29 = C(O) / CH2 / SO2
 G30 = NH2 (SO) / Hy<EC (1-2) Q (1-) N (0-) O (0-) S (0)
 OTHERQ, AN (1-) N, RC (1-2), RS (0-) E5 (0-) E6 (0) OTHER>
 (SO)
 G31 = H / X / alkyl<(1-6)> / 137 / alkoxy<(1-4)> / 142 /
 144 / NH2 (SO) / Hy<EC (1-2) Q (1-) N (0-) O (0-) S (0)
 OTHERQ, AN (1-) N, RC (1-2), RS (0-) E5 (0-) E6 (0) OTHER>

(SO) / NO2 / OH / CN / SO3H / alkyl<(1-4)> (SR Ph) / 146 /
151



G32 = H / alkyl<(1-6)> / Ph (SO) / 170 /
cycloalkyl<(3-7)> / alkyl<(1-4)> (SR Ph) /
alkyl<(2-5)> (SR dialkylamino<(1-4)>)



G33 = Cb<EC (6) C, AR (1-), BD (ALL) N, RC (1), RS (1) E6>
(SO (1) G25) / Hy<EC (1-2) Q (1-2) N (0) OTHERQ (4-5) C,
AN (2-) C, AR (1-), BD (ALL) N, RC (1), RS (1) E6>
(SO (1) G25)


G34 = Cb<EC (10) C, AR (1-), BD (6) N, RC (2),
RS (2) E6 (0) OTHER> (SO) / Hy<EC (1-3) Q (0-) N (0-) O (0-)
S (0) OTHERQ (7-9) C, AN (1-) C, AR (1-), BD (6) N, RC (2),
RS (2) E6 (0) OTHER> (SO)

DER: and pharmaceutically acceptable salts
MPL: claim 1
NTE: substitution is restricted
STE: racemic-diastereomeric mixtures and optical isomers

L37 ANSWER 23 OF 25 MARPAT COPYRIGHT 2005 ACS on STN
AN 120:52843 MARPAT Full-text
TI Hydroxy derivatives of cyclohexadiene and their preparation with
Pseudomonas putida
IN Blacker, Andrew John; Brown, Stephen Martin; Bowden, Martin Charles
PA Zeneca Ltd., UK
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9317994	A1	19930916	WO 1993-GB523	19930312
	W:	AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US			
	RW:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG			
	AU 9336462	A1	19931005	AU 1993-36462	19930312
	EP 630364	A1	19941228	EP 1993-905577	19930312
	EP 630364	B1	19970827		
	R:	DE, GB			
	JP 07506096	T2	19950706	JP 1993-515502	19930312
	US 5508444	A	19960416	US 1994-302648	19941117
PRAI	GB 1992-5505		19920313		
	WO 1993-GB523		19930312		


MSTR 3A




G1 = loweralkylene (SO (1-) G2) / NULL / (SC 20)



G2 = R / (SC X / alkyl<(1-6)> / cycloalkyl<(3-6)> / CF3 / CN / NO2 / Ph (SO (1-) G4) / alkoxycarbonyl<(1-10)> / OH / SH / 18 / CO₂Me)



G4 = R / (SC X / alkyl<(1-6)> / CF3 / CN / NO2 / Ph / 11 / OH / SH / 14)




G5 = alkyl<(1-6)> (SO (1-) G7) / alkylcarbonyl<(1-5)>

G6 = O / S / NH / 16



G7 = X / alkoxy / alkylthio


G9 = O / 27 / CH₂ / 29




G10 = OH / alkoxy<(1-6)> (SO (1-) G7) / alkylcarbonyloxy<(1-5)>

G11 = H / alkyl<(1-6)> (SO (1-) G7) / alkylcarbonyl<(1-5)>

G14 = H / R / (SC X / alkyl<(1-6)> / CF3 / CN / NO2 / Ph / 35 / OH / SH / 38)



G15 = H / R / (SC X / alkyl<(1-6)> / CF3 / CN / NO2 / Ph / 43 / OH / SH / 46)



G16 = H / R / (SC X / alkyl<(1-6)> / CF3 / CN / NO2 / Ph /
48 / OH / SH / 51)

$\text{G}6(0)\text{-O}-\text{G}5$ $\text{G}6-\text{G}5$

G18 = R / (EX X / alkyl<(1-6)> / CF3 / CN / NO2 /
Ph (SO (1-) G4) / alkoxycarbonyl<(1-10)> / OH / SH / 55 /
CO2Me)

$\text{G}19-\text{G}5$

G19 = O / S / 57

$\text{G}5-\text{G}5$

G15+G16= R<TX "moiety necessary to form a ring"> /
(SC CH=CHCH=CH (SO G18))

MPL: claim 19

L37 ANSWER 24 OF 25 MARPAT COPYRIGHT 2005 ACS on STN

AN 119:139256 MARPAT Full-text

TI Preparation of substituted quinazolines as angiotensin II antagonists

IN Primeau, John L.; Garrick, Lloyd M.

PA American Home Products Corp., USA

SO U.S., 18 pp.

CODEN: USXXAM


DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5187168	A	19930216	US 1991-782850	19911024
	US 5236925	A	19930817	US 1992-927032	19920806
	WO 9308170	A1	19930429	WO 1992-US8991	19921023
	W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	AU 9331227	A1	19930521	AU 1993-31227	19921023
	EP 612317	A1	19940831	EP 1992-925018	19921023
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE				
	JP 07500344	T2	19950112	JP 1992-507898	19921023
	US 5256781	A	19931026	US 1993-34030	19930322
PRAI	US 1991-782850		19911024		
	US 1992-927032		19920806		
	WO 1992-US8991		19921023		


MSTR 2




G1 = H / 30 / 33 / CN / Cl / F / I / Br /
perfluoroalkyl<(1-6)> / alkyl<(1-8)> (SO OH) /
alkyl<(1-8)> (SR alkoxy<(1-8)>) / 35 / 37




G2 = H / alkyl<(1-8)> (SO alkoxy<(1-8)>) /
alkyl<(1-8)> (SR OH) / perfluoroalkyl<(1-6)> /
alkyl<(1-6)> (SR G3)
G3 = (1) aryl<(6-12)> (SO (1-) G4) / F / Cl / Br
G4 = F / Cl / Br
G5 = H / alkyl<(1-8)> (SO alkoxy<(1-8)>) /
alkyl<(1-6)> (SR G3)
G6 = 40 / 42




G7 = (1-3) CH2
G8 = 45 / 54-7 55-12 / 57-7 58-12




G9 = H / 47 / alkyl<(1-8)> / perfluoroalkyl<(1-6)> /
alkyl<(1-6)> (SR G3) / 49 / 51




G10 = alkoxy<(1-8)> / OH / F / Cl / Br /
aryl<(6-12)> (SO (1-) G4) / CN / NO2 / 64 / 67 / 76 / 78




G11 = 69 / alkyl<(1-8)> / perfluoroalkyl<(1-6)> /
alkyl<(1-6)> (SR G3) / 71 / 73




G12 = 83-15 82-23 81-22 / 89-15 88-23 92-22 /
95-15 94-23 97-22 / 101-15 100-23 102-22




G13 = 106 / 112 / 117 / SO₃H / 120 / 122




G14 = H / alkyl<(1-8)> (SO alkoxy<(1-8)>) /
alkyl<(1-8)> (SR OH) / perfluoroalkyl<(1-6)> /
alkyl<(1-6)> (SR G3) / CN / NO₂ / 126 / 129 / 131 / 133 /
136 / F / Cl / Br / I / 138



G15 = (1-) H / alkyl<(1-8)> (SO alkoxy<(1-8)>) /
alkyl<(1-8)> (SR OH) / perfluoroalkyl<(1-6)> /
alkyl<(1-6)> (SR G3) / CN / NO₂ / 141 / 144 / 146 / 148 /
151 / F / Cl / Br / I / 153




G16 = alkyl<(1-8)> (SO alkoxy<(1-8)>) /
alkyl<(1-8)> (SR OH) / perfluoroalkyl<(1-6)> /
alkyl<(1-6)> (SR G3) / H / CN / NO₂ / 156 / 159 / 161 / 163 /
166 / F / Cl / Br / I / 168




G17 = CH₂ (SO) / alkylidene (SO (1-) G10)

G18 = O / S / 171 / 173-1 174-4



G19 = H / alkyl<(1-8)> / alkyl<(1-6)> (SR G3)

G20 = O / S / 177 / 179-12 180-15



DER: or pharmaceutically acceptable salts, solvates, and hydrates
MPL: disclosure
NTE: substitution is restricted

L37 ANSWER 25 OF 25 MARPAT COPYRIGHT 2005 ACS on STN

AN 111:232596 MARPAT Full-text

TI Quinoline derivatives, their use in the treatment of hypersensitive ailments, and pharmaceutical compositions containing them

IN Huang, Fu Chi; Galemno, Robert Anthony, Jr.; Campbell, Henry Flud

PA Rorer International (Overseas), Inc., USA

SO Eur. Pat. Appl., 44 pp.

CODEN: EPXXDW


DT Patent

LA English


FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 315399	A2	19890510	EP 1988-310241	19881101
	EP 315399	A3	19901128		
	EP 315399	B1	19960110		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 4920132	A	19900424	US 1987-116420	19871103
	WO 8904305	A1	19890518	WO 1988-US3897	19881101
	W: AU, JP, US				
	AU 8927946	A1	19890601	AU 1989-27946	19881101
	AU 633475	B2	19930204		
	JP 03500889	T2	19910228	JP 1989-500520	19881101
	JP 07107053	B4	19951115		
	AT 132856	E	19960115	AT 1988-310241	19881101
	US 5059610	A	19911022	US 1990-477896	19900420
PRAI	US 1987-116420		19871103		
	WO 1988-US3897		19881101		
OS	CASREACT 111:232596				

MSTR 1





G1 = O / S / 7-1 8-3 / 9-1 10-3 / 11-1 13-3 /
(SC 136-1 138-3)



G2 = O / S

G3 = alkylene (SO aryl)


G4 = O / S / S(O) / SO2 / NH / 21 / C(O) / 23-3 24-5 /
25-3 26-5 / 14-3 15-5 / 16-3 17-5 / 18-3 20-5 /
(SC 139-3 140-5)




G5 = alkyl / aralkyl
 G6 = NH / 29




G7 = O / S / S(O) / SO2 / NH / 31 / C(O) / 37-3 38-15 /
 40-3 41-15




G8 = O / S / S(O) / SO2 / NH / 33 / C(O) / 43-16 44-5 /
 46-16 47-5






G9 = O / S / S(O) / SO2 / NH / 35 / C(O) / 49-18 50-20 /
 52-18 53-20




G10 = alkylene (SO (1-) G11)
 G11 = alkenyl / cycloalkyl / aryl / OH / alkoxy /
 aralkyloxy / NH2 / alkylamino / dialkylamino / aralkylamino /
 acylamino / CONH2 / CO2H / alkoxy carbonyl / tetrazolyl / 55




G12 = acyl
 G13 = quinolinyl (SO (-4) G14)
 G14 = alkyl (SO (1-) X) / OH / alkoxy / CO2H /
 alkoxy carbonyl / X / NO2 / CN / acyl / (SC OMe)
 G15 = phenylene (SO (-2) G17)
 G16 = phenylene (SO (-2) G22)
 G17 = alkyl (SO (1-) X) / OH / alkoxy / X
 G18 = 59 / CN / OH / 71 / 75 / 80 / 85 / 89 / 91 /
 (SC 141 / 151 / 159 / 160)




G19 = OH / alkoxy / aralkyloxy / 61 / 64 / 69




G20 = alkyl (SO (1-) X) / Ph / CH₂Ph
 G21 = H / alkyl / aralkyl
 G22 = alkyl (SO (1-) X) / OH / alkoxy / CO₂H /
 alkoxy carbonyl / X / NO₂ / CN / acyl / (SC OMe / CO₂Me)
 G23 = H / alkyl (SO CO₂H) / alkyl (SR alkoxy carbonyl) /
 (SC CH₂CH₂CHMe₂)
 G24 = OH / 93 / 97 / 103



G25 = O / S / NH / 107 / alkenylene (SO) / alkylene (SO) /
 109-5 110-86 / 111-5 112-86 / 113-5 115-86



G26 = O / S / NH / 116



G27 = alkylene (SO)
 G28 = alkylene (SO) / alkenylene (SO)
 G29 = O / S / NH / 132 / alkenylene (SO) / alkylene (SO) /
 118-5 119-90 / 120-5 121-90 / 122-5 124-90

1G26-T28 1G27-T26 1G27-G26-T28 1N2-G14

G30 = O / S / NH / 134 / alkenylene (SO) / alkylene (SO) /
125-5 126-92 / 127-5 128-92 / 129-5 131-92

1G26-T28 1G27-T26 1G27-G26-T28 1N2-G14

DER: or pharmaceutically acceptable salts
MPL: claim 1
NTE: additional ring formation specified

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☒ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.